Document:

Exhibit 10.2

 

2010 LIVESTOCK PRODUCTS DISTRIBUTION AGREEMENT

 

This Livestock Products Agreement (“Agreement”) effective as of January 1, 2010 (“Effective Date”) is made by and between Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and Walco International, Inc., 7 Village Circle, Suite 200, Westlake, TX 76262 (“WALCO”).

 

WHEREAS, WALCO is in the business of buying and selling animal health products and servicing customers for those products, and

 

WHEREAS, WALCO and Pfizer wish to set forth the terms of their relationship related to the purchase and supply of such products,

 

NOW, THEREFORE, in consideration of the promises and covenants contained herein, the parties hereby agree as follows:

 

Definitions:

 

“PARTICIPATING CUSTOMERS” shall mean customers from the list of customers approved by Pfizer who have entered into a Leaders Edge Agreement with Pfizer.

 

“Products” shall mean the Pfizer cattle and swine products sold to WALCO by Pfizer pursuant to this Agreement (and referenced in Schedule A to this Agreement).

 

“Sales Out” shall mean the reported sales by WALCO to Covansys and accepted by Pfizer.

 

“Strategic Accounts” shall mean all those PARTICIPATING CUSTOMERS listed in Schedule B hereto.

 

1.                                       (a)                                  Pfizer shall continue to promote its Products to certain select customers in the livestock field.  The parties agree that each time a PARTICIPATING CUSTOMER selects WALCO as their supplier and to service that customer’s account, Pfizer shall send to WALCO a Pfizer Suggested Resale Price List which shall specify the Pfizer Products and the Pfizer suggested resale prices quoted to such PARTICIPATING CUSTOMER (hereafter “SUGGESTED RESALE PRICE LIST”).  Each such SUGGESTED RESALE PRICE LIST shall be incorporated into and become part of this Agreement.  Please find the current SUGGESTED RESALE PRICE LIST listed on Schedule C hereto.  Also included on Schedule C is the current Pfizer Livestock Distributor Pricing.  The Products and suggested resale prices are subject to change at any time in Pfizer’s sole discretion upon thirty (30) days prior written notice.

 

(b)                                 (Pfizer reserves the right to add or delete PARTICIPATING CUSTOMERS or Strategic Accounts at any time at Pfizer’s sole discretion.  Pfizer will provide written notice to WALCO of any changes.  Pfizer will notify WALCO of any (i) additions to the Strategic Accounts list within twenty-four (24) hours of Pfizer’s receipt of the customer contract and (ii) removals from the Strategic Accounts list within four (4) business days prior to the removal effective date.

 

 

2.                                       (a)                                  WALCO represents and warrants that for the purposes of this Agreement, it is in the business of purchasing Products from Pfizer for the sole purpose of resale and distribution, is registered within the state(s) with which it does business, is compliant with all pharmacy and distribution licensing requirements within the state(s) with which it does business, and is compliant with and capable of participating in Electronic Data Interchange (EDI).

 

(b)                                 WALCO agrees to purchase from Pfizer, at credit terms agreed to between the parties and as may be further set forth on Pfizer’s invoices, Products sufficient to fulfill demand from all customers to whom WALCO will sell Products in the quantities desired by the customers.

 

(c)                                  WALCO agrees to maintain an inventory of Products equal to /*/ Demand, but excluding all Products indicated on Schedule A as ineligible for RSA payments.  /*/

 

All Products shall count towards the amount held in inventory by WALCO.  WALCO and Pfizer agree to act in good faith to resolve any material differences in the on hand inventory calculations.

 

(d)                                 Pfizer reserves the right to allocate purchases such that WALCO may not purchase more than two (2) months WALCO’s average of the most current Moving Annual Total sales purchases.  Exceptions must be approved by Pfizer’s New York headquarters.

 

(e)                                  WALCO agrees that all sales of Pfizer Products from WALCO to a PARTICIPATING CUSTOMER shall reflect the specific prices for each Product provided for in that PARTICIPATING CUSTOMER’S most recent SUGGESTED RESALE PRICE LIST.  In the event that the price listed on a PARTICIPATING CUSTOMER’S most recent SUGGESTED RESALE PRICE LIST for any particular Product is lower (at the time of consummation of a sale of such particular Products between WALCO and that PARTICIPATING CUSTOMER) than the price paid by WALCO to Pfizer for such Product, Pfizer agrees to credit WALCO’s account for the amount of such difference.

 

3.                                       Nothing herein contained shall create or be deemed to create any relationship between the parties other than as specifically provided for herein.  No employment, partnership, specific or general agency relationship shall exist unless specifically provided for in writing between the parties.  WALCO shall not represent, directly or indirectly, expressly or by implication, that any such relationships exist and/or that WALCO has any authority except as set forth in this Agreement.

 

4.                                       WALCO shall use commercially reasonable efforts to provide appropriate service to the customers to whom WALCO will sell hereunder.  For customers serviced pursuant to this Agreement, WALCO shall:

 

2

 

(a)                                  Store its inventory of Pfizer Products under conditions (including refrigeration where appropriate) in accordance with package labeling or other written instructions from Pfizer to ensure that such Products retain their potency, purity, quality, and identity;

 

(b)                                 Provide to Covansys by the close of business on Friday of each week an inventory report covering all Product inventory purchased from Pfizer and setting forth in dollars at WALCO’s acquisition cost from Pfizer the amount of inventory by species.  WALCO agrees that Pfizer shall have the right, upon reasonable advance notice and during business hours to audit inventory in the possession of WALCO to confirm compliance with this paragraph 4(b) and to confirm the accuracy of the data contained in the report;

 

(c)                                  Provide to Covansys its Health Industry Number, Customer Health Industry Number, Pfizer Product number, transaction date, ship to zip code, number of units and price with respect to each sale of Product, and unit inventories on each Pfizer Product sku that WALCO sells;

 

(d)                                 Provide Sales Out data, which shall include Leaders Edge and Non-Leaders Edge sales, to Covansys within ten (10) working days of the date of each invoice.  WALCO will use its best efforts to ensure Sales Out data integrity and timeliness;

 

(e)                                  Submit all orders to Pfizer via EDI.  EDI report 867 is the acceptable format;

 

(f)                                    Establish any service fee or other charge or discount to any customer including PARTICIPATING CUSTOMERS for Pfizer Products independently and at its sole discretion;

 

(g)                                 Provide regularly scheduled delivery service to its customers and use commercially reasonable efforts to anticipate its customers’ requirements for Pfizer Products.  In the event Pfizer delivers any product order to PARTICIPATING CUSTOMERS (drop ship), no consideration shall be payable to WALCO for that order under paragraph 5 below, provided that Pfizer will pay WALCO for any drop ship if such shipment is made necessary by the unavailability of Pfizer Products;

 

(h)                                 WALCO agrees that credit limits established by Pfizer shall be subject to change upon written notice by Pfizer in its sole discretion and that no Product shipments will be made to WALCO in excess of the established credit limits;

 

(i)                                     Invoice customers in an accurate and timely manner;

 

(j)                                     Refer to that PARTICIPATING CUSTOMERS SUGGESTED RESALE PRICE LIST on each invoice for Pfizer Products;

 

(k)                                  Take no action, whether or not identified above, that would harm the Goodwill or name of Pfizer, or damage the interests of Pfizer or the Products, other than

 

3

 

where supported by sound factual evidence, including, but not limited to, the diversion of Products and statements of false information.  For purposes of this Agreement “Goodwill” shall mean the marketplace advantage of customer patronage and loyalty developed with continuous business under the same name over a period of time; and

 

(l)                                     /*/

 

5.                                       In consideration of WALCO undertaking the obligations set forth herein Pfizer shall make payments to WALCO in accordance with Schedule D hereto.

 

6.                                       All sales of Products to PARTICIPATING CUSTOMER or Strategic Accounts for whom a SUGGESTED RESALE PRICE LIST has been incorporated into this Agreement are covered by this Agreement with regard to compensation payable to WALCO hereunder.  Any transaction involving Products with any customer including a PARTICIPATING CUSTOMER for which WALCO has not been selected by that PARTICIPATING CUSTOMER as the distributor are not covered by this Agreement with regard to compensation payable hereunder.

 

7.                                       (a) WALCO shall not be provided with any rebate, discount or other compensation for Products handled under this Agreement unless specifically set forth herein.  WALCO will NOT be eligible to collect an RSA on any lateral sales to an unauthorized Pfizer distributor.  (Pfizer will provide Walco with a list of authorized Pfizer distributors.)  All sales by Pfizer to WALCO shall be at the then current Pfizer list price but subject to appropriate credits in accordance with paragraph 2(e).  Pfizer shall have the right to raise or change the price of any or all Products to WALCO on /*/ prior written notice.  Pfizer shall be free to limit sales of any or all Products to WALCO in advance of any price increase.

 

(b)                                 The parties agree that Pfizer shall not be obligated to issue credits for any returns that exceed the current average of returns of distributors as specified below unless such returns are the subject of a recall or made at the request of Pfizer.  The current average of returns of distributors for the calendar year of the contract timeline January 1, 2010 to December 31, 2010 shall be:

 

/*/

 

8.                                       The payments described in Schedule D hereto constitute full and complete compensation for WALCO.

 

9.                                       All returns shall be approved by Pfizer and subject to Pfizer’s Returned Goods Policy, attached hereto as Schedule F.  WALCO may not offset payment to Pfizer of invoice amounts as credit for any compensation payable hereunder.  Pfizer shall make bi-monthly payments of appropriate fees to WALCO.

 

10.                                 WALCO and Pfizer agree that, under the specific circumstances delineated in this Section 10, each party, at such party’s sole discretion, may recoup the sums outstanding to it from the other party against those sums which may become due from by such party to the other

 

4

 

party, in that the obligations arise from mutual transactions.  The specific circumstances which will enable each party to initiate recoupment are:

 

(a)                                  The other party becomes insolvent, which shall be defined as:

 

(i)                                     The sum of the other party’s debts is greater than all of the other party’s property (“Balance Sheet Test”); or

 

(ii)                                  The other party is generally not paying its debts as they come due; or

 

(iii)                               The other party has failed to act in good faith for a period in excess of six (6) months to resolve any outstanding invoice or purchase order issues or reconciliations.

 

(b)                                 The other party commences a liquidation of its operations by means of a sale of its assets in their entirety or piecemeal; or

 

(c)                                  The other party ceases its business operations whether or not such cessation is voluntary or involuntary; or;

 

(d)                                 The other party files a proceeding pursuant to the U.S. Bankruptcy Code or any state court proceeding, including an Assignment for the Benefit of Creditors.

 

11.                                 Nothing in this Agreement shall be deemed to preclude WALCO from negotiating a service fee or any other consideration from, or providing any discount or rebate to, any customer, including PARTICIPATING CUSTOMERS for any services provided by WALCO.

 

12.                                 WALCO shall distribute Pfizer Products only under the labeling provided by Pfizer or as otherwise approved in writing by Pfizer; prescribe, recommend, suggest, and advertise each Product for use only under the conditions stated in the labeling provided by Pfizer; and observe all federal, state, and local laws governing the distribution of the Products.

 

13.                                 Nothing in this Agreement shall be deemed to limit Pfizer’s ability to sell any Product at any time to any customer including PARTICIPATING CUSTOMERS or any other party.  Transactions consummated directly between Pfizer and any such customer or other party shall not qualify for any of the compensation payable to WALCO hereunder.  Nothing in this Agreement shall be deemed to limit WALCO’s ability to sell non-Pfizer products at any time to any customer including PARTICIPATING CUSTOMERS or any other party.  WALCO’s active promotion or sale of products not made by Pfizer will not be considered harmful to the Goodwill or name of Pfizer, or the Products, provided that the Pfizer Products are not maligned in any way as prohibited under Section 4(k) of this Agreement.

 

14.                                 EXCEPT AS SET FORTH IN THIS AGREEMENT, IN THE LABELING OF THE PRODUCTS SOLD HEREUNDER, OR AS OTHERWISE SPECIFIED IN WRITING BY PFIZER, PFIZER MAKES NO EXPRESS OR IMPLIED WARRANTIES WITH RESPECT TO THE PRODUCTS.

 

5

 

(a)                                  Pfizer shall defend, indemnify, and hold WALCO harmless from all liabilities, claims, demands, damages, costs and expenses, or money judgments incurred by WALCO or rendered against it resulting from (a) any breach by Pfizer of this Agreement, (b) third party claims or actions for personal injury or property damage which arise out of the distribution or sale of Pfizer products or the failure to warn, except to the extent that such personal injury or property damage arises out of the negligence or willful misconduct of WALCO, and (c) any claim that the Products, as sold by Pfizer, were defective.  In the event Pfizer is found by any court of competent jurisdiction to be liable for any claim based in products liability, then Pfizer shall reimburse WALCO’s reasonable legal fees incurred in the course of cooperating with Pfizer’s defense.  To be covered by this defense and indemnity, WALCO must:  promptly notify Pfizer of any such claim; allow Pfizer to fully control the defense and/or resolution of the claim; and cooperate fully with Pfizer in the matter.  This defense, indemnity and payment for legal fees shall not apply to claims alleging:  WALCO alteration, negligent handling or improper storage of the Products; sale of outdated Products; sale or recommendation of the Products for uses or in a manner not set forth in either the labeling supplied by Pfizer or as otherwise specified by Pfizer in writing; or sale of the Products after receipt of written notice from Pfizer that such sales should be halted.

 

(b)                                 In no event shall either party be liable to the other party for special, collateral, incidental, punitive or consequential damages in connection with or arising out of this Agreement.  Except as provided under subparagraph 14(a), above, total damages recoverable against Pfizer by WALCO shall be exclusively limited to the purchase price of the Products with respect to which damages are claimed.

 

15.                                 WALCO and Pfizer acknowledge that in the performance of their duties hereunder each may obtain access to “Confidential Information” (as defined below) of the other.  WALCO and Pfizer agree that during the term of this Agreement and for a period of three (3) years after the termination of this Agreement, unless specifically permitted in writing by the other party, which permission shall not be unreasonably withheld, especially in connection with a sale of all or a substantial portion of WALCO’s business, to (a) retain in confidence and not disclose to any third party and (b) use only for the purpose of carrying out their duties hereunder, any such Confidential Information.  As used herein the term “Confidential Information” means any information, or data, whether of a business or scientific nature and whether in written, oral or tangible form, relating to Pfizer’s and WALCO’s business or potential business or its research and development activities, not generally available to or known to the public, and not otherwise known to the receiving party, that is disclosed to or learned by the other party pursuant hereto.  “Confidential information” does not mean or include any information:  (a) which is, at the time of disclosure, available to the general public; or (b) which following disclosure becomes available to the general public through no fault of the recipient; or (c) which recipient can demonstrate was in its possession before receipt; or (d) which is disclosed to recipient without restriction on disclosure.  Upon written request from either party after completion of the work provided for hereunder or other termination of this Agreement each party will return to the other party any documents, or copies thereof, or any product samples, containing or constituting Confidential Information disclosed to or generated by either party in connection with this Agreement.

 

6

 

16.                                 All notices or communications given hereunder by one party to the other shall be sent by hand or by first class prepaid registered or recorded delivery post or by facsimile addressed to such party as follows:

 

If to Pfizer:

 

	
 
    	
Pfizer, Inc.
    
	
 
    	
Attention:   President, Animal Health
    
	
 
    	
235   East 42nd Street
    
	
 
    	
New   York, NY 10017
    

 

If to WALCO:

 

	
 
    	
WALCO   International, Inc.
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   TX 76262
    

 

Either party may change its address by giving written notice to the other party.

 

17.                                 This Agreement shall be effective as of January 1, 2010 and shall continue in force until December 31, 2010.  This Agreement may be terminated by either party upon thirty (30) days prior written notice.  Such termination may be without cause.  This Agreement may be terminated immediately by either party upon written notice in the event of a material breach by the other.  In the event WALCO takes any action that harms or damages the interests of Pfizer or the Products, other than where supported by sound factual evidence, including, but not limited to, the diversion of Products and statements of false information, Pfizer may terminate this Agreement immediately upon written notice.

 

18.                                 This Agreement shall be governed, by the laws of the State of New York applicable to contracts made and performed therein.  This Agreement is not assignable without the express written consent of the other party, and may be modified or amended only in writing signed by both parties.

 

19.                                 This Agreement and documents referred to herein embody the entire understanding between the parties hereto, will supersede prior agreements relating to the Products.  No activities conducted pursuant to this Agreement or related thereto, including but not limited to the future planning activities of the parties, shall be deemed to give rise to any obligations on the part of either party other than as expressly provided for herein.

 

7

 

IN WITNESS WHEREOF, intending to be legally bound, the parties have executed this Agreement.

 

	
Walco   International, Inc.
    	
 
    	
Pfizer   Inc.
    
	
 
    	
 
    	
 
    	
 
    
	
By
    	
/s/   James Robison
    	
 
    	
 
    	
 
    
	
Name James Robison
    	
 
    	
By
    	
/s/   Clinton A. Lewis, Jr.
    
	
Title   President and CEO
    	
 
    	
 
    	
Clinton A. Lewis, Jr.
    
	
 
    	
 
    	
 
    	
President, U.S. Operations
    
	
 
    	
 
    	
 
    	
Pfizer Animal Health
    
	
 
    	
 
    	
 
    	
 
    
	
Date
    	
March   3, 2010
    	
 
    	
Date
    	
3/9/10
    
							

 

 

SCHEDULE A

 

FEE ELIGIBLE PRODUCTS

 

2010 Leaders’ Edge RSA Eligibility List

 

	
SKU
    	
 
    	
ITEM DESCRIPTION
    	
 
    	
SIZE
    	
 
    	
RSA
   ELIGIBLE
    	
 
    	
RSA
   (Sales to LE
   Vets & Animal
   Health
   Accounts)
    	
 
    	
RSA
   (Sales to
   Strategic
   Producers)
    	
 
    	
RSA
   Sales to
   LE
   Producers
    	
 
    
	
CATTLE-BIOLOGICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4252
    	
 
    	
Bovi-Shield®   BRSV
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4256
    	
 
    	
Bovi-Shield   BRSV
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5194
    	
 
    	
Bovi-Shield   GOLD® 4
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5195
    	
 
    	
Bovi-Shield   GOLD 4
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5199
    	
 
    	
Bovi-Shield   GOLD® 5
    	
 
    	
5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5196
    	
 
    	
Bovi-Shield   GOLD 5
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5197
    	
 
    	
Bovi-Shield   GOLD 5
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5211
    	
 
    	
Bovi-Shield   GOLD® FP® 5*
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5212
    	
 
    	
Bovi-Shield   GOLD FP 5*
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5321
    	
 
    	
Bovi-Shield   GOLD® FP® 5**
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5322
    	
 
    	
Bovi-Shield   GOLD FP 5**
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5112
    	
 
    	
Bovi-Shield   GOLD® FP® 5 L5*
    	
 
    	
5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5113
    	
 
    	
Bovi-Shield   GOLD FP 5 L5*
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5114
    	
 
    	
Bovi-Shield   GOLD FP 5 L5*
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5323
    	
 
    	
Bovi-Shield   GOLD® FP® 5 L5**
    	
 
    	
5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5324
    	
 
    	
Bovi-Shield   GOLD FP 5 L5**
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5325
    	
 
    	
Bovi-Shield   GOLD FP 5 L5**
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5115
    	
 
    	
Bovi-Shield   GOLD® FP® 5 VL5*
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5116
    	
 
    	
Bovi-Shield   GOLD FP 5 VL5*
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5326
    	
 
    	
Bovi-Shield   GOLD® FP® 5 VL5**
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5327
    	
 
    	
Bovi-Shield   GOLD FP 5 VL5**
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5253
    	
 
    	
Bovi-Shield   GOLD® FP® 5 L5 HB
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5254
    	
 
    	
Bovi-Shield   GOLD FP 5 L5 HB
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5255
    	
 
    	
Bovi-Shield   GOLD® FP® 5 VL5 HB
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5256
    	
 
    	
Bovi-Shield   GOLD FP 5 VL5 HB
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5191
    	
 
    	
Bovi-Shield   GOLD® IBR-BVD
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4179
    	
 
    	
Bovi-Shield®   IBR
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4002
    	
 
    	
Calf-Guard®
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4143
    	
 
    	
CattleMaster®   4+VL5
    	
 
    	
5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4144
    	
 
    	
CattleMaster   4+VL5
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4145
    	
 
    	
CattleMaster   4+VL5
    	
 
    	
25
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5094
    	
 
    	
CattleMaster®   GOLDTM FP® 5
    	
 
    	
5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5095
    	
 
    	
CattleMaster   GOLD FP 5
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5096
    	
 
    	
CattleMaster   GOLD FP 5
    	
 
    	
25
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5124
    	
 
    	
CattleMaster®   GOLDTM FP® 5 L5
    	
 
    	
5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5125
    	
 
    	
CattleMaster   GOLD FP 5 L5
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5126
    	
 
    	
CattleMaster   GOLD FP 5 L5
    	
 
    	
25
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1434
    	
 
    	
E.coli   Bacterin- J-5TM Strain
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1435
    	
 
    	
E.coli   Bacterin- J-5 Strain
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4475
    	
 
    	
Leptoferm-5®
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4477
    	
 
    	
Leptoferm-5
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4988
    	
 
    	
One   Shot®
    	
 
    	
5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4991
    	
 
    	
One   Shot
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4993
    	
 
    	
One   Shot
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5074
    	
 
    	
One   Shot Ultra® 7
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5075
    	
 
    	
One   Shot Ultra 7
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

 

	
5076
    	
 
    	
One   Shot Ultra® 8
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5077
    	
 
    	
One   Shot Ultra 8
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5117
    	
 
    	
PregGuard®   GOLD FP® 10*
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5118
    	
 
    	
PregGuard   GOLD FP 10*
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5328
    	
 
    	
PregGuard®   GOLD FP® 10**
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5329
    	
 
    	
PregGuard   GOLD FP 10**
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4308
    	
 
    	
Resvac®   4/Somubac®
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4307
    	
 
    	
Resvac   4/Somubac
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5241
    	
 
    	
ScourGuard®   4K*
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
. /*/
    	
 
    
	
5242
    	
 
    	
ScourGuard   4K*
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5243
    	
 
    	
ScourGuard®   4KC*
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5244
    	
 
    	
ScourGuard   4KC*
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5331
    	
 
    	
ScourGuard®   4K**
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5332
    	
 
    	
ScourGuard   4K**
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5333
    	
 
    	
ScourGuard®   4KC**
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5334
    	
 
    	
ScourGuard   4KC**
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4255
    	
 
    	
Somubac®
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4254
    	
 
    	
Somubac
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5088
    	
 
    	
Spirovac®
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5090
    	
 
    	
Spirovac
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5200
    	
 
    	
Spirovac®   L5
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5201
    	
 
    	
Spirovac   L5
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5202
    	
 
    	
Spirovac®   VL5
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5203
    	
 
    	
Spirovac   VL5
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4890
    	
 
    	
StayBredTM   VL5
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4892
    	
 
    	
StayBred   VL5
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4904
    	
 
    	
TSV-2®
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4909
    	
 
    	
TSV-2
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4912
    	
 
    	
TSV-2
    	
 
    	
25
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4913
    	
 
    	
TSV-2
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4381
    	
 
    	
Ultrabac®   7
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4379
    	
 
    	
Ultrabac   7
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4380
    	
 
    	
Ultrabac   7
    	
 
    	
200
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4384
    	
 
    	
Ultrabac®   7/Somubac®
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4382
    	
 
    	
Ultrabac   7/Somubac
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4383
    	
 
    	
Ultrabac   7/Somubac
    	
 
    	
200
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4387
    	
 
    	
Ultrabac-8®
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4385
    	
 
    	
Ultrabac-8
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4386
    	
 
    	
Ultrabac-8
    	
 
    	
200
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4388
    	
 
    	
Ultrabac®   CD
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4371
    	
 
    	
Ultrabac   CD
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5062
    	
 
    	
UltraChoice®   7
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5063
    	
 
    	
UltraChoice   7
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5064
    	
 
    	
UltraChoice   7
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5065
    	
 
    	
UltraChoice®   8
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5066
    	
 
    	
UltraChoice   8
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5067
    	
 
    	
UltraChoice   8
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5061
    	
 
    	
UltraChoice®   CD
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4937
    	
 
    	
Vibrin®
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5330
    	
 
    	
SolidBac®   Pinkeye IR/PR®
    	
 
    	
1 Pouch of 50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
CATTLE-ANTI-INFECTIVES
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8171
    	
 
    	
A180®   
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8172
    	
 
    	
A180   
    	
Rx
    	
 
    	
250 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8448
    	
 
    	
Albon®   Bolus
    	
 
    	
5gx50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8449
    	
 
    	
Albon   Bolus
    	
 
    	
15 g x 12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8450
    	
 
    	
Albon   Bolus
    	
 
    	
15 g x 50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8189
    	
 
    	
Draxxin®   Injectable Solution 
    	
Rx
    	
 
    	
50 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8174
    	
 
    	
Draxxin   Injectable Solution
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
																

 

10

 

	
8175
    	
 
    	
Draxxin   Injectable Solution
    	
Rx
    	
 
    	
250 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8176
    	
 
    	
Draxxin   Injectable Solution
    	
Rx
    	
 
    	
500 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1506
    	
 
    	
Excede®   Sterile Suspension
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1431
    	
 
    	
Excenel®   RTU Sterile Suspension
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7959
    	
 
    	
Liquamycin®   LA-200®
    	
 
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7960
    	
 
    	
Liquamycin   LA-200
    	
 
    	
 
    	
250 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7961
    	
 
    	
Liquamycin   LA-200
    	
 
    	
 
    	
500 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1465
    	
 
    	
Naxcel®   Sterile Powder
    	
Rx
    	
 
    	
lq
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1466
    	
 
    	
Naxcel   Sterile Powder
    	
Rx
    	
 
    	
4q
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1463
    	
 
    	
Sterile   Water
    	
 
    	
 
    	
80 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7948
    	
 
    	
Terramycin®   Scour Tabs
    	
 
    	
 
    	
250 mg, 24/btl
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7949
    	
 
    	
Terramycin   Scour Tabs
    	
 
    	
 
    	
250 mg, 100/btl
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
CATTLE-LINCOMIX
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1452
    	
 
    	
Lincomix®   Soluble Powder
    	
 
    	
 
    	
160 g
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1453
    	
 
    	
Lincomix   Soluble Powder
    	
 
    	
 
    	
480 g
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1436
    	
 
    	
Linco-Spectin®
    	
Rx
    	
 
    	
20 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
CATTLE-MASTITIS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1403
    	
 
    	
Albadry   Plus®
    	
 
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1404
    	
 
    	
Albadry   Plus
    	
 
    	
 
    	
144
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2004
    	
 
    	
Nolvasan®   Teat Dip
    	
 
    	
 
    	
lqal
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8169
    	
 
    	
Orbeseal®
    	
 
    	
 
    	
144
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1475
    	
 
    	
Pirsue®   Sterile Solution
    	
Rx
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1476
    	
 
    	
Pirsue   Sterile Solution
    	
Rx
    	
 
    	
144
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1480
    	
 
    	
Quartermaster®
    	
Rx
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1481
    	
 
    	
Quartermaster   (Bulk Pack)
    	
Rx
    	
 
    	
144
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1507
    	
 
    	
Spectramast®   LC
    	
Rx
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1510
    	
 
    	
Spectramast   LC
    	
Rx
    	
 
    	
144
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1508
    	
 
    	
Spectramast®   DC
    	
Rx
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1511
    	
 
    	
Spectramast   DC
    	
Rx
    	
 
    	
144
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
CATTLE-PARACITICIDES
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
7897
    	
 
    	
Dectomax®   1% Injectable
    	
 
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8186
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
 
    	
200 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7899
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
 
    	
500 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7892
    	
 
    	
Dectomax®   Pour-On
    	
 
    	
 
    	
250 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7893
    	
 
    	
Dectomax   Pour-On
    	
 
    	
 
    	
1L
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7894
    	
 
    	
Dectomax   Pour-On
    	
 
    	
 
    	
2.5 L
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7895
    	
 
    	
Dectomax   Pour-On
    	
 
    	
 
    	
5L
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7030
    	
 
    	
Durasect®
    	
 
    	
 
    	
1 gal
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7031
    	
 
    	
Durasect®   II
    	
 
    	
 
    	
450 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7032
    	
 
    	
Durasect   II
    	
 
    	
 
    	
900 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8783
    	
 
    	
Valbazen®
    	
 
    	
 
    	
500 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8784
    	
 
    	
Valbazen
    	
 
    	
 
    	
1L
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8785
    	
 
    	
Valbazen
    	
 
    	
 
    	
5L
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
CATTLE-REPRODUCTION
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1420
    	
 
    	
EAZI-BreedTM   CIDR® Applicator
    	
 
    	
 
    	
Applicator
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1518
    	
 
    	
EAZI-Breed   CIDR Green Applicator
    	
 
    	
 
    	
Applicator
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1421
    	
 
    	
EAZI-Breed   CIDR Insert
    	
 
    	
 
    	
Bag of 10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0135
    	
 
    	
EAZI-BreedTM   CIDR® G Applicator (Sheep)
    	
 
    	
 
    	
Applicator
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1533
    	
 
    	
EAZI-Breed   CIDR G Insert (Sheep)
    	
 
    	
 
    	
Bag of 20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2001
    	
 
    	
Factrel®
    	
Rx
    	
 
    	
20 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1455
    	
 
    	
Lutalyse®   Sterile Solution
    	
Rx
    	
 
    	
30 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1504
    	
 
    	
Lutalyse   Sterile Solution
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2003
    	
 
    	
Nolvalube®
    	
 
    	
 
    	
81b
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

11

 

	
CATTLE-OTHER PHARMACEUTICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8152
    	
 
    	
Entrolyte®   H.E.
    	
 
    	
 
    	
178 g
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2002
    	
 
    	
Hog &   Cattle Vitamins & Electrolytes
    	
 
    	
 
    	
8oz
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1478
    	
 
    	
Predef®   2X
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8112
    	
 
    	
Re-Sorb®
    	
 
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8142
    	
 
    	
Re-Sorb
    	
 
    	
 
    	
72
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8620
    	
 
    	
Therabloat®
    	
 
    	
 
    	
2oz
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
CATTLE-PRODUCTION
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1458
    	
 
    	
MGA®   200 Premix
    	
 
    	
 
    	
50 lb bag
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1459
    	
 
    	
MGA®   500 Liquid Premix
    	
 
    	
 
    	
40 lb drum
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2016
    	
 
    	
Synovex®   C
    	
 
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2014
    	
 
    	
Synovex   C
    	
 
    	
 
    	
Display(20 x 2-10 ds Clips)
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2017
    	
 
    	
Synovex®   Choice
    	
 
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2018
    	
 
    	
Synovex®   H
    	
 
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2019
    	
 
    	
Synovex®   Plus
    	
 
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2022
    	
 
    	
Synovex®   S
    	
 
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
SWINE RESPIRATORY BIOLOGICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5223
    	
 
    	
FluSure   XP®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5224
    	
 
    	
FluSure   XP
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5042
    	
 
    	
pH1N1***
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5043
    	
 
    	
pH1N1***
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2240
    	
 
    	
Suvaxyn®   SIV
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2241
    	
 
    	
Suvaxyn   SIV
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5219
    	
 
    	
FluSure   XP®/FarrowSure® GOLD
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5220
    	
 
    	
FluSure   XP/FarrowSure GOLD
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5221
    	
 
    	
FluSure   XP®/FarrowSure® GOLD Plus B
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5227
    	
 
    	
FluSure   XP®/RespiSure®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5228
    	
 
    	
FluSure   XP/RespiSure
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5231
    	
 
    	
FluSure   XP®/RespiSure-ONE®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5232
    	
 
    	
FluSure   XP/RespiSure-ONE
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5225
    	
 
    	
FluSure   XP®/ER Bac Plus®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5226
    	
 
    	
FluSure   XP/ER Bac Plus
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5233
    	
 
    	
FluSure   XP®/RespiSure-ONE®/ER Bac Plus®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5001
    	
 
    	
RespiSure-ONE®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5002
    	
 
    	
RespiSure-ONE
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5003
    	
 
    	
RespiSure-ONE
    	
 
    	
 
    	
500
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5166
    	
 
    	
RespiSure-ONE®/ER   Bac Plus®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5167
    	
 
    	
RespiSure-ONE/ER   Bac Plus
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5168
    	
 
    	
RespiSure-ONE/ER   Bac Plus
    	
 
    	
 
    	
500
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4606
    	
 
    	
RespiSure®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4618
    	
 
    	
RespiSure
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4589
    	
 
    	
RespiSure
    	
 
    	
 
    	
500
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5169
    	
 
    	
RespiSure®/ER   Bac Plus®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5170
    	
 
    	
RespiSure/ER   Bac Plus
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5171
    	
 
    	
RespiSure/ER   Bac Plus
    	
 
    	
 
    	
500
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2220
    	
 
    	
Suvaxyn®   MH-one
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2221
    	
 
    	
Suvaxyn   MH-one
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2234
    	
 
    	
Suvaxyn®   RespiFend® MH
    	
 
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2235
    	
 
    	
Suvaxyn   RespiFend MH
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2236
    	
 
    	
Suvaxyn   RespiFend MH
    	
 
    	
 
    	
125
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

12

 

	
2237
    	
 
    	
Suvaxyn   RespiFend MH
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2238
    	
 
    	
Suvaxyn®   RespiFend® MH/HPS
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2239
    	
 
    	
Suvaxyn   RespiFend MH/HPS
    	
 
    	
 
    	
125
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2224
    	
 
    	
Suvaxyn®   PCV2
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2225
    	
 
    	
Suvaxyn   PCV2
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5041
    	
 
    	
ER   Bac® Plus
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2214
    	
 
    	
Suvaxyn®   E - oral
    	
 
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2215
    	
 
    	
Suvaxyn   E - oral
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2216
    	
 
    	
Suvaxyn   E - oral
    	
 
    	
 
    	
500
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2212
    	
 
    	
Suvaxyn®   E
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2213
    	
 
    	
Suvaxyn   E
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2232
    	
 
    	
Suvaxyn®   RespiFend® HPS
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2233
    	
 
    	
Suvaxyn   RespiFend HPS
    	
 
    	
 
    	
125
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2231
    	
 
    	
Suvaxyn®   RespiFend® APP
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
SWINE REPRODUCTIVE BIOLOGICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5213
    	
 
    	
ER   Bac® L5 GOLD
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5204
    	
 
    	
FarrowSure®   GOLD
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5248
    	
 
    	
FarrowSure   GOLD
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5206
    	
 
    	
FarrowSure®   GOLD B
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2223
    	
 
    	
Suvaxyn®   P
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2227
    	
 
    	
Suvaxyn®   PLE
    	
 
    	
 
    	
35
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2228
    	
 
    	
Suvaxyn   PLE
    	
 
    	
 
    	
150
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2230
    	
 
    	
Suvaxyn®   PLE+B
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2217
    	
 
    	
Suvaxyn®   LE+B
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4402
    	
 
    	
LitterGuard®
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4410
    	
 
    	
LitterGuard®   LT-C
    	
 
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4452
    	
 
    	
LitterGuard   LT-C
    	
 
    	
 
    	
250
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
SWINE LARGE ANIMAL VIALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8189
    	
 
    	
Draxxin®   Injectable Solution
    	
Rx
    	
 
    	
50 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8174
    	
 
    	
Draxxin   Injectable Solution
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8175
    	
 
    	
Draxxin   Injectable Solution
    	
Rx
    	
 
    	
250 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8176
    	
 
    	
Draxxin   Injectable Solution
    	
Rx
    	
 
    	
500 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1505
    	
 
    	
EXCEDE®   for Swine
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1431
    	
 
    	
Excenel®   RTU Sterile Suspension
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1436
    	
 
    	
Linco-Spectin®
    	
Rx
    	
 
    	
20 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1450
    	
 
    	
Lincomix®   100 mg Injectable
    	
 
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1451
    	
 
    	
Lincomix   300 mg Injectable
    	
 
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1455
    	
 
    	
Lutalyse®   Sterile Solution
    	
Rx
    	
 
    	
30 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1504
    	
 
    	
Lutalyse   Sterile Solution
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1465
    	
 
    	
Naxcel®   Sterile Powder
    	
Rx
    	
 
    	
lfl
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1466
    	
 
    	
Naxcel   Sterile Powder
    	
Rx
    	
 
    	
4q
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1463
    	
 
    	
Sterile   Water
    	
 
    	
 
    	
80 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1478
    	
 
    	
Predef®   2X
    	
Rx
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7897
    	
 
    	
Dectomax®   1% Injectable
    	
 
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8186
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
 
    	
200 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7899
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
 
    	
500 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7959
    	
 
    	
Liquamycin®   LA-200®
    	
 
    	
 
    	
100 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7960
    	
 
    	
Liquamycin   LA-200
    	
 
    	
 
    	
250 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7961
    	
 
    	
Liquamycin   LA-200
    	
 
    	
 
    	
500 mL
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1452
    	
 
    	
Lincomix®   Soluble Powder
    	
 
    	
 
    	
160 g
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1453
    	
 
    	
Lincomix   Soluble Powder
    	
 
    	
 
    	
480 g
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1454
    	
 
    	
LS50
    	
 
    	
 
    	
75 g
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
SWINE-FEED MEDICATIONS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1447
    	
 
    	
Lincomix®   20
    	
 
    	
 
    	
501b
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1448
    	
 
    	
Lincomix®   50
    	
 
    	
 
    	
501b
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

*Product skus will be discontinued once inventory is depleted.

**Product skus will become available once inventory of old skus is depleted.

***pH1N1 product will launch Q1 2010.

 

13

 

SCHEDULE B
 LIST OF STRATEGIC ACCOUNTS

 

“PARTICIPATING CUSTOMERS (Veterinarians, Dealers, Producers, and Strategic Producers) will be clearly identified with current updates within the Leaders’ Edge Enrollment Notifications that are regularly posted to the Pfizer AH Partners website www.pfizerahartners.com.

 

	
Narc ID
    	
 
    	
Name
    	
 
    	
Address
    	
 
    	
City
    	
 
    	
State
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    

 

 

	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    
	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
/*/
    

 

15

 

SCHEDULE C

 

SUGGESTED RESALE PRICE LIST AND DISTRIBUTOR PRICING

 

CATTLE SUGGESTED RETAIL PRICING

EFFECTIVE JANUARY 1, 2010

 

	
ITEM
   NUMBER
    	
 
    	
ITEM DESCRIPTION
    	
 
    	
SIZE
    	
 
    	
CASE
   QUANTITY
    	
 
    	
SUGGESTED
   RETAIL
   PRICE
    
	
 
    	
 
    	
BIOLOGICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4252
    	
 
    	
Bovi-Shield®   BRSV
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4256
    	
 
    	
Bovi-Shield   BRSV
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5194
    	
 
    	
Bovi-Shield   GOLD® 4
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5195
    	
 
    	
Bovi-Shield   GOLD 4
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5199
    	
 
    	
Bovi-Shield   GOLD® 5
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    
	
5196
    	
 
    	
Bovi-Shield   GOLD 5
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5197
    	
 
    	
Bovi-Shield   GOLD 5
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5211
    	
 
    	
Bovi-Shield   GOLD® FP® 5 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5212
    	
 
    	
Bovi-Shield   GOLD FP 5 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5321
    	
 
    	
Bovi-Shield   GOLD® FP® 5 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5322
    	
 
    	
Bovi-Shield   GOLD FP 5 ††
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5112
    	
 
    	
Bovi-Shield   GOLD® FP® 5 L5 †
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    
	
5113
    	
 
    	
Bovi-Shield   GOLD FP 5 L5 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5114
    	
 
    	
Bovi-Shield   GOLD FP 5 L5 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5323
    	
 
    	
Bovi-Shield   GOLD® FP® 5 L5 ††
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    
	
5324
    	
 
    	
Bovi-Shield   GOLD FP 5 L5 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5325
    	
 
    	
Bovi-Shield   GOLD FP 5 L5 ††
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5115
    	
 
    	
Bovi-Shield   GOLD® FP® 5 VL5 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5116
    	
 
    	
Bovi-Shield   GOLD FP 5 VL5 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5326
    	
 
    	
Bovi-Shield   GOLD® FP® 5 VL5 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5327
    	
 
    	
Bovi-Shield   GOLD FP 5 VL5 ††
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5253
    	
 
    	
Bovi-Shield   GOLD® FP® 5 L5 HB
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5254
    	
 
    	
Bovi-Shield   GOLD FP 5 L5 HB
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5255
    	
 
    	
Bovi-Shield   GOLD® FP® 5 VL5 HB
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    
	
5256
    	
 
    	
Bovi-Shield   GOLD FP 5 VL5 HB
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5191
    	
 
    	
Bovi-Shield   GOLD® IBR-BVD
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
4179
    	
 
    	
Bovi-Shield®   IBR
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
4002
    	
 
    	
Calf-Guard®
    	
 
    	
1
    	
 
    	
750
    	
 
    	
/*/
    
	
4143
    	
 
    	
CattleMaster®   4+VL5
    	
 
    	
5
    	
 
    	
100
    	
 
    	
/*/
    
	
4144
    	
 
    	
CattleMaster   4+VL5
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    
	
4145
    	
 
    	
CattleMaster   4+VL5
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    
	
5094
    	
 
    	
CattleMaster®   GOLDTM FP® 5
    	
 
    	
5
    	
 
    	
100
    	
 
    	
/*/
    
	
5095
    	
 
    	
CattleMaster   GOLD FP 5
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    
	
5096
    	
 
    	
CattleMaster   GOLD FP 5
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    
	
5124
    	
 
    	
CattleMaster®   GOLDTM FP® 5 L5
    	
 
    	
5
    	
 
    	
100
    	
 
    	
/*/
    
	
5125
    	
 
    	
CattleMaster   GOLD FP 5 L5
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    
	
5126
    	
 
    	
CattleMaster   GOLD FP 5 L5
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    
	
1434
    	
 
    	
E.coli   Bacterin- J-5TM Strain
    	
 
    	
20
    	
 
    	
42
    	
 
    	
/*/
    
	
1435
    	
 
    	
E.coli   Bacterin- J-5 Strain
    	
 
    	
50
    	
 
    	
36
    	
 
    	
/*/
    
	
4475
    	
 
    	
Leptoferm-5®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4477
    	
 
    	
Leptoferm-5
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
4988
    	
 
    	
One   Shot®
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    

 

 

	
4991
    	
 
    	
One   Shot
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4993
    	
 
    	
One   Shot
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5074
    	
 
    	
One   Shot Ultra® 7
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5075
    	
 
    	
One   Shot Ultra 7
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5076
    	
 
    	
One   Shot Ultra® 8
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5077
    	
 
    	
One   Shot Ultra 8
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5117
    	
 
    	
PregGuard®   GOLD FP® 10 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5118
    	
 
    	
PregGuard   GOLD FP 10 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5328
    	
 
    	
PregGuard®   GOLD FP® 10 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5329
    	
 
    	
PregGuard   GOLD FP 10 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
4308
    	
 
    	
Resvac®   4/Somubac®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4307
    	
 
    	
Resvac   4/Somubac
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
5241
    	
 
    	
ScourGuard®   4K †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5242
    	
 
    	
ScourGuard   4K †
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5243
    	
 
    	
ScourGuard®   4KC†
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5244
    	
 
    	
ScourGuard   4KC †
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5331
    	
 
    	
ScourGuard®   4K ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5332
    	
 
    	
ScourGuard   4K ††
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5333
    	
 
    	
ScourGuard®   4KC ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5334
    	
 
    	
ScourGuard   4KC ††
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
4255
    	
 
    	
Somubac®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4254
    	
 
    	
Somubac
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5088
    	
 
    	
Spirovac®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5090
    	
 
    	
Spirovac
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5200
    	
 
    	
Spirovac®   L5
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5201
    	
 
    	
Spirovac   L5
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5202
    	
 
    	
Spirovac®   VL5
    	
 
    	
10
    	
 
    	
80
    	
 
    	
/*/
    
	
5203
    	
 
    	
Spirovac   VL5
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
4890
    	
 
    	
StayBredTM   VL5
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4892
    	
 
    	
StayBred   VL5
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
4904
    	
 
    	
TSV-2®
    	
 
    	
1
    	
 
    	
750
    	
 
    	
/*/
    
	
4909
    	
 
    	
TSV-2
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4912
    	
 
    	
TSV-2
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    
	
4913
    	
 
    	
TSV-2
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    
	
4381
    	
 
    	
Ultrabac®   7
    	
 
    	
10
    	
 
    	
192
    	
 
    	
/*/
    
	
4379
    	
 
    	
Ultrabac   7
    	
 
    	
50
    	
 
    	
48
    	
 
    	
/*/
    
	
4380
    	
 
    	
Ultrabac   7
    	
 
    	
200
    	
 
    	
12
    	
 
    	
/*/
    
	
4384
    	
 
    	
Ultrabac®   7/Somubac®
    	
 
    	
10
    	
 
    	
192
    	
 
    	
/*/
    
	
4382
    	
 
    	
Ultrabac   7/Somubac
    	
 
    	
50
    	
 
    	
48
    	
 
    	
/*/
    
	
4383
    	
 
    	
Ultrabac   7/Somubac
    	
 
    	
200
    	
 
    	
12
    	
 
    	
/*/
    
	
4387
    	
 
    	
Ultrabac-8®
    	
 
    	
10
    	
 
    	
192
    	
 
    	
/*/
    
	
4385
    	
 
    	
Ultrabac-8
    	
 
    	
50
    	
 
    	
48
    	
 
    	
/*/
    
	
4386
    	
 
    	
Ultrabac-8
    	
 
    	
200
    	
 
    	
12
    	
 
    	
/*/
    
	
4388
    	
 
    	
Ultrabac®   CD
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
4371
    	
 
    	
Ultrabac   CD
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5062
    	
 
    	
UltraChoice®   7
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5063
    	
 
    	
UltraChoice   7
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5064
    	
 
    	
UltraChoice   7
    	
 
    	
250
    	
 
    	
12
    	
 
    	
/*/
    
	
5065
    	
 
    	
UltraChoice®   8
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    
	
5066
    	
 
    	
UltraChoice   8
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
5067
    	
 
    	
UltraChoice   8
    	
 
    	
250
    	
 
    	
12
    	
 
    	
/*/
    
	
5061
    	
 
    	
UltraChoice®   CD
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    
	
4937
    	
 
    	
Vibrin®
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    

 

17

 

	
5330
    	
 
    	
SolidBac®   Pinkeye IR/PR®
    	
 
    	
1 Pouch of 50
    	
 
    	
20 Pouches of 50
    	
 
    	
/*/
    
	
0110
    	
 
    	
Solidoser
    	
 
    	
Gun
    	
 
    	
10
    	
 
    	
/*/
    
	
SBC09003
    	
 
    	
Solidoser   Replacement Needles
    	
 
    	
1 Bag of 5 Needles
    	
 
    	
100 Bags of 5
    	
 
    	
/*/
    
	
 
    	
 
    	
ANTI-INFECTIVES
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8171
    	
 
    	
A180®   
    	
Rx
    	
 
    	
100 mL
    	
 
    	
12
    	
 
    	
/*/
    
	
8172
    	
 
    	
A180   
    	
Rx
    	
 
    	
250 mL
    	
 
    	
6
    	
 
    	
/*/
    
	
8448
    	
 
    	
Albon®   Bolus
    	
 
    	
5gx50
    	
 
    	
12
    	
 
    	
/*/
    
	
8449
    	
 
    	
Albon   Bolus
    	
 
    	
15 g x 12
    	
 
    	
12
    	
 
    	
/*/
    
	
8450
    	
 
    	
Albon   Bolus
    	
 
    	
15 g x 50
    	
 
    	
6
    	
 
    	
/*/
    
	
8189
    	
 
    	
Draxxin®   Injectable Solution 
    	
Rx
    	
 
    	
50 mL
    	
 
    	
40
    	
 
    	
/*/
    
	
8174
    	
 
    	
Draxxin   Injectable Solution 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
12
    	
 
    	
/*/
    
	
8175
    	
 
    	
Draxxin   Injectable Solution 
    	
Rx
    	
 
    	
250 mL
    	
 
    	
6
    	
 
    	
/*/
    
	
8176
    	
 
    	
Draxxin   Injectable Solution 
    	
Rx
    	
 
    	
500 mL
    	
 
    	
6
    	
 
    	
/*/
    
	
1506
    	
 
    	
Excede®   Sterile Suspension 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
10
    	
 
    	
/*/
    
	
1431
    	
 
    	
Excenel®   RTU Sterile Suspension 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
10
    	
 
    	
/*/
    
	
7959
    	
 
    	
Liquamycin®   LA-200®
    	
 
    	
100 mL
    	
 
    	
24
    	
 
    	
/*/
    
	
7960
    	
 
    	
Liquamycin   LA-200
    	
 
    	
250 mL
    	
 
    	
12
    	
 
    	
/*/
    
	
7961
    	
 
    	
Liquamycin   LA-200
    	
 
    	
500 mL
    	
 
    	
6
    	
 
    	
/*/
    
	
1465
    	
 
    	
Naxcel®   Sterile Powder 
    	
Rx
    	
 
    	
1g
    	
 
    	
48
    	
 
    	
/*/
    
	
1466
    	
 
    	
Naxcel   Sterile Powder
    	
Rx
    	
 
    	
4g
    	
 
    	
36
    	
 
    	
/*/
    
	
1463
    	
 
    	
Sterile   Water*
    	
 
    	
80 mL
    	
 
    	
72
    	
 
    	
/*/
    
	
1464
    	
 
    	
Sterile   Water
    	
 
    	
20 mL
    	
 
    	
288
    	
 
    	
/*/
    
	
7948
    	
 
    	
Terramycin®   Scour Tabs
    	
 
    	
250 mg, 24/btl
    	
 
    	
12
    	
 
    	
/*/
    
	
7949
    	
 
    	
Terramycin   Scour Tabs
    	
 
    	
250 mg, 100/btl
    	
 
    	
12
    	
 
    	
/*/
    
	
 
    	
 
    	
LINCOMIX
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1452
    	
 
    	
Lincomix®   Soluble Powder
    	
 
    	
160 g
    	
 
    	
12
    	
 
    	
/*/
    
	
1453
    	
 
    	
Lincomix   Soluble Powder
    	
 
    	
480 g
    	
 
    	
6
    	
 
    	
/*/
    
	
1436
    	
 
    	
Linco-Spectin®   
    	
Rx
    	
 
    	
20 mL
    	
 
    	
72
    	
 
    	
/*/
    
	
 
    	
 
    	
MASTITIS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1403
    	
 
    	
Albadry   Plus®
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    
	
1404
    	
 
    	
Albadry   Plus
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    
	
2004
    	
 
    	
Nolvasan®   Teat Dip
    	
 
    	
lgal
    	
 
    	
4
    	
 
    	
/*/
    
	
8169
    	
 
    	
Orbeseal®
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    
	
1475
    	
 
    	
Pirsue®   Sterile Solution 
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    
	
1476
    	
 
    	
Pirsue   Sterile Solution 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    
	
1480
    	
 
    	
Quartermaster®   
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    
	
1481
    	
 
    	
Quartermaster   (Bulk Pack) 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    
	
1507
    	
 
    	
Spectramast®   LC 
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    
	
1510
    	
 
    	
Spectramast   LC 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    
	
1508
    	
 
    	
Spectramast®   DC 
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    
	
1511
    	
 
    	
Spectramast   DC 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    
	
 
    	
 
    	
PARASITICIDES
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
7897
    	
 
    	
Dectomax®   1% Injectable
    	
 
    	
100 mL
    	
 
    	
24
    	
 
    	
/*/
    
	
8186
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
200 mL
    	
 
    	
12
    	
 
    	
/*/
    
	
7899
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
500 mL
    	
 
    	
6
    	
 
    	
/*/
    
	
5057
    	
 
    	
Dectomax   Injectable Dial-A-Dose Syringe
    	
 
    	
Syringe
    	
 
    	
50
    	
 
    	
/*/
    
	
7892
    	
 
    	
Dectomax®   Pour-On
    	
 
    	
250 mL
    	
 
    	
10
    	
 
    	
/*/
    
	
7893
    	
 
    	
Dectomax   Pour-On
    	
 
    	
1L
    	
 
    	
10
    	
 
    	
/*/
    
	
7894
    	
 
    	
Dectomax   Pour-On
    	
 
    	
2.5 L
    	
 
    	
4
    	
 
    	
/*/
    
	
7895
    	
 
    	
Dectomax   Pour-On
    	
 
    	
5L
    	
 
    	
2
    	
 
    	
/*/
    
	
0109
    	
 
    	
Dectomax   Pour-On Gun
    	
 
    	
Gun
    	
 
    	
12
    	
 
    	
/*/
    
	
7030
    	
 
    	
Durasect®
    	
 
    	
lgal
    	
 
    	
4
    	
 
    	
/*/
    
	
7031
    	
 
    	
Durasect®   II
    	
 
    	
450 mL
    	
 
    	
12
    	
 
    	
/*/
    

 

18

 

	
7032
    	
 
    	
Durasect   II
    	
 
    	
900 mL
    	
 
    	
6
    	
 
    	
/*/
    
	
8783
    	
 
    	
Valbazen®
    	
 
    	
500 mL
    	
 
    	
12
    	
 
    	
/*/
    
	
8784
    	
 
    	
Valbazen
    	
 
    	
1L
    	
 
    	
12
    	
 
    	
/*/
    
	
8785
    	
 
    	
Valbazen
    	
 
    	
5L
    	
 
    	
2
    	
 
    	
/*/
    
	
0325
    	
 
    	
Valbazen   20 mL Gun with Fixed Hook
    	
 
    	
Gun
    	
 
    	
25
    	
 
    	
/*/
    
	
0323
    	
 
    	
Valbazen   50 mL Gun with Fixed Hook
    	
 
    	
Gun
    	
 
    	
20
    	
 
    	
/*/
    
	
0809
    	
 
    	
Valbazen   50 mL Floating Hook
    	
 
    	
Floating Hook
    	
 
    	
20
    	
 
    	
/*/
    
	
0823
    	
 
    	
Valbazen   Power Dose Gun 20 mL
    	
 
    	
Gun
    	
 
    	
20
    	
 
    	
/*/
    
	
 
    	
 
    	
REPRODUCTION
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1421
    	
 
    	
EAZI-Breed   CIDR Insert
    	
 
    	
Bag of 10
    	
 
    	
50 Bags of 10
    	
 
    	
/*/
    
	
1420
    	
 
    	
EAZI-BreedTM   CIDR® Applicator
    	
 
    	
Applicator
    	
 
    	
50
    	
 
    	
/*/
    
	
1518
    	
 
    	
EAZI-Breed   CIDR Green Applicator
    	
 
    	
Applicator
    	
 
    	
50
    	
 
    	
/*/
    
	
1533
    	
 
    	
EAZI-Breed   CIDR G Insert (Sheep)
    	
 
    	
Bag of 20
    	
 
    	
5 Bags of 20
    	
 
    	
/*/
    
	
0135
    	
 
    	
EAZI-BreedTM   CIDR® G Applicator
    	
 
    	
Applicator
    	
 
    	
50
    	
 
    	
/*/
    
	
2001
    	
 
    	
Factrel®   
    	
Rx
    	
 
    	
20 mL
    	
 
    	
24
    	
 
    	
/*/
    
	
1455
    	
 
    	
Lutalyse®   Sterile Solution 
    	
Rx
    	
 
    	
30 mL
    	
 
    	
48
    	
 
    	
/*/
    
	
1504
    	
 
    	
Lutalyse   Sterile Solution 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
10
    	
 
    	
/*/
    
	
2003
    	
 
    	
Nolvalube®
    	
 
    	
8 1b
    	
 
    	
4
    	
 
    	
/*/
    
	
 
    	
 
    	
PRODUCTION
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1458
    	
 
    	
MGA®   200 Premix
    	
 
    	
50 lb Bag
    	
 
    	
1
    	
 
    	
/*/
    
	
1459
    	
 
    	
MGA®   500 Liquid Premix
    	
 
    	
40 lb Drum
    	
 
    	
1
    	
 
    	
/*/
    
	
2016
    	
 
    	
Synovex®   C
    	
 
    	
Box( 10-10 ds clips)
    	
 
    	
50
    	
 
    	
/*/
    
	
2014
    	
 
    	
Synovex   C
    	
 
    	
Display (20 x 2-10 ds clips)
    	
 
    	
10
    	
 
    	
/*/
    
	
2017
    	
 
    	
Synovex®   Choice
    	
 
    	
Box(10-10 ds clips)
    	
 
    	
50
    	
 
    	
/*/
    
	
2018
    	
 
    	
Synovex®   H
    	
 
    	
Box( 10-10 ds clips)
    	
 
    	
50
    	
 
    	
/*/
    
	
2019
    	
 
    	
Synovex®   Plus
    	
 
    	
Box( 10-10 ds clips)
    	
 
    	
10
    	
 
    	
/*/
    
	
2022
    	
 
    	
Synovex®   S
    	
 
    	
Box( 10-10 ds clips)
    	
 
    	
50
    	
 
    	
/*/
    
	
0163
    	
 
    	
Synovex   Revolver §
    	
 
    	
Revolver
    	
 
    	
20
    	
 
    	
/*/
    
	
0159
    	
 
    	
Synovex   SX10 Implant Gun §
    	
 
    	
Gun
    	
 
    	
20
    	
 
    	
/*/
    
	
 
    	
 
    	
OTHER PHARMACEUTICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8152
    	
 
    	
Entrolyte®   H.E.
    	
 
    	
178 g
    	
 
    	
40
    	
 
    	
/*/
    
	
2002
    	
 
    	
Hog &   Cattle Vitamins & Electrolytes
    	
 
    	
8oz
    	
 
    	
40
    	
 
    	
/*/
    
	
1478
    	
 
    	
Predef®   2X 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
6
    	
 
    	
/*/
    
	
8112
    	
 
    	
Re-Sorb®
    	
 
    	
12
    	
 
    	
6
    	
 
    	
/*/
    
	
8142
    	
 
    	
Re-Sorb
    	
 
    	
72
    	
 
    	
1
    	
 
    	
/*/
    
	
8620
    	
 
    	
Therabloat®
    	
 
    	
2oz
    	
 
    	
144
    	
 
    	
/*/
    

 

	
 
    	
 
    	
†   Product skus will be discontinued once inventory is depleted. 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
††   Product skus will become available once inventory of old skus is depleted.
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
*   Sterile water sold only with Naxcel 4 g in like quantities or less.
    	
 
    	
 
    	
 
    

 

19

 

CATTLE DISTRIBUTOR

 

EFFECTIVE JANUARY 1, 2010 TO DECEMBER 31, 2010

 

	
ITEM
   NUMBER
    	
 
    	
ITEM DESCRIPTION
    	
 
    	
SIZE
    	
 
    	
CASE
   QUANTITY
    	
 
    	
DISTRIBUTOR
   PRICE
    	
 
    	
RETURN GOODS
   PRICE
    	
 
    
	
 
    	
 
    	
BIOLOGICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4252
    	
 
    	
Bovi-Shield® BRSV
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4256
    	
 
    	
Bovi-Shield BRSV
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5194
    	
 
    	
Bovi-Shield GOLD® 4
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5195
    	
 
    	
Bovi-Shield GOLD 4
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5199
    	
 
    	
Bovi-Shield GOLD® 5
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5196
    	
 
    	
Bovi-Shield GOLD 5
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5197
    	
 
    	
Bovi-Shield GOLD 5
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5211
    	
 
    	
Bovi-Shield GOLD® FP® 5 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5212
    	
 
    	
Bovi-Shield GOLD FP 5 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5321
    	
 
    	
Bovi-Shield GOLD® FP® 5 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5322
    	
 
    	
Bovi-Shield GOLD FP 5 tt
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5112
    	
 
    	
Bovi-Shield GOLD® FP® 5 L5 †
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5113
    	
 
    	
Bovi-Shield GOLD FP 5 L5 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5114
    	
 
    	
Bovi-Shield GOLD FP 5 L5 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5323
    	
 
    	
Bovi-Shield GOLD® FP® 5 L5 ††
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5324
    	
 
    	
Bovi-Shield GOLD FP 5 L5 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5325
    	
 
    	
Bovi-Shield GOLD FP 5 L5 ††
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5115
    	
 
    	
Bovi-Shield GOLD® FP® 5 VL5 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5116
    	
 
    	
Bovi-Shield GOLD FP 5 VL5 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5326
    	
 
    	
Bovi-Shield GOLD® FP® 5 VL5 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5327
    	
 
    	
Bovi-Shield GOLD FP 5 VL5 ††
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5253
    	
 
    	
Bovi-Shield GOLD® FP® 5 L5 HB
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5254
    	
 
    	
Bovi-Shield GOLD FP 5 L5 HB
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5255
    	
 
    	
Bovi-Shield GOLD® FP® 5 VL5 HB
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5256
    	
 
    	
Bovi-Shield GOLD FP 5 VL5 HB
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5191
    	
 
    	
Bovi-Shield GOLD® IBR-BVD
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4179
    	
 
    	
Bovi-Shield® IBR
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4002
    	
 
    	
Calf-Guard®
    	
 
    	
1
    	
 
    	
750
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4143
    	
 
    	
CattleMaster® 4+VL5
    	
 
    	
5
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4144
    	
 
    	
CattleMaster 4+VL5
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4145
    	
 
    	
CattleMaster 4+VL5
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5094
    	
 
    	
CattleMaster® GOLDTM FP® 5
    	
 
    	
5
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5095
    	
 
    	
CattleMaster GOLD FP 5
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5096
    	
 
    	
CattleMaster GOLD FP 5
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5124
    	
 
    	
CattleMaster® GOLDTM FP® 5 L5
    	
 
    	
5
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5125
    	
 
    	
CattleMaster GOLD FP 5 L5
    	
 
    	
10
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5126
    	
 
    	
CattleMaster GOLD FP 5 L5
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1434
    	
 
    	
E.coli Bacterin- J-5TM Strain
    	
 
    	
20
    	
 
    	
42
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1435
    	
 
    	
E.coli Bacterin- J-5 Strain
    	
 
    	
50
    	
 
    	
36
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4475
    	
 
    	
Leptoferm-5®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4477
    	
 
    	
Leptoferm-5
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4988
    	
 
    	
One Shot®
    	
 
    	
5
    	
 
    	
200
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4991
    	
 
    	
One Shot
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4993
    	
 
    	
One Shot
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5074
    	
 
    	
One Shot Ultra® 7
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5075
    	
 
    	
One Shot Ultra 7
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

 

 

	
 
    	
 
    	
BIOLOGICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5076
    	
 
    	
One   Shot Ultra® 8
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5077
    	
 
    	
One   Shot Ultra 8
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5117
    	
 
    	
PregGuard®   GOLD FP® 10 †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5118
    	
 
    	
PregGuard   GOLD FP 10 †
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5328
    	
 
    	
PregGuard®   GOLD FP® 10 ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5329
    	
 
    	
PregGuard   GOLD FP 10 ††
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4308
    	
 
    	
Resvac®   4/Somubac®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4307
    	
 
    	
Resvac   4/Somubac
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5241
    	
 
    	
ScourGuard®   4K †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5242
    	
 
    	
ScourGuard   4K†
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5243
    	
 
    	
ScourGuard®   4KC †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5244
    	
 
    	
ScourGuard   4KC †
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5331
    	
 
    	
ScourGuard®   4K ††
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5332
    	
 
    	
ScourGuard   4K ††
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5333
    	
 
    	
ScourGuard®   4KC †
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5334
    	
 
    	
ScourGuard   4KC ††
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4255
    	
 
    	
Somubac®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4254
    	
 
    	
Somubac
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5088
    	
 
    	
Spirovac®
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5090
    	
 
    	
Spirovac
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5200
    	
 
    	
Spirovac®   L5
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5201
    	
 
    	
Spirovac   L5
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5202
    	
 
    	
Spirovac®   VL5
    	
 
    	
10
    	
 
    	
80
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5203
    	
 
    	
Spirovac   VL5
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4890
    	
 
    	
StayBredTM   VL5
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4892
    	
 
    	
StayBred   VL5
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4904
    	
 
    	
TSV-2®
    	
 
    	
1
    	
 
    	
750
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4909
    	
 
    	
1   TSV-2
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4912
    	
 
    	
TSV-2
    	
 
    	
25
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4913
    	
 
    	
TSV-2
    	
 
    	
50
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4381
    	
 
    	
Ultrabac®   7
    	
 
    	
10
    	
 
    	
192
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4379
    	
 
    	
Ultrabac   7
    	
 
    	
50
    	
 
    	
48
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4380
    	
 
    	
Ultrabac   7
    	
 
    	
200
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4384
    	
 
    	
Ultrabac®   7/Somubac®
    	
 
    	
10
    	
 
    	
192
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4382
    	
 
    	
Ultrabac   7/Somubac
    	
 
    	
50
    	
 
    	
48
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4383
    	
 
    	
Ultrabac   7/Somubac
    	
 
    	
200
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4387
    	
 
    	
Ultrabac-8®
    	
 
    	
10
    	
 
    	
192
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4385
    	
 
    	
Ultrabac-8
    	
 
    	
50
    	
 
    	
48
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4386
    	
 
    	
Ultrabac-8
    	
 
    	
200
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4388
    	
 
    	
Ultrabac®   CD
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4371
    	
 
    	
Ultrabac   CD
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5062
    	
 
    	
UltraChoice®   7
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5063
    	
 
    	
UltraChoice   7
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5064
    	
 
    	
UltraChoice   7
    	
 
    	
250
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5065
    	
 
    	
UltraChoice®   8
    	
 
    	
10
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5066
    	
 
    	
UltraChoice   8
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5067
    	
 
    	
UltraChoice   8
    	
 
    	
250
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5061
    	
 
    	
UltraChoice®   CD
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
4937
    	
 
    	
Vibrin®
    	
 
    	
50
    	
 
    	
100
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5330
    	
 
    	
SolidBac®   Pinkeye IR/PR®
    	
 
    	
1 Pouch of 50
    	
 
    	
20 Pouches of 50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0110
    	
 
    	
SoliDoser®   §
    	
 
    	
Gun
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
SBC09003
    	
 
    	
SoliDoser   Replacement Needles
    	
 
    	
1 Bag of 5 
    	
 
    	
100 Bags of 5
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

21

 

	
 
    	
 
    	
 
    	
 
    	
Needles
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
ANTI-INFECTIVES
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8171
    	
 
    	
A180®   
    	
Rx
    	
 
    	
100 mL
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8172
    	
 
    	
A180   
    	
Rx
    	
 
    	
250 mL
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8448
    	
 
    	
Albon®   Bolus
    	
 
    	
 
    	
5gx50
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8449
    	
 
    	
Albon   Bolus
    	
 
    	
 
    	
15 g x 12
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8450
    	
 
    	
Albon   Bolus
    	
 
    	
 
    	
15 g x 50
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8189
    	
 
    	
Draxxin®   Injectable Solution 
    	
Rx
    	
 
    	
50 mL
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8174
    	
 
    	
Draxxin   Injectable Solution 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8175
    	
 
    	
Draxxin   Injectable Solution 
    	
Rx
    	
 
    	
250 mL
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8176
    	
 
    	
Draxxin   Injectable Solution 
    	
Rx
    	
 
    	
500 mL
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1506
    	
 
    	
Excede®   Sterile Suspension 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1431
    	
 
    	
Excenel®   RTU Sterile Suspension 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7959
    	
 
    	
Liquamycin®   LA-200®
    	
 
    	
 
    	
100 mL
    	
 
    	
24
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7960
    	
 
    	
Liquamycin   LA-200
    	
 
    	
 
    	
250 mL
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7961
    	
 
    	
Liquamycin   LA-200
    	
 
    	
 
    	
500 mL
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1465
    	
 
    	
Naxcel®   Sterile Powder 
    	
Rx
    	
 
    	
1g
    	
 
    	
48
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1466
    	
 
    	
Naxcel   Sterile Powder 
    	
Rx
    	
 
    	
4g
    	
 
    	
36
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1463
    	
 
    	
Sterile   Water
    	
 
    	
 
    	
80 mL
    	
 
    	
72
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1464
    	
 
    	
Sterile   Water
    	
 
    	
 
    	
20 mL
    	
 
    	
288
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7948
    	
 
    	
Terramycin®   Scour Tabs
    	
 
    	
 
    	
250 mg, 24/btl
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7949
    	
 
    	
Terramycin   Scour Tabs
    	
 
    	
 
    	
250 mg, 100/btl
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
 
    	
 
    	
LINCOMIX
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1452
    	
 
    	
Lincomix®   Soluble Powder
    	
 
    	
 
    	
160 g
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1453
    	
 
    	
Lincomix   Soluble Powder
    	
 
    	
 
    	
480 g
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1436
    	
 
    	
Linco-Spectin®   
    	
Rx
    	
 
    	
20 mL
    	
 
    	
72
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
MASTITIS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1403
    	
 
    	
Albadry   Plus®
    	
 
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1404
    	
 
    	
Albadry   Plus
    	
 
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2004
    	
 
    	
Nolvasan®   Teat Dip
    	
 
    	
 
    	
lgal
    	
 
    	
4
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8169
    	
 
    	
Orbeseal®
    	
 
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1475
    	
 
    	
Pirsue®   Sterile Solution 
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1476
    	
 
    	
Pirsue   Sterile Solution 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1480
    	
 
    	
Quartermaster®   
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1481
    	
 
    	
Quartermaster   (Bulk Pack) 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1507
    	
 
    	
Spectramast®   LC 
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1510
    	
 
    	
Spectramast   LC 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1508
    	
 
    	
Spectramast®   DC 
    	
Rx
    	
 
    	
Box (12 syringes)
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1511
    	
 
    	
Spectramast   DC 
    	
Rx
    	
 
    	
Pail (144 syringes)
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
 
    	
 
    	
PARASITICIDES
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
7897
    	
 
    	
Dectomax®   1% Injectable
    	
 
    	
100 mL
    	
 
    	
24
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

22

 

	
8186
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
200 mL
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7899
    	
 
    	
Dectomax   1% Injectable
    	
 
    	
500 mL
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
5057
    	
 
    	
Dectomax   Injectable Dial-A-Dose Syringe §
    	
 
    	
Syringe
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7892
    	
 
    	
Dectomax®   Pour-On
    	
 
    	
250 mL
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7893
    	
 
    	
Dectomax   Pour-On
    	
 
    	
1L
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7894
    	
 
    	
Dectomax   Pour-On
    	
 
    	
2.5 L
    	
 
    	
4
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7895
    	
 
    	
Dectomax   Pour-On
    	
 
    	
5L
    	
 
    	
2
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0109
    	
 
    	
Dectomax   Pour-On Gun §
    	
 
    	
Gun
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7030
    	
 
    	
Durasect®
    	
 
    	
lgal
    	
 
    	
4
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7031
    	
 
    	
Durasect®   II
    	
 
    	
450 mL
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
7032
    	
 
    	
Durasect   II
    	
 
    	
900 mL
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8783
    	
 
    	
Valbazen®
    	
 
    	
500 mL
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8784
    	
 
    	
Valbazen
    	
 
    	
1L
    	
 
    	
12
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8785
    	
 
    	
Valbazen
    	
 
    	
5L
    	
 
    	
2
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0325
    	
 
    	
Valbazen   20 mL Gun with Fixed Hook§
    	
 
    	
Gun
    	
 
    	
25
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0323
    	
 
    	
Valbazen   50 mL Gun with Fixed Hook§
    	
 
    	
Gun
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0809
    	
 
    	
Valbazen   50 mL Floating Hook §
    	
 
    	
Floating Hook
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0823
    	
 
    	
Valbazen   Power Dose Gun 20 mL §
    	
 
    	
Gun
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
 
    	
 
    	
REPRODUCTION
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1421
    	
 
    	
EAZI-Breed   CIDR Insert
    	
 
    	
Bag of 10
    	
 
    	
50 Bags of 10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1420
    	
 
    	
EAZI-BreedTM   CIDR® Applicator §
    	
 
    	
Applicator
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1518
    	
 
    	
EAZI-Breed   CIDR Green Applicator §
    	
 
    	
Applicator
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1533
    	
 
    	
EAZI-Breed   CIDR G Insert (Sheep)
    	
 
    	
Bag of 20
    	
 
    	
5 Bags of 20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0135
    	
 
    	
EAZI-BreedTM   CIDR® G Applicator (Sheep)§
    	
 
    	
Applicator
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2001
    	
 
    	
Factrel®
    	
 
    	
20 mL
    	
 
    	
24
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1455
    	
 
    	
Lutalyse®   Sterile Solution 
    	
Rx
    	
 
    	
30 mL
    	
 
    	
48
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1504
    	
 
    	
Lutalyse   Sterile Solution 
    	
Rx
    	
 
    	
100 mL
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2003
    	
 
    	
Nolvalube®
    	
 
    	
81b
    	
 
    	
4
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
 
    	
 
    	
PRODUCTION
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1458
    	
 
    	
MGA®   200 Premix
    	
 
    	
50 lb Bag
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1459
    	
 
    	
MGA®   500 Liquid Premix
    	
 
    	
40 lb Drum
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2016
    	
 
    	
Synovex®   C
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2014
    	
 
    	
Synovex   C
    	
 
    	
Display(20 x 2-10 ds Clips)
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2017
    	
 
    	
Synovex®   Choice
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2018
    	
 
    	
Synovex®   H
    	
 
    	
Box(10-10 ds Clips)-1
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2019
    	
 
    	
Synovex®   Plus
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
10
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2022
    	
 
    	
Synovex®   S
    	
 
    	
Box(10-10 ds Clips)
    	
 
    	
50
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
0163
    	
 
    	
Synovex   Revolver §
    	
 
    	
Revolver
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    

 

23

 

	
0159
    	
 
    	
Synovex   Sxl0 Implant Gun §
    	
 
    	
Implant Gun
    	
 
    	
20
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
 
    	
 
    	
OTHER   PHARMACEUTICALS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8152
    	
 
    	
Entrolyte®   H.E.
    	
 
    	
178 g
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
2002
    	
 
    	
Hog &   Cattle Vitamins & Electrolytes
    	
 
    	
8oz
    	
 
    	
40
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
1478
    	
 
    	
Predef®   2X  
    	
Rx
    	
 
    	
100 mL
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8112
    	
 
    	
Re-Sorb®
    	
 
    	
12
    	
 
    	
6
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8142
    	
 
    	
Re-Sorb
    	
 
    	
72
    	
 
    	
1
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
	
8620
    	
 
    	
Therabloat®
    	
 
    	
2oz
    	
 
    	
144
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    
													

 

† Product skus will be discontinued once inventory is depleted.

†† Product skus will become available once inventory of old skus is depleted.

§ Item may be received for free with a qualifying purchase.

Pfizer reserves the right to modify or discontinue this pricing at any time and for any reason.

Case quantities are subject to change.

 

24

 

SCHEDULE D

 

Section A

 

Fee for Logistics

 

	
Definitions:
    	
 
    	
“Fee   Eligible Products” shall mean those Pfizer Products listed in Schedule A   hereto for which a Fee payment will be made to WALCO in accordance with   paragraph 5.
    

 

1)                                      Pfizer shall pay to WALCO a fee for logistics (hereinafter, “Fee”) paid at a rate of (i) a differentiated percentage [see SCHEDULE E for breakdown] on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are producers (but not including Strategic Accounts), (ii) /*/ on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are veterinarians (but not including Strategic Accounts), and (iii) /*/ on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are Strategic Accounts.  For a Veterinarian to receive an RSA on Strategic Producer product sales, the Veterinarian must buy those product quantities directly from Pfizer Animal Health.  Such product purchases must be made within the timeframe of the reported sales to the Strategic Producer in order to receive a /*/ RSA for sales to Leaders’ Edge Strategic Producers.  The Veterinarian also must hold the accounts receivable on those products for the Strategic Producer.  The remaining product purchases to service Leaders’ Edge accounts or Non-Leaders’ Edge accounts may be sourced from an authorized Pfizer distributor or directly from Pfizer Animal Health.  The Fee is calculated on a Product by Product basis and based on the Product price contained in the Participating Customer’s SUGGESTED RESALE PRICE LIST in effect at the time of such Product purchase.  The Fee is contingent on WALCO fulfilling all conditions outlined in paragraph 4 of this Agreement.  The payments made pursuant to this Schedule D, Section A are not payable for sales to anyone other than PARTICIPATING CUSTOMERS.  The Fee is net of any difference between WALCO’s purchase price and the SUGGESTED RESALE PRICE LIST price.  WALCO shall only receive the payments set out in this Schedule D, Section A for sales to PARTICIPATING CUSTOMERS which are consummated after confirmation by Pfizer to WALCO that a customer is a PARTICIPATING CUSTOMER.

 

2)                                      Pfizer shall have the right to audit shipping records of WALCO to confirm delivery of Products to producers or veterinarians in order to assure proper Fee payments under paragraph 1 of this Schedule D, Section A.  Any material misrepresentations by WALCO related to paragraph 1 of this Schedule D, Section A and the party actually taking possession of the products shall void any payments due under paragraph 1 of this Schedule D, Section A.  In addition, WALCO recognizes that the Leaders Edge program is designed as an effective go-to market approach to selling for the benefit of veterinarians and/or dealers who add value in the transaction to their customers as well as value for those customers.  Blatant abuse of the intended structure of the Leaders Edge Program by WALCO (including, but not limited to, falsification of EDI data or establishing false business entities or inserting business entities that add no commercial value to end users purely to obtain additional Fee payments) will subject WALCO to potential forfeiture of all Fee’s paid on those transactions provided for in this Schedule D, Section A at the sole discretion of Pfizer.  Decisions made as a result of Pfizer’s investigations of

 

 

blatant abuse of the intended structure of Leaders Edge are solely Pfizer’s to make and forfeitures of Fees may happen retroactively in the form of credits against future Fee payments.

 

3)                                      The parties agree that WALCO will provide to Pfizer on request and within two (2) business days, proof of delivery on any suspicious (as determined by Pfizer) EDI transaction.  WALCO agrees that Pfizer shall be entitled to audit, either directly or through external auditors hired by Pfizer and upon reasonable notice by Pfizer, WALCO’s books and records for the purpose of determining the accuracy of EDI data for Pfizer Product sales communicated to Pfizer through Covansys.

 

4)                                      Products which are not listed in Schedule A do not qualify for Fee payments.  All such Products shall be purchased by WALCO on a buy sell basis.  If new sku’s are added to Schedule A, Pfizer will communicate this to WALCO on a quarterly basis.

 

26

 

SCHEDULE E

 

Cattle Swine Leaders Edge/Differentiated RSA

 

Effective January 1, 2010 through December 31, 2010 Leaders’ Edge Suppliers will receive a service fee (RSA) for sales to eligible Leaders’ Edge customers as indicated below.

 

RSA Payments

 

	
Sales To ->
    	
 
    	
LE Vet/Dealer
    	
 
    	
LE Strategic
   Producer
    	
 
    	
LE Producer
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Distributor
    	
 
    	
/*/
    	
 
    	
/*/
    	
 
    	
Variable   RSA (See Schedule A)
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Veterinarian
    	
 
    	
/*/
    	
 
    	
/*/
    	
*
    	
Variable   RSA (See Schedule A)
    	
 
    

 

** Veterinarians MUST purchase an equivalent amount of product direct from Pfizer Animal Health to be eligible for a /*/ RSA for sales to Leaders’ Edge Strategic Producers.

 

 

SCHEDULE F

 

Pfizer Returned Goods Policy & Procedure

 

AUDIENCE

 

Customer Service Operations, Finance, Marketing, & Field Force

 

SCOPE

 

Cattle, Swine, Equine, and CAD products purchased directly from Pfizer Animal Health may be returned for credit based on the current Pfizer Animal Health Return Goods Price List providing it is not outside the defined return window.  ONLY CAD products may be returned for exchange providing it is not outside the defined return window.

 

·                                         Cattle, Swine, Equine, and CAD products return window is defined as two months prior and six months beyond the product’s expiration date, (except Revolution 6pk and Rimadyl 180ct, which can be exchanged or credited six months prior to the products expiration date).

·                                          In addition, CAD products may also be returned 12 months after the invoice date for Return Goods Credit only provided that the product has not expired.

 

Cattle, Swine, and Equine Biologicals purchased directly from Pfizer Animal Health may be returned for credit based upon 100% of the customer’s prior calendar year’s pricing.  All other Cattle, Swine, and Equine products will receive credit based upon 90% of the customer’s prior calendar year’s pricing.

 

·                                          Exception #1:  Short dated products (defined as consistently shipping with 4-6 months dating or less, such as ScourGuard) may receive a return goods credit based upon 100% of customer’s current year’s pricing.

·                                          Exception #2:  Newly launched products not available the prior year, will follow the return policy as stated above but pricing will be based off of the current year.

 

Cad Products purchased directly from Pfizer Animal Health may be returned for credit at 75% of current list price or be exchanged for like product in full packaged quantities provided they are within the return window.

 

·                                          Exception #1:  Customers that receive discount pricing due to a contract may have terms per their contract stating they will receive returns pricing at 75% of invoice price.

 

Products sold on a non-returnable basis are not eligible for credit or exchange.  Products sold on a non-returnable basis include:  syringes, rabies tags, Unipet Nutritabs, Roccal-D, Plastic Dispensing Bags, Sterile Water, Terramycin-343, Terramycin Soluble Powder, Eazi-Breed CIDR, Lincomix Soluble Powder, Lincomix Feed, Neomix 325 Commercial Grade, LS 50, and MGA

 

 

A.           Products NOT eligible for exchange include:

 

1                                          Products not purchased directly from Pfizer Animal Health

2                                          Cattle, Swine, and Equine Products

3                                          Products outside the defined return window

4                                          Items returned in less than the original packaged unit (partials)

 

B.             Products NOT eligible for credit include:

 

1                                          Products not purchased directly from Pfizer Animal Health

2                                          Products outside the defined return window

3                                          Items returned in quantities less than the original packaged unit (partials), with the exception of small animal bioiogicals, Amoxi tablets, Clavamox tablets, Albon tablets, Primor, Zeniquin, Cestex, Anipryl, and Temaril-P. Partial returns of these items will be credited in 25% increments.

 

C.             Claims for Breakage or Shortage - Any obvious breakage or shortage must be brought to the attention of Pfizer Animal Health and the carrier.  This must also be noted when signing delivery documents.  Mis-shipments, shortages and concealed damages must be reported to Pfizer Animal Health within 15 business days for distribution (21 days for Veterinarians) from invoice date to receive full invoice credit.  Claims received after this timeframe will not be considered for credit.  Credits for damages and mis-shipments (i.e. CSR or warehouse error) will be matched up to the original invoice and credited at full invoice pricing.

 

D.            Discontinued Products - Discontinued products may not be returned for exchange but can be returned for credit at our current return’s price.  Return of discontinued product must meet all other return requirements detailed in this policy.

 

PROCEDURE

 

Pfizer AH Customer Service will make pick up arrangements for returns of outdated product purchased directly from Pfizer.  Veterinarians or Pfizer Territory Mangers should contact Customer Service to arrange for pick-up at 1-800-733-5500.  Returns for all other classes of trade should be sent freight prepaid to the Pfizer Returns Center located in Lee’s Summit, MO.

 

Customer Service and/or Pfizer Animal Health Territory Manager must complete the Merchandise Return Form (MRF) and forward along with the return shipment to the Pfizer Animal Health Returns Center at One Pfizer Way, Building 200, Lee’s Summit, MO 64081.  The MRF should be marked as credit or exchange, if the return shipment contains both product to be credited, and also product to be exchanged, a separate MRF should be completed for the credit and the exchange.  Credit or exchange will be issued only upon receipt of the product at the Pfizer Animal Health Returns Center.  Product should not be destroyed in the field.  The product must have been purchased directly from Pfizer Animal Health and within the defined returns window.

 

29

 

Distributor accounts should fax a copy of the completed MRF to Major Accounts at 1-800-228-5176 for returns authorization.  Once approved, a copy of the signed form will be faxed back to the distributor to be included in the return shipment.

 

30Exhibit 10.3

 

AMENDED AND RESTATED CREDIT AGREEMENT

 

made and entered into

 

as of September 26, 2006

 

by and among

 

WALCO INTERNATIONAL, INC.

a Delaware corporation (successor by merger to
 Walco International, Inc., a California corporation)

 

EACH OF THE CREDIT PARTIES WHICH IS NOW OR HEREAFTER A
 GUARANTOR HEREUNDER FROM TIME TO TIME,

 

EACH OF THE FINANCIAL INSTITUTIONS WHICH IS
 A SIGNATORY HERETO OR
 WHICH MAY FROM TIME TO TIME
 BECOME A PARTY HERETO,

 

JPMORGAN CHASE BANK, N.A.,

a national banking association
 as Administrative Agent for such Financial Institutions,

 

GENERAL ELECTRIC CAPITAL CORPORATION,

a Delaware corporation
 as Documentation Agent for such Financial Institutions,

 

and

 

J.P. MORGAN SECURITIES INC.,

as sole and exclusive Lead Arranger and Bookrunner

 

 

Index to Credit Agreement

 

	
 
    	
 
    	
 
    	
Page
    
	
1.
    	
Definitions
    	
1
    
	
 
    	
1.1
    	
Certain   Defined Terms
    	
1
    
	
 
    	
1.2
    	
Accounting   Terms and Determinations
    	
35
    
	
 
    	
1.3
    	
UCC   and PPSA Changes
    	
36
    
	
 
    	
 
    	
 
    	
 
    
	
2.
    	
Loans;   Letters of Credit; Notes; Payments; Prepayments; Interest Rates
    	
36
    
	
 
    	
2.1
    	
Commitments
    	
36
    
	
 
    	
2.2
    	
Loans
    	
36
    
	
 
    	
2.3
    	
Commitment   Fees
    	
39
    
	
 
    	
2.4
    	
Termination   and Reductions of Commitments
    	
39
    
	
 
    	
2.5
    	
Mandatory   and Voluntary Prepayments
    	
40
    
	
 
    	
2.6
    	
Notes;   Payments
    	
42
    
	
 
    	
2.7
    	
Application   of Payments and Prepayments
    	
42
    
	
 
    	
2.8
    	
Interest   Rates for Loans
    	
44
    
	
 
    	
2.9
    	
Special   Provisions Applicable to LIBOR Borrowings
    	
45
    
	
 
    	
2.10
    	
Letters   of Credit
    	
48
    
	
 
    	
2.11
    	
Swingline   Loans
    	
53
    
	
 
    	
2.12
    	
Pro-Rata   Treatment
    	
54
    
	
 
    	
2.13
    	
Sharing   of Payments, Etc.
    	
55
    
	
 
    	
2.14
    	
Recapture
    	
56
    
	
 
    	
2.15
    	
Increase   of Total Revolving Credit Commitment
    	
57
    
	
 
    	
 
    	
 
    	
 
    
	
3.
    	
Collateral
    	
59
    
	
 
    	
3.1
    	
Security   Documents
    	
59
    
	
 
    	
3.2
    	
Filing   and Recording
    	
59
    
	
 
    	
 
    	
 
    	
 
    
	
4.
    	
Conditions
    	
60
    
	
 
    	
4.1
    	
All   Loans
    	
60
    
	
 
    	
4.2
    	
First   Loan or Letter of Credit
    	
61
    
	
 
    	
 
    	
 
    	
 
    
	
5.
    	
Representations   and Warranties
    	
63
    
	
 
    	
5.1
    	
Organization
    	
63
    
	
 
    	
5.2
    	
Financial   Statements
    	
63
    
	
 
    	
5.3
    	
Enforceable   Obligations; Authorization
    	
63
    
	
 
    	
5.4
    	
Other   Debt
    	
64
    
	
 
    	
5.5
    	
Litigation
    	
64
    
	
 
    	
5.6
    	
Taxes
    	
64
    
	
 
    	
5.7
    	
No   Material Misstatements
    	
64
    
	
 
    	
5.8
    	
Subsidiaries
    	
65
    
	
 
    	
5.9
    	
Representations   by Others
    	
65
    
	
 
    	
5.10
    	
Permits,   Licenses, Etc.
    	
65
    
	
 
    	
5.11
    	
ERISA
    	
65
    
	
 
    	
5.12
    	
Title   to Properties; Possession Under Leases
    	
65
    
	
 
    	
5.13
    	
Assumed   Names
    	
66
    
	
 
    	
5.14
    	
Investment   Company Act
    	
66
    
	
 
    	
5.15
    	
Public   Utility Holding Company Act
    	
66
    
	
 
    	
5.16
    	
Agreements
    	
66
    

 

i

 

	
 
    	
5.17
    	
Environmental   Matters
    	
67
    
	
 
    	
5.18
    	
No   Change in Credit Criteria or Collection Policies
    	
67
    
	
 
    	
5.19
    	
Solvency
    	
67
    
	
 
    	
5.20
    	
Status   of Collateral
    	
68
    
	
 
    	
5.21
    	
Term   Loan Debt and Second Lien Debt Documents
    	
68
    
	
 
    	
5.22
    	
Transactions   with Related Parties
    	
68
    
	
 
    	
5.23
    	
Patents,   Trademarks and Copyrights
    	
68
    
	
 
    	
 
    	
 
    	
 
    
	
6.
    	
Affirmative   Covenants
    	
69
    
	
 
    	
6.1
    	
Businesses   and Properties
    	
69
    
	
 
    	
6.2
    	
Taxes
    	
69
    
	
 
    	
6.3
    	
Financial   Statements and Information
    	
70
    
	
 
    	
6.4
    	
Inspections;   Field Examinations; Appraisals and Physical Counts
    	
71
    
	
 
    	
6.5
    	
Further   Assurances
    	
72
    
	
 
    	
6.6
    	
Books   and Records
    	
72
    
	
 
    	
6.7
    	
Insurance
    	
72
    
	
 
    	
6.8
    	
ERISA
    	
73
    
	
 
    	
6.9
    	
Use   of Proceeds
    	
73
    
	
 
    	
6.10
    	
Guarantors,   Joinder Agreements
    	
74
    
	
 
    	
6.11
    	
Notice   of Events
    	
75
    
	
 
    	
6.12
    	
Environmental   Matters
    	
75
    
	
 
    	
6.13
    	
End   of Fiscal Year
    	
76
    
	
 
    	
6.14
    	
Pay   Obligations and Perform Other Covenants
    	
76
    
	
 
    	
6.15
    	
Cash   Dominion; Collection and Application of Accounts
    	
76
    
	
 
    	
6.16
    	
Accounts   and Other Collateral Matters
    	
77
    
	
 
    	
6.17
    	
Agreements
    	
77
    
	
 
    	
 
    	
 
    	
 
    
	
7.
    	
Negative   Covenants
    	
78
    
	
 
    	
7.1
    	
Indebtedness
    	
78
    
	
 
    	
7.2
    	
Liens
    	
80
    
	
 
    	
7.3
    	
Contingent   Liabilities
    	
82
    
	
 
    	
7.4
    	
Mergers,   Consolidations and Dispositions and Acquisitions of Assets
    	
82
    
	
 
    	
7.5
    	
Nature   of Business
    	
85
    
	
 
    	
7.6
    	
Transactions   with Related Parties
    	
85
    
	
 
    	
7.7
    	
Investments,   Loans
    	
85
    
	
 
    	
7.8
    	
ERISA   Compliance
    	
86
    
	
 
    	
7.9
    	
Intentionally   Deleted
    	
86
    
	
 
    	
7.10
    	
Change   in Accounting Method
    	
86
    
	
 
    	
7.11
    	
Redemption,   Dividends, Issuance of Equity Interests, Distributions and Restricted   Payments
    	
86
    
	
 
    	
7.12
    	
Fixed   Charge Coverage Ratio
    	
88
    
	
 
    	
7.13
    	
Capital   Expenditures
    	
88
    
	
 
    	
7.14
    	
Intentionally   Deleted
    	
88
    
	
 
    	
7.15
    	
Sale   of Accounts
    	
88
    
	
 
    	
7.16
    	
Sale   and Lease-Back Transactions
    	
89
    
	
 
    	
7.17
    	
Change   of Name or Place of Business
    	
89
    
	
 
    	
7.18
    	
Restrictive   Agreements
    	
89
    

 

ii

 

	
 
    	
7.19
    	
Modification   or Waiver of Documents Governing Term Loan Debt or Second Lien Debt
    	
89
    
	
 
    	
7.20
    	
Availability
    	
89
    
	
 
    	
7.21
    	
Anti-Terrorism   Laws
    	
89
    
	
 
    	
 
    	
 
    	
 
    
	
8.
    	
Events   of Default and Remedies
    	
90
    
	
 
    	
8.1
    	
Events   of Default
    	
90
    
	
 
    	
8.2
    	
Remedies   Cumulative
    	
93
    
	
 
    	
 
    	
 
    	
 
    
	
9.
    	
The   Agent
    	
93
    
	
 
    	
9.1
    	
Appointment,   Powers and Immunities
    	
93
    
	
 
    	
9.2
    	
Reliance
    	
94
    
	
 
    	
9.3
    	
Defaults
    	
94
    
	
 
    	
9.4
    	
Rights   as a Lender
    	
94
    
	
 
    	
9.5
    	
Indemnification
    	
95
    
	
 
    	
9.6
    	
Non-Reliance   on Agent and Other Lenders
    	
95
    
	
 
    	
9.7
    	
Failure   to Act
    	
96
    
	
 
    	
9.8
    	
Resignation   or Removal of Agent
    	
96
    
	
 
    	
 
    	
 
    	
 
    
	
10.
    	
Miscellaneous
    	
96
    
	
 
    	
10.1
    	
No   Waiver
    	
96
    
	
 
    	
10.2
    	
Notices
    	
97
    
	
 
    	
10.3
    	
Governing   Law
    	
97
    
	
 
    	
10.4
    	
Survival;   Parties Bound
    	
97
    
	
 
    	
10.5
    	
Counterparts
    	
97
    
	
 
    	
10.6
    	
Limitation   of Interest
    	
97
    
	
 
    	
10.7
    	
Survival
    	
98
    
	
 
    	
10.8
    	
Captions
    	
98
    
	
 
    	
10.9
    	
Expenses,   Etc.
    	
98
    
	
 
    	
10.10
    	
Indemnification
    	
100
    
	
 
    	
10.11
    	
Amendments,   Waivers, Etc.
    	
101
    
	
 
    	
10.12
    	
Successors   and Assigns
    	
102
    
	
 
    	
10.13
    	
Entire   Agreement
    	
105
    
	
 
    	
10.14
    	
Severability
    	
106
    
	
 
    	
10.15
    	
Disclosures
    	
106
    
	
 
    	
10.16
    	
Capital   Adequacy
    	
106
    
	
 
    	
10.17
    	
Taxes
    	
107
    
	
 
    	
10.18
    	
Waiver   of Claims
    	
109
    
	
 
    	
10.19
    	
Right   of Setoff
    	
109
    
	
 
    	
10.20
    	
Waiver   of Right to Jury Trial
    	
110
    
	
 
    	
10.21
    	
Additional   Provisions Regarding Collection of Accounts and other Collateral
    	
110
    
	
 
    	
10.22
    	
Hedging   Obligations; Cash Management Obligations
    	
111
    
	
 
    	
10.23
    	
Construction
    	
113
    
	
 
    	
10.24
    	
Joint   and Several Obligations
    	
114
    
	
 
    	
10.25
    	
USA   Patriot Act
    	
114
    
	
 
    	
10.26
    	
Confidentiality
    	
114
    
	
 
    	
10.27
    	
No   Rights, Duties or Obligations of Documentation Agent
    	
114
    

 

iii

 

EXECUTION VERSION

 

AMENDED AND RESTATED CREDIT AGREEMENT

 

THIS AMENDED AND RESTATED CREDIT AGREEMENT (together with all amendments, modifications and supplements hereto and restatements hereof, this “Agreement”) is made and entered into as of September 26, 2006, by and among WALCO INTERNATIONAL, INC. (“Borrower”), a Delaware corporation (successor by merger to Walco International, Inc., a California corporation), EACH OF THE CREDIT PARTIES WHICH IS NOW OR HEREAFTER A GUARANTOR HEREUNDER, EACH OF THE FINANCIAL INSTITUTIONS WHICH IS A SIGNATORY HERETO OR WHICH MAY FROM TIME TO TIME BECOME A PARTY HERETO (individually, a “Lender” and collectively, the “Lenders”), JPMORGAN CHASE BANK, N.A. (“JPMorgan”), a national banking association, as Administrative Agent for the Lenders (in such capacity, together with its successors in such capacity, the “Agent”), and GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation, as Documentation Agent for the Lenders (in such capacity, together with its successors in such capacity, the “Documentation Agent”).

 

W  I  T  N  E  S  S  E  T  H:

 

Reference is hereby made to that certain Credit Agreement dated as of June 30, 2005, executed by and among the Borrower, the Credit Parties named therein, the Lenders, the Agent, and the Documentation Agent (the “Original Agreement”).

 

In connection with the execution of that certain Term Loan Agreement of even date herewith, by the Borrower, the Credit Parties named therein, the lenders now or hereafter party thereto (the “New Term Lenders”) and Wilmington Trust Company, a Delaware banking corporation, as Administrative Agent for the New Term Lenders, pursuant to which the New Term Lenders will make available to the Borrower of a new $45,000,000 term loan facility to effectively refinance, replace and increase the existing Term Loans (as defined in the Original Agreement), the Borrower, the undersigned Credit Parties, the Agent and the Lenders now desire to amend and restate the Original Agreement in its entirety.  Accordingly, the Original Agreement is hereby amended and restated in its entirety to hereafter be and read as follows:

 

THAT, in consideration of the mutual covenants, agreements and undertakings herein contained, the parties hereto agree as follows:

 

1.             Definitions.

 

1.1           Certain Defined Terms.  Unless a particular word or phrase is otherwise defined or the context otherwise requires, capitalized words and phrases used in the Loan Documents have the meanings provided below.

 

Accounts shall have the meaning set forth in Article 9 of the UCC and in the PPSA.

 

Adjusted LIBOR Rate shall mean, with respect to any LIBOR Borrowing for any Interest Period, an interest rate per annum (rounded upwards, if necessary, to the next 1/16 of 1%) equal

 

1

 

to the sum of (a) the product of (i) the LIBOR Rate in effect for such Interest Period and (ii) Statutory Reserves and (b) the Applicable Margin.

 

Affiliate of any Person shall mean any other Person which controls or is controlled by or under common control with such Person.  For purposes of this definition, “control” (including “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person through the ownership of securities or by contract; provided that no Lender shall be an Affiliate of the Borrower.  Without limiting the generality of the foregoing, control of the right to vote of five percent (5%) or more of all voting securities of a Person or beneficial ownership of five percent (5%) of the outstanding equity interests in such Person shall be deemed to be control for purposes of compliance with the provisions of Section 7.6 hereof; provided, however, that with respect to any key management employees of the Borrower, control of the right to vote of five percent (5%) or greater, but less than fifteen percent (15%), of all voting securities of the Parent and/or the Borrower or beneficial ownership of five percent (5%) or greater, but less than fifteen percent (15%), of the outstanding equity interests in the Parent and/or the Borrower by such key management employee shall not be deemed to be control for purposes of compliance with the provisions of Section 7.6 hereof.

 

Agent shall have the meaning specified in the preamble to this Agreement.

 

Alternate Base Rate shall mean, for any day, a rate per annum (rounded upwards to the nearest 1/16 of 1%) equal to the sum of (a) the greater of (i) the Prime Rate (computed on the basis of the actual number of days elapsed over a 360-day year) in effect on such day, and (ii) the Federal Funds Effective Rate (computed on the basis of the actual number of days elapsed over a 360-day year) in effect for such day plus 1/2 of 1% and (b) the Applicable Margin.  For purposes of this Agreement, any change in the Alternate Base Rate due to a change in the Prime Rate or Federal Funds Effective Rate shall be effective on the effective date of such change in the Prime Rate or Federal Funds Effective Rate, respectively.  If for any reason the Agent shall have determined (which determination shall be conclusive and binding, absent manifest error) that it is unable to ascertain the Federal Funds Effective Rate for any reason, including the inability or failure of the Agent to obtain sufficient quotations in accordance with the terms hereof, the Alternate Base Rate shall be determined without regard to clause (a)(ii) until the circumstances giving rise to such inability no longer exist.

 

Alternate Base Rate Borrowing shall mean, as of any date, that portion of the principal balance of the Loans bearing interest at the Alternate Base Rate as of such date.

 

Annual Audited Financial Statements shall mean (a) the annual financial statements of the Credit Parties and their Subsidiaries, including all notes thereto, which statements shall include, on a Consolidated basis, a balance sheet as of the end of such fiscal year and a statement of operations, a retained earnings statement and a statement of cash flows for such fiscal year, all setting forth in comparative form the corresponding figures from the previous fiscal year and accompanied by a report and opinion of independent certified public accountants with an accounting firm of national standing and with a reputation satisfactory to the Agent, which report shall not contain any material qualification (and be without comment as to the accountants’ opinion whether the Borrower is a “going concern” or can continue to be a “going concern”),

 

2

 

except that such report may contain qualification with respect to new accounting principles mandated by the Financial Accounting Standards Board (or its successor organization), and shall state that such financial statements, in the opinion of such accountants, present fairly, in all material respects, the financial position of such Person as of the date thereof and the results of its operations and cash flows for the period covered thereby in conformity with GAAP and (b) to the extent required by the Agent, annual consolidating financial statements of the Credit Parties and their Subsidiaries containing a balance sheet as of the end of such fiscal year and a statement of operations for such fiscal year prepared in reasonable detail.  Such statements shall be accompanied by a certificate of such accountants that in making the appropriate audit and/or investigation in connection with such report and opinion, such accountants did not become aware of any Default or Event of Default with respect to any of the financial covenants set forth in Sections 7.12, 7.13 and 7.14 hereof, or if in the opinion of such accountant any such Default or Event of Default exists, a description of the nature and status thereof.

 

Applicable Lending Office shall mean, with respect to each Lender, such Lender’s Domestic Lending Office in the case of an Alternate Base Rate Borrowing and such Lender’s LIBOR Lending Office in the case of a LIBOR Borrowing.

 

Applicable Margin shall mean, a rate per annum of 2.00% for LIBOR Borrowings and a rate per annum of .50% for Alternate Base Rate Borrowings; provided, however, that as of the end of each fiscal quarter of the Borrower (commencing with the period ending December 31, 2005), the Applicable Margin shall be adjusted upward or downward, as applicable, to the respective amounts shown in the schedule below based on the Leverage Ratio for the Credit Parties and their Subsidiaries, on a Consolidated basis, tested as of the end of the applicable fiscal quarter of the Credit Parties.  For purposes hereof, any such adjustment in the respective amounts of the Applicable Margin, whether upward or downward, shall be effective ten (10) Business Days after the applicable Annual Audited Financial Statements or the Monthly Unaudited Financial Statements of the Credit Parties have been delivered to and received by the Agent in accordance with the terms of Sections 6.3(a) and 6.3(b) hereof; provided, however, if any such financial statements are not delivered in a timely manner as required under the terms of Sections 6.3(a) and 6.3(b) hereof, the Applicable Margin from the date such financial statements were due until ten (10) Business Days after Agent and Lenders receive the same will be the highest level set forth below for the Applicable Margin.

 

	
Leverage Ratio
    	
 
    	
Per Annum Percentage for
   Revolving Credit LIBOR
   Borrowings
    	
 
    	
Per Annum Percentage for
   Revolving Credit Alternate
   Base Rate Borrowings
    	
 
    
	
Greater than or equal to 6.5x
    	
 
    	
2.50
    	
%
    	
1.00
    	
%
    
	
Less than 6.50x, but greater than or equal to   5.25x
    	
 
    	
2.25
    	
%
    	
0.75
    	
%
    
	
Less than 5.25x, but greater than or equal to   4.25x
    	
 
    	
2.00
    	
%
    	
0.50
    	
%
    
	
Less than 4.25x, but greater than or equal to   3.25x
    	
 
    	
1.75
    	
%
    	
0.25
    	
%
    
	
Less than 3.25x
    	
 
    	
1.50
    	
%
    	
0.00
    	
%
    

 

3

 

Applications shall mean all applications and agreements for Letters of Credit, or similar instruments or agreements, in Proper Form, now or hereafter executed by any Person in connection with any Letter of Credit now or hereafter issued or to be issued under the terms hereof at the request of the Borrower.

 

Approved Fund means any Person (other than a natural person) that is engaged in making, purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.

 

Assignment and Acceptance shall have the meaning specified in Section 10.12(c) hereof.

 

Availability shall mean at any time (a) the lesser at such time of (i) the Total Revolving Credit Commitment (as such amount may be reduced in accordance with the provisions of this Agreement) and (ii) the Borrowing Base, less (b) the sum of (i) the aggregate amount of each Lender’s Revolving Credit Exposure at such time, (ii) the aggregate amount of accrued and unpaid interest outstanding under the Revolving Loans at such time, (iii) all other outstanding Obligations hereunder or any other Loan Documents which are due and payable at such time, including without limitation, Commitment Fees, fees related to any Letters of Credit, and legal fees and other amounts payable under Section 10.9 hereof, and (iv) all Reserves against Availability established by the Agent from time to time.

 

Blocked Person shall mean (i) a Person that is listed in the annex to, or is otherwise subject to the provisions of, the Executive Order No. 13224; (ii) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, the Executive Order No. 13224; (iii) a Person or entity with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law; (iv) a Person or entity that commits, threatens or conspires to commit or supports “terrorism” as defined in the Executive Order No. 13224; (v) a Person or entity that is named as a “specially designated national” on the most current list published by the U.S. Treasury Department Office of Foreign Asset Control at its official website or any replacement website or other replacement official publication of such list, or (vi) a Person or entity who is affiliated or associated with a Person or entity listed above.

 

Borrower shall have the meaning specified in the preamble of this Agreement.

 

Borrowing Base shall mean, as of any date, the amount of the then most recent computation of the Borrowing Base, determined by calculating the amount equal to the following:

 

4

 

(a)           85% of Eligible Accounts; plus

 

(b)           the lesser of (i) 65% of Eligible Inventory (valued, in each case, at the lower of cost or fair market value on a first-in, first-out basis), and (ii) 85% of the Net Recovery Rate of Eligible Inventory; provided, however, that during the period commencing on April 1 and ending on September 30 of each calendar year, the 65% advance rate for Eligible Inventory contained in clause (i) above shall, at the discretion of the Agent, be increased to up to 75% and the 85% advance rate for the Net Recovery Rate of Eligible Inventory contained in clause (ii) above shall, at the discretion of the Agent, be increased to up to 100%; plus

 

(c)           the lesser of (i) $10,000,000 or (ii) the sum of (1) up to 75% of the Net Recovery Rate of the Eligible Equipment, and (2) up to 75% of the fair market value of the Eligible Real Estate; provided, however, that the 75% advance rate for the Net Recovery Rate of Eligible Equipment and the 75% advance rate for Eligible Real Estate contained in clause (ii) above shall be subject to the Equipment and Real Estate Annual Adjustments; less

 

(d)           all Reserves against the Borrowing Base established by the Agent from time to time.

 

Notwithstanding anything to the contrary set forth in the immediately preceding sentence, the Agent reserves the right to adjust downward, to a level acceptable to the Agent in its Permitted Discretion, the advance rates set forth above for Eligible Accounts if the average dilution percentage for all Accounts of the Credit Parties ever exceeds five percent (5%).  For purposes hereof, “average dilution percentage” shall mean for each dollar of gross sales by the Credit Parties (other than the Parent), the average percentage of such dollar of gross sales that is not collected by such Credit Parties for any reason, including without limitation, any credits, rebates, refunds, returns, discounts or any other reason.  The Borrowing Base may be computed by the Agent on as frequent as a daily basis (based on all information reasonably available to the Agent, including without limitation, the periodic reports and listings delivered to the Agent in accordance with Sections 6.3(e), (f) and (g) hereof).

 

Business Day shall mean a day when the principal office in New York City of the Agent is open for business and the Lenders’ Applicable Lending Offices are generally open for business; provided, however, that with respect to LIBOR Borrowings, Business Day shall also mean a day on which transactions in dollar deposits between lenders may be carried on in the London eurodollar interbank market.

 

Business Entity shall mean corporations, partnerships, limited liability companies, joint ventures, joint stock associations, business trusts and other business entities.

 

Canadian Subsidiary shall mean any Subsidiary of that is organized and domiciled in the Canada.

 

Capital Expenditures shall mean, with respect to any Person for any period, all capital expenditures of such Person, on a Consolidated basis, for such period (including without limitation, the aggregate amount of Capital Lease Obligations incurred during such period which

 

5

 

are required to be capitalized and reported as a liability on the consolidated balance sheet of such Person), determined in accordance with GAAP, consistently applied.  For the avoidance of doubt, the term “Capital Expenditures” shall not include those items described in Section 7.4(e)(7).

 

Capital Lease Obligations shall mean the obligations of a Person to pay that portion of rent or other amounts constituting payments of principal under a lease of (or other agreement conveying the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital lease on a balance sheet of such Person under GAAP (including Statement of Financial Accounting Standards No. 13 of the Financial Accounting Standards Board, as amended), provided that for purposes of this Agreement, the amount of such obligations shall be only the capitalized amount thereof, determined in accordance with GAAP (including such Statement No. 13).

 

Cash Dividends shall mean, with respect to any Person for any period, all fixed and calculable cash dividend payments actually made with respect to any Equity Interests of such Person for such period.

 

Cash Management Obligations shall mean any and all obligations and liabilities of Borrower or any of its Subsidiaries to the Agent, JPMorgan, any other Lender or any of their respective Affiliates, now existing or hereafter arising, whether direct, indirect, joint, several, or joint and several, arising under or in any way relating to or incurred in connection with (a) any deposit accounts maintained by Borrower or any of its Subsidiaries with the Agent, JPMorgan, any other Lender or any of their respective Affiliates, (b) any cash management services or treasury administration services provided by Agent, JPMorgan, any other Lender or any of their respective Affiliates (c) any documentation relating thereto, or (d) any services or transactions relating thereto, including without limitation, daylight overdraft exposure and credit card, debit card and other similar products; provided, however, that with respect to any such obligations and liabilities owing by the Borrower or any of its Subsidiaries to any Lender other than the Agent, such other Lender notifies the Agent in writing of the amount of such obligations and liabilities not less frequently than once each calendar month or more frequently as the Agent requires pursuant to written notice delivered to the Lenders.

 

Change of Control shall mean the occurrence of any of the following at any time after the Closing Date:

 

(a)           at any time prior the consummation of an initial public offering of any Equity Interests in the Parent, Charlesbank and/or its respective Affiliates shall fail to either (i) beneficially own in the aggregate, directly or indirectly, more than 50% of the aggregate voting power of all issued and outstanding classes of Equity Interests in the Parent having the right to elect Board of Directors of the Parent, or (ii) have the right to cause enough of their nominees in the aggregate to be elected or appointed, and remain serving at all times as, Board of Directors of the Parent so as to constitute a majority of such Board of Directors;

 

(b)           at any time after the consummation of an initial public offering of any Equity Interests in the Parent, any Person and/or its respective Affiliates shall either (i)

 

6

 

beneficially own in the aggregate, directly or indirectly, 35% or more of the aggregate voting power of all issued and outstanding classes of Equity Interests in the Parent having the right to elect Board of Directors of the Parent, or (ii) have the right to cause enough of their nominees in the aggregate to be elected or appointed, and remain serving at all times as, Board of Directors of the Parent so as to constitute a majority of such Board of Directors;

 

(c)           at any time the Parent shall cease to own directly, free and clear of all Liens (other than in favor of the Agent for the ratable benefit of the Lenders and subordinate and inferior Liens permitted under Section 7.2), both legal title to and beneficial ownership of 100% of all issued and outstanding Equity Interests of the Borrower; provided, however, that a transfer of the legal title to and beneficial ownership of Equity Interests of the Borrower having no more than 10% of the aggregate voting power of all classes of Equity Interests in the Borrower or 10% of the total economic equity interests of the Borrower to management employees of the Borrower shall not trigger a Change of Control;

 

(d)           at any time (i) the Parent shall cease to have the right to elect, directly or indirectly, by virtue of beneficial ownership of Equity Interests of the Borrower, contract or otherwise, at least a majority in number of the members of the Board of Directors of the Borrower or (ii) less than a majority in number of the members of the Board of Directors of the Borrower shall have been elected or appointed, directly or indirectly, by the Parent; or

 

(e)           the occurrence of a Change of Control (as defined in the Second Lien Debt Documents).

 

As used above, “beneficially own” shall have the same meaning as defined in Rules 13d-3 and 13d-5 of the Securities and Exchange Act of 1934, as amended, or any successor provision thereto.

 

Charlesbank shall mean Charlesbank Equity Fund VI, Limited Partnership, a Massachusetts limited partnership.

 

Closing Date shall mean the date of this Agreement.

 

Code shall mean the Internal Revenue Code of 1986, as amended, as now or hereafter in effect, together with all regulations, rulings and interpretations thereof or thereunder by the Internal Revenue Service.

 

Collateral shall mean all collateral and security as described in the Security Documents.

 

Collateral Access Agreement shall mean any landlord waiver, subordination or other agreement, in form and substance satisfactory to the Agent, between the Agent and any third party (including any warehouseman, bailee or other similar Person) in possession of any Collateral or any landlord of any Credit Party for any real Property where any Collateral is located, as such landlord waiver or other agreement may be amended, restated, or otherwise modified from time to time.

 

7

 

Collateral Agent shall mean JPMorgan, in its capacity as the collateral agent of the holders of the Obligations and the Term Loan Debt with respect to the Collateral, in accordance with and pursuant to the terms of the First Lien Intercreditor Agreement, and any successor collateral agent under the terms of the First Lien Intercreditor Agreement.

 

Commitment Fee, with respect to any Lender, shall have the meaning assigned to it in Section 2.3.

 

Commitment Percentage shall mean, with respect to any Lender, (a) prior to the termination of the Total Revolving Credit Commitment, the ratio, expressed as a percentage, of such Lender’s Commitment to the Total Revolving Credit Commitment, and (b) after the termination of the Total Revolving Credit Commitment, the ratio, expressed as a percentage, of the amount of such Lender’s outstanding Loans and its portion of the Letter of Credit Exposure Amount and the Swingline Exposure to the aggregate amount of all outstanding Loans and the total Letter of Credit Exposure Amount and the Swingline Exposure.

 

Consequential Loss shall mean, with respect to (a) the payment of principal of or interest on a LIBOR Borrowing on a day other than the last day of the applicable Interest Period, (b) the failure to borrow or convert a LIBOR Borrowing on the date specified by the Borrower for any reason, or (c) any cessation of the Adjusted LIBOR Rate to apply to the Loans or any part thereof pursuant to Section 2.9 hereof, in each case whether voluntary or involuntary, any loss, expense, penalty, premium or liability incurred by any of the Lenders or the Agent as a result thereof, including without limitation, any interest paid by any of the Lenders to lenders of funds borrowed by it to make or carry the Loans and any other costs and expenses sustained or incurred in liquidating or employing deposits from third parties acquired to effect or maintain the Loans.

 

Consolidated shall mean, for any Person, as applied to any financial or accounting term, such term determined on a consolidated basis in accordance with GAAP (except as otherwise required herein) for such Person and all Subsidiaries thereof.

 

Contingent Obligation shall mean, as to any Person, any obligation of such Person guaranteeing the payment or performance of any Indebtedness, leases, dividends or other obligations (collectively “primary obligations”) of any other Person (the “primary obligor”), whether directly or indirectly, including without limitation, any obligation of the Person for whom Contingent Obligations is being determined, (a) to purchase any such primary obligation or other property constituting direct or indirect security therefor, (b) assume or contingently agree to become or be secondarily liable in respect of any such primary obligation, (c) to advance or supply funds (i) for the purchase or payment of any such primary obligation or (ii) to maintain working capital or equity capital for the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (d) to purchase property, securities or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to make payment of such primary obligation, or (e) otherwise to assure or hold harmless the owner of such primary obligation against loss in respect thereof; provided, however, that the term “Contingent Obligation” shall not include endorsements of checks or other negotiable instruments in the ordinary course of business.

 

8

 

Contribution Agreement shall mean any Contribution Agreement executed by and among the Borrower and its Subsidiaries, as the same may be amended, modified, supplemented, restated and joined in pursuant to a Joinder Agreement, from time to time.

 

Credit Parties shall mean the Borrower and the Guarantors, and Credit Party shall mean any one of such Persons.

 

Debt Service Expense shall mean, with respect to the Credit Parties for any period, the aggregate of regularly scheduled principal payments of all Funded Debt (including, without limitation, regularly scheduled principal payments of the Term Loan Debt and any mandatory principal payments of the Term Loan Debt based upon Excess Cash Flow (as defined in the Term Loan Debt Purchase Agreement), but excluding any principal payments of the Revolving Loans to the extent there is not an equivalent permanent reduction in the Total Revolving Credit Commitment), made or to be made by such Person during such period, on a Consolidated basis, in accordance with GAAP, consistently applied.  Notwithstanding the foregoing, for purposes of calculating the Debt Service Expense for any period ending prior to the first anniversary of the Closing Date, the component of the Debt Service Expense for regularly scheduled principal payments of the Term Loan Debt (but not any other regularly scheduled principal payments of any other Funded Debt, including without limitation, any scheduled payments of the Term Loan Debt based upon Excess Cash Flow, as defined in the Term Loan Debt Purchase Agreement) shall be deemed to be $450,000.

 

Default Rate shall mean, on any day, as follows:  (a) with respect to principal which is outstanding under any Note, the sum of the Interest Option otherwise applicable thereto on such day plus two percent per annum (it being understood that if any such applicable Interest Option is based on the Adjusted LIBOR Rate, the Default Rate with respect to the applicable principal amount shall only be calculated with reference to the applicable Adjusted LIBOR Rate until the Interest Period applicable thereto expires, and upon the expiration of such applicable Interest Period, the Default Rate for such applicable principal amount shall be computed on the basis of the Alternate Base Rate for such day plus two percent per annum), and (b) with respect to accrued interest, fees and other Obligations (other than past due principal outstanding under any Note), the sum of the Alternate Base Rate for such day plus two percent per annum.

 

Discontinued Operations shall mean, as of any day, operations of any Credit Party or any of its Subsidiaries which have been discontinued, and which, as of such day, have been fully terminated, disposed of or liquidated.

 

Domestic Lending Office shall mean, with respect to any Lender, the office of such Lender specified as its “Domestic Lending Office” opposite its name on the signature pages hereof, or such other office of such Lender as such Lender may from time to time specify to the Borrower and the Agent.

 

Domestic Subsidiary shall mean any Subsidiary of that is organized and domiciled in the Unites States of America.

 

EBITDA shall mean, with respect to the Credit Parties for any period, Net Income for such period plus (a) without duplication and to only the extent deducted in determining Net

 

9

 

Income for such period, the sum of (i) Interest Expense, (ii) federal, state and local income or franchise taxes, (iii) all amounts attributable to depreciation and amortization expense, (iv) any extraordinary charges, (v) Permitted Management Fees and customary and reasonable director’s fees and board expenses for board of directors of the Credit Parties, (vi) amounts used to repurchase from Charlesbank and/or any of its Affiliates the equity securities of the Parent to the extent included within Permitted Affiliate Transactions, and (vii) any other non-cash charges (including without limitation, (A) the issuance of restricted stock or stock options, (B) equity losses of Affiliates that are not a Subsidiary of any Credit Party, and (C) all charges attributable to the use of the purchase accounting method), but excluding any non-cash charge in respect of an item that was included in Net Income in a prior period and any non-cash charge that relates to the write-down or write-off of Inventory, minus (b) without duplication and to the extent included in Net Income, (i) any cash payments made during such period in respect of non-cash charges described in clause (a)(vii) taken in a prior period and (ii) any extraordinary gains and any non-cash items of income, in each case of such Person for such period, computed and calculated, without duplication, on a Consolidated basis and in accordance with GAAP, consistently applied.

 

Eligible Assignee shall mean (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved Fund, or (iv) any other commercial lender, finance company, insurance company, financial institution or fund reasonably acceptable to the Agent and the Borrower; provided, however, that if an Event of Default has occurred which has not been waived or cured to the satisfaction of the Agent and the Required Lenders, such approval by the Borrower shall not be required.

 

Eligible Accounts shall mean, as at any date of determination thereof, all Accounts of any one or more of the Credit Parties (other than (i) the Parent and (ii) Subsidiaries of the Borrower that are not wholly-owned by the Borrower, directly or indirectly) which comply with all of the following requirements:

 

(a)                                  all payments due on the Account have been billed and invoiced in a timely fashion and in the normal course of business;

 

(b)                                 the Account has payment terms of 30 days or less, or if the Account has payment terms of 31 to 180 days, such Accounts having payment terms of 31 to 180 days shall not constitute more than ten percent (10%) of the total Eligible Accounts;

 

(c)                                  no payment on the Account is more than 60 days past due;

 

(d)                                 the Account has been created by the applicable Credit Party in the ordinary course of business from a completed, outright and lawful sale of goods, to which such goods have been shipped and title has passed to the applicable account debtor on an absolute sales basis, or from the rendering of services by or on behalf of such Credit Party and is deemed “earned” under the applicable service contract or other agreement between such Credit Party and the applicable account debtor;

 

(e)                                  the Account is Collateral hereunder and is subject to a first priority perfected Lien in favor of the Agent for the ratable benefit of the Lenders and is free and clear of all other Liens of any nature whatsoever (except for Liens permitted under

 

10

 

Sections 7.2 (b), (d) and (e) below which do not have priority over the Lien in favor of the Agent);

 

(f)                                    more than fifty percent (50%) of all billed Accounts owing to by the applicable account debtor to the Credit Parties are Eligible Accounts;

 

(g)                                 if applicable, the Account together with all other Accounts owing from the applicable debtor and its Affiliates to the Credit Parties is not in excess of thirty percent (30%) of the aggregate Eligible Accounts (it being agreed that for purposes of this subparagraph, only the aggregate amount of such Accounts owing from the applicable debtor and its Affiliates in excess of such 30% concentration threshold shall be excluded from Eligible Accounts);

 

(h)                                 the Account does not arise out of a bill-and-hold, guaranteed sale, sale-and-return, consignment, sale-on-approval, progress billing, promotional (including samples), C.O.D. or cash in advance arrangement;

 

(i)                                     the Account is not subject to any setoff, contra, offset, deduction, dispute, charge back, credit, counterclaim or other defense arising out of the transactions represented by the Account or independently thereof (but in each case regarding an undisputed liquidated sum, only to the extent of such undisputed sum, and in each case regarding a disputed sum or claim, only to the extent of the sum or amount claimed by the party adverse to the applicable Credit Party);

 

(j)                                     the applicable account debtor has finally accepted the goods or services from the sale out of which the Account arose and has not (1) objected to such account debtor’s liability thereon, (2) rejected any of such services or goods or (3) returned or repossessed any of such goods, except for goods returned in the ordinary course of business for which, in the case of goods returned, goods of equal or greater value have been shipped in return;

 

(k)                                  the Account must not be “performance” related and subject to future adjustment;

 

(1)                                  the applicable account debtor is not any Governmental Authority, unless such account debtor is the United States of America (or any agency, instrumentality, department or other political subdivision thereof) and there has been compliance satisfactory to the Agent in all respects with the Federal Assignment of Claims Act;

 

(m)                               the applicable account debtor is not a director, officer, employee or any Affiliate of any of the Credit Parties;

 

(n)                                 the applicable account debtor must not be a natural Person and must be organized under the laws of any state or province, or have its principal place of business located within the United States or Canada (to the extent located in a Canadian province in which the PPSA is in effect), except for Accounts fully insured or backed by a letter of credit in all respects acceptable to the Agent in its Permitted Discretion;

 

11

 

(o)                                 the Account is not evidenced by a promissory note or other instrument or by chattel paper;

 

(p)                                 the Account complies with all material Legal Requirements (including without limitation, all usury laws, fair credit reporting and billing laws, fair debt collection practices and rules, and regulations relating to truth in lending and other similar matters);

 

(q)                                 the Account is in full force and effect and constitutes a legal, valid and binding obligation of the applicable account debtor enforceable in accordance with the terms thereof;

 

(r)                                    the Account is denominated in and provides for payment by the applicable account debtor in U.S. dollars or Canadian dollars (with the Borrower being required to report for Borrowing Base purposes the U.S. dollar equivalent amount of Canadian dollar denominated Accounts, and in determining the Borrowing Base for any purpose, the Agent shall be entitled at any time to redetermine at any time the U.S. dollar equivalent of Canadian dollar denominated Accounts based upon the most recent applicable information then available to the Agent);

 

(s)                                  the Account has not been and is not required to be charged or written off as uncollectible in accordance with GAAP; and

 

(t)                                    except for Accounts fully backed by a letter of credit in all respects acceptable to the Agent in its sole reasonable credit judgment, the credit standing of the applicable account debtor in relation to the amount of credit extended has not become unsatisfactory to the Agent in its Permitted Discretion.

 

Standards of eligibility for Eligible Accounts may be fixed and revised from time to time solely by the Agent based on events, conditions or other circumstances arising or discovered after the Closing Date which adversely affect or could reasonably be expected to adversely affect the Eligible Accounts in the Permitted Discretion of the Agent, and the Agent may from time to time in its Permitted Discretion exclude particular Accounts from the definition of Eligible Accounts; provided, that the Agent shall use reasonable efforts to give the Borrower written notice within five (5) Business Days after the effective date of any change in such standards of eligibility or exclusions.  Additionally, in determining the amount of an Eligible Account, the face amount of an Account shall be reduced by, without duplication, to the extent not reflected in such face amount, (i) unpaid sales, excise or similar taxes owed by any of the Credit Parties, (ii) the amount of all accrued and actual discounts, claims, credits or credits pending, promotional program allowances, price adjustments, finance charges or other allowances, whether issued, owing, granted or outstanding (including any amount that any Credit Party may be obligated to rebate to the applicable account debtor pursuant to the terms of any agreement or understanding (written or oral)) and (iii) the aggregate amount of all cash received in respect of such Account but not yet applied by the Credit Parties to reduce the amount of such Account.  Notwithstanding anything to the contrary contained in this Agreement or any other Loan Document, no Accounts purchased or otherwise acquired through any acquisition or other Investment permitted hereunder after the Closing Date shall be deemed to constitute Eligible Accounts for purposes

 

12

 

hereof unless and until the Agent shall have conducted a field examination (at the Borrower’s cost and expense) of the applicable books, records and operations for the assets or Subsidiary so acquired in order to reasonably satisfy the Agent that the Accounts so acquired generally satisfy the above-described standards of eligibility.

 

Eligible Equipment shall mean, as at any date of determination thereof, all Equipment of any one or more of the Credit Parties (other than (i) the Parent and (ii) Subsidiaries of the Borrower that are not wholly-owned by the Borrower, directly or indirectly) which complies with all of the following requirements:

 

(a)                                  good title to such Equipment is owned by and recorded on the books and records of the applicable Credit Party;

 

(b)                                 the applicable Credit Party has the right to subject such Equipment to a Lien in favor of the Agent for the ratable benefit of the Lenders, and such Equipment is subject to a first priority perfected Lien in favor of the Agent and is free and clear of all other Liens of any nature whatsoever (except for Liens permitted under Sections 7.2 (b) and (e) below which do not have priority over the Lien in favor of the Agent);

 

(c)                                  the full purchase price for such Equipment has been paid by the applicable Credit Party;

 

(d)                                 such Equipment is located at a real Property location either owned or leased by any of the Credit Parties, so long as such leased facility is covered by either (i) a Collateral Access Agreement delivered to the Agent by the lessor thereof or (ii) a Reserve for rent, charges, and other amounts due or to become due with respect to such facility has been established by the Agent in its Permitted Discretion;

 

(e)                                  such Equipment is in good working order and condition (ordinary wear and tear excepted) and is used or held for use by the applicable Credit Party in the ordinary course of business of such Credit Party;

 

(f)                                    such Equipment is not subject to any agreement which restricts the ability of the applicable Credit Party to use, sell, transport or dispose of such Equipment or which restricts the Agent’s ability to take possession of, sell or otherwise dispose of such Equipment; and

 

(g)                                 such Equipment does not constitute “fixtures” under the applicable laws of the jurisdiction in which such Equipment is located.

 

Standards of eligibility for Eligible Equipment may be fixed and revised from time to time solely by the Agent based on events, conditions or other circumstances arising or discovered after the Closing Date which adversely affect or could reasonably be expected to adversely affect Eligible Equipment in the Permitted Discretion of the Agent, and the Agent may from time to time in its Permitted Discretion exclude particular Equipment from the definition of Eligible Equipment; provided, that the Agent shall use reasonable efforts to give the Borrower written notice within five (5) Business Days after the effective date of any change in such standards of eligibility or

 

13

 

exclusions.  Notwithstanding anything to the contrary contained in this Agreement or any other Loan Document, no Equipment purchased or otherwise acquired through any acquisition or other Investment permitted hereunder after the Closing Date shall be deemed to constitute Eligible Equipment for purposes hereof unless and until the Agent shall have received an satisfactory appraisal of such Equipment and conducted a field examination (both at the Borrower’s cost and expense) of the applicable books, records and operations for the assets or Subsidiary so acquired in order to reasonably satisfy the Agent that the Equipment so acquired generally satisfies the above-described standards of eligibility.

 

Eligible Inventory shall mean all finished goods Inventory of any one or more of the Credit Parties (other than (i) the Parent and (ii) Subsidiaries of the Borrower that are not wholly-owned by the Borrower, directly or indirectly) which complies with all of the following requirements:

 

(a)                                  good title to such Inventory is owned by and recorded on the books and records of the applicable Credit Party in the ordinary course of business;

 

(b)                                 such Inventory is valued in accordance with GAAP on a first in, first out basis at the lower of fair market value or cost;

 

(c)                                  such Inventory is Collateral hereunder and is subject to a first priority perfected Lien in favor of the Agent for the ratable benefit of the Lenders and is free and clear of all other Liens of any nature whatsoever (except for Liens permitted under Sections 7.2 (b), (d) and (e) below which do not have priority over the Lien in favor of the Agent);

 

(d)                                 such Inventory meets all applicable laws and standards imposed by any Governmental Authority having regulatory authority over it;

 

(e)                                  such Inventory is in good condition, is not returned, shopworn, defective or damaged, and is currently usable or saleable in the ordinary course of business of the Credit Parties;

 

(f)                                    such Inventory is not raw materials or work-in-progress Inventory, is not scrap or remnants Inventory and is not display items or manufacturing, replacement, packaging or shipping supplies or materials;

 

(g)                                 such Inventory must not be in transit and must be housed or stored in the United States or Canada at either a real Property location either owned or leased by any of the Credit Parties or a public warehouse facility utilized by any of the Credit Parties, so long as such leased facility or public warehouse facility is covered by either (i) a Collateral Access Agreement delivered to the Agent by the lessor or operator thereof or (ii) a Reserve for rent, charges, and other amounts due or to become due with respect to such facility has been established by the Agent in its Permitted Discretion; provided, however, that Inventory in transit for which title to such Inventory has transferred to any of the Credit Parties, such Inventory has been physically received by any of the Credit Parties in the continental United States or Canada, and such Inventory is adequately insured by the Credit Parties

 

14

 

in accordance with the other provisions of this Agreement and the other Loan Documents shall not be excluded from Eligible Inventory solely as result of the in-transit nature of such Inventory;

 

(h)                                 such Inventory is not in the possession of or control of any bailee (other than a warehouseman as described above) or any agent or processor for or customer of the Borrower or any of its applicable Subsidiaries, unless either (A) such bailee, agent or processor has executed and delivered to the Agent a Collateral Access Agreement, or (B) an adequate Reserve for charges, and other amounts due or to become due with respect to such bailee, agent or processor has been established by the Agent in its Permitted Discretion;

 

(i)                                     such Inventory must be adequately insured to the reasonable satisfaction of the Agent pursuant to insurance coverage required by this Agreement and the Security Documents;

 

(j)                                     such Inventory has not been sold and must not be on consignment; provided, that Inventory subject to bill-and-hold arrangements with account debtors shall not be excluded from Eligible Inventory solely as result of the bill-and-hold nature of such Inventory, so long as such bill-and-hold Inventory is not subject to any Lien or other claim by any bill-and-hold account debtor;

 

(k)                                  such Inventory is not obsolete or slow moving;

 

(1)                                  such Inventory is not manufactured, produced or sold pursuant to any license or other similar agreement of any patent, trademark or copyright owned or sublicensed by any Person other than a Credit Party, unless (A) such owner or sublicensor has executed and delivered to the Agent an agreement reasonably satisfactory to the Agent consenting to the Agent’s Lien against all Inventory subject to such license or other similar agreement and permitting the Agent to resale such Inventory upon terms acceptable to the Agent in the event of foreclosure or other recovery of such Inventory by the Agent, or (B) the applicable license or other similar agreement of any patent, trademark or copyright does not directly or indirectly restrict, in the Agent’s reasonable judgment, the Agent’s ability to resale such Inventory without further consent of the applicable licensor in the event of foreclosure or other recovery of such Inventory by the Agent; and

 

(m)                               the Agent has not deemed such Inventory ineligible because the Agent considers such Inventory in its Permitted Discretion to be unmarketable or the value thereof to be impaired or its ability to realize such value to be insecure.

 

Standards of eligibility for Eligible Inventory may be fixed and revised from time to time solely by the Agent based on events, conditions or other circumstances arising or discovered after the Closing Date which adversely affect or could reasonably be expected to adversely affect Eligible Inventory in the Permitted Discretion of the Agent, and the Agent may from time to time in its Permitted Discretion exclude particular Inventory from the definition of Eligible Inventory;

 

15

 

provided, that the Agent shall use reasonable efforts to give the Borrower written notice within five (5) Business Days after the effective date of any change in such standards of eligibility or exclusions.  Notwithstanding anything to the contrary contained in this Agreement or any other Loan Document, no Inventory purchased or otherwise acquired through any acquisition or other Investment permitted hereunder after the Closing Date shall be included within the Borrowing Base for purposes hereof unless and until the Agent shall have received a satisfactory appraisal of such Inventory and conducted a field examination (both at the Borrower’s cost and expense) of the applicable books, records and operations for the assets or Subsidiary so acquired in order to reasonably satisfy the Agent that the Inventory so acquired generally satisfies the above-described standards of eligibility.

 

Eligible Real Estate shall mean the Real Estate (other than Excluded Real Estate) owned by any one or more of the Credit Parties (other than (i) the Parent, (ii) Subsidiaries of the Borrower that are not wholly-owned by the Borrower, directly or indirectly, or (iii) any non-Domestic Subsidiary) which complies with all of the following requirements:

 

(a)                                  fee simple title to such Real Estate is owned by and recorded on the books and records of the applicable Credit Party;

 

(b)                                 the Agent is satisfied that all actions necessary or desirable in order to create perfected first priority Lien on such real Property have been taken, including, the filing and recording of Mortgages, such real Property is adequately protected by fully-paid valid title insurance with endorsements and in amounts acceptable to the Agent, insuring that the Agent, for the ratable benefit of the Lenders, has a perfected first priority Lien on such real Property, and such real Property is free and clear of all other Liens of any nature whatsoever (except for Liens permitted under Sections 7.2 (b), (d) and (e) below which do not have priority over the Lien in favor of the Agent);

 

(c)                                  the full purchase price for such real Property has been paid by the applicable Credit Party;

 

(d)                                 an appraisal report has been delivered to the Agent in form, scope and substance satisfactory to the Agent; and

 

(e)                                  the Agent shall have received an environmental assessment report covering such real Property and such report shall not indicate that any pending, threatened or existing material Environmental Claim or material Environmental Liabilities exists or that such real Property is not in compliance with any Requirements of Environmental Law in any material respect.

 

Standards of eligibility for Eligible Real Estate may be fixed and revised from time to time solely by the Agent based on events, conditions or other circumstances arising or discovered after the Closing Date which adversely affect or could reasonably be expected to adversely affect Eligible Real Estate in the Permitted Discretion of the Agent, and the Agent may from time to time in its Permitted Discretion exclude particular parcels of the Real Estate from the definition of Eligible Real Estate; provided, that the Agent shall use reasonable efforts to give the Borrower written

 

16

 

notice within five (5) Business Days after the effective date of any change in such standards of eligibility or exclusions.

 

Environmental Claim shall mean any third party (including any Governmental Authority) action, lawsuit, claim or proceeding (including claims or proceedings at common law) which seeks to impose or alleges any liability for (i) pollution or contamination by, or releases or threatened releases of, Hazardous Substances into the air, surface water, ground water or land or the clean-up, abatement, removal, remediation or monitoring of such pollution, contamination or Hazardous Substances; (ii) generation, recycling, reclamation, handling, treatment, storage, disposal or transportation of Hazardous Substances; (iii) exposure to Hazardous Substances; (iv) the safety or health of employees or other Persons in connection with any of the activities specified in any other subclause of this definition; or (v) the manufacture, processing, distribution in commerce, presence or use of Hazardous Substances.  An “Environmental Claim” includes a common law action, as well as a proceeding to issue, modify or terminate an Environmental Permit, or to adopt or amend a regulation, to the extent that such a proceeding attempts to redress violations of the applicable permit, license, or regulation as alleged by any Governmental Authority.

 

Environmental Liabilities shall mean all liabilities arising from any Environmental Claim or Requirement of Environmental Law under any theory of recovery, at law or in equity, and whether based on negligence, strict liability or otherwise, including:  remedial, removal, response, abatement, restoration (including natural resources), investigative, or monitoring liabilities, personal injury and damage to property, natural resources or injuries to persons, and any other related costs, expenses, losses, damages, penalties, fines or liabilities, including attorney’s fees and court costs.  Environmental Liability shall mean any one of them.

 

Environmental Permit shall mean any permit, license, approval or other authorization under any applicable law or regulation of the United States or of any state, municipality or other subdivision thereof relating to pollution or protection of health or the environment, including laws or regulations relating to emissions, discharges, releases or threatened releases of pollutants, contaminants, Hazardous Substances or toxic materials or wastes into ambient air, surface water, ground water or land, or otherwise relating to the manufacture, processing, distribution, recycling, presence, use, treatment, storage, disposal, transport, or handling of wastes, pollutants, contaminants or Hazardous Substances.

 

Equipment shall have the meaning set forth in Article 9 of the UCC and in the PPSA.

 

Equipment and Real Estate Annual Adjustments shall mean annual adjustments of the advance rates for the Eligible Equipment and Eligible Real Estate components of the Borrowing Base, based upon either (a) annual reductions in such advance rates, based upon a straight-line amortization basis over a seven (7) year period for the Eligible Equipment advance rate and a ten (10) year period for the Eligible Real Estate advance rate, or (b) annual recalculations (with no increases in such advance rates possible) based upon annual reappraisals of the Equipment and Real Estate Collateral, with the Borrower having the annual option (each such annual option to be exercisable on or before April 30 of each calendar year) to select which of the foregoing options shall be applicable for the annual period ending as of June 30 of the applicable calendar year.  If the amortization option is selected by the Borrower for any annual period ending after

 

17

 

the Borrower has previously selected the reappraisal option for a prior annual period, the applicable 7-year and 10-year amortization periods for such advance rate reductions described above shall commence (or recommence, if applicable) as of the annual period ending immediately after the last such annual period for which the reappraisal option has been selected, and thereafter, to the extent selected by the Borrower, annual amortization reductions shall occur on such amortization basis unless and until the Borrower selects the reappraisal option for any subsequent annual period (it being agreed that any selection by the Borrower of the reappraisal option for any annual period shall cause the applicable 7-year and 10-year amortization periods for such advance rate reductions to recommence as of the next annual period, if applicable, for which the Borrower selects the amortization option).  If the annual reappraisal option is selected by the Borrower for any annual period, then any requisite reduction of the applicable advance rate(s) shall be implemented on June 30 of the applicable calendar year (or as soon thereafter as the requisite appraisal results are received by the Agent), it being agreed that the Agent shall commence such annual reappraisals when required in order to have the applicable appraisal results by June 30 of the applicable calendar year.

 

Equity Interests shall mean as to a Business Entity, all capital stock, partnership interests, membership interests or other indicia of equity rights, including without limitation, any warrants, options or other rights to acquire such interests, issued by such Business Entity from time to time.

 

ERISA shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time, and all rules, regulations, rulings and interpretations adopted by the Internal Revenue Service or the Department of Labor thereunder.

 

ERISA Affiliate shall mean any trade or business (whether or not incorporated) which together with the Borrower or any Subsidiary of the Borrower would be treated as a single employer under the provisions of Title I or Title IV of ERISA.

 

Event of Default shall mean any of the events specified in Section 8.1 hereof or otherwise specified as an Event of Default in any other Loan Document, provided there has been satisfied any requirement in connection with any such event for the giving of notice or the lapse of time, or both, and Default shall mean any of such events, whether or not any such requirement for the giving of notice, or the lapse of any applicable grace or curative period (if any), or both, has been satisfied.

 

Excess Interest Amount shall have the meaning attributed to such term in Section 2.14 hereof.

 

Excluded Real Estate shall mean each of the real Properties listed as “excluded real estate” on Schedule 1.1(a).

 

Federal Funds Effective Rate shall mean, for any day, a rate per annum equal to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published for

 

18

 

any day which is a Business Day, the average of the quotations for the day of such transactions received by the Agent from three Federal funds brokers of recognized standing selected by it.

 

Financed Capital Expenditures shall mean (i) Capital Expenditures which are financed at the time of purchase with Indebtedness otherwise permitted hereunder, and (ii) Capital Lease Obligations to the extent the same constitute Capital Expenditures otherwise permitted hereunder.

 

First Lien Intercreditor Agreement shall mean the Intercreditor and Collateral Agency Agreement dated effective as of the Closing Date, by and among the Borrower, the other Credit Parties, the Agent, as the representative of the holders of the Obligations, the Collateral Agent, as the representative of the holders of the Obligations and the Term Loan Debt, and Wilmington Trust Company, a Delaware banking corporation, as the representative of the holders of the Term Loan Debt, as the same may be amended, modified, supplemented, renewed, restated or replaced in accordance with the terms of this Agreement.

 

Fixed Charge Coverage Ratio shall mean, with respect to the Credit Parties and their Subsidiaries for any period, the ratio of (a) EBITDA less (i) Unfinanced Capital Expenditures less (ii) cash payments of federal, state and local income or franchise taxes to (b) the sum of (i) Debt Service Expense, (ii) cash Interest Expense, and (iii) Unfinanced Cash Dividends, in each case of such Person for the applicable period, computed and calculated on a Consolidated basis in accordance with GAAP, consistently applied and without duplication.  All components of the Fixed Charge Coverage Ratio shall be determined (1) on a Consolidated basis for the twelve (12) most recent consecutive calendar months ending on or prior to the date of determination and (2) in accordance with GAAP, consistently applied.

 

Funded Debt shall mean, as to a particular Person at any particular time, the sum of (a) all obligations for borrowed money (whether as a direct obligor on a promissory note, bond, debenture or other similar instrument, as a reimbursement obligor with respect to an issued letter of credit or similar instrument, as an obligor under a Contingent Obligation in respect of borrowed money, or as any other type of direct or contingent obligor), and (b) all Capital Lease Obligations (other than the interest component of such obligations), each calculated without duplication, on a Consolidated basis, and in accordance with GAAP.

 

GAAP shall mean, as to a particular Person, those principles and practices (a) which are recognized as such by the Financial Accounting Standards Board or successor organization, and (b) which are consistently applied (or with respect to which any change in principles and practice mandated by the Financial Accounting Standards Board or successor organization are disclosed in writing to the Agent) for all periods after the date hereof in a manner consistent with the manner in which such principles and practices were applied to the most recent audited financial statements of the relevant Person furnished to the Agent and the Lenders prior to the Closing Date (or with respect to which any change in principles and practice mandated by the Financial Accounting Standards Board or successor organization are disclosed in writing to the Agent).

 

Governmental Authority shall mean any foreign governmental authority, the United States of America, any state of the United States and any political subdivision of any of the foregoing, and any agency, instrumentality, department, commission, board, bureau, central

 

19

 

bank, authority, court or other tribunal, in each case whether executive, legislative, judicial, regulatory or administrative, having jurisdiction over the Agent, any of the Lenders, any Credit Party, any Subsidiary of any Credit Party, or their respective Property.

 

Grantor shall mean any Grantor, Assignor, Pledgor or Debtor, as such terms are defined in any of the Security Documents.

 

Guarantors shall mean the Parent and its Subsidiaries, other than the Borrower and any non-Domestic Subsidiaries not required to become a Guarantor pursuant to Section 6.10.  In no event shall Inactive Subsidiaries shall be required to execute or join in a Guaranty or any applicable Security Agreements except as required under the terms of Section 6.10.

 

Guaranty shall mean each and every guaranty of the Obligations from time to time executed and delivered to the Agent by any Guarantor, as amended, supplemented, modified, joined in pursuant to a Joinder Agreement and restated from time to time.

 

Hazardous Substance shall mean any hazardous or toxic waste, substance or product or material defined or regulated by any Requirements of Environmental Law, including solid waste (as defined under The Resource Conservation and Recovery Act or its regulations, as amended), petroleum and any fraction thereof and any radioactive materials and waste.

 

Hedging Obligations of a Person shall mean any and all obligations of such Person, whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor), under (a) any and all agreements, devices or arrangements designed to protect at least one of the parties thereto from the fluctuations of interest rates, exchange rates or forward rates applicable to such party’s assets, liabilities or exchange transactions, including, but not limited to, dollar-denominated or cross-currency interest rate exchange agreements, forward currency exchange agreements, interest rate cap or collateral protection agreements, forward rate currency or interest rate options, puts and warrants, and (b) any and all cancellations, buy backs, reversals, terminations or assignments of any of the foregoing; provided, however, that with respect to any such obligations owing by the Borrower or any other Credit Party to any Lender other than the Agent, such other Lender notifies the Agent in writing of the amount of such obligations not less frequently than once each calendar month or more frequently as the Agent requires pursuant to written notice delivered to the Lenders.

 

Highest Lawful Rate shall mean, with respect to the Agent or any Lender, the maximum nonusurious rate of interest permitted to be charged by, as applicable, the Agent or such Lender under applicable laws (if any) of the United States or any state from time to time in effect.

 

Inactive Subsidiaries shall mean each of the Subsidiaries listed as inactive on Schedule 5.8.

 

Indebtedness shall mean, as to any Person, without duplication:  (a) all indebtedness (including principal, interest, fees and charges) of such Person for borrowed money; (b) any other indebtedness which is evidenced by a bond, debenture or similar instrument; (c) all Capital Lease Obligations of such Person; (d) all obligations of such Person for the deferred purchase price of Property or services (except current trade accounts payable arising in the ordinary course

 

20

 

of business and current accrued expenses, not the result of borrowing, arising in the ordinary course of business); (e) all reimbursement obligations of such Person in respect of outstanding letters of credit, acceptances and similar obligations created for the account of such Person; (f) all indebtedness, liabilities, and obligations secured by any Lien on any Property owned by such Person even though such Person has not assumed or has not otherwise become liable for the payment of any such indebtedness, liabilities or obligations secured by such Lien, but only to the extent of the value of the Property subject to such Lien (or, if less, the amount of the underlying indebtedness, liability or obligation); (g) all Cash Management Obligations of such Person and net liabilities of such Person in respect of Hedging Obligations (calculated on a basis satisfactory to the Agent and in accordance with accepted practice); (h) all liabilities of such Person in respect of unfunded vested benefits under any Plan; and (i) all other indebtedness, liabilities and obligations of such Person which are required to be included or listed in the liabilities section of such Person’s balance sheet according to GAAP; provided, that such term shall not mean or include (1) any Indebtedness in respect of which monies sufficient to pay and discharge the same in full (either on the expressed date of maturity thereof or on such earlier date as such Indebtedness may be duly called for redemption and payment) shall be deposited with a depository, agency or trustee acceptable to the Agent in trust for the payment thereof, (2) any operating leases entered into in the ordinary course of business (to the extent such operating leases do not constitute Capital Lease Obligations) or (3) Permitted Management Fees.

 

Interest Expense shall mean, for any period, the total interest expense of the Credit Parties and their Subsidiaries, determined on a Consolidated basis in accordance with GAAP, consistently applied, and shall in any event include, without limitation, (a) the amortization or write-off of debt discounts, (b) the amortization or write-off of all debt issuance costs, commissions, discounts and other fees payable in connection with the incurrence, amendment or refinancing of Indebtedness (including all commissions, discounts and other fees and charges owed with respect to letters of credit and bankers’ acceptance financing), (c) the portion of payments under Capital Lease Obligation allocable to interest expense, and (d) net costs under Hedging Obligations in respect of interest rates to the extent such net costs are allocable to such period in accordance with GAAP.

 

Interest Option shall have the meaning specified in Section 2.8(a) hereof.

 

Interest Payment Dates shall mean (a) for Alternate Base Rate Borrowings (other than Swingline Loans), (1) the last Business Day of each calendar month prior to the Revolving Credit Termination Date, and (2) the Revolving Credit Termination Date; (b) for LIBOR Borrowings, (1) if the Interest Period applicable to such LIBOR Borrowing is equal to or less than three (3) months, the end of such Interest Period, and (2) in all other cases, on that day which is three (3) calendar months following the first day of the applicable Interest Period (or, if there be no corresponding day, on the next succeeding day which is a Business Day) and at the end of such Interest Period; and (c) for Swingline Loans, (1) the last Business Day of each calendar month prior to the earlier to occur of the Revolving Credit Termination Date or the date such Swingline Loans are required to be paid with proceeds of Revolving Loans in accordance with Section 2.11(c), and (2) the earlier to occur of the Revolving Credit Termination Date or the date such Swingline Loans are required to be paid with proceeds of Revolving Loans in accordance with Section 2.11(c).

 

21

 

Interest Period shall mean the period commencing on the date of the applicable LIBOR Borrowing and ending on the numerically corresponding day (or, if there is no numerically corresponding day, on the last day) in the calendar month that is one (1), two (2), three (3) or six (6) months thereafter, as the Borrower may elect in accordance herewith; provided, however, that (a) if an Interest Period would end on a day that is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day, unless such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day, (b) no Interest Period shall end later than the Revolving Credit Termination Date, and (c) interest shall accrue from and including the first day of an Interest Period to, but excluding, the last day of such Interest Period.

 

Inventory shall have the meaning set forth in Article 9 of the UCC and in the PPSA.

 

Investment shall mean the purchase or other acquisition of any securities or Indebtedness of, or the making of any loan, advance, extension of credit, transfer of Property or capital contribution to, or the incurring of any Contingent Obligation in respect of the Indebtedness of, any Person.

 

Joinder Agreement shall mean any agreement, in Proper Form, executed by a Subsidiary of any Credit Party from time to time in accordance with Section 6.10 hereof, pursuant to which such Subsidiary joins in the execution and delivery of this Agreement, a Guaranty, the applicable Security Documents and the Contribution Agreement.

 

JPMorgan shall mean JPMorgan Chase Bank, N.A., a national banking association, together with its successors and assigns.

 

Legal Requirement shall mean any law, statute, ordinance, decree, requirement, order, judgment, rule, regulation (or interpretation of any of the foregoing) of, and the terms of any license or permit issued by, any Governmental Authority.

 

Lender or Lenders shall have the meaning specified in the preamble of this Agreement.  Unless the context otherwise requires, the term “Lenders” shall include the Swingline Lender.

 

Letters of Credit shall mean Standby Letters of Credit and Trade Letters of Credit.  Letter of Credit shall mean any one of the Standby Letters of Credit or Trade Letters of Credit.

 

Letter of Credit Advances shall mean all sums which may from time to time be paid by any and all of the Lenders pursuant to any and all of the Letters of Credit, together with all other sums, fees, reimbursements or other obligations which may be due to the Agent or any of the Lenders pursuant to any of the Letters of Credit.

 

Letter of Credit Exposure Amount shall mean at any time the sum of (i) the aggregate undrawn amount of all Letters of Credit outstanding at such time plus (ii) the aggregate amount of all Letter of Credit Advances for which the Lenders have not been reimbursed and which remain unpaid at such time.

 

Leverage Ratio shall mean, with respect to the Credit Parties and their Subsidiaries as of any date that the Leverage Ratio is calculated, the ratio of (a) Funded Debt of the Credit Parties

 

22

 

and their Subsidiaries as of such date to (b)(i) EBITDA for the Credit Parties and their Subsidiaries for the applicable calculation period.  For purposes of calculating the Leverage Ratio, the components of the Leverage Ratio shall be determined on a Consolidated basis and the EBITDA component shall be determined for the four most recent consecutive fiscal quarters of the Credit Parties ending on or prior to the date of determination.

 

LIBOR Borrowing shall mean, as of any date, that portion of the principal balance of the Loans bearing interest at the Adjusted LIBOR Rate as of such date.

 

LIBOR Lending Office shall mean, with respect to any Lender, the office of such Lender specified as its “LIBOR Lending Office” opposite or below its name on the signature pages hereof, or (if no such office is specified, its Domestic Lending Office), or such other office of such Lender as such Lender may from time to time specify in writing to the Borrower and the Agent.

 

LIBOR Rate shall mean, with respect to any LIBOR Borrowing for any Interest Period, an interest rate per annum equal to the rate appearing on Page 3750 of the Dow Jones Market Service (or, if no such page exists, on any successor or substitute page providing rate quotations comparable to those currently provided on such page of the Dow Jones Market Service, as determined by the Agent from time to time for purposes of providing quotations of interest rates applicable to dollar deposits in the London interbank market) at approximately 11:00 a.m., London time, two Business Days before the commencement of such Interest Period as the composite offered rate for dollar deposits approximately equal in principal amount to the Agent’s portion of such LIBOR Borrowing and for a maturity equal to the applicable Interest Period.  In the event that such rate is not available at such time for any reason, then the “LIBOR Rate” with respect to such LIBOR Borrowing for such Interest Period shall be the average interest rate per annum (rounded upwards, if necessary, to the next 1/16 of 1%) at which dollar deposits of $5,000,000 and for a maturity equal to the applicable Interest Period are offered by the principal London office of the Agent in immediately available funds in the London interbank market at approximately 11:00 a.m., London time, two Business Days before the commencement of such Interest Period.

 

Lien shall mean, with respect to any asset of any Person, (a) any mortgage, pledge, charge, encumbrance, security interest, collateral assignment or other lien or restriction of any kind on such asset, whether based on common law, constitutional provision, statute or contract, (b) the interest of any vendor or a lessor under any conditional sale agreement, title retention agreement or capital lease relating to such asset, (c) in the case of securities, any purchase option, call or similar right of a third party with respect to such securities, or (d) any other right of or arrangement with any creditor to have such creditor’s claim satisfied out of such assets, or the proceeds therefrom, prior to the general creditors of such Person owning such assets.

 

Loan Documents shall mean this Agreement, the Notes, the Applications, the Security Documents, the Guaranties, the Contribution Agreement, the Joinder Agreements, the Letters of Credit, the First Lien Intercreditor Agreement, the Second Lien Intercreditor Agreement, all instruments, certificates and agreements now or hereafter executed and delivered to the Agent and/or the Lenders in connection with or pursuant to any of the foregoing (including without limitation, any fee letter between the Agent, JPMorgan and/or any of its Affiliates and the

 

23

 

Borrower relating to the transactions contemplated by this Agreement), and all amendments, modifications, renewals, extensions, increases and rearrangements of, and substitutions for, any of the foregoing.

 

Loans shall mean the Revolving Loans and the Swingline Loans.  Loan shall mean any one of the Revolving Loans or the Swingline Loans.

 

Lockbox Agreement shall collectively mean one or more lockbox agreements required by the Agent, in Proper Form, to be executed and delivered to JPMorgan by the Borrower and each of its Subsidiaries required by the Agent, together with all modifications and/or replacements thereof which are approved in writing by the Agent, for purposes of facilitating the collection of Accounts in accordance with the terms of Section 6.15 hereof.  On or prior to the Closing Date, the Borrower and each of its applicable Subsidiaries has executed and delivered to JPMorgan one or more Lockbox Agreements in Proper Form.  No Inactive Subsidiary shall be required to execute and deliver any Lockbox Agreement unless and until such Inactive Subsidiary is required to become a Guarantor under the terms of Section 6.10.

 

Material Adverse Effect shall mean a material adverse effect on (a) the business, assets, property, or condition (financial or otherwise) of the Credit Parties taken as a whole, (b) the ability of the Credit Parties to perform or pay the Obligations in accordance with the terms hereof or of any other Loan Document, (c) the validity or enforceability of this Agreement, any of the Notes or any other Loan Documents or the rights or remedies of the Agent or the Lenders hereunder or thereunder, or (d) the validity or enforceability of the Agent’s Lien on any material portion of the Collateral or the priority of such Lien.

 

Monthly Unaudited Financial Statements shall mean the financial statements of the Credit Parties and their Subsidiaries, including all notes thereto, which statements shall include (a) a balance sheet as of the end of the respective calendar month or fiscal quarter, as applicable, (b) a statement of operations for such respective calendar month or fiscal quarter, as applicable, and for the fiscal year to date, subject to normal year-end adjustments, all setting forth in comparative form the corresponding figures for the corresponding period of the preceding fiscal year and for the Credit Parties’ Consolidated projections for such period and (c) a statement of cash flows for the fiscal year to date, subject to normal year-end adjustments, setting forth in comparative form the corresponding figures in the corresponding period of the preceding fiscal year and for the Credit Parties’ Consolidated projections for such period, all prepared in reasonable detail and in accordance with GAAP and certified by a Responsible Officer of the Parent as fairly and accurately presenting in all material respects the financial condition and results of operations of the Credit Parties and their Subsidiaries, on a Consolidated basis, at the dates and for the periods indicated therein.  The Monthly Unaudited Financial Statements for the Credit Parties and their Subsidiaries shall be prepared on a Consolidated basis, and to the extent required by the Agent, a consolidating basis, the parties recognizing that such consolidating statements will be prepared in accordance with GAAP only to the extent normal and customary.

 

Mortgages shall mean any mortgage, deed of trust or other agreement which conveys or evidences a Lien in favor of the Agent, for the ratable benefit of the Lenders, on real property (including the Real Estate, other than Excluded Real Estate) of any Credit Party (other than the Parent), including any amendment, modification or supplement thereto.

 

24

 

Net Income shall mean, for any period, the consolidated net income (or loss) of the Credit Parties and their Subsidiaries, determined on a Consolidated basis in accordance with GAAP; provided that there shall be excluded (a) the income (or deficit) of any Person accrued prior to the date it becomes a Subsidiary of any Credit Party or is merged into or consolidated with any Credit Party or any of its Subsidiaries, (b) the income (or deficit) of any Person (other than a Subsidiary of any Credit Party) in which any Credit Party or any of its Subsidiaries has an ownership interest, except to the extent that any such income is actually received by such Credit Party or such Subsidiary in the form of dividends or similar distributions and (c) the undistributed earnings of any Subsidiary of any Credit Party to the extent that the declaration or payment of dividends or similar distributions by such Subsidiary is not at the time permitted by the terms of any contractual obligation (other than under any Loan Document) or any Legal Requirement applicable to such Subsidiary.

 

Net Working Capital shall mean, on any date of calculation thereof, the remainder of (a) the aggregate amount of Eligible Accounts and Eligible Inventory (valued, in each case, at the lower of cost or fair market value on a first-in first-out basis) as determined in accordance with GAAP consistently applied, minus (b) the Consolidated current liabilities of all Credit Parties determined on such date in accordance with GAAP.

 

Net Recovery Rate shall mean the “net recovery value percentage” or “net recovery rate” under an orderly liquidation scenario for the Inventory or Equipment, as applicable, of the applicable Credit Parties, as specifically set forth and described in the most recent “net orderly liquidation value” appraisal of such Inventory or Equipment, as applicable, received by and acceptable to the Agent in all respects.

 

Notes shall mean the Revolving Credit Notes and the Swingline Note.  Note shall mean any one of such promissory notes.

 

Obligations shall mean, without duplication, all obligations, liabilities and Indebtedness of the Borrower and the Guarantors with respect to (a) the Security Documents and all other Loan Documents, including without limitation, (i) the principal of and interest on the Loans and (ii) the payment or performance of all other obligations, liabilities and Indebtedness of the Borrower or the Guarantors to the Agent and the Lenders hereunder, under the Notes, under the Letters of Credit, under the Applications or under any one or more of the other Loan Documents, including all fees, costs, expenses and indemnity obligations hereunder and thereunder, (b) all Hedging Obligations at any time entered into by the Borrower or any of its Subsidiaries with the Agent, JPMorgan, any other Lender or any of their respective Affiliates, and (c) all Cash Management Obligations.  The Obligations include interest (including post-petition interest, whether or not such interest would be an allowable claim under any applicable bankruptcy or other similar proceeding) and other obligations accruing or arising after (a) commencement of any case under any bankruptcy or similar laws by or against the Borrower or any Guarantor or (b) the personal liability of the Borrower or any Guarantor for the Obligations shall be discharged or otherwise cease to exist by operation of law or for any other reason.

 

Officer’s Certificate shall mean a certificate substantially in the form of Exhibit C attached hereto.

 

25

 

Organizational Documents shall mean, with respect to a corporation, the certificate of incorporation, articles of incorporation and bylaws of such corporation; with respect to a limited partnership, the limited partnership agreement and certificate of limited partnership of such limited partnership; with respect to a joint venture, the joint venture agreement establishing such joint venture; with respect to a limited liability company, the articles of organization or certificate of formation and regulations or limited liability company agreement of such limited liability company; and with respect to a trust, the instrument establishing such trust; in each case including any and all modifications thereof as of the date of the Loan Document referring to such Organizational Document and any and all future modifications thereof which are materially adverse to the Lenders and which are consented to by the Agent.

 

Parent shall mean collectively Walco International Holdings, Inc. a Delaware corporation, Steer Intermediate Corporation, a Delaware corporation, Walco Holdings, Inc., a Delaware corporation, and Walco Intermediate, Inc., a Delaware corporation.  When the context of any applicable provision hereof requires that each such entity be referred to separately and not collectively, the term Parent shall be construed accordingly.

 

Parties shall mean all Persons other than the Agent, the Collateral Agent or any Lender executing any Loan Documents.

 

PBGC shall mean the Pension Benefit Guaranty Corporation.

 

Permitted Affiliate Transactions shall mean any of the following:  (a) transactions with or among any Credit Party and any wholly-owned Subsidiary of any Credit Party that is a Guarantor; (b) reasonable and customary directors’ fees, reasonable and customary directors’ indemnifications and similar arrangements for directors and officers of the Credit Parties or any of its Subsidiaries entered into in the ordinary course of business, together with any payments made under any such indemnification arrangements; (c) customary and reasonable loans and advances to officers, directors and employees of the Credit Parties or any of their Subsidiaries for travel, entertainment, moving and other relocation expenses, in each case made in the ordinary course of business; (d) the incurrence of intercompany Indebtedness permitted pursuant to Section 7.1(g) hereof; (e) Permitted Management Fees; and (f) other transactions, contracts or agreements existing on the date of this Agreement and which are set forth on Schedule 7.6 attached hereto, together with any renewals and extensions of such existing transactions, contracts or agreements, so long as such renewals and extensions are upon terms and conditions substantially identical to the terms and conditions set forth in such existing transactions, contracts and agreements (or otherwise no less favorable to the applicable Credit Party and its Subsidiaries, as applicable).

 

Permitted Discretion shall mean a determination made, in good faith and in the exercise of reasonable (from the perspective of a secured asset based lender) business judgment, and in the event of any material change in the determination of any Reserves, the Borrowing Base or eligibility of any components of the Borrowing Base made by the Agent exercising its Permitted Discretion, the Administrative Agent shall use reasonable efforts to give Borrower written notice thereof promptly thereafter.

 

26

 

Permitted Investment Securities shall mean each of the following, to the extent the same is pledged as additional Collateral hereunder and is subject to a first priority perfected Lien in favor of the Agent for the ratable benefit of the Lenders (including a control or dominion agreement from any applicable Person in favor of the Agent that is in all respects satisfactory to the Agent):  (a) readily marketable, direct obligations of the United States of America or any agency or wholly owned corporation thereof which are backed by the full faith and credit of the United States, maturing within one (1) year after the date of acquisition thereof, (b) certificates of deposit, commercial paper (if rated no lower than A-1/P-1) or other short-term direct obligations of (i) JPMorgan or (ii) any other domestic financial institution having capital and surplus in excess of $5,000,000,000, maturing within six months after the date of acquisition thereof, (c) money market funds having aggregate assets in excess of $5,000,000,000, and (d) other Investments mutually agreed to in writing by the Borrower and the Agent.

 

Permitted Management Fees shall mean management fees, monitoring fees and/or service fees payable to Charlesbank and/or any of its Affiliates in an amount up to, but not exceeding $250,000 in the aggregate during any fiscal year of the Credit Parties, plus reimbursement to Charlesbank and/or any of its Affiliates of reasonable and customary out-of-pocket expenses incurred in connection with such management services provided by Charlesbank and/or any of its Affiliates, provided that if any Event of Default has occurred and is continuing at the time for payment of such fees or expense reimbursement, as applicable (or would occur after giving effect thereto), such fees and expense reimbursement shall accrue and be payable only upon the cure (or waiver) of such Event of Default.

 

Permitted Overadvance shall have the meaning specified in Section 2.2(h) hereof.

 

Person shall mean any individual, corporation, business trust, unincorporated organization or association, partnership, joint venture, limited liability company, Governmental Authority or any other form of entity.

 

Plan shall mean any plan subject to Title IV of ERISA and maintained for employees of the Borrower or of any member of a “controlled group of corporations”, as such term is defined in the Code, of which the Borrower, any of its Subsidiaries or any ERISA Affiliate it may acquire from time to time is a part, or any such plan to which the Borrower, any of its Subsidiaries or any ERISA Affiliate is required to contribute on behalf of its employees.

 

PPSA shall mean the Personal Property Security Act (Alberta), as amended.

 

Prime Rate shall mean the rate of interest per annum publicly announced from time to time by JPMorgan, or its successor financial institution, if any, at its principal office in New York City as its prime rate in effect at such time.  Without notice to the Borrower or any other Person, the Prime Rate shall change automatically from time to time as and in the amount by which said prime rate shall fluctuate, with each such change to be effective as of the date of each change in such prime rate.  THE PRIME RATE IS A REFERENCE RATE AND DOES NOT NECESSARILY REPRESENT THE LOWEST OR BEST RATE ACTUALLY CHARGED BY JPMORGAN OR SUCH SUCCESSOR FINANCIAL INSTITUTION TO ANY OF ITS CUSTOMERS.  JPMORGAN OR SUCH SUCCESSOR FINANCIAL INSTITUTION MAY

 

27

 

MAKE COMMERCIAL LOANS OR OTHER LOANS AT RATES OF INTEREST AT, ABOVE AND BELOW THE PRIME RATE.

 

Principal Office shall mean the principal office in New York City of the Agent, or such other place as the Agent may from time to time by notice to the Borrower designate.

 

Prohibited Transaction shall mean any non-exempt prohibited transaction set forth in Section 406 of ERISA or Section 4975 of the Code.

 

Proper Form shall mean in form and substance satisfactory to the Agent.

 

Property shall mean any interest in any kind of property or asset, whether real, personal or mixed, tangible or intangible.

 

Rate Selection Date shall mean that Business Day which is (a) in the case of the Alternate Base Rate Borrowings, the date of such borrowing, or (b) in the case of LIBOR Borrowings, the date three (3) Business Days preceding the first day of any proposed Interest Period.

 

Rate Selection Notice shall have the meaning specified in Section 2.8(b)(1) hereof.

 

Real Estate shall mean each of the real Properties listed on Schedule 1.1(a) attached hereto.

 

Refinancing Indebtedness shall mean any Indebtedness of any Credit Parties or any of its Subsidiaries issued in exchange for, or the net proceeds of which are used to extend, refinance, renew, replace, defease or refund, other Indebtedness of such Person, provided, that:

 

(a)           such Refinancing Indebtedness is incurred only by such Persons who are obligors on the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded,

 

(b)           the principal amount of such Refinancing Indebtedness does not exceed the then outstanding principal amount of the Indebtedness so extended, refinanced, renewed, replaced, defeased or refunded;

 

(c)           the interest rate or rates to accrue under such Refinancing Indebtedness do not exceed the lesser of (i) the interest rate or rates then accruing on the Indebtedness so extended, refinanced, renewed, replaced, defeased or refunded or (ii) the prevailing market interest rate or rates which are then applicable to, and generally available for, Indebtedness which is similar in type, amount, maturity and other terms to the Indebtedness so extended, refinanced, renewed, replaced, defeased or refunded;

 

(d)           the maturities, amortization schedules, covenants, defaults, remedies, subordination provisions (with respect to any Subordinated Indebtedness), collateral security provisions (or absence thereof) and other terms of such Refinancing Indebtedness are in each case the same or more favorable to the applicable Credit Party and/or its applicable Subsidiaries as those in the Indebtedness so extended, refinanced, renewed, replaced, defeased or refunded;

 

28

 

(e)           no Default or Event of Default has occurred and is continuing or would result from the issuance or origination of such Refinancing Indebtedness;

 

(f)            if the Indebtedness that is extended, refinanced, renewed, replaced, defeased or refunded was subordinated in right of payment to the Obligations and/or priority as to the Liens of the Collateral Agent for the ratable benefit of the Lenders, then the terms and conditions of such Refinancing Indebtedness must include subordination terms and conditions that are at least as favorable to the Agent and the Lenders as those that were applicable to the extended, refinanced, renewed, replaced, defeased or refunded Indebtedness; and

 

(g)           if the Indebtedness being refinanced is subject to the First Lien Intercreditor Agreement and the Second Lien Intercreditor Agreement, such Refinancing Indebtedness is either (1) permitted under the terms of the First Lien Intercreditor Agreement and the Second Lien Intercreditor Agreement and will remain subject to the terms of the First Lien Intercreditor Agreement and the Second Lien Intercreditor Agreement or (2) subject to an intercreditor agreement on terms no less favorable to the Agent and the Lenders as those contained in the First Lien Intercreditor Agreement and the Second Lien Intercreditor Agreement.

 

Regulation D shall mean Regulation D of the Board of Governors of the Federal Reserve System from time to time in effect and shall include any successor or other regulation relating to reserve requirements applicable to member Lenders of the Federal Reserve System.

 

Regulatory Change shall mean, with respect to any Lender, any change on or after the date of this Agreement in any Legal Requirement (including Regulation D) or the adoption or making on or after such date of any Legal Requirement applying to a class of Lenders including such Lender under any Legal Requirement (whether or not having the force of law) by any Governmental Authority charged with the interpretation or administration thereof.

 

Reportable Event shall mean a “reportable event” as defined in Section 4043(c) of ERISA for which the notice requirement is not waived by the regulations thereunder.

 

Request for Extension of Credit shall mean a written request for extension of credit substantially in the form of Exhibit D attached hereto.

 

Required Lenders shall mean Lenders having greater than 66.67% of the Total Revolving Credit Commitment; provided that after termination of the Total Revolving Credit Commitment, Required Lenders shall mean Lenders having greater than 66.67% of the aggregate amount of the outstanding Loans (other than the Swingline Loans), Letter of Credit Exposure Amount and Swingline Exposure; and provided further, however, if only two (2) Lenders are then parties to this Agreement, Required Lenders shall mean both of such Lenders.

 

Requirements of Environmental Law shall mean all requirements imposed by any law (including The Resource Conservation and Recovery Act, The Comprehensive Environmental Response, Compensation, and Liability Act, the Clean Water Act, the Clean Air Act, and any state analogues of any of the foregoing), rule, regulation, or order of any Governmental Authority which relate to (i) pollution, protection or clean-up of the air, surface water, ground

 

29

 

water, soils, or subsurface strata; (ii) solid, liquid or gaseous waste or Hazardous Substance generation, recycling, reclamation, release, threatened release, treatment, storage, disposal or transportation; (iii) exposure of Persons or property to Hazardous Substances; (iv) the manufacture, presence, processing, distribution in commerce, use, discharge, releases, threatened releases, or emissions of Hazardous Substances into the environment; or (v) the storage of any Hazardous Substances.  Requirement of Environmental Law shall mean any one of them.

 

Reserves shall mean any and all reserves established by the Agent in its Permitted Discretion with respect to Availability, the Borrowing Base or in accordance with another provision of this Agreement or any other Loan Document for purposes of reducing Borrower’s ability to utilize any portion of the Unused Revolving Credit Commitments of all Lenders, including without limitation, Reserves established in the aggregate amount of all liabilities in respect of all Cash Management Obligations and all net liabilities in respect of all Hedging Obligations, as calculated on a basis satisfactory to the Agent and in accordance with accepted practice, of the Borrower or any of its Subsidiaries to Agent or any other Lender.

 

Responsible Officer shall mean, with respect to any Person, the chief executive officer, the president, any vice president, the chief financial officer, the controller or the treasurer of such Person.

 

Revolving Credit Commitment shall mean, as to any Lender, the obligation of such Lender to make Revolving Loans and incur liability for the Letter of Credit Exposure Amount and the Swingline Loans in an aggregate principal amount at any one time outstanding up to, but not exceeding, the amount set forth as such Lender’s Revolving Credit Commitment in Schedule 1.1(b) attached hereto (as the same may be reduced from time to time pursuant to Section 2.4 hereof).

 

Revolving Credit Commitment Percentage shall mean, with respect to any Lender, the ratio, expressed as a percentage, of such Lender’s Revolving Credit Commitment to the Total Revolving Credit Commitment.

 

Revolving Credit Exposure shall mean on any day, as to a particular Lender, the sum of (a) the outstanding principal balance of such Lender’s Revolving Credit Note on such day plus (b) the product of (i) such Lender’s Revolving Credit Commitment Percentage times (ii) the sum of the Letter of Credit Exposure Amount and the Swingline Exposure on such day.

 

Revolving Credit LIBOR Borrowing shall mean, as of any date, that portion of the principal balance of the Revolving Loans bearing interest at the Adjusted LIBOR Rate as of such date.

 

Revolving Credit Notes shall mean the promissory notes, each substantially in the form of Exhibit A attached hereto, of the Borrower evidencing the Revolving Loans, payable to the order of the respective Lenders in the amount of said Lender’s Revolving Credit Commitment, and all renewals, extensions, modifications, rearrangements and replacements thereof substitutions therefor.  Revolving Credit Note shall mean any of such promissory notes.

 

Revolving Credit Termination Date shall mean the earlier of (a) June 30, 2010, (b) any date that the Total Revolving Credit Commitment is terminated in full by the Borrower pursuant

 

30

 

to Section 2.4 hereof, and (c) any date the Revolving Credit Termination Date is accelerated or the Total Revolving Credit Commitment is accelerated by the Agent pursuant to Section 8.1 hereof.

 

Revolving Loans shall mean the Revolving Loans made pursuant to Section 2.1 hereof.  Revolving Loan shall mean one of such Revolving Loans.

 

Second Lien Debt shall mean the Indebtedness of the Borrower evidenced by one or more senior secured notes issued by the Borrower, at a par value of $85,000,000 in aggregate principal amount, said senior notes to be (a) secured by a secondary Lien against the Collateral which is in all respects inferior and subordinate to the Collateral Agent’s Lien against the Collateral for the ratable benefit of the Lenders and (b) due not earlier than (i) June 30, 2011 for the $40,000,000 “Loan A” portion thereof as described in the Second Lien Debt Purchase Agreement and (ii) five (5) years after the Closing Date for the $45,000,000 “Loan B” portion thereof as described in the Second Lien Debt Purchase Agreement, and to otherwise be in Proper Form.

 

Second Lien Debt Documents shall mean the senior secured notes evidencing the Second Lien Debt, the Second Lien Debt Purchase Agreement and all other agreements, documents and instruments executed and delivered in connection therewith, in each case as in effect (i) on June 30, 2005 for the $40,000,000 “Loan A” portion thereof as described in the Second Lien Debt Purchase Agreement, and (ii) as of the Closing Date for the $45,000,000 “Loan B” portion thereof as described in the Second Lien Debt Purchase Agreement, as each of the same may be amended, modified, supplemented, renewed, restated or replaced in accordance with the terms of this Agreement.

 

Second Lien Debt Purchase Agreement shall mean the Amended and Restated Secured Term Loan Agreement dated effective as of the Closing Date, by and among the Borrower, the other Credit Parties and Merrill Lynch PCG, Inc., as the initial purchaser and holder of all of the Second Lien Debt, as the same may be amended, modified, supplemented, renewed, restated or replaced in accordance with the terms of this Agreement.

 

Second Lien Debt Transaction shall mean the transactions contemplated to occur under or in connection with the Second Lien Debt Documents.

 

Second Lien Intercreditor Agreement shall mean the Amended and Restated Intercreditor Agreement dated effective as of the Closing Date, by and among the Borrower, the other Credit Parties, the Collateral Agent, as the representative of the holders of the Obligations and the holders of the Term Loan Debt, and Merrill Lynch PCG, Inc., as the representative of the holders of the Second Lien Debt, as the same may be amended, modified, supplemented, renewed, restated or replaced in accordance with the terms of this Agreement.

 

Security Agreements shall mean (a) the Amended and Restated Security Agreement (Personal Property-Borrower) dated effective as of the Closing Date, between the Borrower and the Collateral Agent, for the ratable benefit of the Lenders and the holders of the Term Loan Debt, covering all Accounts, Inventory, Equipment and all other tangible and intangible personal Property of the Borrower as more particularly described therein, (b) the Amended and Restated Security Agreement (Personal Property-Domestic Subsidiaries) dated effective as of the Closing

 

31

 

Date, between each of the Borrower’s Domestic Subsidiaries that is a Guarantor and the Collateral Agent, for the ratable benefit of the Lenders and the holders of the Term Loan Debt, covering all Accounts, Inventory, Equipment and other tangible and intangible personal Property of each of the Borrower’s Domestic Subsidiaries that is a Guarantor as more particularly described therein, as the same may hereafter be joined in pursuant to a Joinder Agreement, (c) the Amended and Restated Security Agreement (Personal Property-Canadian Subsidiaries) dated effective as of the Closing Date, between each of the Borrower’s Canadian Subsidiaries that is a Guarantor and the Collateral Agent, for the ratable benefit of the Lenders and the holders of the Term Loan Debt, covering all Accounts, Inventory, Equipment and other tangible and intangible personal Property of each of the Borrower’s Canadian Subsidiaries that is a Guarantor as more particularly described therein, as the same may hereafter be joined in pursuant to a Joinder Agreement, (d) the Amended and Restated Pledge Agreement dated effective as of the Closing Date, between the Borrower and the Collateral Agent, for the ratable benefit of the Lenders and the holders of the Term Loan Debt, covering (i) all issued and outstanding Equity Interests in each of the Borrower’s direct Subsidiaries that is a Guarantor and (ii) 65% of all issued and outstanding Equity Interests in each of the Borrower’s non-Domestic Subsidiaries that is not a Guarantor, (e) the Amended and Restated Pledge Agreement dated effective as of the Closing Date, between Province Livestock Supply, Ltd. and the Collateral Agent, for the ratable benefit of the Lenders and the holders of the Term Loan Debt, covering all issued and outstanding Equity Interests in each of the Borrower’s Subsidiaries that is a Guarantor and for which Province Livestock Supply, Ltd. is the parent, (f) the Amended and Restated Pledge Agreement dated effective as of the Closing Date, between Walco Intermediate, Inc. and the Collateral Agent for the ratable benefit of the Lenders and the holders of the Term Loan Debt, covering all Equity Interests in the Borrower, (g) any and all other security agreements, pledge agreements, collateral assignments or other similar documents now or hereafter executed in favor of the Collateral Agent, for the ratable benefit of the Lenders and the holders of the Term Loan Debt, as security for the payment or performance of any and/or all of the Obligations, and (h) any amendment, modification, restatement or supplement of all or any of the above-described agreements and assignments.

 

Security Documents shall mean the Security Agreements, the Mortgages, all related financing statements and any and all other agreements, mortgages, deeds of trust, chattel mortgages, security agreements, pledges, guaranties, assignments of income, assignments of contract rights, assignments or pledges of stock or partnership interests, standby agreements, subordination agreements, undertakings and other instruments and financing statements now or hereafter executed and delivered as security for the payment and performance of the Obligations, as any of them may from time to time be amended, modified, restated or supplemented.  Notwithstanding the foregoing or any other provision herein or in any Term Loan Debt Document or any Security Document to the contrary, the real property Collateral and the Liens of any Security Documents covering any real property Collateral shall only secure the Obligations and the Collateral Obligations (as defined in the First Lien Intercreditor Agreement) and shall not secure any of the Term Loan Debt.

 

Standby Letters of Credit shall mean all standby letters of credit issued by the Agent for the account or liability of the Borrower pursuant to the terms set forth in this Agreement.

 

32

 

Statutory Reserves shall mean a fraction (expressed as a decimal), the numerator of which is the number one and the denominator of which is the number one minus the aggregate of the maximum reserve percentage (including without limitation, any marginal, special, emergency or supplemental reserves) expressed as a decimal, established by the Board of Governors of the Federal Reserve System of the United States and any other banking authority to which any Lender is subject with respect to the Adjusted LIBOR Rate for Eurocurrency Liabilities (as defined in Regulation D), including without limitation, those reserve percentages imposed under Regulation D.

 

Subordinated Indebtedness shall mean, with respect to any Credit Party, Indebtedness subordinated in right of payment to the Credit Parties’ monetary Obligations on terms satisfactory to and approved in writing by the Agent and the Required Lenders, in their discretion, so long as all other terms thereof (including without limitation, regularly scheduled payments and financial and negative covenants) are satisfactory to and approved in writing by the Agent and the Required Lenders, in their discretion.

 

Subsidiary shall mean, as to a particular parent Business Entity, any Business Entity of which more than fifty percent (50%) of the Equity Interests issued by such Business Entity is at the time directly or indirectly owned by such parent Business Entity or by one or more of its Affiliates.

 

Swingline Exposure means, at any time, the aggregate principal amount of all Swing Loans outstanding at such time.

 

Swingline Lender shall mean JPMorgan or any other Lender that becomes the Agent, in each case in its capacity as the Swingline Lender hereunder.

 

Swingline Loans shall mean the Swingline Loans made pursuant to Section 2.11(a) hereof.  Swingline Loan shall mean any one of such Swingline Loans.

 

Swingline Note shall mean the promissory note, substantially in the form of Exhibit B attached hereto, of the Borrower evidencing the Swingline Loans, payable to the order of the Swingline Lenders in the original principal amount of $15,000,000, and all renewals, extensions, modifications, rearrangements and replacements thereof substitutions therefor.

 

Term Loan Debt shall mean the Indebtedness of the Borrower evidenced by one or more senior secured notes issued by the Borrower, at a par value of $45,000,000 in aggregate principal amount, said senior notes to be (a) secured by a first Lien against the Collateral which is governed by the terms of the First Lien Intercreditor Agreement and (b) due not earlier than May 31, 2011 and to otherwise be in Proper Form.

 

Term Loan Debt Documents shall mean the senior secured notes evidencing the Term Loan Debt, the Term Loan Debt Purchase Agreement and all other agreements, documents and instruments executed and delivered in connection therewith, in each case as in effect on the Closing Date and as each of the same may be amended, modified, supplemented, renewed, restated or replaced in accordance with the terms of this Agreement.

 

33

 

Term Loan Debt Purchase Agreement shall mean the Term Loan Agreement dated effective as of the Closing Date, by and among the Borrower, the other Credit Parties, the initial purchaser(s) and holder(s) of all of the Term Loan Debt, and Wilmington Trust Company, a Delaware banking corporation, as the administrative agent for such holder(s) of the Term Loan Debt, as the same may be amended, modified, supplemented, renewed, restated or replaced in accordance with the terms of this Agreement.

 

Term Loan Debt Transaction shall mean the transactions contemplated to occur under or in connection with the Term Loan Debt Documents.

 

Total Revolving Credit Commitment shall mean, on any day, the aggregate of all of the Lenders’ Revolving Credit Commitments on such day.  As of the Closing Date, the Total Revolving Credit Commitment is $110,000,000.

 

Trade Letters of Credit shall mean all trade or documentary letters of credit issued by the Agent for the account or liability of the Borrower pursuant to the terms set forth in this Agreement.

 

Tri-Party Agreements shall collectively mean tri-party agreements, in Proper Form, to be executed and delivered by and among JPMorgan, the Borrower (and each of its Subsidiaries required by the Agent) and the applicable financial institutions described in Schedule 6.15 attached hereto, together with all modifications and/or replacements thereof which are approved in writing by the Collateral Agent, for purposes of either (a) facilitating the collection of Accounts in accordance with the terms of Section 6.15 hereof, to the extent payments of Accounts are processed through cash management services (including lockbox arrangements) provided by any such specified financial institution and/or deposited in one or more accounts maintained by the Borrower or its applicable Subsidiary with any such specified financial institution or (b) evidencing control for purposes of perfection of the Collateral Agent’s Lien, for the ratable benefit of the Lenders, against one or more deposit accounts maintained by the Borrower or its applicable Subsidiary with any such specified financial institution.  As of the Closing Date, Schedule 6.15 attached hereto describes all such accounts to be covered by a Tri-Party Agreement and specifies whether the applicable Tri-Party Agreement is for purposes of facilitating the collection of Accounts or perfecting the Collateral Agent’s Lien against such accounts.  The Borrower agrees that neither the Borrower nor any of its Subsidiaries shall establish any additional deposit accounts permitted to be maintained hereunder with a financial institution other than JPMorgan unless such additional deposit accounts are covered by a Tri-Party Agreement.

 

UCC shall mean the Uniform Commercial Code as in effect from time to time in the State of New York or of any other state the laws of which are required as a result thereof to be applied in connection with the attachment, perfection or priority of, or remedies with respect to, the Agent’s or any Lender’s Lien on any Collateral.

 

Unfinanced Capital Expenditures shall mean all Capital Expenditures other than Financed Capital Expenditures.

 

34

 

Unfinanced Cash Dividends shall mean, with respect to any Person for any period, all Cash Dividends of such Person for such period that are not paid either from net proceeds of the Term Loan Debt or from net proceeds of any other permitted Indebtedness of such Person incurred after the Closing Date.

 

Unused Revolving Credit Commitment shall mean, as to a particular Lender, the daily difference of such Lender’s Revolving Credit Commitment on such day less the Revolving Credit Exposure applicable to such Lender on such day.

 

1.2           Accounting Terms and Determinations.  Except where specifically otherwise provided:

 

(a)           The symbol “$” and the word “dollars” shall mean lawful money of the United States of America.

 

(b)           Any accounting term not otherwise defined shall have the meaning ascribed to it under GAAP.  If any of the Credit Parties are required after the Closing Date to implement any change(s) in its accounting principles and practice as a result of any changes in GAAP mandated by the Financial Accounting Standards Board or successor organization, and if such change(s) result in any material change in the method of calculation of the Fixed Charge Coverage Ratio, Leverage Ratio and/or any other financial covenant under this Agreement, then for all periods after the date of implementation of such change(s) until one or more appropriate amendments of this Agreement addressing such change(s) in GAAP are negotiated, executed and delivered by the parties hereto in a form acceptable to all such parties, the Fixed Charge Coverage Ratio, Leverage Ratio and/or such other financial covenant, as applicable, shall be calculated hereunder utilizing GAAP as in effect prior to such change(s).

 

(c)           Unless otherwise expressly provided, any accounting concept and all financial covenants shall be determined on a Consolidated basis, and financial measurements shall be computed without duplication.

 

(d)           Wherever the term “including” or any of its correlatives appears in the Loan Documents, it shall be read as if it were written “including (by way of example and without limiting the generality of the subject or concept referred to)”.

 

(e)           Wherever the word “herein” or “hereof is used in any Loan Document, it is a reference to that entire Loan Document and not just to the subdivision of it in which the word is used.

 

(f)            References in any Loan Document to Section numbers are references to the Sections of such Loan Document.

 

(g)           References in any Loan Document to Exhibits, Schedules, Annexes and Appendices are to the Exhibits, Schedules, Annexes and Appendices to such Loan Document, and they shall be deemed incorporated into such Loan Document by reference.

 

(h)           Any term defined in the Loan Documents which refers to a particular agreement, instrument or document shall also mean, refer to and include all modifications,

 

35

 

amendments, supplements, restatements, renewals, extensions and substitutions of the same; provided, that nothing in this subsection shall be construed to authorize any such modification, amendment, supplement, restatement, renewal, extension or substitution except as may be permitted by other provisions of the Loan Documents.

 

(i)            All times of day used in the Loan Documents mean local time in Chicago, Illinois.

 

(j)            Defined terms may be used in the singular or plural, as the context requires.

 

1.3           UCC and PPSA Changes.  All terms used herein which are defined in the UCC and/or the PPSA shall, unless otherwise provided, have the meanings ascribed to them in the UCC and/or the PPSA, as applicable, both as in effect on the date of this Agreement and as hereafter amended.  The parties intend that the terms used herein which are defined in the UCC and/or the PPSA, as applicable, have, at all times, the broadest and most inclusive meanings possible.  Accordingly, if the UCC and/or the PPSA, as applicable, shall in the future be amended or held by a court to define any term used herein more broadly or inclusively than the UCC and/or the PPSA, as applicable, in effect on the date of this Agreement, then such term as used herein shall be given such broadened meaning.  If the UCC and/or the PPSA, as applicable, shall in the future be amended or held by a court to define any term used herein more narrowly, or less inclusively, than the UCC and/or the PPSA, as applicable, in effect on the date of this Agreement, such amendment or holding shall be disregarded in defining terms used in this Agreement.

 

2.             Loans; Letters of Credit; Notes; Payments; Prepayments; Interest Rates.

 

2.1           Commitments.  Subject to the terms and conditions hereof, each Lender, severally and not jointly, agrees to make Revolving Loans to the Borrower from time to time on and after the Closing Date until, but not including, the Revolving Credit Termination Date, in an aggregate principal amount at any one time outstanding (including such Lender’s Revolving Credit Commitment Percentage of the Letter of Credit Exposure Amount and the Swingline Exposure at such time) up to, but not exceeding such Lender’s Revolving Credit Commitment.  Notwithstanding the foregoing, the aggregate principal amount of the Revolving Loans outstanding at any time shall not exceed (a) the lesser of (i) the Total Revolving Credit Commitment and (ii) the Borrowing Base at such time less (b) the Letter of Credit Exposure Amount and the Swingline Exposure at such time less (c) the aggregate amount of the items specified in clauses (b)(ii) through (b)(iv) of the definition of “Availability.”  Subject to the conditions herein, any such Revolving Loan prepaid prior to the Revolving Credit Termination Date may be reborrowed as an additional Revolving Loan by the Borrower pursuant to the terms of this Agreement.

 

2.2           Loans.

 

(a)           Subject to Sections 4.1 and 4.2 hereof, (i) all Loans (other than Swingline Loans) shall be advanced and made ratably by the Lenders in accordance with the Lenders’

 

36

 

respective Revolving Credit Commitments, and (ii) the initial Revolving Loans shall be made on the Closing Date by the Lenders upon the execution of this Agreement.

 

(b)           When requesting a Revolving Loan hereunder, the Borrower shall give the Agent notice of a request for a Loan in accordance with Section 4.1(a) hereof; provided, however, no notice of a request for a Revolving Loan in accordance with Section 4.1(a) hereof shall be required to be presented by the Borrower to the Agent if a check, wire transfer request or other item issued by the Borrower shall be presented for payment against any controlled disbursement account maintained with the Agent in connection with the account or accounts established and maintained by the Agent for the purposes of deposits and collections of Accounts in accordance with Section 6.15(a) hereof, and the Agent shall then cause the Lenders (subject to the settlement delay provisions of Section 2.2(f) hereof) to make a Revolving Loan for the purpose of crediting said controlled disbursement account in an amount sufficient to permit such check, wire transfer request or other item to be honored if (i) such Revolving Loan is to be made prior to the Revolving Credit Termination Date, (ii) the Availability would be equal to or greater than zero after giving effect to such Revolving Loan, and, if applicable, the resulting payment of any Obligations to be contemporaneously paid with the proceeds of such requested Revolving Loan, and (iii) no Default or Event of Default shall have occurred which is then continuing.  Each such Revolving Loan advanced for the purpose of crediting any such controlled disbursement account shall be deemed to be an Alternate Base Rate Borrowing until a Rate Selection Notice is otherwise properly presented for such Alternate Base Rate Borrowing converting such borrowing to a LIBOR borrowing.  Notwithstanding anything to the contrary contained in Section 2.11, if any request for a Loan in accordance with Section 4.1(a) hereof requests Revolving Loans in the form of Alternate Base Rate Borrowings, the Agent may make a Swingline Loan available to the Borrower in an aggregate amount not to exceed the amount of such requested Revolving Loans, and the aggregate amount of the corresponding requested Revolving Loans shall be reduced accordingly by the principal amount of such Swingline Loan.  Except as otherwise provided in the settlement delay provisions of Section 2.2(f) hereof, the Agent shall promptly advise the Lenders of any notice of a request for a Loan (other than a Swingline Loan) given pursuant to Section 4.1(a) or of any such Revolving Loan advanced for purposes of crediting any such controlled disbursement account and of each Lender’s portion of a requested borrowing (based on such Lender’s Revolving Credit Commitment Percentage).

 

(c)           Except as otherwise provided or specified in the settlement delay provisions of Section 2.2(f) below, each Lender shall make its Revolving Loans available on the proposed dates thereof by causing its Applicable Lending Office to pay the amount required to the Agent at the Principal Office in immediately available funds not later than 1:00 p.m., and the Agent shall as soon as practicable, but in no event later than 5:00 p.m. on such date, credit the amount so received to a general deposit account designated and maintained by the Borrower with the Agent at the Principal Office.  If a requested Revolving Loan shall not occur on the Closing Date or any date specified by the Borrower as set forth in the applicable Request for Extension of Credit, as the case may be, because all of the conditions for such Revolving Loan set forth herein or in any of the other Loan Documents shall not have been met, the Agent shall return the amounts so received from the Lenders in respect of such requested Revolving Loan to the applicable Lenders as soon as practicable.

 

37

 

(d)           The obligations of the Lenders hereunder are several and not joint; therefore, notwithstanding anything herein to the contrary:  (i) no Lender shall be required to make Revolving Loans at any one time outstanding in excess of such Lender’s Revolving Credit Commitment; (ii) if a Lender fails to make a Revolving Loan as and when required hereunder and the Borrower subsequently makes a repayment on the Revolving Loans, such repayment shall be shared among the non-defaulting Lenders in accordance with the respective Revolving Credit Commitment Percentages until each non-defaulting Lender has received its Revolving Credit Commitment Percentage of all of the outstanding Revolving Loans, after which the balance of such repayment shall be applied against such defaulting Lender’s Commitment Percentage of the outstanding Revolving Loans; and (iii) the failure of any Lender to make any Revolving Loan or any payment in respect of its participation in Swing Loans and Letter of Credit Advances shall not in itself relieve any other Lender of its obligation to lend hereunder (provided, that no Lender shall be responsible for the failure of any other Lender to make a Loan such other Lender is obligated to make hereunder).

 

(e)           The Revolving Loans made by the Lenders on any date and the Swing Loans made by the Swingline Lender shall be in integral multiples of $1.00; provided, however, that the LIBOR Borrowings made on any date shall be in minimum aggregate principal amounts of $1,000,000, with any increases over such minimal amount being in integral aggregate multiples of $500,000.

 

(f)            The arrangements between the Agent and the Lenders with respect to making and advancing the Revolving Loans and making payments under Letters of Credit shall be handled on the following basis:  no less than once a week, the Agent will provide each Lender with a statement showing, for the period of time since the date of the most recent of such statements previously provided, the aggregate principal amount of new Revolving Loans made to the Borrower, the aggregate amount of new Letter of Credit Advances which have not been reimbursed, the aggregate face amount of new Letters of Credit issued for the account of the Borrower, the aggregate principal amount of new Swingline Loans made to the Borrower, the amount of remittances and payments actually collected and applied by the Agent to reduce the outstanding principal balance of the Revolving Loans, to reduce the outstanding principal balance of the Swingline Loans and to reimburse Letter of Credit Advances during such period and the outstanding principal balances of the Revolving Loans and the Swingline Loans and the aggregate Letter of Credit Exposure Amount outstanding at the end of such period.  If a Lender’s pro-rata share (based on such Lender’s Revolving Credit Commitment Percentage) of the Revolving Loans and the unreimbursed Letter of Credit Advances made during such period exceeds such Lender’s pro-rata share of remittances and payments applied to reduce the Revolving Loans and reimburse Letter of Credit Advances during such period, the difference will be paid and made available in same day funds by such Lender to the Agent, and if such Lender’s pro-rata share (based on such Lender’s Revolving Credit Commitment Percentage) of remittances and payments applied to reduce the Revolving Loans and reimburse Letter of Credit Advances during such period exceeds such Lender’s pro-rata share (based on such Lender’s Revolving Credit Commitment Percentage) of the Revolving Loans and the unreimbursed Letter of Credit Advances made during such period, the difference will be paid and made available in same day funds by the Agent to such Lender.

 

38

 

(g)           The Agent shall render to the Borrower each month a statement of the Borrower’s account of all transactions of the type described in Section 2.2(f) hereof, which shall be deemed to be correct and accepted by and be binding upon the Borrower unless the Agent receives a written statement of the Borrower’s exceptions to such account statement within sixty (60) days after such statement was rendered to the Borrower.

 

(h)           Notwithstanding anything to the contrary set forth in this Section 2.2 or in any other provision of this Agreement, the Agent, on its own initiative and in its sole discretion, but for the ratable benefit of the Lenders, may extend Revolving Loans or issue Letters of Credit in excess of Availability (collectively “Permitted Overadvances”) in an aggregate amount at any one time not exceeding $10,000,000, upon and subject to the following terms:  (i) no Permitted Overadvances shall cause the aggregate amount of any Lender’s Revolving Credit Exposure to exceed such Lender’s Revolving Credit Commitment; (ii) no Permitted Overadvances shall be outstanding for more than thirty (30) consecutive days; (iii) either (A) the Agent in good faith believed that no Permitted Overadvance existed or would result at the time of such Permitted Overadvance or (B) the applicable Permitted Overadvance results from (1) a change in the standards of eligibility for any component of the Borrowing Base and/or an increase in Reserves as determined by the Agent in accordance with the other terms of this Agreement, (2) a determination by Agent that certain components previously included in the Borrowing Base should be excluded from eligibility under the Borrowing Base, or (3) the payment by the Agent of any amounts reasonably required to maintain, protect or realize upon the Collateral or to prevent a cessation of business by the Borrower or any of its Subsidiaries; and (iv) no more than two (2) Permitted Overadvances can be extended by the Agent during any 180 consecutive day period.

 

2.3           Commitment Fees.  In consideration of each Lender’s Revolving Credit Commitment, the Borrower agrees to pay to the Agent for the account of each Lender a commitment fee (each a “Commitment Fee”) (computed on the basis of the actual number of days elapsed in a year composed of 360 days, subject to the terms of Section 10.6 hereof) in an amount equal to the product of (A) 0.375% times (B) such Lender’s average Unused Revolving Credit Commitment for the applicable calculation period; provided, however, that such Lender’s pro rata share of the Swingline Exposure shall be disregarded for purposes of calculating such Lender’s Unused Revolving Credit Commitment for Commitment Fee purposes, except in respect of the Swingline Lender, whose Unused Revolving Credit Commitment for Commitment Fee purposes shall be reduced by the Swingline Exposure.  The Commitment Fee shall be due and payable in arrears (i) on the last Business Day of each September, December, March and June prior to the Revolving Credit Termination Date, commencing September 30, 2005, and (ii) on the Revolving Credit Termination Date, with each Commitment Fee to commence to accrue as of the date hereof and to be effective as to any reduction in the Total Revolving Credit Commitment pursuant to Section 2.4(a) below as of the date of any such decrease, and each Commitment Fee shall cease to accrue (except with respect to interest at the Default Rate on any unpaid portion thereof) on the Revolving Credit Termination Date.  All past due Commitment Fees shall bear interest at the Default Rate and shall be payable upon demand by the Agent.

 

39

 

2.4           Termination and Reductions of Commitments.

 

(a)           Upon at least five (5) Business Days’ prior irrevocable written notice to the Agent, the Borrower may at any time in whole permanently terminate, or from time to time in part permanently reduce (except as noted below), the Total Revolving Credit Commitment ratably among the Lenders in accordance with the amounts of their Revolving Credit Commitments; provided, however, that the Total Revolving Credit Commitment shall not be reduced at any time to an amount less than the aggregate of each Lender’s Revolving Credit Exposure outstanding at such time.  Each partial reduction of the Total Revolving Credit Commitment shall be in a minimum of $1,000,000, or an integral multiple of $100,000 in excess thereof.

 

(b)           Simultaneously with any termination or reduction of the Total Revolving Credit Commitment pursuant to Section 2.4(a) above, the Borrower hereby agrees to pay to each Lender, through the Agent, the Commitment Fee due and owing through and including the date of such reduction on the amount of the Revolving Credit Commitment of such Lender so reduced.

 

(c)           To effect the payment of any and all Commitment Fees and all other Obligations outstanding and owing hereunder or under any other Loan Documents, subject to the provisions of Sections 2.1 and 4.1 hereof, the Agent may, but shall not be obligated to, cause the Lenders to make a Revolving Loan or request that the Swingline Lender make a Swingline Loan if (i) such Revolving Loan or Swingline Loan, as applicable, is to be made prior to the Revolving Credit Termination Date, (ii) the Availability would be equal to or greater than zero after giving effect to such Revolving Loan or Swingline Loan, as applicable, and the resulting payment of Commitment Fees to be contemporaneously paid with the proceeds of such Loan, and (iii) no Default or Event of Default shall have occurred which is then continuing.  The inability of the Agent to cause the payment of any such Commitment Fees or other Obligations in accordance with the preceding sentence shall not in any way whatsoever affect the Borrower’s and Guarantors’ obligation to otherwise pay such amounts in accordance with the applicable terms hereof or of any other Loan Documents.

 

2.5           Mandatory and Voluntary Prepayments.

 

(a)           If the Revolving Credit Exposure applicable to a Lender at any time exceeds such Lender’s Revolving Credit Commitment, the Agent shall notify the Borrower of such excess amount (such notice being permitted to be given orally and need not be in writing) and the Borrower shall immediately make a prepayment on such Lender’s Revolving Credit Note or otherwise reimburse such Lender for Letter of Credit Advances or cause one or more Swingline Loans to be prepaid or one or more Letters of Credit to be canceled and surrendered in an amount sufficient to reduce such Lender’s Revolving Credit Exposure to an amount no greater than such Lender’s Revolving Credit Commitment.  Any prepayments required by this subparagraph (a) shall be applied to outstanding Alternate Base Rate Borrowings up to the full amount thereof before such prepayments are applied to outstanding LIBOR Borrowings (together with any Consequential Loss resulting from such prepayment).

 

(b)           The Borrower shall make prepayments of the Revolving Loans and the Swingline Loans from time to time so that the Availability equals or exceeds zero at all times.  Specifically, if the Availability at any time is less than zero, the Agent shall notify the Borrower

 

40

 

of the deficiency (such notice being permitted to be given orally and need not be in writing) and the Borrower shall immediately make a prepayment on the Revolving Credit Notes or otherwise reimburse the Agent for Letter of Credit Advances or cause one or more Swingline Loans to be prepaid or one or more Letters of Credit to be canceled and surrendered in an amount sufficient to cause the Availability to be at least equal to zero.  Any prepayments required by this subparagraph (b) shall be applied to outstanding Alternate Base Rate Borrowings up to the full amount thereof before such prepayments are applied to outstanding LIBOR Borrowings (together with any Consequential Loss resulting from such prepayment).

 

(c)           In addition to the mandatory prepayments required by Sections 2.5(a) and 2.5(b) above, the Borrower shall have the right, at its option, to prepay any of the Loans in whole at any time or in part from time to time, without premium or penalty, except as otherwise provided in this Section 2.5 or subsections (a), (b) or (c) of Section 2.9 hereof.  Each prepayment of Swingline Loans or Revolving Loans Alternate Rate Borrowings may be made in any amount, and such prepayments shall be applied against the Revolving Credit Notes or the Swingline Note, as applicable.  Prepayments under this subparagraph (d) shall be subject to the following additional conditions:

 

(1)           In giving notice of prepayment as hereinafter provided, the Borrower shall specify, for the purpose of paragraphs (2) and (3) immediately following, the manner of application of such prepayment as between Alternate Base Rate Borrowings and LIBOR Rate Borrowings; provided, that in no event shall any LIBOR Rate Borrowing (whether Revolving Loans or Terms Loans) be partially prepaid.

 

(2)           Prepayments applied to any LIBOR Rate Borrowing may be made on any Business Day, provided, that (i) the Borrower shall have given the Agent at least five (5) Business Days’ prior irrevocable written or telecopied notice of such prepayment (other than automatic payments of Revolving Loans with proceeds from lockboxes in accordance with the terms of Section 6.15(b).  for which no prior notice of prepayment shall be required), specifying the principal amount of the LIBOR Borrowing to be prepaid, the particular LIBOR Borrowing to which such prepayment is to be applied and the prepayment date; and (ii) if such prepayment is made on any day other than the last day of the Interest Period corresponding to the LIBOR Borrowing to be prepaid, the Borrower shall pay upon demand directly to the Agent for the account of the Lenders the Consequential Loss as a result of such prepayment.

 

(3)           Prepayments applied to any Alternate Base Rate Borrowing may be made on any Business Day, provided, that with respect thereto (other than automatic payments of Revolving Loans with proceeds from lockboxes in accordance with the terms of Section 6.15(b).  for which no prior notice of prepayment shall be required), the Borrower shall have given the Agent prior irrevocable written notice or notice by telephone (which is to be promptly confirmed in writing) of any such prepayment on the Business Day of such prepayment, specifying the principal amount of the Alternate Base Rate Borrowing to be prepaid.

 

(d)           If any notice of any prepayment has been given, the principal amount specified in such notice, together with (in the case of any prepayment of a LIBOR Borrowing)

 

41

 

interest thereon to the date of prepayment and any resulting Consequential Loss, shall be due and payable on such prepayment date.

 

2.6           Notes; Payments.

 

(a)           Subject to the provisions of Section 10.12 hereof relating to replacement and substitution of the Notes, (i) all Revolving Loans made by a Lender to the Borrower shall be evidenced by a single Revolving Credit Note dated as of the Closing Date, delivered and payable to such Lender in a principal amount equal to such Lender’s Revolving Credit Commitment as of the Closing Date, and (ii) all Swingline Loans made by the Swingline Lender to the Borrower shall be evidenced by a single Swingline Note dated as of June 30, 2005, delivered and payable to the Swingline Lender in a principal amount equal to $15,000,000.

 

(b)           The outstanding principal balance of each and every Revolving Loan, as evidenced by the Revolving Credit Notes, shall mature and be fully due and payable on the Revolving Credit Termination Date.  The outstanding principal balance of each and every Swingline Loan, as evidenced by the Swingline Note, shall mature and be fully due and payable on the earlier to occur of the Revolving Credit Termination Date or the date such Swingline Loans are required to be paid with proceeds of Revolving Loans in accordance with Section 2.11(c).

 

(c)           Subject to Section 10.6 hereof, the Borrower hereby agrees to pay accrued interest on the unpaid principal balance of the Loans on the Interest Payment Dates, commencing with the first of such dates to occur after the date hereof.  After the Revolving Credit Termination Date, accrued and unpaid interest on the Revolving Loans and the Swingline Loans shall be payable on demand.

 

(d)           To effect payment of accrued interest owing on the Loans as of the Interest Payment Dates, subject to the provisions of Sections 2.1 and 4.1 hereof, the Agent may, but shall not be obligated to, cause the Lenders to make a Revolving Loan or request that the Swingline Lender make a Swingline Loan to pay in full the amount of accrued interest owing and payable on the Loans as of the respective Interest Payment Date, if (i) such Revolving Loan or Swingline Loan, as applicable, is to be made prior to the Revolving Credit Termination Date, (ii) the Availability would be equal to or greater than zero after giving effect to such Revolving Loan or Swingline Loan, as applicable, and the resulting payment of accrued interest to be contemporaneously paid with the proceeds of such Loan, and (iii) no Default or Event of Default shall have occurred which is then continuing.  The inability of the Agent to cause a payment of any accrued interest owing on the Loans on any Interest Payment Date in accordance with the preceding sentence shall not in any way whatsoever effect the Borrower’s and any Guarantor’s obligation to otherwise pay such amounts in accordance with the applicable terms hereof or any other Loan Documents.

 

2.7           Application of Payments and Prepayments.

 

(a)           Prepayments on the Revolving Credit Notes shall be applied to payment of the aggregate unpaid principal amounts of the Revolving Credit Notes, with the balance of any such prepayments, if any, being applied to accrued interest.  Payments of accrued interest on

 

42

 

each Revolving Credit Note in accordance with Section 2.6(c) hereof shall be applied to the aggregate accrued interest then outstanding under the Revolving Credit Notes, while payment by the Borrower of the aggregate principal amount outstanding under the Revolving Credit Notes on the Revolving Credit Termination Date shall be applied to principal.

 

(b)           Prepayments on the Swingline Note shall be applied to payment of the aggregate unpaid principal amount of the Swingline Note, with the balance of any such prepayments, if any, being applied to accrued interest.  Payments of accrued interest on the Swingline Note in accordance with Section 2.6(c) hereof shall be applied to the aggregate accrued interest then outstanding under the Swingline Note, while payment by the Borrower of the aggregate principal amount outstanding under the Swingline Note on the Revolving Credit Termination Date shall be applied to principal.

 

(c)           All payments remitted to the Agent and all such payments not relating to principal or interest of specific Loans, or not constituting payment of specific fees or other specific Obligations, and all proceeds of Collateral received by the Agent, shall be applied, ratably, subject to the provisions of this Agreement, first, to pay any fees, indemnities or expense reimbursements then due to the Agent from any Credit Party (other than fees, indemnities and expenses relating to Cash Management Obligations and Hedging Obligations); second, to pay any fees or expense reimbursements then due to the Lenders from any Credit Party (other than fees, indemnities and expenses relating to Cash Management Obligations and Hedging Obligations); third, to pay interest due in respect of all Swingline Loans; fourth, to pay interest due in respect of all Revolving Loans; fifth, to pay or prepay principal of the Swingline Loans; sixth, to pay or prepay principal of the Revolving Loans and unpaid reimbursement obligations in respect of Letters of Credit; seventh, to the payment of any other Obligation due to the Agent or any Lender (other than any Hedging Obligations and Cash Management Obligations); and eighth, to the payment of any Hedging Obligations and Cash Management Obligations.  Notwithstanding anything to the contrary contained in this Agreement, unless so directed by the Borrower, or unless an Event of Default has occurred and is continuing, neither the Agent nor any Lender shall apply any payments which it receives to any LIBOR Borrowing, except (a) on the expiration date of the Interest Period applicable to any such LIBOR Borrowing, or (b) in the event, and only to the extent, that there are no outstanding Alternate Base Rate Borrowings and the Borrower has consented to such application.

 

(d)           Except for any settlement delay provided or specified in Section 2.2(f) hereof, each payment or prepayment received by the Agent hereunder or under any Note for the account of a Lender shall be paid promptly to such Lender, in immediately available funds.  If the Agent fails to send to any Lender the product of such Lender’s Revolving Credit Commitment Percentage times the aggregate amount of any such payment or prepayment received by the Agent for the account of all the Lenders by the close of business on the date such payment was deemed received by the Agent in accordance with Section 2.7(e) below, the Agent shall pay to such Lender interest on such Lender’s pro-rata portion of such payment timely received by the Agent from such date of receipt by the Agent to the date that such Lender receives its pro-rata portion of such payment, such interest to accrue at the Federal Funds Effective Rate and to be payable upon written request from such Lender.

 

43

 

(e)           Other than automatic payments of Obligations with proceeds from lockboxes in accordance with the terms of Section 6.15(b), all sums payable by the Borrower to the Agent hereunder or pursuant to the Notes or any of the other Loan Documents for its own account or the account of the Lenders shall be payable in United States dollars in immediately available funds not later than 12:00 noon on the date such payment or prepayment is due and shall be made without set-off, counterclaim or deduction of any kind.  Any such payment or prepayment received and accepted by the Agent after 12:00 noon shall be considered for all purposes (including the payment of interest, to the extent permitted by law) as having been made on the next succeeding Business Day.  All such payments or prepayments shall be made at the Principal Office.  If any payment or prepayment becomes due and payable on a day which is not a Business Day, then the date for the payment thereof shall be extended to the next succeeding Business Day and interest shall be payable thereon at the then applicable rate per annum during such extension.

 

2.8           Interest Rates for Loans.

 

(a)           Subject to Section 10.6 hereof, the Notes shall bear interest on their respective outstanding principal balances at the Alternate Base Rate; provided, that (1) all principal outstanding, whether then due and payable, after the occurrence of an Event of Default which has not been cured to the satisfaction of the Agent and the Required Lenders or waived in writing by the Agent and the Required Lenders shall bear interest at the Default Rate, which shall be due and payable upon demand, (2) past due principal and interest shall bear interest at the Default Rate, which shall be payable on demand, and (3) subject to the provisions hereof, the Borrower shall have the option of having all or any portion of the principal balances from time to time outstanding under the Notes (other than Swingline Loans) bear interest until their respective maturities at a rate per annum equal to the Adjusted LIBOR Rate (together with the Alternate Base Rate, individually herein called an “Interest Option” and collectively called “Interest Options”).  The records of the Agent, with respect to Interest Options, Interest Periods and the amounts of Loans to which they are applicable shall be binding and conclusive, absent manifest error.  Interest on the Loans shall be calculated at the Alternate Base Rate, except where it is expressly provided pursuant to this Agreement that the Adjusted LIBOR Rate is to apply.

 

(b)           The Borrower shall have the right to designate or convert its Interest Options in accordance with the provisions hereof.  Provided no Default or Event of Default has occurred and is continuing, and subject to the provisions of the last sentence of Subsection 2.8(a) hereinabove and the provisions of Section 2.9 hereof, the Borrower may elect to have the Adjusted LIBOR Rate apply or continue to apply to all or any portion of the principal balances of the Notes.  Each change in Interest Options shall be a conversion of the rate of interest applicable to the specified portion of the Loans, but such conversion alone shall not change the outstanding principal balance of the Notes.  The Interest Options shall be designated or converted in the manner provided below:

 

(1)           The Borrower shall give the Agent notice by telephone, promptly confirmed by written notice (the “Rate Selection Notice”) substantially in the form of Exhibit E hereto.  Each such telephone and written notice shall specify the amount and type of borrowings which are the subject of the designation, if any; the amount and type of borrowings into which such borrowings are to be converted or for which an Interest

 

44

 

Option is designated; the proposed date for the designation or conversion (which, in the case of conversion of LIBOR Borrowings, shall be the last day of the Interest Period applicable thereto) and the Interest Period or Periods, if any, selected by the Borrower.  Such notice by telephone shall be irrevocable and shall be given to the Agent no later than the applicable Rate Selection Date.  If (a) a new Revolving Loan is to be a LIBOR Borrowing, (b) an existing LIBOR Borrowing is maturing at the time that a new Revolving Loan is being requested and the Borrower is electing to have such existing portion of the outstanding principal balance of the Revolving Credit Notes going forward bear interest at the same Interest Option and for the same Interest Period as the new Revolving Loan, or (c) a portion of an Alternate Rate Borrowing is to be converted so as to bear interest at the same Interest Option and for the same Interest Period as the new Revolving Loan, then the Rate Selection Notice shall be included in the Request for Extension of Credit applicable to the new Revolving Loan, which shall be given to the Agent no later than the applicable Rate Selection Date.

 

(2)           No more than five (5) LIBOR Borrowings and corresponding Interest Periods shall be outstanding at any one time.  Each LIBOR Borrowing shall be in a minimum aggregate principal amount of at least $500,000 for each Lender, with any increases over such minimum amount being in integral aggregate multiples of $100,000 for each Lender.

 

(3)           Principal included in any borrowing shall not be included in any other borrowing which exists at the same time.

 

(4)           Each designation or conversion shall occur on a Business Day.

 

(5)           Except as provided in Section 2.9 hereof, no LIBOR Borrowing shall be converted on any day other than the last day of the applicable Interest Period.

 

(6)           The Agent shall promptly advise the Lenders of any Rate Selection Notice given pursuant to this Section 2.8 and of each Lender’s pro-rata portion of such designation or conversion hereunder.

 

(c)           All interest and fees (including the Commitment Fee, but excluding any prepayment fee owing pursuant to Section 2.4 hereof) will be computed on the basis of a year of 360 days and actual days elapsed (including the first day but excluding the last day) occurring in the period for which payable, unless the effect of so computing shall be to cause the rate of interest to exceed the Highest Lawful Rate.

 

2.9           Special Provisions Applicable to LIBOR Borrowings.

 

(a)           If, after the date of this Agreement, the adoption of any applicable Legal Requirement or any change in any applicable Legal Requirement or in the interpretation or administration thereof by any Governmental Authority or compliance by the Agent or any Lender with any request or directive (whether or not having the force of law) of any Governmental Authority shall at any time make it unlawful or impracticable for any Lender to permit the establishment of or to maintain any LIBOR Borrowing, the commitment of the Lenders to establish or maintain the Adjusted LIBOR Rate affected by such adoption or change

 

45

 

shall forthwith be canceled, the Agent or such Lender shall use reasonable efforts to give the Borrower written notice thereof within a reasonable time after discovery of such adoption or change by the Agent or such Lender, as applicable (it being agreed, however, that any failure to provide such notice to the Borrower shall not in any manner affect the rights under this Section 2.9(a) of the Agent or any Lender), and the Borrower shall forthwith, upon demand by the Agent to the Borrower, (1) convert the Adjusted LIBOR Rate with respect to which such demand was made to the Alternate Base Rate; (2) pay all accrued and unpaid interest to date on the amount so converted; and (3) pay any amounts required to compensate the Agent and the Lenders for any additional cost or expense which the Agent or any Lender may incur as a result of such adoption of or change in such Legal Requirement or in the interpretation or administration thereof and any Consequential Loss which the Agent or any Lender may incur as a result of such conversion to the Alternate Base Rate.  If, when the Agent so notifies the Borrower, the Borrower has given a Rate Selection Notice specifying one or more borrowings of the type with respect to which such demand was made but the selected Interest Period or Interest Periods has not yet begun, such Rate Selection Notice shall be deemed to be of no force and effect, as if never made, and the balance of the Loans specified in such Rate Selection Notice shall bear interest at the Alternate Base Rate until a different available Interest Option shall be designated in accordance herewith.

 

(b)           If the adoption of any applicable Legal Requirement or any change in any applicable Legal Requirement or in the interpretation or administration thereof by any Governmental Authority or compliance by the Agent or any Lender with any request or directive (whether or not having the force of law) from any Governmental Authority shall at any time as a result of any portion of the principal balance of the Notes being maintained on the basis of the Adjusted LIBOR Rate:

 

(1)           impose, modify, increase or deem applicable any reserve requirement (excluding that portion of any reserve requirement included in the calculation of the Statutory Reserves), special deposit requirement or similar requirement (including state law requirements and Regulation D) imposed, modified, increased or deemed applicable by any Governmental Authority against assets held by the Agent or any Lender, or against deposits or accounts in or for the account of the Agent or any Lender, or against loans made by the Agent or any Lender, or against any other funds, obligations or other Property owned or held by the Agent or any Lender; or

 

(2)           impose on the Agent or any Lender any other materially restrictive or limiting condition regarding any LIBOR Borrowing;

 

and the result of any of the foregoing is to increase the cost to any Lender of agreeing to make or of making, renewing or maintaining such borrowing on the basis of the Adjusted LIBOR Rate, or reduce the amount of principal or interest received by any Lender, then the Agent or such Lender shall use reasonable efforts to give the Borrower written notice thereof within a reasonable time after discovery of such adoption or change by the Agent or such Lender, as applicable (it being agreed, however, that any failure to provide such notice to the Borrower shall not in any manner affect the rights under this Section 2.9(b) of the Agent or any Lender), and, upon demand by such Lender, the Borrower shall pay to such Lender, from time to time as specified by such Lender, additional amounts which shall compensate such Lender for such increased cost or reduced amount.  Such Lender will promptly notify the Borrower in writing of any event, upon

 

46

 

becoming actually aware of it, which will entitle any Lender to additional amounts pursuant to this paragraph.  Such Lender’s determination of the amount of any such increased cost, increased reserve requirement or reduced amount shall be conclusive and binding, absent manifest error, provided that the calculation thereof and reason therefore is certified and is set forth in reasonable detail in such certification by such Lender.

 

The Borrower shall have the right, if it receives from any Lender any notice referred to in the preceding paragraph, upon three (3) Business Days’ notice to the Agent, either (i) to repay in full (but not in part) any borrowing with respect to which such notice was given, together with any accrued interest thereon, or (ii) to convert the Adjusted LIBOR Rate in effect with respect to such borrowing from such Lender to the Alternate Base Rate; provided, that any such repayment or conversion shall be accompanied by payment of (x) the amount required to compensate the appropriate Lender or Lenders for the increased cost or reduced amount referred to in the preceding paragraph; (y) all accrued and unpaid interest to date on the amount so repaid or converted; and (z) any Consequential Loss which may be incurred as a result of such repayment or conversion.  Additionally, if it receives from any Lender any notice referred to in the preceding paragraph, the Borrower shall also have the corresponding rights in Section 10.16(c).

 

(c)           If for any reason with respect to any Interest Period the Agent shall have in good faith determined (which determination shall be conclusive and binding upon the Borrower) that:  (1) the Agent is unable through its customary general practices to determine a rate at which the Agent is offered deposits in United States dollars by prime banks in the London interbank market, in the appropriate amount for the appropriate period, or by reason of circumstances affecting the London interbank market, generally, the Agent is not being offered deposits for the applicable Interest Period and in an amount equal to the amount of the Agent’s pro-rata portion of any LIBOR Borrowing requested by the Borrower, or (2) the Adjusted LIBOR Rate will not adequately and fairly reflect the cost to any Lender of making and maintaining any LIBOR Borrowing hereunder for any proposed Interest Period, then the Agent shall give the Borrower notice thereof and thereupon, (A) any Rate Selection Notice previously given by the Borrower designating an Adjusted LIBOR Rate which has not commenced as of the date of such notice from the Agent shall be deemed for all purposes hereof to be of no force and effect, as if never given, and (B) until the circumstances giving rise to such notice from the Agent no longer exist, each Rate Selection Notice requesting an Adjusted LIBOR Rate shall be deemed a request for an Alternate Base Rate Borrowing, and each outstanding LIBOR Borrowing then in effect shall be converted, without any notice to or from the Borrower, upon the termination of the Interest Period then in effect to an Alternate Base Rate Borrowing.

 

(d)           Each Credit Party, jointly and severally with all other Credit Parties, hereby agrees to indemnify the Agent and each of the Lenders against and hold each of them harmless from any Consequential Loss which it may incur or sustain as a consequence of any prepayment (mandatory or optional) or default by the Borrower in the payment of any principal amount of or interest on each Note or any failure by the Borrower to convert or to borrow any LIBOR Borrowing on the date specified by the Borrower.  This agreement shall survive the payment of each Note.  A certificate as to any additional amounts payable to the Agent or any Lender pursuant to this paragraph, detailing the basis therefore and submitted by the Agent or such Lender to the Borrower

 

47

 

shall be conclusive and binding upon the Credit Parties, absent manifest error, provided the calculation thereof is set forth in reasonable detail in such notice.

 

(e)           If the Borrower requests quotes of the Adjusted LIBOR Rate for different Interest Periods being considered for election by the Borrower, the Agent will use reasonable efforts to provide such quotes to the Borrower promptly.  However, all such quotes provided shall be representative only and shall not be binding on the Agent or any Lender, nor shall they be determinative, directly or indirectly, of any Adjusted LIBOR Rate or any component of any such rate, nor will the Borrower’s failure to receive or the Agent’s failure to provide any requested quote or quotes either (1) excuse or extend the time for performance of any obligation of the Borrower or for the exercise of any right, option or election of the Borrower or (2) impose any duty or liability on the Agent or any Lender.  If the Borrower requests a list of the Business Days in any calendar month, the Agent will use reasonable efforts to provide such list promptly.  However, any such list provided shall be understood to identify only those days which the Agent believes in good faith at the time such list is prepared will be the Business Days for such month.  The Agent shall not have any liability for any failure to provide, delay in providing, error or mistake in or omission from, any such quote or list.

 

(f)            With respect to any Lender having a LIBOR Lending Office which differs from its Domestic Lending Office, all Loans advanced by such Lender’s LIBOR Lending Office shall be deemed to have been made by such Lender and the obligation of the Borrower to repay such Loans shall nevertheless be to such Lender and shall be deemed held by such Lender, to the extent of such portions of the Loan, for the account of such Lender’s LIBOR Lending Office.

 

(g)           Notwithstanding any provision of this Agreement to the contrary, each Lender shall be entitled to fund and maintain its funding of all or any part of the Loans hereunder in any manner it sees fit, it being understood, however, that for the purposes of this Agreement, all determinations hereunder shall be made as if such Lender had actually funded and maintained its portion of each LIBOR Borrowing during each Interest Period for the Loans through the purchase of deposits having a maturity corresponding to such Interest Period and bearing an interest rate equal to the LIBOR Rate for such Interest Period.

 

(h)           The Borrower’s obligation to pay increased costs and Consequential Loss with regard to each LIBOR Borrowing as specified in this Section 2.9 hereof shall survive termination of this Agreement.

 

2.10         Letters of Credit.

 

(a)           Subject to the terms and conditions contained herein, the Borrower shall have the right to utilize a portion of the Total Revolving Credit Commitment from time to time prior to the Revolving Credit Termination Date to obtain from the Agent one or more Letters of Credit for the account of the Borrower in such amounts and in favor of such beneficiaries as the Borrower from time to time shall request; provided, that in no event shall the Agent have any obligation to or shall the Agent in any event issue any Letter of Credit if (i) the face amount of such Letter of Credit, plus the Letter of Credit Exposure Amount at such time would exceed $20,000,000, (ii) the face amount of such Letter of Credit, plus the aggregate of each Lender’s Revolving Credit Exposure at such time, would exceed the Availability, (iii) such Letter of

 

48

 

Credit would have an expiry date beyond the earlier to occur of (1) five (5) Business Days prior to the scheduled Revolving Credit Termination Date, (2) with respect to Standby Letters of Credit, one full year after the issuance date of such Standby Letter of Credit, or (3) with respect to Trade Letters of Credit, one hundred eighty (180) days after the issuance date of such Trade Letter of Credit; provided, however, that any Standby Letter of Credit with a one-year term may provide for automatic renewals thereof for additional one-year periods (which shall in no event extend beyond five (5) Business Days prior to the scheduled Revolving Credit Termination Date), (iv) such Letter of Credit is not in a form and does not contain terms satisfactory to the Agent in its sole and absolute discretion, (v) the Borrower has not executed and delivered such Applications and other instruments and agreements relating to such Letter of Credit as the Agent shall have reasonably requested, (vi) any Default or Event of Default has occurred and is continuing, or (vii) such Letter of Credit is not being issued or has not been issued in connection with transactions occurring in the ordinary course of business of the Borrower or any of its Subsidiaries.  Each Letter of Credit may be issued for the account of or used by the Borrower or any of its Subsidiaries, but the Borrower shall have full liability for each Letter of Credit.

 

(b)           If requesting the issuance of any Letter of Credit, the Borrower shall give at least five (5) Business Days’ prior written notice to the Agent, at its Domestic Lending Office, which written notice shall be the requisite Application for a Letter of Credit on the Agent’s customary form.  In accordance with the provisions of Section 2.2(f) hereof, the Agent shall periodically notify each Lender that a Letter of Credit has been requested in the amount reflected in such Application and inform such Lender of the amount of its pro-rata portion of such proposed Letter of Credit (based upon such Lender’s Revolving Credit Commitment Percentage).

 

(c)           Simultaneously with the Agent’s issuance and delivery of any Letter of Credit, the Agent shall be deemed, without further action, to have sold to each other Lender, and such other Lender shall be deemed, without further action by any party hereto, to have purchased from the Agent, a participation interest (which participation shall be nonrecourse to the Agent) equal to such other Lender’s Revolving Credit Commitment Percentage at such time in such Letter of Credit and all of the Letter of Credit Exposure Amount related to such Letter of Credit, provided that such participation interest shall not cause any of such other Lender’s Revolving Credit Exposure to exceed such Lender’s Revolving Credit Commitment.  Each Lender acknowledges and agrees that its obligation to acquire participations in each Letter of Credit, as well as its obligation to make the payments specified in this Section 2.10 and the right of the Agent to receive the same in the manner specified herein, are absolute and unconditional and shall not be affected by any circumstance whatsoever, including without limitation, the occurrence and continuance of a Default or Event of Default hereunder, and that each such payment shall be made without any offset, abatement, withholding or reduction whatsoever.

 

(d)           The Borrower promises to pay to the order of the Agent the amount of all Letter of Credit Advances.  Each Letter of Credit Advance shall be considered for all purposes as a demand obligation owing by the Borrower to the Agent, and each Letter of Credit Advance shall bear interest from the date thereof at the Default Rate, without notice of presentment, demand, protest or other formalities of any kind (said past due interest on such Letter of Credit Advance being payable on demand).  To effect repayment of any such Letter of Credit Advance, the Agent shall automatically satisfy such Letter of Credit Advance (subject to the terms and conditions of Sections 2.1 and 4.1, hereof) by causing the Lenders to make a Revolving Loan or

 

49

 

the Swingline Lender to make a Swingline Loan if (i) such Letter of Credit Advance is (and such Revolving Loan or Swingline Loan, as applicable, is to be) made prior to the Revolving Credit Termination Date, (ii) the Availability would be equal to or greater than zero after giving effect to such Revolving Loan or Swingline Loan, as applicable, and the resulting repayment of such Letter of Credit Advance to be contemporaneously paid with the proceeds of such Loan, and (iii) no Default or Event of Default shall have occurred which is then continuing.  The unavailability of a Revolving Loan or Swingline Loan to effect repayment of any such Letter of Credit Advance in accordance with the preceding sentence shall not in any way whatsoever affect the Borrower’s obligation to pay each Letter of Credit Advance on demand and to pay interest at the Default Rate on the amount of such unreimbursed Letter of Credit Advance.  Except for any settlement delay provided in Section 2.2(f), the Agent will pay to each Lender such Lender’s Commitment Percentage of all amounts received from the Borrower by the Agent, if any, for application, in whole or in part, against the Letter of Credit Advances in respect to any Letter of Credit, but only to the extent such Lender has made its full pro-rata payment of each drawing under the Letter of Credit to which such Letter of Credit Advance relates.  All rights, powers, benefits and privileges of this Agreement with respect to the Revolving Credit Notes, all security therefor (including the Collateral) and guaranties thereof (including the Guaranties) and all restrictions, provisions for repayment or acceleration and all other covenants, warranties, representations and agreements of the Borrower contained in this Agreement with respect to the Revolving Credit Notes shall apply to such Letter of Credit Advances.

 

(e)           In consideration of the issuance of each Letter of Credit pursuant to the provisions of this Section 2.10, the Borrower agrees to pay (subject to Section 10.6 hereof) to the Agent for the ratable benefit of the Lenders a letter of credit fee (computed on the basis of the actual number of days elapsed in a year composed of 360 days) in an amount equal to the product of (a) the Applicable Margin in effect for LIBOR Borrowings of Revolving Loans for the applicable period times (b) the undrawn upon amount of the applicable Letter of Credit, with each letter of credit fee to commence to accrue as of the date of issuance of such Letter of Credit and to be effective as to any reductions in the undrawn amount of such Letter of Credit as of the date of any such reduction (whether resulting from payments thereunder by the Agent, by agreement of the beneficiary thereunder or automatically by the terms of the Letter of Credit).  Each letter of credit fee shall cease to accrue (except with respect to interest at the Default Rate on any unpaid portion thereof) on the date that such Letter of Credit expires, is returned to the Agent undrawn upon by the beneficiary thereof or is fully paid by the Agent.  Said letter of credit fees shall be payable in arrears to the Agent at its Principal Office in immediately available funds (i) on the first Business Day of each calendar month that such Letter of Credit remains open, and (ii) on the date that such Letter of Credit expires, is returned to the Agent undrawn upon by the beneficiary thereof or is fully paid by the Agent.  All past due letter of credit fees shall bear interest at the Default Rate and shall be payable upon demand by the Agent.  The Agent will pay to each Lender, as soon as practicable after receiving any payment of letter of credit fees described in the preceding sentence, an amount equal to the product of (A) such Lender’s Revolving Credit Commitment Percentage times (B) the amount of such fees received.  If the Agent fails to send to any Lender such Lender’s pro-rata portion of any payment of such letter of credit fees timely received by the Agent by the close of business on the Business Day such payment was received by the Agent, the Agent shall pay to such Lender interest on such Lender’s pro-rata portion of such letter of credit fees timely received by the Agent from such date of receipt by the Agent to the date that such Lender receives its pro-rata portion of such payment,

 

50

 

such interest to accrue at the Federal Funds Effective Rate and to be payable upon written request from such Lender.

 

(f)            The Borrower hereby agrees to pay to the Agent for the Agent’s sole benefit a fronting fee equal to 0.125% of the face amount of each Letter of Credit issued hereunder.  Fronting fees shall be payable on the date of issuance of the applicable Letter of Credit.  The Borrower also hereby agrees to pay to the Agent for the Agent’s sole benefit any and all documentary, processing, amendment, negotiation, payment and other normal and customary fees which are charged by the Agent in connection with the issuance, amendment, cancellation, negotiation or transfer of any of Letter of Credit and the presentation or payment of any draw under any such Letter of Credit, with all of such amounts being due and payable to the Agent upon demand.

 

(g)           The obligations of the Borrower under this Agreement in respect of the Letters of Credit and all Letter of Credit Advances are absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Agreement, under all circumstances whatsoever, including the following circumstances:

 

(1)           any lack of validity or enforceability of this Agreement, any Letter of Credit or any Loan Document;

 

(2)           any amendment or waiver of default under or any consent to departure from the terms of this Agreement or any Letter of Credit without the express prior written consent of the Agent;

 

(3)           the existence of any claim, set-off, defense or other right which any beneficiary or any transferee of any Letter of Credit (or any entities for whom any such beneficiary or any such transferee may be acting), or any Person (other than the Agent or the Lenders) may have, whether in connection with this Agreement, the Letters of Credit, the transactions contemplated hereby or any unrelated transaction;

 

(4)           any statement, draft, certificate, or any other document presented under any Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect whatsoever; provided, that the Agent will examine each document presented under each Letter of Credit to ascertain that such document appears on its face to comply with the terms thereof; and

 

(5)           any other circumstance or happening whatsoever, whether or not similar to any of the foregoing.

 

In the event that any restriction or limitation is imposed upon or determined or held to be applicable to the Agent, any Lender or the Borrower by, under or pursuant to any Legal Requirement now or hereafter in effect or by reason of any interpretation thereof by any Governmental Authority, which in the respective sole judgment of the Agent or any Lender would prevent any Lender from legally incurring liability under a Letter of Credit issued or proposed to be issued hereunder, then the Agent shall give prompt written notice thereof to the Borrower, whereupon the Agent shall have no obligation to issue any additional Letters of Credit

 

51

 

then or at any time thereafter.  In addition, if as a result of any Regulatory Change which imposes, modifies or deems applicable (x) any tax, reserve, special deposit or similar requirement against any Letters of Credit issued or participated to by any Lender; (y) any fee, expense or assessment against the Letters of Credit issued by the Agent or any Lender for deposit insurance, or (z) any other charge, expense or condition which increases the actual cost to the Agent or any Lender of issuing or maintaining such Letters of Credit, or reduces any amount Account by the Agent or any Lender hereunder in respect of any Letter of Credit or any participation therein (which increase in cost, or reduction in amount Account, shall be the result of the Agent’s or such Lender’s reasonable allocation of the aggregate of such increases or reductions resulting from such event), then the Borrower (subject to Section 10.6 hereof) shall pay to the Agent or such Lender, upon demand and from time to time, amounts sufficient to compensate such Person for each such increase from the effective date of such increase to the date of demand therefor.  Each such demand shall be accompanied by a certificate setting forth in reasonable detail the calculation of the amount then being demanded in accordance with the preceding sentence and each such certificate shall be conclusive absent manifest error.

 

(h)           Each Credit Party, jointly and severally with all other Credit Parties, hereby indemnifies and holds harmless each Lender and the Agent from and against any and all claims and damages, losses, liabilities, costs or expenses which such Lender or the Agent may incur (or which may be claimed against such lender or the agent by any person whatsoever) in connection with the execution and delivery or transfer of or payment or failure to pay under any Letter of Credit, including any claims, damages, losses, liabilities, costs or expenses which the Agent or such Lender, as the case may be, may incur (whether incurred as a result of, its own negligence or otherwise) by reason of or in connection with the failure of any other Lender (whether as a result of its own negligence or otherwise) to fulfill or comply with its obligations to the Agent or such Lender, as the case may be, hereunder (but nothing herein contained shall affect any rights the Credit Parties may have against such defaulting Lender); provided, that the Credit Parties shall not be required to indemnify any Lender or the Agent for any claims, damages, losses, liabilities, costs or expenses to the extent, but only to the extent, caused by (i) the willful misconduct or gross negligence of the party seeking indemnification or such party’s willful and knowing breach of any Loan Document or (ii) such Lender’s or the Agent’s (as the case may be) failure to pay under any Letter of Credit after the presentation to it of a request required to be paid under applicable law.  Nothing in this Section 2.10(h) is intended to limit the obligations of the Borrower or any other Credit Party under any other provision of this Agreement or any other Loan Document.

 

(i)            The Agent shall review, on behalf of the Lenders, each draft and any accompanying documents presented under a Letter of Credit.  Promptly after it shall have ascertained that any draft and any accompanying documents presented under such Letter of Credit appear on their face to be in substantial conformity with the terms and conditions of such Letter of Credit, the Agent shall make the appropriate payment to the beneficiary of such Letter of Credit.  Subject to the settlement delay provisions of Section 2.2(f) hereof, the Agent shall give telephonic or facsimile notice to the Lenders of the receipt and amount of any draft presented under any Letter of Credit and the date on which payment thereon will be made, and each of the Lenders shall, by 12:00 noon, on the date such payment is to be made under such Letter of Credit, pay in immediately available funds, an amount equal to the product of (A) such

 

52

 

Lender’s Revolving Credit Commitment Percentage times (B) the amount of such payment to be made by the Agent to the beneficiary under such Letter of Credit.  Any Lender failing to timely deliver its requisite portion of any such payment shall deliver the same to the Agent as soon as possible thereafter, together with interest on such amount for each day from the due date for such payment to the date of payment by such Lender to the Agent of such amount at a rate of interest per annum equal to the Federal Funds Effective Rate for such period.  Each Lender hereby absolutely and unconditionally assumes, as primary obligor and not as a surety, and agrees to pay and discharge, and to indemnify and hold the Agent harmless from liability and respect of, such Lender’s pro-rata share (based on such Lender’s Revolving Credit Commitment Percentage) of any amounts owing by such Lender to the Agent in accordance with the immediately preceding sentence.  Nothing herein shall be deemed to require any Lender to pay to the Agent any amount as reimbursement for any payment made by the Agent to acquire (discount) for its own account prior to maturity thereof any acceptance created under a Letter of Credit.

 

2.11         Swingline Loans.

 

(a)           Subject to the terms and conditions hereof, the Swingline Lender may, in its sole discretion, make loans for the Swingline Lender’s own account (each a “Swingline Loan”) to the extent the same would otherwise have been available to the Borrower under the Total Revolving Credit Commitment in an aggregate principal amount at any one time outstanding up to, but not exceeding, $15,000,000; provided, however, that at no time shall the Swingline Lender make any Swingline Loan to the extent that, after giving effect to such Swingline Loan, the aggregate amount of each Lender’s Revolving Credit Exposure at such time would exceed the Availability or the amount of any Lender’s Revolving Credit Exposure at such time would exceed such Lender’s Revolving Credit Commitment; and provided further, however, that the Swingline Lender shall not, without the consent of the Required Lenders, make any Swingline Loan if any Event of Default exists of which the Swingline Lender has actual knowledge.  Each Swingline Loan shall be an Alternate Base Rate Borrowing and shall in any event mature no later than the Revolving Credit Termination Date.  Subject to the conditions herein and within the limits set forth in the first sentence of this paragraph, any Swingline Loan prepaid prior to the Revolving Credit Termination Date may be reborrowed as an additional Swingline Loan by the Borrower pursuant to the terms of this Agreement.

 

(b)           To request a Swingline Loan, the Borrower shall notify the Agent of such request by telephone (confirmed by telecopy), not later than 1:00 p.m., on the day of a proposed Swingline Loan.  Each such notice shall be irrevocable and shall specify the requested date (which shall be a Business Day) and amount of the requested Swingline Loan.  The Agent will promptly advise the Swingline Lender of any such notice received from the Borrower, and subject to the terms of this Agreement, the Swingline Lender may make a Swingline Loan available to the Borrower by means of a credit to the general deposit account of the Borrower with the Swingline Lender by 5:00 p.m. on the requested date of such Swingline Loan.

 

(c)           The Swingline Lender may demand at any time (but in no event shall such demand be made less frequently than once per each calendar month) that each Lender pay to the Agent, for the account of the Swingline Lender, in the manner provided below, such Lender’s Revolving Credit Commitment Percentage of all or a portion of the outstanding Swingline Loans, which demand shall be made through the Agent, shall be in writing and shall specify the

 

53

 

outstanding principal amount of Swingline Loans demanded to be paid.  The Agent shall forward notice of each such demand to each Lender on the day such demand is received by the Agent (except that any such notice or demand received by the Agent after 1:00 p.m. on any Business Day or any such demand received on a day that is not a Business Day shall not be required to be forwarded to the Lenders by the Agent until the next succeeding Business Day), together with a statement prepared by the Agent specifying the amount of each Lender’s Revolving Credit Commitment Percentage of the aggregate principal amount of the Swingline Loans stated to be outstanding in such notice or demanded to be paid pursuant to such demand, and, notwithstanding whether or not the conditions precedent set forth in Sections 4.1 or 4.2 shall have been satisfied (which conditions precedent, for the purposes of payment of Swingline Loans only, the Lenders hereby irrevocably waive), each Lender shall, before 10:00 a.m. on the Business Day next succeeding the date of such Lender’s receipt of such notice, make available to the Agent, in immediately available funds, for the account of the Swingline Lender, the amount specified in such statement, provided that such amount shall not cause such Lender’s Revolving Credit Exposure to exceed such Lender’s Revolving Credit Commitment.  Upon such payment by a Lender, such Lender shall, except as provided in Section 2.11(d) below, be deemed to have made a Revolving Loan to the Borrower in the amount of such payment.  The Borrower agrees that all such Revolving Loans so deemed made shall be deemed to have been requested by it and directs that all proceeds thereof shall be used to repay the Swingline Loans to the Swingline Lender, and the Agent shall use such funds received from the Lenders to repay the Swingline Loans to the Swingline Lender.  To the extent that any Lender fails to make such payment available to the Agent for the account of the Swingline Lender, the Borrower shall repay such Swingline Loan on demand.

 

(d)           Upon the occurrence of any Event of Default described in Sections 8.1(o) through 8.1(r), each Lender shall acquire, without recourse or warranty, an undivided participation in each Swingline Loan otherwise required to be repaid by such Lender pursuant to Section 2.11(c) above, which participation shall be in a principal amount equal to such Lender’s Revolving Credit Commitment Percentage of such Swingline Loan, by paying to the Swingline Lender on the date on which such Lender would otherwise have been required to make a payment in respect of such Swingline Loan pursuant to Section 2.11(c) above, in immediately available funds, an amount equal to such Lender’s Revolving Credit Commitment Percentage of such Swing Loan.  If all or part of such amount is not in fact made available by such Lender to the Swingline Lender on such date, the Swingline Lender shall be entitled to recover any such unpaid amount on demand from such Lender together with interest accrued from such date at the Federal Funds Rate for the first Business Day after such payment was due and thereafter at the rate of interest then applicable to Alternate Base Rate Borrowings.

 

(e)           From and after the date on which any Lender (i) is deemed to have made a Revolving Loan pursuant to Section 2.11(c) above with respect to any Swingline Loan or (ii) purchases an undivided participation interest in a Swingline Loan pursuant to Section 2.11(d) above, the Swingline Lender shall promptly distribute to such Lender such Lender’s Revolving Credit Commitment Percentage of all payments of principal of and interest received by the Swingline Lender on account of such Swingline Loan other than those received from a Lender pursuant to Sections 2.11(c) or (d) above.

 

54

 

2.12         Pro-Rata Treatment.

 

(a)           Except to the extent otherwise provided herein (including without limitation, as specified in Sections 2.2(f), 2.10(b) and 2.12(c) hereof):  (a) each borrowing from the Lenders under Section 2.1 hereof shall be made, each payment of Commitment Fees shall be made and applied for the account of the Lenders, and each termination or reduction of the Revolving Credit Commitments of the Lenders under Section 2.4 hereof shall be applied, pro-rata, according to each Lender’s Revolving Credit Commitment Percentage; (b) each payment or prepayment by the Borrower of principal of or interest on Loans (other than Swingline Loans) shall be made to the Agent for the account of the Lenders pro-rata in accordance with the respective unpaid principal amounts of such Loans held by the Lenders, and amounts payable with respect to Swingline Loans shall be paid only to the Swingline Lender; (c) the Lenders (other than the Agent) shall purchase from the Agent participations in the Letters of Credit to the extent of their respective Revolving Credit Commitment Percentages upon issuance by the Agent of each Letter of Credit as otherwise provided for herein, and (d) the Lenders (other than the Swingline Lender) shall purchase from the Swingline Lender participations in the Swingline Loans to the extent of their respective Revolving Credit Commitment Percentages upon request by the Swingline Lender as otherwise provided for herein.

 

(b)           Except for any settlement delay provided or specified in Section 2.2(f), unless the Agent shall have been notified in writing by any Lender prior to the date of a proposed Loan (other than a Swingline Loan) that such Lender will not make the amount that would constitute such Lender’s Revolving Credit Commitment Percentage of such Loan on such date available to the Agent at the Principal Office, the Agent may assume that such Lender has made such amount available to the Agent on such date, and the Agent may, in reliance upon such assumption and subject to the terms and conditions of this Agreement, make such amount available to the Borrower by depositing the same, in immediately available funds, in a general deposit account designated and maintained by the Borrower with the Agent at the Principal Office.  Any Lender failing to timely deliver its requisite portion of such Loan shall deliver the same to the Agent as soon as possible thereafter, together with interest on such amount for each day from the due date for such payment to the date of payment by such Lender to the Agent of such amount at a rate of interest per annum equal to the Federal Funds Effective Rate for such period.  In addition, the Borrower hereby agrees that upon demand by the Agent, the Borrower shall reimburse the Agent for any such amount which any Lender has failed to timely deliver to the Agent, but which the Agent may have previously made available to the Borrower in accordance with the other provisions of this Section 2.12(b).  If a requested Loan shall not occur on any date specified by the Borrower as set forth in the applicable Request for Extension of Credit because all of the conditions for such Loan set forth herein or in any of the other Loan Documents shall have not been met, the Agent shall return the amounts so received from the Lenders in respect of such requested Loan to the applicable Lenders as soon as practicable.

 

(c)           Notwithstanding any provision to the contrary contained in this Section 2.12 or in any other provision hereof, each Lender shall only receive interest upon and a portion of the Commitment Fee paid hereunder based upon the amount of funds actually advanced by such Lender to Borrower from time to time.

 

2.13         Sharing of Payments, Etc.  Each of the Credit Parties agrees that, in addition to (and without limitation of) any right of set-off, bankers’ lien or counterclaim a Lender may otherwise have, each Lender shall be entitled, at its option, to offset balances held by it for the

 

55

 

account of any of the Credit Parties at any of its offices against any principal of or interest on any of such Lender’s Loans to the Borrower hereunder, such Lender’s Revolving Credit Commitment Percentage of the Letter of Credit Exposure Amount, the Swingline Exposure or any other Obligation of the Borrower hereunder (regardless of whether such Obligations of the Borrower are then due and regardless of whether such offset balances are then due to the Borrower), in which case it shall promptly notify the Borrower and the Agent thereof, provided, that such Lender’s failure to give such notice shall not affect the validity thereof.  If a Lender shall obtain payment (other than the Swingline Lender obtaining payment of all or any portion of a Swingline Loan) of any principal of or interest on any Loan made by it under this Agreement, any Letter of Credit Exposure Amount, any Swingline Exposure or other obligation then due to such Lender hereunder, through the exercise of any right of set-off (including, without limitation, any right of set-off or lien granted under Section 10.19 hereof), banker’s lien, counterclaim or similar right, or otherwise, it shall promptly purchase from the other Lenders participations in the Loans made by, the Letter of Credit Exposure Amount or the Swingline Exposure of, or the other obligations of the Borrower hereunder of, the other Lenders in such amounts, and make such other adjustments from time to time as shall be equitable to the end that all the Lenders shall share the benefit of such payment (net of any expenses which may be incurred by such Lender in obtaining or preserving such benefit) pro-rata in accordance with their respective Revolving Credit Commitment Percentages.  To such end all the Lenders shall make appropriate adjustments among themselves (by the resale of participations sold or otherwise) if such payment is rescinded or must otherwise be restored.  Each of the Credit Parties agrees, to the fullest extent it may effectively do so under applicable law, that any Lender so purchasing a participation in the Loans made by, Letter of Credit Exposure Amount or the Swingline Exposure of, or other obligations hereunder of, the other Lenders may exercise all rights of set-off, bankers’ lien, counterclaim or similar rights with respect to such participation as fully as if such Lender were a direct holder of said Loans, Letter of Credit Exposure Amount, Swingline Exposure or other obligations in the amount of such participation.  Nothing contained herein shall require any Lender to exercise any such right or shall affect the right of any Lender to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation of the Borrower.

 

2.14         Recapture.  If on any Interest Payment Date the Agent does not receive for the account of one or more Lenders payment in full of interest computed at the Alternate Base Rate and/or the Adjusted LIBOR Rate, as applicable (computed without regard to any limitation by the Highest Lawful Rate), because the sum of the Alternate Base Rate and/or the Adjusted LIBOR Rate, as applicable (so computed), exceeds or has exceeded the Highest Lawful Rate applicable to such Lenders, the Borrower shall pay to the Agent for the account of such Lenders, in addition to interest otherwise required, on each Interest Payment Date thereafter, the Excess Interest Amount (calculated as of each such subsequent Interest Payment Date); provided, that in no event shall the Borrower be required to pay, for any computation period, interest at a rate exceeding the Highest Lawful Rate applicable to such Lenders during such period.  As used herein, the term “Excess Interest Amount” shall mean, on any day, the amount by which (a) the amount of all interest which would have accrued prior to such day on the outstanding principal of the Notes of the applicable Lender (had the Alternate Base Rate and/or the Adjusted LIBOR Rate, as applicable, at all times been in effect without limitation by the Highest Lawful Rate applicable to such Lender) exceeds (b) the aggregate amount of interest actually paid to the Agent for the account of such Lender on its Notes on or prior to such day.

 

56

 

2.15         Increase of Total Revolving Credit Commitment.

 

(a)           At any time after the Closing Date, provided that no Default or Event of Default shall have occurred and be continuing, the Borrower may request from time to time one or more increases of the Total Revolving Credit Commitment by notice to the Agent in writing of the amount of each such proposed increase (each such notice, a “Revolving Credit Commitment Increase Notice”).  Any such Revolving Credit Commitment Increase Notice must offer each Lender the opportunity to subscribe for its pro rata share of the requested increase in the Total Revolving Credit Commitment, and the Agent shall promptly provide to each Lender a copy of any Revolving Credit Commitment Increase Notice received by the Agent.  Within ten (10) Business Days after receipt by the Agent of the applicable Revolving Credit Commitment Increase Notice, each Lender wishing to subscribe for its pro rata share of the requested increase in the Total Revolving Credit Commitment must deliver written notice of such fact to the Agent.  If any portion of the requested increase in the Total Revolving Credit Commitment is not subscribed for by the Lenders within such 10-day period, the Borrower may, in its sole discretion, but with the consent of the Agent as to any Person that is not at such time a Lender (which consent shall not be unreasonably withheld or delayed, so long as such Person is an Eligible Assignee), offer to any existing Lender or to one or more additional banks or financial institutions the opportunity to participate in all or a portion of such unsubscribed portion of the requested increase in the Total Revolving Credit Commitment pursuant to Section 2.15(b) or(c) below, as applicable.

 

(b)           Any additional bank or financial institution that the Borrower selects to offer a participation in the unsubscribed portion of the requested increase in the Total Revolving Credit Commitment, and that elects to become a party to this Agreement and obtain a Revolving Credit Commitment, shall execute an agreement (a “New Lender Agreement”), in the form required by the Agent, with the Borrower and the Agent, whereupon such bank or financial institution (a “New Lender”) shall become a Lender for all purposes hereunder to the same extent as if originally a party hereto and shall be bound by and entitled to the benefits of this Agreement, and Schedule 1.1(b) shall be deemed to add the name and Revolving Credit Commitment of such New Lender, provided that the Revolving Credit Commitment of any such New Lender shall be in an amount not less than $5,000,000.

 

(c)           Any Lender that accepts an offer by the Borrower to increase its Revolving Credit Commitment pursuant to this Section 2.15 shall, in each case, execute a commitment increase agreement (a “Revolving Credit Commitment Increase Agreement”), in the form required by the Agent, with the Borrower and the Agent, whereupon such Lender shall be bound by and entitled to the benefits of this Agreement with respect to the full amount of its Revolving Credit Commitment as so increased, and Schedule 1.1(b) hereof shall be deemed to be amended to reflect such increase in the Revolving Credit Commitment of such Lender.

 

(d)           The effectiveness of any New Lender Agreement or Revolving Credit Commitment Increase Agreement shall be contingent upon receipt by the Agent of such corporate resolutions of the Borrower, if any, as the Agent shall reasonably request with respect thereto.

 

57

 

(e)           If any bank or financial institution becomes a New Lender pursuant to Section 2.15(b) or if any Lender’s Revolving Credit Commitment is increased pursuant to Section 2.15(c), additional Revolving Loans and additional liability for Letter of Credits and Swingline Loans made or issued on or after the effectiveness thereof (the “Re-Allocation Date”) shall be made pro rata (and the Commitment Percentage of each Lender shall be correspondingly adjusted) based on each Lender’s (including each New Lender’s) respective Revolving Credit Commitment in effect on and after such Re-Allocation Date (except to the extent that any such pro rata borrowings or incurring of liability would result in any Lender making an aggregate principal amount of Revolving Loans and incurring liability for the Letter of Credit Exposure Amount and Swingline Exposure in excess of its Revolving Credit Commitment, in which case such excess amount will be allocated to, and made or incurred by, such New Lender and/or Lenders with such increased Revolving Credit Commitments to the extent of, and pro rata based on, their respective Revolving Credit Commitments), and continuations of Revolving Loans at the Adjusted LIBOR Rate that are outstanding on such Re-Allocation Date shall be effected by repayment of such Revolving Loans on the last day of the Interest Period applicable thereto and the extension of new Revolving Loans at the Adjusted LIBOR Rate pro rata based on the Lenders’ respective Revolving Credit Commitments in effect on and after such Re-Allocation Date.  In the event that on any such Re-Allocation Date there are Revolving Loans outstanding that are Alternate Base Rate Borrowings, the Borrower shall make prepayments thereof and borrow new Revolving Loans at the Alternate Base Rate so that, after giving effect thereto, the Revolving Loans outstanding at the Alternate Base Rate are held pro rata based on the Lenders’ respective Revolving Credit Commitments in effect on and after such Re-Allocation Date.  In the event that on any such Re-Allocation Date there are outstanding Revolving Loans that are LIBOR Borrowings, such Revolving Loans shall remain outstanding with the respective holders thereof until the expiration of their respective Interest Periods (unless the Borrower elects to prepay any thereof in accordance with the applicable provisions of this Agreement), and interest on and repayments of such Revolving Loans will be paid thereon to the respective Lenders holding such Revolving Loans pro rata based on the respective principal amounts thereof outstanding and each Lender’s Revolving Credit Exposure will be adjusted accordingly until the end of the applicable Interest Periods then in effect for such outstanding Revolving Loans, at which time no such adjustment shall thereafter be made.

 

(f)            Notwithstanding anything to the contrary in this Section 2.15, (i) no Lender shall have any obligation to increase its Revolving Credit Commitment under this Section 2.15 unless it agrees in writing to do so in its sole discretion, (ii) no Lender shall have any right to decrease the amount of its Revolving Credit Commitment as a result of any requested increase of the Total Revolving Credit Commitment pursuant to this Section 2.15, (iii) the Agent shall have no obligation to find or locate any New Lender to participate in any unsubscribed portion of any increase in the Total Revolving Credit Commitment requested by the Borrower, (iv) each increase in the Total Revolving Credit Commitment requested by the Borrower shall not be less than $10,000,000, (v) after giving effect to any increase in the Total Revolving Credit Commitment pursuant to this Section 2.15, the Total Revolving Credit Commitment shall not exceed $150,000,000, and (vi) in the event the Borrower reduces the Total Revolving Credit Commitment pursuant to Section 2.4 or any other provision of this Agreement, the ability of the Borrower to request increases in the Total Revolving Credit Commitment pursuant to this Section 2.15 shall automatically terminate.

 

58

 

(g)           The Borrower shall execute and deliver to the Agent (for delivery by the Agent to each applicable Lender) a new Revolving Credit Note for Revolving Loans payable to each applicable Lender (including each New Lender) participating in any increase of the Total Revolving Credit Commitment in the original principal amount of such Lender’s Revolving Credit Commitment after giving effect to any such increase of the Total Revolving Credit Commitment; provided, however, that the execution and delivery of any such new Revolving Credit Note to an existing Lender shall be conditioned upon and subject to the surrender by such existing Lender to the Agent (for delivery by the Agent to the Borrower) of such Lender’s then existing Revolving Credit Note in the amount of its Revolving Credit Commitment prior to such increase in the Total Revolving Credit Commitment.

 

3.             Collateral.

 

3.1           Security Documents.  The Loans and all other Obligations shall be secured by the Collateral, as and to the extent described in the Security Documents, the First Lien Intercreditor Agreement and the Second Lien Intercreditor Agreement, and the Agent and the Lenders are entitled to the benefits thereof.  The Credit Parties shall duly execute and deliver the Security Documents, all consents of third parties necessary to permit the effective granting of the Liens created thereby, and other documents, all in Proper Form, as may be reasonably required by the Agent to grant to the Agent, for the ratable benefit of the Lenders, a valid, perfected and enforceable first priority Lien on and security interest in the Collateral (subject only to the Liens permitted under Section 7.2 hereof), including without limitation, any and all original stock certificates, stock transfer powers, assignments and other documents and instruments necessary or desirable under the laws of any applicable jurisdiction with regard to the Equity Interests covered by any Security Agreement.

 

3.2           Filing and Recording.  The Credit Parties shall, at their sole cost and expense, cooperate with the Agent in causing all financing statements and other Security Documents pursuant to this Agreement to be duly recorded and/or filed or otherwise perfected in all places necessary to perfect the Liens of the Agent, in the opinion of the Agent, and the Credit Parties shall take such other actions as the Agent may reasonably request, in order to perfect and protect the Liens of the Agent, for the ratable benefit of the Lenders, in the Collateral.  Each of the Credit Parties, to the extent permitted by law, hereby authorizes the Agent to file any financing statement, Mortgage or other Security Document in respect of any Lien created pursuant to the Security Documents which may at any time be required to perfect such Liens or which, in the reasonable opinion of the Agent, may at any time be desirable, although the same may have been executed only by the Agent or, at the option of the Agent, to sign such financing statement on behalf of any Credit Party, and file the same, and each of the Credit Parties hereby irrevocably designates the Agent, its agents, representatives and designees as its agent and attorney-in-fact for this purpose.  In the event that any re-recording or refiling thereof (or the filing of any statements of continuation or assignment of any financing statement) is required to protect and preserve such Lien, the Credit Parties shall, at the Credit Parties’ cost and expense, cause the same to be recorded and/or refiled at the time and in the manner requested by the Agent.

 

59

 

4.             Conditions.

 

4.1           All Loans.  The obligation of each Lender to make any Loan (other than a Swingline Loan, which shall be governed exclusively by the terms of Section 2.11) and the obligation of the Agent to issue any Letter of Credit is subject to the satisfaction of the following conditions:

 

(a)           the Agent shall have received the following, all of which shall be duly executed and in Proper Form:  (1) in the case of a Loan, other than a Revolving Loan for the purposes described in Sections 2.2(b), 2.4(c), 2.6(d) and 2.10(d),

 

(i)            with respect to each Alternate Base Rate Borrowing, Agent shall have received by no later than 1:00 p.m. on the applicable Rate Selection Date, telephonic notice from the Borrower of the proposed date and amount of such Loan, and by no later than 2:00 p.m. Central time on the applicable Rate Selection Date, a Request for Extension of Credit, signed by a Responsible Officer of the Borrower, and

 

(ii)           with respect to each LIBOR Borrowing, Agent shall have received by no later than 12:00 noon on the applicable Rate Selection Date, telephonic notice from the Borrower of the proposed date and amount of such Loan, and no later than 1:00 p.m. on the applicable Rate Selection Date, a Request for Extension of Credit, signed by a Responsible Officer of the Borrower,

 

or, in the case of issuance of a Letter of Credit, a completed Application (as may be required by the Agent) signed by a Responsible Officer of the Borrower by 12:00 noon five (5) Business Days prior to the proposed date of issuance of such Letter of Credit and payment of the first letter of credit fee as and by the time required in Section 2.10 of this Agreement, along with, in each case, such financial information as the Agent may reasonably require to substantiate compliance with all financial covenants contained herein by the Borrower if the Agent reasonably believes at such time that the Borrower is not then in compliance with any of the financial covenants contained herein; and (2) such other Applications, certificates and other documents as the Agent may reasonably require;

 

(b)           Availability must be in excess of or equal to zero, after giving effect to the requested Revolving Loan(s) or Letter(s) of Credit and, if applicable, the resulting payment of any Obligations to be contemporaneously paid with the proceeds of such requested Revolving Loan;

 

(c)           all representations and warranties of any of the Credit Parties set forth in this Agreement and in any other Loan Document shall be true and correct in all material respects with the same effect as though made on and as of such date, except for (i) those representations and warranties which relate only to the Closing Date and (ii) those changes in such representations and warranties otherwise permitted by the terms of this Agreement;

 

(d)           there shall have occurred no Material Adverse Effect, after giving effect to the requested Loan(s) or Letter(s) of Credit;

 

(e)           no Default or Event of Default shall have occurred and be continuing;

 

60

 

(f)            if requested by the Agent, it shall have received a certificate executed by a Responsible Officer of the Borrower as to the compliance with subparagraphs (b) through (e) above;

 

(g)           the making of such Loan or the issuance of such Letter of Credit, shall not be prohibited by, or subject the Agent or any Lender to, any penalty or onerous condition under any Legal Requirement; and

 

(h)           the Borrower shall have paid all legal fees and other expenses of the type described in Section 10.9 hereof for which invoices have been presented through the date of such Loan or the issuance of such Letter of Credit.

 

4.2           First Loan or Letter of Credit.  In addition to the matters described in Section 4.1 hereof, the obligation of any Lender to make the initial Loan or the obligation of the Agent to issue the first Letter of Credit is subject to the receipt by the Agent of each of the following, in Proper Form:

 

(a)           this Agreement and all other Loan Documents to be executed and delivered as of the Closing Date by the applicable Credit Parties;

 

(b)           a certificate of corporate resolutions and incumbency executed by the Secretary or an Assistant Secretary of the Borrower dated as of the date hereof, authorizing (i) the Borrower’s entering into the transactions contemplated hereby and (ii) the delivery by the Borrower of this Agreement and all other Loan Documents to be executed and delivered as of the Closing Date by the Borrower;

 

(c)           a certificate of corporate resolutions and incumbency executed by the Secretary or an Assistant Secretary of each of the Guarantors dated as of the date hereof, authorizing each of the Guarantors to (i) enter into the transactions contemplated hereby and (ii) deliver this Agreement and all other Loan Documents to be executed and delivered as of the Closing Date by the Guarantors;

 

(d)           certificates from the Secretary of State or other appropriate public official of the State of Delaware as to the continued existence and good standing of the Borrower in the State of Delaware and from the State of California as to the qualification to do business and good standing of the Borrower in the State of California;

 

(e)           certificates from the Secretary of State or other appropriate public official as to the continued existence and good standing of each of the Guarantors in its applicable State of formation;

 

(f)            certificates from the appropriate public officials of the States of Texas, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas, Nebraska, New Mexico, Oklahoma, South Dakota, Tennessee, Utah and Wisconsin for the Borrower, Walco Holdings, Inc., Walco Intermediate, Inc., and/or their Domestic Subsidiaries that are Guarantors, as to the good standing and qualification as a foreign corporation, to the extent it is necessary to be qualified to do business as a foreign corporation in these jurisdictions;

 

61

 

(g)           one copy of each of the Term Loan Debt Documents, including all amendments and schedules thereto, certified as true and correct copies by a Responsible Officer of the Borrower, together with evidence that all of the Term Loan Debt Documents are in full force and effect, and all material consents, approvals and filings required by any Governmental Authority in connection with any and all Term Loan Debt Documents have been obtained and made;

 

(h)           evidence that the Term Loan Debt Transaction is contemporaneously being duly and validly consummated on the Closing Date without modification, amendment or waiver of any material provisions of any of the Term Loan Debt Documents (except for such modifications, amendments or waivers as shall have been approved in writing by the Required Lenders), all in accordance with the terms, conditions and provisions of the Term Loan Debt Documents;

 

(i)            the Borrower’s receipt on the Closing Date of the entire $45,000,000 amount of proceeds of the Term Loan Debt, net of customary and reasonable closing costs, and the Borrower’s application of such net proceeds in full satisfaction and payment of the Term Loans (as defined in the Original Agreement), with the balance of such net proceeds being applied against the Revolving Loans;

 

(j)            the First Lien Intercreditor Agreement;

 

(k)           the Second Lien Intercreditor Agreement and the Second Lien Debt Purchase Agreement executed by Merrill Lynch PCG, Inc. and all other parties thereto, whereby Merrill Lynch PCG, Inc. and such other parties, (1) consent to the Term Loan Debt, and (2) increase to $210,000,000 the maximum combined funded principal amount permitted under the Loans and the Term Loans (as defined in the Term Loan Debt Purchase Agreement), all upon terms acceptable to and approved by the Agent in its discretion;

 

(l)            a legal opinion from Goodwin Procter LLP, the independent counsel for the Credit Parties, dated as of the Closing Date, addressed to the Agent and acceptable in all respects to the Agent in its sole reasonable discretion;

 

(m)          certificates of insurance satisfactory to the Collateral Agent in all respects evidencing the existence of all insurance required to be maintained by the Borrower and its Subsidiaries pursuant to the terms of this Agreement, the Security Documents and the Term Loan Debt Documents;

 

(n)           payment by the Borrower to the Lenders, the Agent and the Agent’s applicable Affiliates of all fees required to be paid under the Loan Documents and any separate fee letter with the Agent and the Agent’s applicable Affiliates, and all expenses required to be paid under the Loan Documents for which invoices have been presented; and

 

(o)           all other Loan Documents and any other instruments or documents consistent with the terms of this Agreement and relating to the transactions contemplated hereby as the Agent may reasonably request, executed by the Credit Parties or any other Person required by the Agent.

 

62

 

5.             Representations and Warranties.

 

Each of the Credit Parties represents and warrants to the Agent and the Lenders, as to itself and each other Credit Party, that:

 

5.1           Organization.  Each Credit Party is duly organized, validly existing and in good standing under the laws of the state of its incorporation or formation; has all power and authority under its organizational documents to own its respective Property and assets and to conduct its respective businesses as presently conducted; and is duly qualified to do business and in good standing in each and every state jurisdiction where its respective business requires such qualification, except for those jurisdictions in which the failure to qualify and/or be in good standing would not reasonably be expected to result in a Material Adverse Effect.

 

5.2           Financial Statements.

 

(a)           The Consolidated financial statements of the Credit Parties and their Subsidiaries delivered to the Agent and the Lenders in connection with this Agreement, including without limitation, (i) the Annual Audited Financial Statements dated as of June 30, 2005 and (ii) the Monthly Unaudited Financial Statements dated as of June 30, 2006, fairly present in all material respects, in accordance with GAAP, the Consolidated financial condition and the results of operations of the Credit Parties and their Subsidiaries as of the dates and for the periods indicated, subject to year-end audit adjustments and the absence of footnotes in the case of such unaudited or any pro forma statements, and no Material Adverse Effect has occurred since the dates of such financial statements.

 

(b)           The Credit Parties have heretofore furnished to the Agent, for the calendar months from the projected Closing Date through June 30, 2007 and for each fiscal year of the Credit Parties thereafter through the Revolving Credit Termination Date, projected income statements, balance sheets and cash flows of the Credit Parties and their Subsidiaries, on a Consolidated basis, together with one or more schedules demonstrating prospective compliance with all financial covenants contained in this Agreement, such projections disclosing all material assumptions made by the Credit Parties in formulating such projections.  The projections are based upon estimates and assumptions which the Credit Parties believe are reasonable in light of the conditions which existed as of the time the projections were made, have been prepared on the basis of the material assumptions stated therein and reflect as of the Closing Date an estimate believed reasonable by the Credit Parties as to the results of operations and other information projected therein.

 

5.3           Enforceable Obligations; Authorization.  The Loan Documents are legal, valid and binding obligations of the respective Credit Parties executing and delivering the same, enforceable against such Credit Parties in accordance with their respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium, and other similar laws affecting creditors rights generally and by general equitable principles regardless of whether considered in a proceeding in equity or at law.  The execution, delivery and performance of the Loan Documents have all been duly authorized by all necessary corporate, and if necessary shareholder, action; are within the power and authority of each of the Credit Parties; do not and will not violate any Legal Requirement material to the business, assets or operations of any of

 

63

 

the Credit Parties taken as a whole or the Organizational Documents of any of the Credit Parties; do not and will not constitute a default under, any material agreement or instrument by which any of the Credit Parties or any material portion of any of the Credit Parties’ Property is bound or affected; and do not and will not result in the creation of any Lien upon any Property of any of the Credit Parties except as expressly contemplated therein.  All necessary approvals of any Governmental Authority and all other requisite material permits, registrations and consents for the performance have been obtained for the delivery and performance of the Loan Documents.

 

5.4           Other Debt.  Except as set forth on Schedule 5.4 attached hereto, no Credit Party is in default in the payment of any other Indebtedness or under any agreement, mortgage, deed of trust, security agreement or lease to which it is a party, the result of which would or could reasonably be expected to result in a Material Adverse Effect.

 

5.5           Litigation.  Except as set forth on Schedule 5.5 attached hereto, to the knowledge of the Credit Parties, there is no litigation or administrative proceeding pending or threatened against, nor any outstanding judgment, order or decree affecting, any of the Credit Parties or any of their Subsidiaries before or by any Governmental Authority or arbitral body as to which there is a reasonable possibility of an adverse determination and which individually or in the aggregate have, or if adversely determined could reasonably be expected to have, a Material Adverse Effect.  Except as set forth on Schedule 5.5 attached hereto, as of the Closing Date there is no litigation or administrative proceeding pending against, nor any outstanding judgment, order or decree affecting, any of the Credit Parties or any of their Subsidiaries before or by any Governmental Authority or arbitral body.  Except as set forth on Schedule 5.5 attached hereto, none of the Credit Parties, nor any of their Subsidiaries, is knowingly in material default with respect to any judgment, writ, rule, regulation, order or decree of any Governmental Authority.

 

5.6           Taxes.  Except as set forth on Schedule 5.6 attached hereto, the Credit Parties and their Subsidiaries have filed all federal, state, local or foreign tax returns required to have been filed by them and paid all taxes shown thereon to be due, except those for which extensions have been obtained, and except for those which are being contested in good faith and by appropriate proceedings if adequate reserves with respect thereto are maintained in accordance with GAAP.  There is no outstanding federal audit by the Internal Revenue Service of the income tax returns of any of the Credit Parties or any of their Subsidiaries claimed or raised in writing, and none of the Credit Parties or any of their Subsidiaries have, as of the Closing Date, any extension of time with respect to an assessment or deficiency relating to any Federal tax return that is still in effect.  None of the Credit Parties or any of their Subsidiaries have, as of the Closing Date, any extension of time with respect to an assessment or deficiency relating to any state, local or foreign tax return that is still in effect, other than extensions with respect to tax liabilities where the failure by the applicable Credit Party to pay such tax liabilities would not have a Material Adverse Effect.  None of the Credit Parties or any of their Subsidiaries is a party to any tax sharing arrangement with any Person (other than the affiliated group of which Walco Holdings is the parent).

 

5.7           No Material Misstatements.  No information, report, financial statement, exhibit or schedule prepared and furnished by or on behalf of any Credit Party to the Agent or any Lender in connection with this Agreement or any other Loan Documents knowingly contains any material misstatement of fact or knowingly omits to state any material fact necessary to make the

 

64

 

statements therein, in the light of the circumstances under which they were made, not misleading at the time prepared or furnished.

 

5.8           Subsidiaries.  As of the date hereof, the Credit Parties have no Subsidiaries other than as listed on Schedule 5.8 attached hereto.  Except as expressly indicated on Schedule 5.8 attached hereto, as of the Closing Date, each of the Subsidiaries listed on Schedule 5.8 is wholly owned by the applicable Credit Party.  As of the Closing Date, Schedule 5.8 sets forth (a) the jurisdiction of incorporation or organization of each Subsidiary of the Credit Parties, and (b) the percentage of the applicable Credit Party’s ownership of the Equity Interests of each Subsidiary of the Credit Parties.

 

5.9           Representations by Others.  All representations and warranties made by or on behalf of any of the Credit Parties in any Loan Document shall constitute representations and warranties of the Credit Parties hereunder.

 

5.10         Permits, Licenses, Etc.  Each of the Credit Parties possess all material permits from each applicable Governmental Authority, licenses from each applicable Governmental Authority, patents, patent rights, trademarks, trademark rights, trade names, trade name rights and copyrights which are reasonably required to conduct their respective businesses.

 

5.11         ERISA.  No Reportable Event has occurred with respect to any Plan which, when taken together with all other such Reportable Events for which liability is reasonably expected to occur, could reasonably be expected to result in any material liability.  Each Plan complies in all material respects with all applicable provisions of ERISA, and the Borrower or each ERISA Affiliate have filed all reports required by ERISA and the Code to be filed with respect to each Plan.  The Borrower does not have any knowledge of any event which could reasonably be expected to result in a liability of the Borrower or any ERISA Affiliate to the PBGC other than for applicable premiums.  No accumulated funding deficiency (as defined in Section 302 of ERISA and Section 412 of the Code), whether or not waived, exists with respect to any Plan.  No event has occurred and no condition exists that could reasonably be expected to constitute grounds for a Plan to be terminated under circumstances which would cause the Lien provided under Section 4068 of ERISA to attach to any Property of the Borrower or any ERISA Affiliate.  No event has occurred and no condition exists that could reasonably be expected to cause the Lien provided under Section 302 of ERISA or Section 412 of the Code to attach to any Property of the Borrower or any ERISA Affiliate.

 

5.12         Title to Properties; Possession Under Leases.

 

(a)           Except as set forth on Schedule 5.12 attached hereto, the Credit Parties and each of their respective Subsidiaries have good and marketable title to, or a valid leasehold interest in, all of their respective Property and assets that are material to their respective business taken as a whole shown on the most recent Consolidated balance sheet for the Credit Parties and their Subsidiaries provided under the terms of Section 6.3(a) or Section 6.3(b), and all assets and Property that are material to their respective business taken as a whole, acquired since the date of such respective balance sheets, except for such Property as is no longer used or useful in the conduct of their respective businesses or as have been disposed of in the ordinary course of business or otherwise in accordance with this Agreement, and except for minor defects in title

 

65

 

that do not interfere with the ability of the Credit Parties or any of their Subsidiaries to conduct their respective businesses as now conducted or as otherwise disclosed in the title insurance delivered to the Agent in accordance with Section 4.2(cc).  All such assets and Property are free and clear of all Liens other than those permitted by Section 7.2 hereof.

 

(b)           Except as set forth on Schedule 5.12 attached hereto, the Borrower and each of its Subsidiaries have no knowledge of any material default under any material leases to which any of them is a party and under which any of them is in occupancy, except where non-compliance does not affect the Borrower’s or such Subsidiary’s use or occupancy thereof, as applicable, and all such material leases are in full force and effect.  Schedule 5.12 attached hereto sets forth each of such leases of real Property in existence as of the Closing Date, and upon the request of the Agent, the Borrower will provide the Agent with complete and correct copies of all of such leases of real Property then in effect.

 

5.13         Assumed Names.  As of the Closing Date, neither the Borrower, nor any of its Subsidiaries, is currently conducting its business under any assumed name or names, except as set forth on Schedule 5.13 attached hereto.  Upon written request by the Agent, the Borrower shall promptly furnish the Agent with a then current listing of all assumed names that the Borrower and/or any of its Subsidiaries is then utilizing in conducting their respective businesses.

 

5.14         Investment Company Act.  None of the Credit Parties or any of their Subsidiaries is an investment company within the meaning of the Investment Company Act of 1940, as amended.

 

5.15         Public Utility Holding Company Act.  None of the Credit Parties or any of their Subsidiaries is a “public utility company,” or an “affiliate” or a “subsidiary company” of a “public utility company,” or a “holding company,” or a “subsidiary company” of a “registered holding company,” or an “affiliate” of a “registered holding company” as such terms are defined in the Public Utility Holding Company Act of 1935, as amended (“PUHCA”).

 

5.16         Agreements.  Schedule 5.16 attached hereto is a complete and correct list, as of the Closing Date (after giving effect to the Term Loan Debt Transaction), of (i) all credit agreements or indentures for borrowed money and capitalized leases to which any of the Credit Parties or any of their Subsidiaries is a party and all Property of any of the Credit Parties or any of their Subsidiaries subject to any Lien securing such Indebtedness or capitalized lease obligation, (ii) each letter of credit and guaranty to which any of the Credit Parties or any of their Subsidiaries is a party, (iii) all other material instruments in effect as of the date hereof providing for, evidencing, securing or otherwise relating to any Indebtedness for borrowed money of any of the Credit Parties or any of their Subsidiaries (other than the Indebtedness hereunder), and (iv) all obligations of any of the Credit Parties or any of their Subsidiaries to issuers of appeal bonds issued for account of any Credit Party or any of its Subsidiaries.  The Borrower shall, upon, request by the Agent, deliver to the Agent and the Lenders a complete and correct copy of all such credit agreements, indentures, capitalized leases, letters of credit, guarantees and other instruments described in Schedule 5.16 or arising after the date hereof, including any modifications or supplements thereto, as in effect on the date hereof.

 

66

 

5.17         Environmental Matters.  Except as disclosed on Schedule 5.17 attached hereto or in any of the environmental assessments or studies described on Schedule 5.17 attached hereto, to the Credit Parties’ knowledge:  (a) each of the Credit Parties and their Subsidiaries are in material compliance with all limitations, restrictions, conditions, standards, prohibitions, requirements, obligations, schedules and timetables contained in any applicable Requirement of Environmental Law or Environmental Permit reasonably necessary to the conduct of any material aspect of the business of any Credit Party or any of its Subsidiaries; (b) each of the Credit Parties and their Subsidiaries (i) have obtained and maintained in effect all Environmental Permits reasonably necessary to the conduct of any material aspect of the business of any Credit Party or any of its Subsidiaries, (ii) along with their respective Properties (whether leased or owned) have been and are in material compliance with all applicable Requirements of Environmental Law and Environmental Permits, (iii) along with their respective Properties (whether leased or owned) are not subject to any material (A) Environmental Claims or (B) Environmental Liabilities arising from or based upon any act, omission, event, condition or circumstance occurring or existing on or prior to the date hereof, and (iv) have not received individually or collectively any notice of any material violation or alleged material violation of any Requirements of Environmental Law or Environmental Permit or any Environmental Claim in connection with their respective Properties; and (c) none of the Credit Parties or any of their Subsidiaries has actual knowledge of any material violation of any applicable Requirements of Environmental Law and Environmental Permits by, or of any material Environmental Claims or Environmental Liabilities arising against, any of the prior owners or operators and predecessors in interest with respect to any of the Credit Parties’ or any of their Subsidiaries’ respective Property.

 

5.18         No Change in Credit Criteria or Collection Policies.  To the best knowledge of the Credit Parties, there has been no material adverse change in credit criteria or collection policies concerning Accounts of Borrower or any of its Subsidiaries since the date of the field exam described in Section 4.2(k) which has had or which is likely to have, in the reasonable judgment of any Responsible Officer of the Borrower, a Material Adverse Effect.

 

5.19         Solvency.

 

(a)           Immediately after the consummation of the Term Loan Debt Transaction and the other transactions contemplated hereunder to occur on the Closing Date, (i) the fair value of the assets of each Credit Party, at a fair valuation, will exceed its debts and liabilities, subordinated, contingent or otherwise; (ii) the present fair saleable value of the property of each Credit Party will be greater than the amount that will be required to pay the probable liability of its debts and other liabilities, subordinated, contingent or otherwise, as such debts and other liabilities become absolute and matured; (iii) each Credit Party will be able to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured; and (iv) each Credit Party will not have unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted after the Closing Date; provided, however, that for purposes of the foregoing representations and warranties by the Canadian Subsidiaries of the Borrower set forth in clauses (i), (ii) and (iii), the contingent liabilities of such Canadian Subsidiaries under the terms of the Guaranty and under the terms of the guaranty by such Canadian Subsidiaries of the Term Loan Debt and the Second Lien Debt shall be excluded.  Notwithstanding the foregoing proviso,

 

67

 

however, each Canadian Subsidiary of the Borrower represents and warrants that applicable Canadian bankruptcy and insolvency laws do not provide such Canadian Subsidiary with any fraudulent conveyance or other similar defense to the enforcement of such Canadian Subsidiary’s Obligations under the Guaranty or any applicable Security Document to which such Canadian Subsidiary is a party.

 

(b)           No Credit Party intends to, or will permit any of its Subsidiaries to, and no Credit Party believes that it or any of its Subsidiaries will, incur debts beyond its ability to pay such debts as they mature, taking into account the timing of and amounts of cash to be received by it or any such Subsidiary and the timing of the amounts of cash to be payable on or in respect of its Indebtedness or the Indebtedness of any such Subsidiary.

 

5.20         Status of Collateral.  The Credit Parties are and shall be the sole owners, free and clear of all Liens except in favor of the Agent or otherwise permitted under Section 7.2 hereunder, of and fully authorized to sell, transfer, pledge and/or grant a security interest in all of the Collateral (other than Excluded Collateral, as defined in the applicable Security Documents), and (b) to the Credit Parties’ knowledge, each Account included within the Borrowing Base meets the requirements of the definition of Eligible Account, each item of Inventory included within the Borrowing Base meets the requirements of the definition of Eligible Inventory, each item of Equipment included within the Borrowing Base meets the requirements of the definition of Eligible Equipment, and each parcel of Real Estate (other than the Excluded Real Estate) meets the requirements of the definition of Eligible Real Estate.

 

5.21         Term Loan Debt and Second Lien Debt Documents.  Each of the Term Loan Debt Documents and the Second Lien Debt Documents constitutes the valid and binding obligation of the applicable Credit Parties, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, and moratorium laws and other laws affecting creditors’ rights generally and by general principles of equity regardless of whether considered in a proceeding in equity or at law.  The Credit Parties have no knowledge that any of the representations and warranties contained in any of the Term Loan Debt Documents or any of the Second Lien Debt Documents were not true and correct in all material respects on and as of the date given or, except as consented to by the Agent in writing or otherwise disclosed in writing to the Agent prior to the Closing Date, that any of the material terms thereof have been modified, amended or waived other than as permitted under Section 7.19.

 

5.22         Transactions with Related Parties.  Except as set forth on Schedule 5.22 attached hereto, any and all transactions, contracts, or other agreements existing on the Closing Date which have been entered into by and among any Credit Party and any officer, director, shareholder or Affiliate of any of the Credit Parties (other than Permitted Affiliate Transactions), has been entered into and made upon terms and conditions not less favorable to the applicable Credit Parties than those terms which could have been obtained from wholly independent and unrelated sources.

 

5.23         Patents, Trademarks and Copyrights.  Schedule 5.23 hereto sets forth a true, accurate and complete listing, as of the date hereof, of all patents, registered trademarks and copyrights, and applications therefor, of each of the Credit Parties and each of their Subsidiaries as of the Closing Date.  Except as created or permitted under the Loan Documents, no Lien

 

68

 

exists with respect to the interest of any Credit Party or any of its Subsidiaries in any such patents, registered trademarks or copyrights or applications therefor, and no Credit Party or any of its Subsidiaries has transferred or subordinated any interest it may have in such patents, registered trademarks and copyrights and applications therefor.  The Borrower shall, from time to time as necessary, deliver to the Agent an updated Schedule 5.23 to this Agreement, together with a certificate of a Responsible Officer of the Borrower certifying that the information set forth on such schedule is true, correct and complete as of such date, which schedule may be used to prepare additional Security Agreements, if necessary.

 

6.             Affirmative Covenants.

 

Until the Revolving Credit Commitments have expired or been terminated and the Obligations shall have been paid in full and all Letters of Credit shall have expired or terminated, each Credit Party executing this Agreement covenants and agrees, jointly and severally with all of the Credit Parties, to perform and observe (and cause each of its Subsidiaries to perform and observe) each and all of the following covenants and agreements:

 

6.1           Businesses and Properties.  At all times:  (a) do or cause to be done all things necessary to obtain, preserve, renew and keep in full force and effect the rights, licenses, permits, franchises, patents, copyrights, trademarks and trade names material to the conduct of its businesses; (b) maintain and operate such businesses in the same general manner in which they are presently conducted and operated, provided that the foregoing shall not prohibit any merger, consolidation, liquidation, dissolution or any discontinuance or sale of such business permitted under Section 7.4; (c) comply in all material respects with all Legal Requirements applicable to the operation of such businesses whether now in effect or hereafter enacted (including without limitation, all Legal Requirements relating to public and employee health and safety and all Environmental Laws) and with any and all other Legal Requirements; and (d) keep and maintain all Property material to the conduct of such businesses in good repair, working order and condition, ordinary wear and tear excepted, and from time to time make, or cause to be made, all necessary repairs, renewals, additions, improvements and replacements thereto necessary in order that the business carried on in connection therewith may be properly conducted at all times.

 

6.2           Taxes.  Pay and discharge promptly when due (giving effect to all extensions of time permitted by the applicable Governmental Authority) all taxes, assessments and governmental charges or levies imposed upon it or upon its income or profits or in respect of its Property, before the same shall become delinquent or in default, as well as all lawful claims for labor, materials and supplies or otherwise, which, if unpaid, might give rise to Liens upon such properties or any part thereof (except as otherwise permitted by Section 7.2 hereof), unless being contested in good faith by appropriate proceedings and as to which adequate reserves in an amount not less than the aggregate amount secured by such Liens have been established in accordance with GAAP; provided, however, that such contested amounts giving rise to such Liens shall be immediately paid upon commencement of any procedure or proceeding to foreclose any of such Liens unless the same shall be validly stayed by a court of competent jurisdiction or a surety bond, which is satisfactory in all respects to the Agent, is delivered to the Agent for the ratable benefit of the Lenders in an amount no less than such contested amounts.

 

69

 

6.3           Financial Statements and Information.  Furnish to the Agent each of the following:

 

(a)           as soon as available and in any event within ninety (90) days after the end of each fiscal year of the Credit Parties, Annual Audited Financial Statements of the Credit Parties and their Subsidiaries;

 

(b)           as soon as available and in any event within thirty (30) days after the end of each calendar month, Monthly Unaudited Financial Statements of the Credit Parties and their Subsidiaries;

 

(c)           concurrently with the financial statements provided for in Subsections 6.3(a) and 6.3(b) hereof, (1) an Officer’s Certificate, signed by a Responsible Officer of applicable Credit Party, and (2) if applicable, a written certificate in Proper Form, identifying each Subsidiary which is otherwise required by the provisions of Section 6.10 hereof to become a Guarantor at the request of the Agent, but which has not yet done so as of the date of such certificate, and providing an explanation of the reasons why each such Subsidiary is not a Guarantor, signed by a Responsible Officer of the applicable Credit Party;

 

(d)           as soon as available and in any event within five (5) Business Days after the date of issuance thereof (if any such audit report or management letter is ever issued), any (1) interim or special audit report made by independent accountants of the books of the Credit Parties or any of their Subsidiaries or (2) management letter prepared by the independent public accountants who reported on the financial statements provided for in Subsection 6.3(a) above, with respect to the internal audit and financial controls of the Credit Parties and their Subsidiaries;

 

(e)           as soon as available and in any event within twenty (20) days after the end of each calendar month, an Accounts report in a form as may be reasonably required or requested by the Agent setting forth the sales, collections and total customer debits and credits for the Borrower, on a Consolidated and consolidating basis, for such month, certified by a Responsible Officer of the Borrower; provided, however, that when Availability is less than $15,000,000 for ten (10) consecutive Business Days, such Accounts report shall be furnished weekly within three (3) Business Days after the end of each week, and such weekly reporting shall remain in effect thereafter until Availability is $15,000,000 or greater for thirty (30) consecutive days;

 

(f)            as soon as available and in any event within twenty (20) days after the end of each calendar month, an Inventory Designation Report in the form of Exhibit G;

 

(g)           as soon as available and in any event within twenty (20) days after the end of each calendar month, Account agings and reconciliations, accounts payable agings and reconciliations, lockbox statements and all other schedules, computations and other information, all in reasonable detail, as may be reasonably required or requested by the Agent with regard to the Borrower and its Subsidiaries, all certified by a Responsible Officer of the Borrower;

 

(h)           as soon as available and in any event within twenty (20) days after the end of each calendar month, a Borrowing Base Compliance Certificate, signed by a Responsible Officer of the Borrower in the form attached hereto as Exhibit F;

 

70

 

(i)            as soon as available and in any event within thirty (30) days prior to the commencement of each fiscal year of the Credit Parties, management-prepared Consolidated financial projections of the Credit Parties and their Subsidiaries for the immediately following three (3) fiscal years (setting forth such projections on both an annual basis and on a monthly basis for the upcoming fiscal year and on an annual basis only for the two (2) fiscal years thereafter), such projections to be prepared and submitted in such format and detail as reasonably requested by the Agent; and

 

(j)            such other information relating to the financial condition, operations and business affairs of any Credit Party or any of its Subsidiaries as from time to time may be reasonably requested by the Agent.

 

The Agent reserves the right to require information required to be delivered in Sections 6.3(e)-(h) as frequently as weekly at any time an Event of Default does not exist based on the Agent’s Permitted Discretion or more frequently at any time Event of Default exists.

 

6.4           Inspections; Field Examinations; Appraisals and Physical Counts.

 

(a)           Upon reasonable notice (which may be telephonic notice), at all reasonable times and as often as the Agent may request, permit any authorized representative designated by the Agent, including without limitation, any consultant engaged by the Agent, together with any authorized representatives of any Lender desiring to accompany the Agent, to visit and inspect the Properties and financial records of the Credit Parties and to make extracts from such financial records and permit any authorized representative designated by the Agent (together with any accompanying representatives of any Lender) to discuss the affairs, finances and condition of the Credit Parties with any Responsible Officer and the Credit Parties’ independent public accountants, as applicable.  The Agent agrees that it shall schedule any meeting with any such independent public accountant through the Borrower, and a Responsible Officer of the Borrower shall have the right to be present at any such meeting.

 

(b)           The Agent and any consultant of the Agent shall each have the right to examine (and any authorized representatives of any Lender shall have the right to accompany the Agent during any such examination), as often as the Agent may request, the existence and condition of the Accounts, books and records of the Borrower and its Subsidiaries and to review their compliance with the terms and conditions of this Agreement and the other Loan Documents, subject to governmental confidentiality requirements.  The Agent shall also have the right to verify with any and all customers of the Borrower and its Subsidiaries the existence and condition of the Accounts, as often as the Agent may require, without prior notice to or consent of the Borrower or any of its Subsidiaries.  Without in any way limiting the foregoing, the Agent shall have the right to (i) conduct field examinations of the Borrower and its Subsidiaries operations at the Borrower’s expense as often as the Agent may request and (ii) to order and obtain an appraisal of the Inventory, the Equipment and/or the Real Estate of the Borrower and its Subsidiaries by an appraisal firm satisfactory to the Agent as often as the Agent may request.  Without in any way limiting the foregoing, the Borrower agrees to cooperate and to cause its Subsidiaries to cooperate in all respects with the Agent and its representatives and consultants in connection with any and all inspections, examinations and other actions taken by the Agent or any of its representatives or consultants pursuant to this Section 6.4.  The Borrower hereby

 

71

 

agrees to promptly pay, upon demand by the Agent (or the applicable Lender, if appropriate), any and all fees and expenses incurred by the Agent or any Lender in connection with any inspection, examination, appraisal or review permitted by the terms of this Section 6.4; provided, however, that so long as no Default or Event of Default is continuing, the Borrower shall only be obligated to pay for (x) two field examinations during each consecutive 12-month period (limited to the prevailing rate then charged for field examinations, which is initially anticipated to be $850.00 per day per examiner, plus all out-of-pocket expenses of the Agent related to such filed examinations), (y) one Inventory appraisals during each consecutive 12-month period, and (z) one Equipment appraisal and one Real Estate appraisal of all real property then included within Eligible Real Estate during any consecutive 12-month period, but only if the Borrower has elected the reappraisal option for the applicable annual Equipment and Real Estate Annual Adjustments (other than the initial field examinations and appraisals for any Accounts, Equipment and/or Inventory acquired through an acquisition or other Investment permitted under the terms of this agreement, it being agreed that the Borrower shall be obligated to pay for each such initial field examination and/or appraisal, as applicable, conducted with respect to each such acquisition or Investment); provided further, however, that the Borrower shall only be obligated to pay or reimburse such fees and expenses of any Lender other than the Agent to the extent incurred by such Lender after the occurrence of any Default or Event of Default which has not been cured to the satisfaction of the Agent or waived in writing by the Agent and the Required Lenders.

 

6.5           Further Assurances.  Upon request by the Agent, promptly execute and deliver any and all other and further agreements and instruments and take such further action as may be reasonably requested by the Agent to (a) cure any defect in the execution and delivery of any Loan Document or more fully to describe particular aspects of any of the Credit Parties’ agreements set forth in the Loan Documents or so intended to be, (b) to carry out the provisions and purposes of this Agreement an the other Loan Documents, and (c) grant, preserve, protect and perfect the first priority Liens created or intended to be created by the Security Documents in the Collateral.

 

6.6           Books and Records.  Maintain financial records and books in accordance with accepted financial practice and GAAP.

 

6.7           Insurance.

 

(a)           Keep its insurable Properties adequately insured at all times by financially sound and reputable insurers.

 

(b)           Maintain such other insurance, to such extent and against such risks, including fire and other risks insured against by extended coverage and employee liability, as is customary with companies similarly situated and in the same or similar businesses, provided, however, that such insurance shall insure the Property of the Borrower and each of its Subsidiaries against all risk of physical damage, including without limitation, loss by fire, explosion, theft, fraud and such other casualties as may be reasonably satisfactory to the Agent, but in no event at any time in an amount less than the replacement value of the Collateral.

 

72

 

(c)           Maintain in full force and effect worker’s compensation coverage and public liability insurance against claims for personal injury or death or property damage occurring upon, in, about or in connection with its operations and with the use of any Properties owned, occupied or controlled by the Borrower or any of its Subsidiaries, in such amounts as the Agent shall reasonably deem necessary.

 

(d)           Maintain such other insurance as may be required by law or as may be reasonably requested by the Agent for purposes of assuring compliance with this Section 6.1.

 

All insurance covering tangible personal Property subject to a Lien in favor of the Agent for the benefit of the Lenders granted pursuant to the Security Documents shall provide that, in the case of each separate loss, the full amount of insurance proceeds shall be payable to the Agent and shall further provide for at least 30 days’ prior written notice to the Agent of the cancellation or substantial modification thereof.

 

6.8           ERISA.  At all times, except where a failure to comply with any of the following, individually or in the aggregate, would or could reasonably be expected to result in a material obligation or liability of any Credit Party:  (a) make contributions to each Plan in a timely manner and in an amount sufficient to comply with the minimum funding standards requirements of ERISA; (b) immediately upon acquiring knowledge of (i) any Reportable Event in connection with any Plan for which no administrative or statutory exemption exists or (ii) any Prohibited Transaction in connection with any Plan, that could result in the imposition of material damages or a material excise tax on the Borrower or any Subsidiary thereof, furnish the Agent a statement executed by a Responsible Officer of the Borrower or such Subsidiary setting forth the details thereof and the action which the Borrower or any such Subsidiary proposes to take with respect thereto and, when known, any action taken by the Internal Revenue Service with respect thereto; (c) notify the Agent promptly upon receipt by the Borrower or any Subsidiary thereof of any notice of the institution of any proceedings or other actions which may result in the termination of any Plan by the PBGC and furnish the Agent with copies of such notice; (d) pay when due, or within any applicable grace period allowed by the PBGC, all required premium payments to the PBGC; (e) furnish the Agent with copies of the annual report for each Plan filed with the Internal Revenue Service not later than ten (10) days after the Agent requests such report; (f) furnish the Agent with copies of any request for waiver of the funding standards or extension of the amortization periods required by Sections 303 and 304 of ERISA or Section 412 of the Code promptly after the request is submitted to the Secretary of the Treasury, the Department of Labor or the Internal Revenue Service, as the case may be; and (g) pay when due all installment contributions required under Section 302 of ERISA or Section 412 of the Code or within 10 days of a failure to make any such required contributions when due furnish the Agent with written notice of such failure.

 

6.9           Use of Proceeds.  Subject to the terms and conditions contained herein, use the proceeds of the Loans for (a) financing ongoing working capital needs of the Borrower and its Subsidiaries not otherwise prohibited herein, including without limitation, the issuance of Letters of Credit for the account of the Borrower or any of its Subsidiaries in accordance with and subject to the terms of this Agreement; (b) general corporate purposes of the Borrower or any of its Subsidiaries in the ordinary course of business not otherwise prohibited herein; (c) payment of the Obligations, as provided in this Agreement; (d) financing purchases and acquisitions

 

73

 

permitted to be made by the Borrower under the terms of Section 7.4(e)(7); and (e) financing dividends and distributions permitted to be made by the Borrower under the terms of Section 7.11; provided, that no proceeds of any Loan shall be used (w) for the purpose of purchasing or carrying directly or indirectly any margin stock as defined in Regulation U (“Reg U”) of the Board of Governors of the Federal Reserve System, (x) for the purpose of reducing or retiring any Indebtedness which was originally incurred to purchase or carry any such margin stock, (y) for any other purpose which would cause such Loan to be a “purpose credit” within the meaning of Reg U and (z) for any purpose which would constitute a violation of Reg U or of Regulations G, T or X of the Board of Governors of the Federal Reserve System or any successor regulation of any thereof or of any other rule, statute or regulation governing margin stock from time to time.

 

6.10         Guarantors, Joinder Agreements.  Promptly inform the Agent of the creation or acquisition of any Subsidiary of any Credit Party or the commencement of any business operations by any Inactive Subsidiary after the Closing Date and, within thirty (30) days after the written request of the Agent delivered in accordance with Section 10.2 below, cause (a) each such Subsidiary that is a Domestic Subsidiary or created under the laws of Canada to become a Guarantor by execution and delivery to the Agent, for the ratable benefit of the Lenders, of a Guaranty or a Joinder Agreement (if a Joinder Agreement is requested by the Agent in lieu of a Guaranty), (b) a first priority perfected security interest (pari passu with a first priority security interest securing the Term Loan Debt in accordance with and subject to the terms of the First Lien Intercreditor Agreement) to be granted to the Collateral Agent in all of the Equity Interests of such Subsidiary owned by any Credit Party or any of its other Subsidiaries if such newly acquired or created Subsidiary or previously Inactive Subsidiary is a Domestic Subsidiary or created under the laws of Canada, or if such newly acquired or created Subsidiary or previously Inactive Subsidiary is not a Domestic Subsidiary or a Subsidiary created under the laws of Canada, then not more than sixty-five percent (65%) of all issued and outstanding Equity Interests of such Subsidiary shall be pledged as Collateral pursuant to the foregoing pledge requirement for Equity Interests, (c) cause each such Subsidiary that is a Domestic Subsidiary or created under the laws of Canada to grant to the Collateral Agent a security interest securing the Obligations that is pari passu with a first priority security interest securing the Term Loan Debt in accordance with and subject to the terms of the First Lien Intercreditor Agreement (subject only to (i) Liens permitted under Sections 7.2(b) and (e) as to Accounts and Permitted Investment Securities which do not have priority over the Lien of Collateral Agent, (ii) Liens permitted under Section 7.2 as to all other Collateral which do not have priority over the Lien of Collateral Agent, and (iii) purchase money Liens existing as of the date of acquisition by Borrower or any other Subsidiary of the Borrower of such newly acquired Subsidiary, if applicable) in all Accounts, Inventory, Equipment, general intangibles and other tangible and intangible personal Property and all real Property owned at any time by such Subsidiary and all products and proceeds thereof (subject to similar exceptions as set forth in the Security Documents), and (d) cause such Subsidiary to deliver to the Agent such related certificates, legal opinions and documents (including Organizational Documents) as the Agent may reasonably require; provided, however, that any Subsidiary that is not a Domestic Subsidiary or created under the laws of Canada shall not be required to become a Guarantor or grant any Liens hereunder.  To the extent reasonably feasible, all of the foregoing requirements shall be affected by the execution and delivery of a Joinder Agreement in a form acceptable to the Agent.

 

74

 

6.11         Notice of Events.  Notify the Agent within one (1) Business Day after any Responsible Officer of any of the Credit Parties acquires knowledge of the occurrence of, or if any of the Credit Parties causes or intends to cause, as the case may be, any of the following:  (i) the institution of any lawsuit, administrative proceeding or investigation affecting any Credit Party or any of its Subsidiaries, including without limitation, any audit by the Internal Revenue Service, the adverse determination under which could reasonably be expected to have a Material Adverse Effect; (ii) any development or change in the business or affairs of any Credit Party or any of its Subsidiaries which has had or which is likely to have, in the reasonable judgment of any Responsible Officer of any of the Credit Parties, a Material Adverse Effect; (iii) any Event of Default or Default, together with a reasonably detailed statement by a Responsible Officer on behalf of the Borrower of the steps being taken to cure the effect of such Event of Default or Default; (iv) the occurrence of a default or event of default by any Credit Party or any of its Subsidiaries under any agreement or series of related agreements to which it is a party, which default or event of default could reasonably be expected to have a Material Adverse Effect; (v) any material violation by, or investigation of any Credit Party or any of its Subsidiaries in connection with any actual or alleged material violation of any Legal Requirement imposed by the Environmental Protection Agency, the Occupational Safety and Health Administration or any other Governmental Authority which has or is likely to have, in the reasonable judgment of any Responsible Officer of any Credit Party, a Material Adverse Effect; (vi) any significant change in the accuracy of any material representations and warranties of the any Credit Party or any of its Subsidiaries in this Agreement or any other Loan Document (including without limitation, the representations and warranties in Section 5.20(b)); (vii) the delivery of any written notice of default or event of default to any Credit Party by any representative or holder of any Term Loan Debt or the Second Lien Debt; (viii) any amendment or modification of the Second Lien Debt Documents or the Term Loan Debt Documents, such notice to be accompanied by copies of the actual amendment or modification documents; and (ix) any of the following:  (1) the occurrence of a Reportable Event with respect to any Plan; (2) the institution of any steps by the Borrower, any ERISA Affiliate, the PBGC or any other Person to terminate any Plan; (3) the institution of any steps by the Borrower or any ERISA Affiliate to withdraw from any Plan; (4) a Prohibited Transaction in connection with any Plan; (5) any material increase in the contingent liability of the Borrower or any Subsidiary of the Borrower with respect to any post-retirement welfare liability; or (6) the taking of any action by, or the threatening of the taking of any action by, the Internal Revenue Service, the Department of Labor or the PBGC with respect to any of the foregoing.

 

6.12         Environmental Matters.  Without limiting the generality of Section 6.1(c) hereof, (a) comply in all material respects with all material limitations, restrictions, conditions, standards, prohibitions, requirements, obligations, schedules and timetables contained in any applicable Requirement of Environmental Law, or Environmental Permit; (b) obtain and maintain in effect all Environmental Permits reasonably necessary to the conduct of any material aspect of its business; and (c) keep its Property free of any Environmental Claims or Environmental Liabilities, other than Environmental Claims or Environmental Liabilities, contingent or otherwise, disclosed in Schedule 5.17 attached hereto or any of the environmental assessments or studies described in Schedule 5.17 attached hereto.  In the event that any Credit Party or any of its Subsidiaries receives any demand or claim from any Person, including without limitation, any Governmental Authority, asserting the liability of any Credit Party or any of its Subsidiaries as a result of any Environmental Liabilities or requesting or requiring that any

 

75

 

Environmental Liabilities be remediated by any Credit Party or any of its Subsidiaries, such Credit Party agrees to promptly take action and thereafter diligently pursue the same to completion in a manner necessary to cause the applicable Environmental Liabilities to be remediated as soon as reasonably possible in accordance with all applicable Requirements of Environmental Law.  Each Credit Party, jointly and severally with all other Credit Parties, hereby indemnifies and agrees to hold the Agent and the Lenders harmless from and against any and all liability, loss, damage, suit, action or proceeding arising out of its respective business or the business of any of its Subsidiaries, pertaining to any Environmental Liabilities, including without limitation, claims of any Governmental Authority or any other Person arising under any Requirement of Environmental Law; provided, that the foregoing indemnity shall not apply to the extent, but only to the extent the applicable liability, loss, damage, suit, action or proceeding is caused by the willful misconduct, knowing and willful breach of any Loan Document or gross negligence of the party seeking indemnification.

 

6.13         End of Fiscal Year.  Cause each of its fiscal years to end on June 30th of the applicable year.

 

6.14         Pay Obligations and Perform Other Covenants.  Make full and timely payment of the Obligations, whether now existing or hereafter arising, as and when due and payable, duly comply with all of the terms and covenants contained in this Agreement and in each of the other Loan Documents at all times and places and in the manner set forth therein, and except for the filing of continuation statements and the making of other filings by the Agent as secured party or assignee, at all times take all actions necessary to maintain the Liens and security interests provided for under or pursuant to this Agreement and the Security Documents as valid perfected first priority Liens on the Collateral intended to be covered thereby (pari passu with the first priority Liens securing the Term Loan Debt in accordance with and subject to the terms of the First Lien Intercreditor Agreement and subject only to the Liens expressly permitted by Section 7.2 hereof) and supply all information to the Agent necessary for such maintenance.

 

6.15         Cash Dominion; Collection and Application of Accounts.

 

(a)           At the Borrower’s own cost and expense, arrange (and cause each of its Subsidiaries to arrange) for remittances on all Accounts to be made (i) directly to one or more lockboxes designated by the Collateral Agent under the terms of the Lockbox Agreement, (ii) directly to one or more deposit accounts with a third-party financial institution linked to a lockbox, cash management or similar depository system maintained with a third-party financial institution, so long as (A) such deposit accounts and systems are subject to and covered by a Tri-Party Agreement that facilitates the collection of Accounts by the Collateral Agent in accordance with the terms of this Section 6.15, and (B) the Borrower and its Subsidiaries cease to utilize all principal depository accounts and lockbox, cash management and depository systems maintained with any third-party financial institution on or before thirty (30) days after the Closing Date, or (iii) in such other manner as the Agent may direct.  All remittances on all Accounts processed through the lockboxes and received by the Collateral Agent in accordance with this Section 6.15(a) shall at all times be promptly deposited in one or more controlled disbursement or other accounts designated by the Collateral Agent, subject to withdrawal by the Collateral Agent only, as hereinafter provided and in connection therewith, the Collateral Agent and JPMorgan are

 

76

 

irrevocably authorized to cause all remittances on all Accounts received by the Collateral Agent or JPMorgan from whatever means, whether pursuant to the Lockbox Agreement, any Tri-Party Agreement or otherwise, to be promptly deposited in such account or accounts designated by the Collateral Agent.  All remittances and payments that are deposited in accordance with the foregoing will be applied by the Collateral Agent on the same day received (or on the next Business Day in the case of remittances and payments received after 11:00 a.m.) to reduce the outstanding balance of the Revolving Loans, subject to the continued accrual of interest for one (1) Business Day (or two Business Days in the case of remittances and payments received after 11:00 a.m.) on the Revolving Loan balances paid by such remittances and payments and in any event subject to final collection in cash of the item deposited.

 

(b)           Notwithstanding any provision to the contrary in this Section 6.15, the Borrower and its Subsidiaries shall be permitted to have from time to time local depository accounts maintained with financial institutions other than JPMorgan for local remittances, payroll, trust and escrow services of the Borrower and its Subsidiaries in the ordinary course of business, with not more than $500,000 in the aggregate being permitted to be held in all such local depository or remittance accounts at any one time, provided in each case all such accounts remain subject to a Tri-Party Agreement and which such permitted amounts in such accounts shall not be subject to periodic sweeps to a controlled disbursement account with the Collateral Agent unless an Event of Default then exists.

 

(c)           Except as otherwise permitted under Section 6.15(b) above, the Borrower and its Subsidiaries shall cause all payments, if any, received by the Borrower or any of its Subsidiaries on account of Accounts which are not forwarded directly to the above-described lockbox(es) or accounts (whether in the form of cash, checks, notes, drafts, bills of exchanges, money orders or otherwise) to be promptly deposited in the form received (but with any endorsements of the Borrower or the applicable Subsidiary necessary for deposit or collection) in the account or accounts designated by the Collateral Agent in accordance with the provisions of Section 6.15(a) above.

 

6.16         Accounts and Other Collateral Matters.  Maintain books and records pertaining to the respective Collateral owned by any Credit Party in detail, form and scope as the Agent shall reasonably require.  Each Credit Party will, promptly after any of its Responsible Officers learns thereof, report to the Agent any material loss or destruction of, or substantial damage to, any of the Collateral, and any other matters materially affecting the value, enforceability or collectibility of any of the Collateral.  If any amount payable under or in connection with any Account is evidenced by a promissory note or other instrument, as such terms are defined in the Uniform Commercial Code, such promissory note or instrument shall be promptly pledged, endorsed, assigned and delivered to the Agent as additional Collateral if the original principal amount of such promissory note or instrument is $50,000 or greater.  No Credit Party shall redate, or allow any of its Subsidiaries to redate, any invoice or sale or without written notice to the Agent, make or allow to be made sales on extended dating beyond that customary in the industry.  No Credit Party nor any of its Subsidiaries shall be entitled to pledge the Agent’s or any Lender’s credit on any purchases or for any purpose whatsoever.

 

6.17         Agreements.  Promptly after Agent’s request, the Borrower shall deliver or cause to be delivered to the Agent copies of all material employment agreements, management fee

 

77

 

agreements, tax sharing agreements, loan agreements, notes and other documentation evidencing any Indebtedness of any Credit Party or any of its Subsidiaries which the Agent may request.

 

7.             Negative Covenants.

 

Until the Revolving Credit Commitments have expired or been terminated and the Obligations shall have been paid in full and all Letters of Credit shall have expired or terminated, each Credit Party executing this Agreement covenants and agrees, jointly and severally with all of the Credit Parties, that it will not do (and will not suffer or permit any of its Subsidiaries, if any, to do) any of the following:

 

7.1           Indebtedness.  Create, incur, suffer or permit to exist, or assume or guarantee or become or remain liable with respect to any Indebtedness, absolute, contingent, or otherwise, except the following:

 

(a)           Indebtedness to the Lenders and the Agent pursuant hereto;

 

(b)           Indebtedness secured by Liens permitted by Section 7.2 hereof;

 

(c)           Purchase money Indebtedness (including the amount of any Capital Lease Obligations required to be capitalized and included as a liability on the consolidated balance sheet of the Borrower and its Subsidiaries) incurred to finance Capital Expenditures (to the extent otherwise permitted hereunder);

 

(d)           The Term Loan Debt and the Second Lien Debt, with no renewals, extensions or increases of any thereof being permitted (other than “payments-in-kind” of accrued and unpaid interest), unless the same has been approved in writing by the Agent and the Required Lenders, or in the case of the Term Loan Debt, the same is expressly permitted under the terms of the First Lien Intercreditor Agreement;

 

(e)           Other liabilities or Indebtedness existing on the date of this Agreement and set forth on Schedule 5.16 attached hereto;

 

(f)            Current accounts payable and unsecured current liabilities (including current accrued expenses), not the result of borrowings, to vendors, suppliers, landlords, lessors and persons providing services, for expenditures on ordinary trade terms for goods and services normally required by the Borrower or any of its Subsidiaries in the ordinary course of business;

 

(g)           Indebtedness of any Guarantor (other than the Parent) to the Borrower or to any other Guarantor (other than the Parent), or the Indebtedness of the Borrower to any Guarantor (other than the Parent), provided that no such Indebtedness may be cancelled, compromised or otherwise discounted in any respect without the written consent of the Required Lenders;

 

(h)           Current and deferred taxes and other assessments and governmental charges (to the extent permitted by Section 7.2(e) hereof);

 

78

 

(i)            Customary and prudent Hedging Obligations entered into in the ordinary course of business with the Agent, any Lender or any of their respective Affiliates for the sole purpose of protecting the Borrower and its Subsidiaries against fluctuations in interest rates, currency exchange rates and similar risks, so long as such Hedging Obligations are not speculative in nature and are incurred in the normal course of business and consistent with industry practices;

 

(j)            Refinancing Indebtedness, to the extent the same relates to any Indebtedness permitted by Sections 7.1(c) and 7.1(e) hereof;

 

(k)           Contingent Liabilities permitted pursuant to Section 7.3;

 

(l)            Indebtedness arising under any performance or surety bond entered in the ordinary course of business;

 

(m)          Unsecured Indebtedness assumed, acquired or incurred pursuant to any acquisition permitted under Section 7.4(e)(7), provided, that (1) all such Indebtedness constitutes Subordinated Indebtedness, and (2) the aggregate principal amount of all such Indebtedness assumed, acquired or incurred, together with the cash purchase price paid, in connection with all such acquisitions permitted under Section 7.4(e)(7) does not exceed in the aggregate during the period from the Closing Date through the Revolving Credit Termination Date the applicable aggregate consideration limits set forth in Section 7.4(e)(7);

 

(n)           Indebtedness incurred to finance the purchase or maintenance of publicly-tradable securities owned by any Credit Party, so long as (1) such Indebtedness is secured by all such securities, (2) such Indebtedness does not exceed $500,000 in the aggregate at any one time outstanding, and (3) Availability is $15,000,000 or greater at all times for the 90-day period prior to such purchase or acquisition and immediately after giving effect to the applicable down payment for such securities then being acquired;

 

(o)           Subordinated Indebtedness of Walco International Holdings, Inc. or Steer Intermediate Corporation, provided, that accrued and unpaid interest on such Indebtedness shall only be payable in the form of “payments-in-kind”; and

 

(p)           Other Indebtedness in an aggregate amount not to exceed at any one time outstanding the difference between $3,000,000 and the principal amount of Indebtedness then outstanding and permitted under Section 7.1 (n).

 

The Agent, the Lenders and each Credit Party agree that, notwithstanding anything contained in Section 7.1(g) or in any other provision contained in this Agreement which may appear to be to the contrary, the payment of any and all Indebtedness permitted by Sections 7.1(g) hereof, including without limitation, all Indebtedness now or hereafter outstanding and owing by any Credit Party to another Credit Party under the Contribution Agreement (together with any and all Liens from time to time securing the same as permitted by Section 7.2(i) hereof), is hereby made and at all times hereafter shall be inferior and subordinate in all respects to the Obligations from time to time owing to the Agent or any Lender pursuant hereto and to any Lien against any Collateral from time to time now or hereafter securing any of such Obligations pursuant to the terms hereof and the Security Documents.  Additionally, the Agent,

 

79

 

the Lenders and each Credit Party agree that, notwithstanding anything contained in any provision of this Agreement, any and all contractual, statutory or constitutional Liens which may now or hereafter held by the Borrower against any Property of any of the Borrower’s Subsidiaries as a result of any intercompany lease or sublease by the Borrower to any of its Subsidiaries of any real Property owned or leased by the Borrower are, and at all times hereafter shall be, inferior and subordinate in all respects to any Lien now or hereafter held by the Agent, for the ratable benefit of the Lenders, against any Collateral as security for any of the Obligations pursuant to the terms hereof and the Security Documents.  Each of the Credit Parties agrees to execute and deliver on its own behalf, and to cause to be executed and delivered by and on behalf of any of its Subsidiaries, any and all subordination agreements, in form and content reasonably acceptable to the Agent, which the Agent may hereafter require to further evidence the subordination of the payment of the Indebtedness permitted by Section 7.1(g) above, the Liens permitted by Section 7.2(i) and any such contractual, statutory or constitutional landlord’s Liens held by the Borrower.

 

7.2           Liens.  Create or suffer to exist any Lien upon any of its Property (including without limitation, Equity Interests in any Credit Party’s Subsidiaries) now owned or hereafter acquired, or acquire any Property upon any conditional sale or other title retention device or arrangement or any purchase money security agreement; provided, however, that the Credit Parties and their Subsidiaries (or any of them) may create or suffer to exist:

 

(a)           Liens in effect on the date hereof and which are described on Schedule 7.2 attached hereto, provided, that the Property covered thereby does not increase in scope and such Liens may not be renewed and extended, unless the same relate to Refinancing Indebtedness permitted by Section 7.1(e) above;

 

(b)           Liens against the Collateral in favor of the Collateral Agent for the ratable benefit of the Lenders as security for the Obligations and the holders of the Term Loan Debt in accordance with and subject to the terms of the First Intercreditor Agreement), and subordinate and inferior Liens against the Collateral securing the Second Lien Debt;

 

(c)           Liens incurred and pledges and deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance, old-age pensions and other social security benefits (not including any lien described in Section 412(m) of the Code);

 

(d)           Liens imposed by law, such as carriers’, warehousemen’s, mechanics’, materialmen’s, vendors’ and landlords’ liens and other similar liens, incurred in good faith in the ordinary course of business and securing obligations which are incurred in the ordinary course of business and are not overdue for a period of more than 30 days or which are being contested in good faith by appropriate proceedings pursued in good faith and as to which the Borrower or any of its Subsidiaries, as the case may be, shall, to the extent required by GAAP, consistently applied, have set aside on its books adequate reserves;

 

(e)           Liens securing the payment of taxes, assessments and governmental charges or levies (excluding any Lien imposed pursuant to any of the provisions of ERISA), that are not delinquent, are permitted by Section 6.2 hereof, or are being diligently contested in good

 

80

 

faith by appropriate proceedings and as to which adequate reserves have been established in accordance with GAAP; provided, however, that (1) a Reserve against Availability will be established in an amount equal to the aggregate amount of any and all such federal, state or local taxes which are being diligently contested and (2) the aggregate amount of overdue taxes being diligently contested in good faith at any one time secured by such Liens shall not exceed $1,000,000;

 

(f)            Zoning restrictions, easements, licenses, reservations, provisions, covenants, conditions, waivers, restrictions on the use of property or minor irregularities of title (and with respect to leasehold interests, mortgages, obligations, liens and other encumbrances incurred, created, assumed or permitted to exist and arising by, through or under a landlord or owner of the leased property, with or without consent of the lessee) which do not in the aggregate materially detract from the value of its property or assets or materially impair the use thereof in the operation of its business;

 

(g)           Liens securing the performance of bids, tenders, leases, contracts (other than for the repayment of borrowed money), statutory obligations, surety, customs and appeal bonds and other obligations of like nature, incurred as an incident to and in the ordinary course of business;

 

(h)           Purchase money Liens securing the Indebtedness permitted by Section 7.1(c) above, provided, as a result of the creation of any such Lien, (i) no Default or Event of Default shall have occurred and is continuing, (ii) the principal amount of such Lien does not exceed 100% of the purchase price of the asset acquired with such permitted Indebtedness plus accrued interest on such Indebtedness plus protective advances made by the holder of such permitted Indebtedness, and (iii) such Lien shall not apply to any other Property other than the asset acquired with such purchase money Indebtedness;

 

(i)            Liens in favor of the Borrower or any Guarantor (other than the Parent) securing any Indebtedness permitted pursuant to Sections 7.1(g) hereof;

 

(j)            Liens on fixed assets securing Indebtedness permitted to be assumed, acquired or incurred in connection with acquisitions permitted under Section 7.4(e)(7), provided, (i) the applicable Lien existed on the applicable Property prior to the acquisition thereof by the Borrower or any Subsidiary or existed on any Property of any Person that becomes a Subsidiary of the Borrower after the date hereof prior to the time such Person becomes a Subsidiary, (ii) the applicable Lien shall not apply to any other Property of the Borrower or any Subsidiary, and (iii) the applicable Lien shall secure only those obligations which it secures on the date of the applicable acquisition or the date such Person becomes a Subsidiary, as the case may be;

 

(k)           Liens consisting of bankers’ liens and rights of setoff, but only to the extent permitted under any applicable Tri-Party Agreements, and in each case, arising by operation of law, and Liens on documents presented in letter of credit drawings; and

 

(l)            Liens on securities securing Indebtedness to the extent permitted in accordance with Section 7.1(n).

 

81

 

Provided, however, notwithstanding anything contained above in this Section 7.2 to the contrary, if any of the permitted Liens are of the type that are being contested in good faith by appropriate proceedings as to the Borrower or any of its Subsidiaries, the Indebtedness giving rise to such contested Lien(s) must be immediately paid upon commencement of any foreclosure process or proceeding with respect to such Lien(s) unless the same shall be effectively stayed or a surety bond with respect thereto (which is satisfactory in all respects to the Agent), is posted.

 

7.3           Contingent Liabilities.  Create, incur, suffer or permit to exist, directly or indirectly, any Contingent Obligations, other than:

 

(a)           The Obligations of each Guarantor to the Agent and the Lenders under the terms of any Guaranty;

 

(b)           The guarantees by the Parent and any other Credit Party of the Borrower of the Term Loan Debt and/or the Second Lien Debt;

 

(c)           Any Contingent Obligations of the Borrower under any Hedging Obligations permitted by Section 7.1(i) above;

 

(d)           The guarantees by the Borrower of any Indebtedness of any other Credit Party or by any Credit Party of any Indebtedness of the Borrower if such Indebtedness so guaranteed is permitted under the terms of Section 7.1 above;

 

(e)           Endorsements of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;

 

(f)            Obligations in respect of Letters of Credit;

 

(g)           Agreements evidencing any Hedging Obligations to the extent permitted by Section 7.3(c); and

 

(h)           obligations relating to Liens permitted under Sections 7.2(c), 7(d), 7(e), 7(f)or 7(g).

 

7.4           Mergers, Consolidations and Dispositions and Acquisitions of Assets.  In any single transaction or series of related transactions, directly or indirectly:

 

(a)           Wind up its affairs, liquidate or dissolve;

 

(b)           Be a party to any merger or consolidation;

 

(c)           Sell, convey, lease, transfer or otherwise dispose of all or any portion of the assets (except for (1) the sale of Inventory in the ordinary course of business for fair and adequate consideration and (2) the sale of equipment, fixtures and other assets in accordance with the terms of Section 7.4(e)(5) below) of the Borrower and/or its Subsidiaries, or agree to take any such action;

 

82

 

(d)           Sell, assign, pledge, transfer or otherwise dispose of, or in any way part with control of, any Equity Interests of any of its Subsidiaries or any Indebtedness or obligations of any character of any of its Subsidiaries, or permit any such Subsidiary to do so with respect to any Equity Interests of any other Subsidiary or any Indebtedness or obligations of any character of the Borrower or any of its Subsidiaries, or permit any of its Subsidiaries to issue any additional Equity Interests other than to the Borrower or any wholly-owned Subsidiary of the Borrower; or

 

(e)           Purchase or otherwise acquire, directly or indirectly, in a single transaction or a series of related transactions, all or a substantial portion of the assets of any Person or any shares of Equity Interests of, or similar interest in, any Person;

 

provided, however that notwithstanding the foregoing, any of the following described actions may be undertaken, so long as no Default or Event of Default then exists or would exist immediately after giving effect to the applicable event:

 

(1)           any Business Entity comprising the Parent may merge or consolidate with any other Business Entity comprising the Parent or may be dissolved or liquidated, so long as such dissolution or liquidation results in all assets of such Business Entity being owned by another Business Entity comprising the Parent;

 

(2)           any Subsidiary of the Borrower may merge or consolidate with the Borrower or any other Subsidiary of the Borrower, provided, that if one or more of the entities so merging or consolidating was a Guarantor, and if the surviving entity is not the Borrower or is not yet a Guarantor, such surviving entity must become a Credit Party simultaneously with such merger by executing and delivering to the Collateral Agent a Joinder Agreement, together with all requested Security Documents, as required at such time by the Agent, appropriately completed in Proper Form;

 

(3)           any of the Borrower’s Subsidiaries may sell, lease, transfer or otherwise dispose of any of its assets to the Borrower or any other Subsidiary of the Borrower, provided, that if the entity selling, leasing, transferring or otherwise disposing of its assets is a Guarantor, and if the entity to whom the sale, lease, transfer or other disposition was made is not the Borrower or is not yet a Guarantor, such entity must become a Credit Party simultaneously with the consummation of such lease, transfer or disposition by executing and delivering to the Collateral Agent a Joinder Agreement, together with all requested Security Documents, as required at such time by the Agent, appropriately completed in Proper Form;

 

(4)           any Subsidiary of the Borrower may be dissolved or liquidated, so long as such dissolution or liquidation results in all assets of such Subsidiary being owned by the Borrower or a Subsidiary; provided, that if the entity dissolving or liquidating is a Guarantor, and if the entity to whom all assets of such dissolving or liquidating entity are transferred is not the Borrower or is not yet a Guarantor, such entity to whom such assets are being transferred must become a Credit Party simultaneously with the consummation of such dissolution or liquidation by executing and delivering to the Collateral Agent a Joinder Agreement, together with all requested Security

 

83

 

Documents, as required at such time by the Agent, appropriately completed in Proper Form;

 

(5)           the Borrower and its Subsidiaries may (i) sell, exchange or otherwise dispose of Permitted Investment Securities in the ordinary course of business; (ii) terminate, surrender or sublease a lease of real Property by the Borrower or any of its Subsidiaries in the ordinary course of business; (iii) sell Equipment that is obsolete, worn out or no longer needed in the business of the Borrower or any of its Subsidiaries; (iv) enter into sale-leaseback transactions relating to Property having a fair market value not to exceed $1,000,000 in the aggregate during the period from the Closing Date through the Revolving Credit Termination Date; and (v) sell any other fixed assets (including real Property, equipment and fixtures) having a fair market value not to exceed $1,000,000 in the aggregate during the period from June 30, 2005 through the Revolving Credit Termination Date; provided that all proceeds of any of the foregoing (other than Section 7.4(e)(5)(h) above) shall be paid to the Collateral Agent for application to outstanding Obligations and Term Loan Debt, to the extent then outstanding, in accordance with the terms of the First Lien Intercreditor Agreement;

 

(6)           to the extent any Collateral is sold or otherwise disposed of as permitted by this Section 7.4, such Collateral shall be sold or otherwise disposed of free and clear of the Liens of the Security Documents and the Collateral Agent shall take such actions, including executing and filing appropriate releases, as are appropriate in connection therewith, and no approval of any of Lenders shall be required therefor;

 

(7)           the Borrower and/or any other Credit Party may purchase or otherwise acquire, directly or indirectly, in a single transaction or a series of related transactions, all or a substantial portion of the assets of any Person or all or a majority of issued and outstanding shares of Equity Interests of, or similar interest in, any Person, so long as (a) immediately after giving effect to the applicable purchase or acquisition, no Default or Event of Default exists (including without limitation, the Credit Parties are in compliance with the Fixed Charge Coverage Ratio requirements of Section 7.12, tested on a pro forma basis assuming that such purchase or acquisition had occurred at the beginning of the four (4) most recent consecutive fiscal quarters of the Credit Parties ending on or immediately prior to the date of such purchase or acquisition), (b) average Availability at all times for the ninety (90)-day period prior to such purchase or acquisition, as well as Availability immediately after giving effect to the applicable purchase or acquisition, is $20,000,000 or greater, (c) the aggregate purchase price paid (including without limitation, any Indebtedness permitted to be assumed, acquired or incurred by the Borrower and/or any of its Subsidiaries in connection therewith under Section 7.1(m)) for all such purchases and acquisitions does not exceed $60,000,000 in the aggregate during the period from June 30, 2005 through the Revolving Credit Termination Date for all such other purchases and acquisitions, and (d) if the purchase price paid (including without limitation, any Indebtedness permitted to be assumed, acquired or incurred by the Borrower and/or any of its Subsidiaries in connection therewith under Section 7.l(m)) for the applicable purchase or acquisition exceeds $15,000,000 in the aggregate, the Required Lenders shall have consented in writing to such purchase or acquisition; and

 

84

 

(8)           The Credit Parties may make Investments to the extent permitted by Section 7.7.

 

7.5           Nature of Business.  Materially change the nature of its business or enter into any business (or at any time own, directly or indirectly, a majority of the Equity Interests of any entity which is engaged in any business) which is substantially different from the business in which the Borrower and its Subsidiaries are engaged in as of the Closing Date.

 

7.6           Transactions with Related Parties.  Except for any Permitted Affiliate Transactions, enter into or be a party to any other transaction, contract or agreement of any kind with any officer, director, shareholder, partner, employee or Affiliate of any Credit Party (including, without limitation, the purchase from, sale to or exchange of property with, or the rendering of any service by or for, any such Person), unless such transaction, contract or agreement is in the ordinary course of and pursuant to the reasonable requirements of the Borrower’s or any of its Subsidiaries’ business and is made upon fair and reasonable terms and conditions not less favorable to such Person than those which could have been obtained in a comparable transaction from wholly independent and unrelated sources.

 

7.7           Investments, Loans.  Make, directly or indirectly, any loan or advance to or have any Investment in any Person, or make any commitment to make such loan, advance or Investment, except:

 

(a)           Equity Interests of any Credit Party acquired or issued in accordance with the other provisions of this Agreement, including without limitation, the provisions of Section 6.10 above, or Equity Interests of any other Subsidiary of any Credit Party with the prior written consent of the Agent;

 

(b)           Permitted Investment Securities;

 

(c)           loans otherwise permitted by the provisions of Section 7.1 (g) above;

 

(d)           loans to employees of the Borrower or any Subsidiary made in the ordinary course of business, so long as the aggregate amount of all such loans outstanding at any time does not exceed $100,000;

 

(e)           Investments of the Borrower and the other Credit Parties permitted under the terms of Section 7.4(e)(7);

 

(f)            Investments consisting of Guarantees permitted by Section 7.3(d);

 

(g)           Investments consisting of deferred payment obligations in connection with sales of assets permitted under Section 7.4(e)(5); and

 

(h)           Other Investments, including joint venture interests in non-Subsidiary entities, in the aggregate amount not to exceed $500,000, provided that such Investments have been approved by the Agent, such approval not to be unreasonably withheld if (1) the aggregate amount of such Investments does not exceed $500,000 in the aggregate during the period from the Closing Date through the Revolving Credit Termination Date, and (2) Availability is

 

85

 

$15,000,000 or greater at all times for the 90-day period prior to such Investment and immediately after giving effect to such Investment.

 

7.8           ERISA Compliance.

 

(a)           At any time engage in any Prohibited Transaction with respect to a Plan which could reasonably be expected to result in a material liability; or permit any Plan to be terminated in a manner which could result in the imposition of a Lien on any Property of the Borrower or any of its Subsidiaries pursuant to ERISA.

 

(b)           Engage in any transaction in connection with which the Borrower or any Subsidiary thereof would or could reasonably be expected to be subject to either a material civil penalty assessed pursuant to the provisions of Section 502 of ERISA or a material tax imposed under the provisions of Section 4975 of the Code.

 

(c)           Terminate any Plan in a “distress termination” under Section 4041 of ERISA, or take any other action which could reasonably be expected to result in a material liability of the Borrower or any Subsidiary thereof to the PBGC.

 

(d)           Fail to make payment when due of all amounts which, under the provisions of any Plan, the Borrower or any Subsidiary thereof is required to pay as contributions thereto, or, with respect to any Plan, permit to exist any material “accumulated funding deficiency” (within the meaning of Section 302 of ERISA and Section 412 of the Code), whether or not waived, with respect thereto.

 

(e)           Adopt an amendment to any Plan requiring the provision of security under Section 307 of ERISA or Section 401(a)(29) of the Code.

 

7.9           Intentionally Deleted.

 

7.10         Change in Accounting Method.  Make or permit any change in accounting method or financial reporting practices except as may be required by GAAP, as in effect from time to time.

 

7.11         Redemption, Dividends, Issuance of Equity Interests, Distributions and Restricted Payments.  At any time, other than any Permitted Affiliate Transactions:

 

(a)           Redeem (whether as a result of mandatory or optional redemption obligations or rights), purchase, retire or otherwise acquire, directly or indirectly, any of its Equity Interests, any warrants or other similar instruments or set aside any amount for any such purpose;

 

(b)           Declare or pay, directly or indirectly, (i) any dividend or fund any redemption, purchase, retirement or other acquisition of its Equity Interests, except (1) dividends paid to the Borrower or any Guarantor which is a direct parent of the Subsidiary paying the dividend (other than Cash Dividends to the Parent, which shall not be paid at any time), and (2) non-cash dividends paid to the holders of any Equity Interests of the Borrower or the Parent in the form of additional Equity Interests of the Borrower or the Parent, as applicable, or (ii) any

 

86

 

management, consulting or monitoring fees to any Affiliate of the Borrower or the Parent or any officer, director, shareholder, partner or employee of any Affiliate of the Borrower or the Parent, except management or consulting fees paid to the Borrower or any Guarantor (other than the Parent, to which no management or consulting fees shall be paid);

 

(c)           Issue any additional Equity Interests in the Borrower, except for Equity Interests issued to the Parent;

 

(d)           Make any other distribution of any Property, cash, securities or a combination thereof, with respect to (whether by reduction of capital or otherwise) any Equity Interests except as permitted in Section 7.11(b) above;

 

(e)           Set apart any money for a sinking fund or other analogous fund for any dividend or other distribution on its Equity Interests or for any redemption, purchase, retirement, or other acquisition of any of its Equity Interests; or

 

(f)            Redeem (whether as a result of mandatory or optional redemption obligations or rights), purchase, defease or retire for value, or make any principal payment or prepayment on, the Term Loan Debt, the Second Lien Debt or any Subordinated Indebtedness prior to the Revolving Credit Termination Date; provided that (i) regularly scheduled payments of accrued and unpaid interest (including such payments prohibited from being paid because of the existence of a Default or Event of Default when the same were otherwise due and payable) may be made on the Term Loan Debt and the Second Lien Debt, so long as no Default or Event of Default shall have occurred and be continuing or would otherwise occur as a result of any such payment of accrued and unpaid interest, (ii) regularly scheduled principal installments (including such payments prohibited from being paid because of the existence of a Default or Event of Default when the same were otherwise due and payable) may be made on the Term Loan Debt, so long as no Default or Event of Default shall have occurred and be continuing or would otherwise occur as a result of any such payment of regularly scheduled principal installments, (iii) annual mandatory prepayments equal to 25% of the Borrower’s and its Subsidiaries’ Excess Cash Flow (as defined in the Term Loan Debt Purchase Agreement) for each fiscal year (commencing with the fiscal year ending June 30, 2008) may be made, so long as (A) immediately after giving effect to the applicable prepayment, no Default or Event of Default exists, and (B) average Availability at all times for the sixty (60)-day period prior to such prepayment, as well as Availability immediately after giving effect to the applicable prepayment, is $15,000,000 or greater; and (iv) voluntary prepayments of the Term Loan Debt, in whole or in part, shall be permitted so long as (A) immediately after giving effect to the applicable prepayment, no Default or Event of Default exists, (B) any prepayments prior to the first anniversary of the Closing Date do not require a prepayment fee or premium greater than 1 % of the outstanding principal balance being prepaid, and (C) any prepayments on or after the first anniversary of the Closing Date do not require or result in any prepayment fee or premium being paid (it being agreed that any of the foregoing conditions requiring that no Default or Event of Default exists or would otherwise occur as a result of the applicable payment shall include the requirement that the Credit Parties are in compliance with the Fixed Charge Coverage Ratio requirements of Section 7.12, tested on a pro forma basis assuming that the applicable payment had occurred at the beginning of the twelve (12) most recent consecutive calendar months ending on or immediately prior to the date of such payment);

 

87

 

provided, however that notwithstanding the foregoing, any payments, dividends or distributions on and any redemptions, purchases, retirements or other acquisitions of Equity Interests otherwise prohibited under Sections 7.11(b) or (e) shall be permitted to be made by the applicable Credit Party, so long as (1) immediately after giving effect to the applicable payment, dividend or distribution on or redemption, purchase, retirement or other acquisition of Equity Interests, no Default or Event of Default exists (including without limitation, the Credit Parties are in compliance with the Fixed Charge Coverage Ratio requirements of Section 7.12, tested on a pro forma basis assuming that payment, dividend, or distribution on or redemption, purchase, retirement or other acquisition of Equity Interests had occurred at the beginning of the twelve (12) most recent consecutive calendar months ending on or immediately prior to the date of such payment, dividend, distribution, redemption, purchase, retirement or acquisition of Equity Interests), (2) average Availability at all times for the ninety (90)-day period prior to such payment, dividend or distribution on or redemption, purchase, retirement or other acquisition of Equity Interests, as well as Availability immediately after giving effect to the applicable payment, dividend, distribution, redemption, purchase, retirement or acquisition of Equity Interests, is equal to or greater than the sum of (A) $20,000,000 and (B) the amount that would be payable as a mandatory prepayment under the Term Loan Debt based upon Excess Cash Flow (as defined in the Term Loan Debt Purchase Agreement) for the then applicable fiscal year assuming such mandatory prepayment were calculated and payable under the Term Loan Debt Purchase Agreement as of the date of payment of such applicable payment, dividend, distribution, redemption, purchase, retirement or acquisition of Equity Interests, and (3) the aggregate amount of all such payments, dividends or distributions on and redemptions, purchases, retirements or other acquisitions of Equity Interests actually made from the Closing Date through the Revolving Credit Termination Date (excluding “payments-in-kind” of accrued and unpaid interest) does not exceed $55,000,000.  Notwithstanding the foregoing, however, in no event shall any payment, dividend, distribution, redemption, purchase, retirement or acquisition of Equity Interests otherwise permitted under the terms of the preceding sentence be made to the extent the same is prohibited under the terms of the Term Loan Debt Documents or the Second Lien Debt Documents.

 

7.12         Fixed Charge Coverage Ratio.  Permit the Fixed Charge Coverage Ratio of the Credit Parties and their Subsidiaries, on a Consolidated basis, to be less than 1.10 to 1.0 at any time on and after June 30, 2006.

 

7.13         Capital Expenditures.  Permit the Credit Parties and their Subsidiaries, on a Consolidated basis, to make or incur Capital Expenditures (not including in the definition of Capital Expenditures for this purpose any Capital Expenditures included in any future acquisition permitted under Section 7.4(e)(7)) in excess of $5,000,000 in the aggregate during each fiscal year ending on or after June 30, 2006.

 

7.14         Intentionally Deleted.

 

7.15         Sale of Accounts.  Sell, assign, discount (other than customary and reasonable discounts in the ordinary course of business), transfer or otherwise dispose of any Accounts, promissory notes, drafts or trade acceptances or other rights to receive payment held by it, with or without recourse.

 

88

 

7.16         Sale and Lease-Back Transactions.  Except as otherwise permitted under Section 7.4(e)(5)(iv), enter into any arrangement, directly or indirectly, with any Person whereby any Credit Party or any of its Subsidiaries shall sell or transfer any Property, real or personal, which is used or useful in its business, whether now owned or hereafter acquired, and thereafter rent or lease such Property or other Property which such Credit Party or such Subsidiary intends to use for substantially the same purpose or purposes as the Property being sold or transferred.

 

7.17         Change of Name or Place of Business.  Permit any Credit Party or any of its Subsidiaries to change its address, name, jurisdiction of organization, location of its chief executive office or principal place of business or the place it keeps its material books and records, unless such Credit Party has (a) notified the Agent of such change in writing at least thirty (30) days before the effective date of such change, (b) taken such action, reasonably satisfactory to the Agent, to have caused the Liens against all Collateral in favor of the Agent for the ratable benefit of the Lenders to be at all times fully perfected and in full force and effect and (c) delivered such certificates of Governmental Authorities as the Agent may require substantiating such name change.

 

7.18         Restrictive Agreements.  Other than as imposed by law, identified on Schedule 7.18, or provided in this Agreement, the Term Loan Debt Purchase Agreement and the Second Lien Debt Purchase Agreement, directly or indirectly agree to restrict or condition (a) the payment of any dividends or other distributions to the Borrower or any of its Subsidiaries; (b) the payment of any Indebtedness owed to the Borrower or any of its Subsidiaries; (c) the making of any loans or advances to the Borrower or any of its Subsidiaries; or (d) the transfer of any of its properties or assets to the Borrower or any of its Subsidiaries.

 

7.19         Modification or Waiver of Documents Governing Term Loan Debt or Second Lien Debt.  Request, join in or otherwise consent to any modification, amendment or waiver of any material term of any of the Term Loan Debt Documents, except as expressly permitted under the terms of the First Lien Intercreditor Agreement, or the Second Lien Debt Documents.

 

7.20         Availability.  Allow Availability to be less than zero at any time, except in connection with a Permitted Overadvance until required to be paid by the Borrower in accordance with the terms hereof.

 

7.21         Anti-Terrorism Laws.  (a) Knowingly conduct any business or engage in any transaction or dealing with any Blocked Person, including the making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person.

 

(b)           Knowingly deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to the Executive Order No. 13224.

 

(c)           Knowingly engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in the Executive Order No. 13224, the USA PATRIOT Act or any other Anti-Terrorism Law.

 

89

 

The Borrower shall, and shall cause each other Credit Party to, deliver to Agent any certification or other evidence requested from time to time by the Agent in its sole discretion, confirming such Credit Party’s compliance with this Section 7.21.

 

8.             Events of Default and Remedies.

 

8.1           Events of Default.  If any of the following events shall occur and be continuing, then the Agent may (and, if directed by the Required Lenders, shall), by written notice (or facsimile notice) to the Borrower, take any or all of the following actions at the same or different times:  (1) accelerate the Revolving Credit Termination Date and declare the Notes, all Letter of Credit Advances, the Commitment Fees and all other Obligations then outstanding to be, and thereupon the Notes, said Letter of Credit Advances, the Commitment Fees and all other Obligations shall forthwith become, immediately due and payable, without further notice of any kind, notice of intention to accelerate, presentment and demand or protest, or other notice of any kind all of which are hereby expressly WAIVED by the Borrower; (2) terminate all or any portion of the Revolving Credit Commitments and any obligation to issue any additional Letters of Credit; (3) demand that the Borrower and the Guarantors provide the Agent, for the ratable benefit of the Lenders, and the Borrower and the Guarantors jointly and severally agree upon such demand to, provide cash collateral in an amount equal to the aggregate Letter of Credit Exposure Amount then outstanding, on terms and pursuant to documents in agreement and satisfactory in all respects to the Agent; and (4) exercise any and all other rights pursuant to the Loan Documents or available under applicable law:

 

(a)           The Borrower shall fail to pay or prepay any Obligation (including principal, interest, fees or any other amount) as and when due and payable, whether at the due date thereof (by acceleration, lapse of time or otherwise) or at any date fixed for prepayment thereof in accordance with the other provisions of this Agreement; or

 

(b)           An Event of Default (as defined in either or both of the Term Loan Debt Documents or the Second Lien Debt Documents) shall occur, or the Borrower or any of its Subsidiaries (i) shall fail to pay when due, or within any applicable period of grace, any other Indebtedness (excluding the Term Loan Debt, the Second Lien Debt and Indebtedness outstanding hereunder) aggregating in excess of $250,000 in principal amount unless such payment is being contested in good faith (by appropriate proceedings) and adequate reserves have been provided therefor, or (ii) shall default (beyond any applicable grace and curative periods) in any other manner with respect to any other Indebtedness (excluding the Term Loan Debt, the Second Lien Debt and Indebtedness outstanding hereunder) aggregating in excess of $250,000 in principal amount if the effect of any such default or event of default shall be to accelerate or to permit the holder of any such other Indebtedness, at its option, to accelerate the maturity of such Indebtedness prior to the stated maturity thereof; or

 

(c)           Any representation or warranty made or deemed made by the Borrower or any Guarantor in connection with any Loan Document or in any certificate, report, notice or financial statement furnished at any time in connection with this Agreement shall prove to have been incorrect, false or misleading in any material respect when made or deemed to have been made; or

 

90

 

(d)           Except as provided in Sections 8.1(a) or 8.1(e), Default shall occur in the punctual and complete performance or observance of any covenant, condition or agreement to be observed or performed on the part of the Borrower, any of its Subsidiaries or the Parent pursuant to the terms of any provision of this Agreement or any other Loan Document, and such Default remains uncured five (5) Business Days after the earlier to occur of (1) the Agent giving written notice of such Default to the Borrower or (2) any Responsible Officer of the Borrower or any of its Subsidiaries acquired actual knowledge of the existence of such Default; or

 

(e)           Default shall occur in the punctual and complete performance or observance of any covenant, condition or agreement to be observed or performed on the part of any Credit Party or any of its Subsidiaries pursuant to the terms of Section 6.2, Section 6.9, Section 6.11 or Article 7 hereof; or

 

(f)            Final judgment or judgments (or any decree or decrees for the payment of any fine or any penalty) for the payment of an uninsured money award in excess of $500,000 in the aggregate shall be rendered against any Credit Party or any of its Subsidiaries and the same shall remain undischarged and unpaid for a period of thirty (30) days during which execution shall not be effectively stayed or bonded; or

 

(g)           Any Credit Party or any of its Subsidiaries shall have concealed, removed, or permitted to be concealed or removed, any part of its Property, with intent to hinder, delay or defraud its creditors or any of them, or made or suffered a transfer of any of its Property which is or could reasonably be expected to be fraudulent under any bankruptcy, fraudulent conveyance or similar law; or

 

(h)           Intentionally Deleted; or

 

(i)            Any of the following shall occur where such occurrence could reasonably be expected to result in any material liability of any Credit Party:  (1) a Reportable Event shall have occurred with respect to a Plan; (2) the filing by the Borrower, any ERISA Affiliate, or an administrator of any Plan of a notice of intent to terminate such Plan under the provisions of Section 4041 of ERISA; (3) the receipt of notice by the Borrower, any ERISA Affiliate or an administrator of a Plan that the PBGC has instituted proceedings to terminate (or appoint a trustee to administer) such a Plan; (4) any other event or condition exists which might reasonably be expected to, in the opinion of the Agent, constitute grounds under the provisions of Section 4042 of ERISA for the termination of or the appointment of a trustee to administer any Plan by the PBGC; (5) a Plan shall fail to maintain a minimum funding standard required by Section 412 of the Code for any plan year or a waiver of standard is granted under the provisions of Section 412(d) of the Code; (6) the Borrower or any ERISA Affiliate has incurred, or is likely to incur, a liability under the provisions of Section 4062, 4063, 4064 or 4201 of ERISA; (7) the Borrower or any ERISA Affiliate fails to pay the full amount of an installment required under Section 412(m) of the Code; (8) any Prohibited Transaction involving any Plan; or (9) the occurrence of any other event or condition with respect to any Plan which would constitute an event of default or default under any other material agreement entered into by the Borrower or any ERISA Affiliate; or

 

91

 

(j)            This Agreement, any Note, any of the Security Documents or any other Loan Documents, or any material provision thereof, shall for any reason cease to be, or shall be asserted by any Credit Party, not to be, a legal, valid and binding obligation of any Credit Party, enforceable in accordance with its terms, or the Lien purported to be created by any of the Security Documents shall for any reason cease to be, or be asserted by any Credit Party not to be, a valid, first priority perfected Lien (pari passu with a first priority Lien securing the Term Loan Debt in accordance with and subject to the terms of the First Lien Intercreditor Agreement) against any material portion of the Collateral (except to the extent otherwise permitted under this Agreement or any of the Security Documents); or

 

(k)           The Borrower or any of its Subsidiaries which is a party to the Lockbox Agreement or any Tri-Party Agreement fails to perform and observe, and/or cause to be performed and observed, all material covenants, provisions and conditions to be performed, discharged and observed by the Borrower or any such Subsidiary under the terms of the Lockbox Agreement or any Tri-Party Agreement; or

 

(l)            Any financial institution (other than JPMorgan) which is a party to any Tri-Party Agreement fails to perform and observe, and/or cause to be performed and observed, all material covenants, provisions and conditions to be performed, discharged and observed by such financial institution under the terms of any Tri-Party Agreement and such failure remains uncured (or such defaulting financial institution and applicable Tri-Party Agreement is not replaced by the Borrower with a substitute financial institution and replacement Tri-Party Agreement both reasonably acceptable to the Agent) five (5) Business Days after the Agent gives written notice of such failure to the Borrower; or

 

(m)          A Change of Control shall occur; or

 

(n)           Any Credit Party or any of its Subsidiaries shall suffer any writ of attachment or execution or any similar process to be issued or levied against it or any substantial part of its Property having an aggregate value in excess of $500,000 which is not released, stayed, bonded or vacated within thirty (30) days after its issue or levy.

 

In addition, if any of the following events shall occur, then (1) the Notes, the Letter of Credit Advances, the Commitment Fees and all other Obligations then outstanding and payable hereunder shall automatically, without demand, presentment, protest, notice of intent to accelerate, notice of acceleration or other notice to any Person of any kind, all of which are hereby expressly WAIVED by the Borrower, become immediately due and payable and (2) all Revolving Credit Commitments and further obligations to issue any additional Letters of Credit shall be immediately and automatically terminated.

 

(o)           Any Credit Party or any of its Subsidiaries shall commence a voluntary proceeding seeking liquidation, reorganization, or other relief with respect to itself or its debts under any bankruptcy, insolvency, or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian, or other similar official of it or a substantial part of its property or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it or shall make a general assignment for the benefit of creditors or shall generally fail to

 

92

 

pay its debts as they become due or shall take any corporate action to authorize any of the foregoing; or

 

(p)           An involuntary proceeding shall be commenced against any Credit Party or any of its Subsidiaries seeking liquidation, reorganization, or other relief with respect to it or its debts under any bankruptcy, insolvency, or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian, or other similar official for it or a substantial part of its property, and such involuntary proceeding shall remain undismissed and unstayed for a period of 60 days; or

 

(q)           Any involuntary order shall be entered in any proceeding against any Credit Party or any of its Subsidiaries decreeing the dissolution, liquidation or split-up thereof, and such order shall remain in effect for sixty (60) days; or

 

(r)            Any Credit Party or any of its Subsidiaries shall admit in writing its inability to pay its debts as they become due or fail generally to pay its debts as they become due.

 

8.2           Remedies Cumulative.  No remedy, right or power conferred upon the Agent or any Lender is intended to be exclusive of any other remedy, right or power given hereunder or now or hereafter existing at law, in equity, or otherwise, and all such remedies, rights and powers shall be cumulative.

 

9.             The Agent.

 

9.1           Appointment, Powers and Immunities.  Each Lender hereby irrevocably appoints and authorizes the Agent to act as its agent hereunder and under the Letters of Credit and the other Loan Documents with such powers as are specifically delegated to the Agent by the terms hereof and thereof, together with such other powers as are reasonably incidental thereto.  Each Lender hereby irrevocably appoints and authorizes the Agent to act as its agent under the Letters of Credit which the Agent has issued with such powers as are specifically delegated to the Agent by the terms hereof and thereof, together with such other powers as are reasonably incidental thereto.  The Agent (which such term as used in this Section 9, shall, in each case, include reference to its Affiliates and its own and its Affiliates’ officers, directors, employees’ and agents) (a) shall not have duties or responsibilities except those expressly set forth in this Agreement, the Letters of Credit and the other Loan Documents, and shall not by reason of this Agreement or any other Loan Document be a trustee for any Lender; (b) shall not be responsible to any Lender for any recitals, statements, representations or warranties contained in this Agreement, the Letters of Credit or any other Loan Document, or in any certificate or other document referred to or provided for in, or received by any of them under, this Agreement, the Letters of Credit or any other Loan Document, or for the value, validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement, the Letters of Credit or any other Loan Document or any other certificate or document referred to or provided for herein or therein or any property covered thereby or for any failure by any Party or any other Person (other than the Agent) to perform any of its obligations hereunder or thereunder; (c) shall not be required to initiate or conduct any litigation or collection proceedings hereunder or under the Letters of Credit or any other Loan Document except to the extent requested by the Required Lenders, provided that the Agent shall not be required to take any action which exposes the Agent to

 

93

 

personal liability or which is contrary to this Agreement or any other Loan Documents or applicable law, and (d) shall not be responsible for any action taken or omitted to be taken by it hereunder or under the Letters of Credit or any other Loan Document or any other document or instrument referred to or provided for herein or therein or in connection herewith or therewith.  INCLUDING PURSUANT TO ITS OWN NEGLIGENCE, except for its own gross negligence or willful misconduct.  The Agent may employ agents and attorneys-in-fact and shall not be responsible for the negligence or misconduct of any such agents or attorneys-in-fact selected by them with reasonable care.  Without in any way limiting any of the foregoing, each Lender acknowledges that the Agent shall not have any greater responsibility in the operation of the Letters of Credit than is specified in the Uniform Customs and Practice for Documentary Credits (1993 Revision, International Chamber of Commerce Publication No. 500 or any successor publication).  In any foreclosure proceeding concerning any collateral for the Notes, each holder of a Note if bidding for its own account or for its own account and the accounts of other Lenders is prohibited from including in the amount of its bid an amount to be applied as a credit against its Note or the Notes of the other Lenders, instead such holder must bid in cash only.  However, in any such foreclosure proceeding, the Agent may (but shall not be obligated to) submit a bid for all Lenders (including itself) in the form of a credit against the Notes of all of the Lenders, and the Agent or its designee may (but shall not be obligated to), with the consent of the Required Lenders, accept title to such collateral for and on behalf of all Lenders.

 

9.2           Reliance.  The Agent shall be entitled to rely upon any certification, notice or other communication (including any thereof by telephone, telex, telegram or cable) believed by it to be genuine and correct and to have been signed or sent by or on behalf of the proper Person or Persons, and upon advice and statements of legal counsel (which may be counsel for the Borrower), independent accountants and other experts selected by the Agent.  As to any matters not expressly provided for by this Agreement, the Letters of Credit or any other Loan Document, the Agent shall in all cases be fully protected in acting, or in refraining from acting, hereunder and thereunder in accordance with instructions of the Required Lenders, and any action taken or failure to act pursuant thereto shall be binding on all of the Lenders.

 

9.3           Defaults.  The Agent shall not be deemed to have knowledge of the occurrence of a Default or Event of Default (other than the non-payment of principal of or interest on Loans, non-payment of reimbursements of Letters of Credit Advances, or nonpayment of Commitment Fees or Letter of Credit fees payable hereunder or under any other Loan Documents) unless it has received written notice from a Lender or a Credit Party specifying such Default or Event of Default and stating that such notice is a “Notice of Default.”  In the event that the Agent receives such a notice of the occurrence of a Default or Event of Default, the Agent shall give prompt notice thereof to the Lenders (and shall give each Lender prompt notice of each such non-payment).  The Agent shall (subject to Section 9.7 hereof) take such action with respect to such Default or Event of Default as shall be directed by the Required Lenders and within its rights under the Loan Documents and at law or in equity, provided that, unless and until the Agent shall have received such directions, the Agent may (but shall not be obligated to) take such action, or refrain from taking such action, permitted or within its rights under any of the Loan Documents or under applicable law with respect to such Default or Event of Default.

 

9.4           Rights as a Lender.  With respect to its Revolving Credit Commitment, the Loans and any Letter of Credit Exposure Amount, the Agent in its capacity as a Lender hereunder shall

 

94

 

have the same rights and powers hereunder as any other Lender and may exercise the same as though it were not acting as the Agent, and the term “Lender” or “Lenders” shall, unless the context otherwise indicates, includes the Agent in its individual capacity.  The Agent may (without having to account therefor to any Lender) accept deposits from, lend money to and generally engage in any kind of banking, trust, letter of credit, agency or other business with any Credit Party (and any of its Affiliates) as if it were not acting as the Agent, and the Agent may accept fees and other consideration from any Credit Party (in addition to the fees heretofore agreed to between the Borrower or any other Credit Party and the Agent) for services in connection with this Agreement or otherwise without having to account for the same to the Lenders.

 

9.5           Indemnification.  The Lenders agree to indemnify the Agent (to the extent not reimbursed under Section 2.10(g), Section 10.9 or Section 10.10 hereof, but without limiting the obligations of the Borrower and the other Credit Parties under said Sections 2.10(g), 10.9 and 10.10), ratably in accordance with their respective Revolving Credit Commitments, for any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind and nature whatsoever (INCLUDING THE CONSEQUENCES OF THE NEGLIGENCE OF SUCH INDEMNIFIED PERSON, but excluding the gross negligence or willful misconduct of such indemnified person) which may be imposed on, incurred by or asserted against the Agent in any way relating to or arising out of this Agreement, the Letters of Credit or any other Loan Document or any other documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby (including the costs and expenses which the Borrower and the other Credit Parties is obligated to pay under Sections 2.10(g), 10.9 and 10.10 hereof but excluding, unless a Default or Event of Default has occurred and is continuing, normal administrative costs and expenses incident to the performance of its agency duties hereunder) or the enforcement of any of the terms hereof or thereof or of any such other documents, INCLUDING THE NEGLIGENCE OF SUCH INDEMNIFIED PERSON, but excluding the gross negligence or willful misconduct of such indemnified person.  The obligations of the Lenders under this Section 9.5 shall survive the termination of this Agreement and the repayment of the Indebtedness arising in connection with this Agreement.

 

9.6           Non-Reliance on Agent and Other Lenders.  Each Lender agrees that it has received current financial information with respect to the Borrower and the other Credit Parties and that it has independently and without reliance on the Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis of the Borrower and the other Credit Parties and decision to enter into this Agreement and that it will, independently and without reliance upon the Agent or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own analysis and decisions in taking or not taking action under this Agreement or any of the other Loan Documents.  The Agent shall not be required to keep itself informed as to the performance or observance by any Party of this Agreement, the Letters of Credit or any of the other Loan Documents or any other document referred to or provided for herein or therein or to inspect the properties or books of the Borrower or any other Credit Party.  Except for notices, reports and other documents and information expressly required to be furnished to the Lenders by the Agent, under the Letters of Credit or the other Loan Documents, the Agent shall not have any duty or

 

95

 

responsibility to provide any Lender with any credit or other information concerning the affairs, financial condition or business of the Borrower or any other Credit Party (or any of their Affiliates) which may come into the possession of the Agent.

 

9.7           Failure to Act.  Except for action expressly required of the Agent hereunder, under the Letters of Credit and under the other Loan Documents, the Agent shall in all cases be fully justified in failing or refusing to act hereunder and thereunder unless it shall receive further assurances to its satisfaction by the Lenders of their indemnification obligations under Section 9.5 hereof against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action.

 

9.8           Resignation or Removal of Agent.  Subject to the appointment and acceptance of a successor Agent as provided below, the Agent may resign at any time by giving notice thereof to the Lenders and the Borrower, and the Agent may be removed at any time with or without cause by the Required Lenders.  Upon any such resignation or removal, the Required Lenders shall have the right to appoint a successor Agent reasonably acceptable to the Borrower.  If no successor Agent shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Agent’s giving of notice of resignation or the Required Lenders’ removal of the retiring Agent, then the retiring Agent may, on behalf of the Lenders, appoint a successor Agent reasonably acceptable to the Borrower; provided, however, that if an Event of Default has occurred which has not been waived or cured to the satisfaction of the Agent and the Required Lenders, the Borrower’s approval of a successor Agent shall not be required.  Any successor Agent shall be a Lender which has an office in the United States with a combined capital and surplus of at least $2,000,000,000.  Upon the acceptance of any appointment as Agent hereunder by a successor Agent, such successor Agent shall thereupon succeed to and become vested with all the rights, powers, privileges and duties of the retiring Agent, and the retiring Agent shall be discharged from its duties and obligations hereunder.  Such successor Agent shall promptly specify by notice to the Borrower and the Lenders its office for the purpose of any notices and payments hereunder.  After any retiring Agent’s resignation or removal hereunder as Agent, the provisions of this Section 9 shall continue in effect for its benefit in respect of any actions taken or omitted to be taken by it while it was acting as the Agent.

 

10.           Miscellaneous.

 

10.1         No Waiver.  No waiver of any Default or Event of Default shall be deemed to be a waiver of any other Default or Event of Default.  No failure to exercise and no delay on the part of the Agent or any Lender in exercising any right or power under any Loan Document or at law or in equity shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or the abandonment or discontinuance of steps to enforce any such right or power, preclude any further or other exercise thereof or the exercise of any other right or power.  No course of dealing between any Credit Party and the Agent or any Lender shall operate as a waiver of any right or power of the Agent or any Lender.  No notice to or demand on any Credit Party or any other Person shall entitle any Credit Party or any other Person to any other or further notice or demand in similar or other circumstances.

 

96

 

10.2         Notices.  Except as otherwise expressly permitted hereunder or under any other Loan Document, all notices under the Loan Documents shall be in writing and either (i) delivered to the intended recipient, (ii) mailed by registered or certified mail, return receipt requested, or (iii) sent by facsimile (promptly confirmed by mail, except for any notice pursuant to Section 4.1(a) hereof which need not be confirmed by mail), in each case to the intended recipient at the “Address for Notices” specified below its name on the signature pages hereof; or, as to any Lender who is a signatory hereto, at such other address as shall be designated by such Lender in a notice to the Borrower and the Agent given in accordance with this Section 10.2 or to such other address as a party may designate in a notice given in accordance with the provisions of this Section 10.2.  The Borrower may change its address for purposes hereof by providing written notice of such address change to the Lenders and the Agent in accordance with the provisions of this Section 10.2, with any such change in address only being effective ten (10) Business Days after such change of address has been deemed given in accordance with the provisions hereof.  Notices shall be deemed to have been given (whether actually received or not) when delivered (or, if mailed, on the next Business Day after deposit of such notice into the mail); however, the notices required or permitted by Sections 2.2(b) and 4.1(a) hereof shall be effective only when actually received by the Agent.

 

10.3         Governing Law.  Unless otherwise specified therein, each Loan Document shall be governed by and construed in accordance with the laws of the State of New York (other than the conflicts of laws principles thereof) and the United States of America.

 

10.4         Survival; Parties Bound.  All representations, warranties, covenants and agreements made by or on behalf of any Credit Party in connection herewith shall survive the execution and delivery of the Loan Documents and shall not be affected by any investigation made by any Person.  The term of this Agreement shall be until the termination or lapse of all Revolving Credit Commitments, the final maturity of each Note, the payment of all amounts due under the Loan Documents, and the return in undrafted form of all outstanding Letters of Credit (or the cash collateralization of all outstanding Letters of Credit in an amount equal to the aggregate Letter of Credit Exposure Amount then outstanding).

 

10.5         Counterparts.  This Agreement may be executed in several identical counterparts, and by the parties hereto on separate counterparts, and each counterpart, when so executed and delivered, shall constitute an original instrument, and all such separate counterparts shall constitute but one and the same instrument.

 

10.6         Limitation of Interest.  The Borrower, the other Credit Parties and the Lenders intend to strictly comply with all applicable laws, including applicable usury laws, if any.  Accordingly, the provisions of this Section 10.6 shall govern and control over every other provision of this Agreement or any other Loan Document which conflicts or is inconsistent with this Section, even if such provision declares that it controls.  As used in this Section, the term “interest” includes the aggregate of all charges, fees, benefits or other compensation which constitute interest under applicable law, provided, that, to the maximum extent permitted by applicable law, (a) any non-principal payment shall be characterized as an expense or as compensation for something other than the use, forbearance or detention of money and not as interest, and (b) all interest at any time contracted for, reserved, charged or received shall be amortized, prorated, allocated and spread, in equal or in unequal parts during the full term of the

 

97

 

Loans and the Revolving Credit Commitments so that interest for the entire term does not exceed the Highest Lawful Rate.  In no event shall the Borrower, any other Credit Party or any other Person be obligated to pay, or the Agent or any Lender have any right or privilege to reserve, receive or retain, (Y) any interest in excess of the maximum amount of nonusurious interest permitted under the laws of the United Stales or of any state, if any, which are applicable to the Agent or such Lender, respectively, or (Z) total interest in excess of the amount which the Agent or such Lender could lawfully have contracted for, reserved, received, retained or charged had the interest been calculated for the full term of the Loans at the Highest Lawful Rate, if any, applicable to the Agent or such Lender.  None of the terms and provisions contained in this Agreement or in any other Loan Document which directly or indirectly relate to interest shall ever be construed without reference to this Section 10.6, or be construed to create a contract to pay any Lender for the use, forbearance or detention of money at an interest rate in excess of the Highest Lawful Rate applicable to such Lender.  If the term of any Loans or the Notes is shortened by reason of acceleration of maturity as a result of any Default or Event of Default or by any other cause, or by reason of any required or permitted prepayment, and if for that (or any other) reason the Agent or any Lender at any time is owed or receives (and/or has received) interest in excess of interest calculated at the Highest Lawful Rate applicable to the Agent or such Lender, then and in any such event all of any such excess interest owed to or received by the Agent or such Lender shall be canceled automatically as of the date of such acceleration, prepayment or other event which produces the excess, and, if such excess interest has been paid to the Agent or such Lender, it shall be credited pro tanto against the then-outstanding principal balance of the Obligations to the Agent or such Lender, effective as of the date or dates when the event occurs which causes it to be excess interest, until such excess is exhausted or all of such principal has been fully paid and satisfied, whichever occurs first, and any remaining balance of such excess shall be promptly refunded to its payor.

 

10.7         Survival.  The obligations of the Borrower or any other Credit Party, as applicable, under Sections 2.3, 2.4(b), 2.9, 2.10(g), 10.9, 10.10 and 10.17 hereof shall survive the repayment of the Loans and all other Obligations, the termination of the Revolving Credit Commitments and the cancellation or expiration of the Letters of Credit.

 

10.8         Captions.  The headings and captions appearing in the Loan Documents have been included solely for convenience and shall not be considered in construing the Loan Documents.

 

10.9         Expenses, Etc.  The Borrower agrees to pay or reimburse on demand of the Agent the following:  (a) the reasonable fees, expenses, disbursements and other charges of Locke Liddell & Sapp LLP, counsel to the Agent, or any other legal counsel engaged by the Agent in connection with (i) the preparation, execution and delivery of this Agreement (including the exhibits and schedules hereto) and the Loan Documents and the making of the Loans and the issuance of Letters of Credit hereunder and (ii) any modification, supplement or waiver of any of the terms of this Agreement, the Letters of Credit or any other Loan Document; (b) all out-of-pocket costs and expenses (including the fees, disbursements and other charges of counsel to the Agent and of one separate counsel for Lenders other than the Agent), in connection with any Default or Event of Default or the enforcement of this Agreement, the Letters of Credit or any other Loan Documents; (c) all transfer, stamp, documentary or other similar taxes, assessments or charges levied on or against the Agent or any Lender by any governmental or revenue

 

98

 

authority in respect of this Agreement, any Letter of Credit or any other Loan Document; (d) all out-of-pocket costs, expenses, taxes, assessments and other charges incurred by the Agent in connection with any filing, registration, recording or perfection of any security interest contemplated by this Agreement, any other Loan Document, and the cost of title insurance for any Mortgage; (e) expenses of due diligence incurred by the Agent prior to or as of the Closing Date.

 

Except as otherwise expressly limited elsewhere in this Agreement or in any other Loan Document, the Borrower shall pay (i) all reasonable, documented out-of-pocket expenses incurred by the Agent and its Affiliates, including the reasonable fees, charges and disbursements of counsel for the Agent, in connection with the syndication and distribution (including, without limitation, via the internet or through a service such as Intralinks) of the credit facilities provided for herein, the preparation and administration of the Loan Documents or any amendments, modifications or waivers of the provisions of the Loan Documents (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) all reasonable out-of-pocket expenses incurred by the Agent in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all out-of-pocket expenses incurred by the Agent or any Lender, including the fees, charges and disbursements of any counsel for the Agent and of one separate counsel for Lenders other than the Agent, in connection with the enforcement, collection or protection of its rights in connection with the Loan Documents, including its rights under this Section, or in connection with the Loans made or Letters of Credit issued hereunder, including all such out-of pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit.  Expenses being reimbursed by the Borrower under this Section include, without limiting the generality of the foregoing, costs and expenses (subject to express limitations set forth elsewhere in this Agreement or in any other Loan Document) incurred in connection with:

 

(i)            appraisals;

 

(ii)           field examinations and the preparation of appraisal, field examination or audit reports based on the fees charged by a third party retained by the Agent or the internally allocated fees for each Person employed by the Agent with respect to each field examination;

 

(iii)          lien and title searches and title insurance;

 

(iv)          environmental reviews;

 

(v)           taxes, fees and other charges for recording the Mortgages, filing financing statements and continuations, and other actions to perfect, protect, and continue the Agent’s Liens;

 

(vi)          sums paid or incurred to take any action required of any Credit Party under the Loan Documents that such Credit Party fails to pay or take; and

 

(vii)         forwarding loan proceeds, collecting checks and other items of payment, and establishing and maintaining the accounts and lockboxes, and costs and expenses of preserving and protecting the Collateral.

 

99

 

10.10       Indemnification.  Each Credit Party, jointly and severally with all other Credit Parties, hereby agrees to indemnify the Agent, the Lenders and each Affiliate thereof and their respective directors, officers, employees and agents from, and hold each of them harmless against, any and all losses, liabilities (including Environmental Liabilities), claims (including Environmental Claims) or damages to which any of them may become subject, insofar as such losses, liabilities, claims or damages arise out of or result from any (a) actual or proposed use by the Borrower or any other Credit Party of the proceeds of any extension of credit (whether a Loan or a Letter of Credit) by any Lender hereunder, (b) breach by any Credit Party of this Agreement or any other Loan Document, (c) violation by any Credit Party or any of its Subsidiaries of any law, rule, regulation or order including any Requirements of Environmental Law, (d) Liens or security interests granted on any Property pursuant to or under the Loan Documents, to the extent resulting from any Hazardous Substance located in, on or under any such Property, (e) ownership by the Lenders or the Agent of any Property following foreclosure under the Loan Documents, to the extent such losses, liabilities, claims or damages arise out of or result from any Hazardous Substance, located in, on or under such Property prior to or at the time of such foreclosure, including losses, liabilities, claims or damages which are imposed upon Persons under laws relating to or regulating Hazardous Substances, solely by virtue of ownership, (f) any Lender or the Agent being deemed an operator of any such Property by a court or other regulatory or administrative agency or tribunal or other third party, to the extent such losses, liabilities, claims or damages arise out of or result from any Hazardous Substance, petroleum, petroleum product or petroleum waste located in on or under such Property at or prior to the date of any foreclosure thereon under the Loan Document, or (g) investigation, litigation or other proceeding (including any threatened investigation or proceeding) relating to any of the foregoing (including any proceeding brought by any Credit Party against the Agent, any Lender and/or their respective Affiliates), and each Credit Party, jointly and severally with all other Credit Parties, agrees to reimburse the Agent and each Lender, and each Affiliate thereof and their respective directors, officers, employees, counsel and agents, upon demand for any out-of-pocket expenses (including reasonable legal fees) incurred in connection with any such investigation or proceeding, AND WHETHER ANY SUCH LOSS, LIABILITY, CLAIM OR DAMAGE RESULTS FROM THE NEGLIGENCE OF ANY SUCH INDEMNIFIED PERSON; but excluding any such losses, liabilities, claims, damages or expenses incurred by a Person or any Affiliate thereof or their respective directors, officers, employees, counsel or agents by reason of (i) the gross negligence or willful misconduct of or willful and knowing breach of any Loan Document by such Person, affiliate, director, officer, employee or agent or (ii) ownership or operation of any Property by the Lenders or the Agent following foreclosure under the Loan Documents to the extent, but only to the extent, such losses, liabilities, etc. are attributable to the post-foreclosure actions of the Lender or the Agent.  Promptly after receipt by an indemnified person of notice of any claim or the commencement of any action, such indemnified person shall, if any claim in respect thereof is to be made against any Credit Party under this Section 10.10, notify the such Credit Party in writing of the claim or the commencement of that action.  The Credit Parties shall not be liable for any settlement of any such claim or action involving the payment of monetary damages effected without its written consent not to be unreasonably withheld.  If any such claim or action shall be brought against an indemnified person, it shall notify the

 

100

 

applicable Credit Parties thereof, and such Credit Parties shall be entitled to participate in the joint defense thereof.

 

10.11       Amendments, Waivers, Etc.

 

(a)           Neither this Agreement nor any other Loan Document nor any provision hereof or thereof may be waived, amended or modified except (i) in the case of this Agreement, pursuant to an agreement or agreements in writing entered into by the Borrower, the Agent and the Required Lenders or (ii) in the case of any other Loan Document, pursuant to an agreement or agreements in writing entered into by the Agent and the Credit Party or Credit Parties that are parties thereto, with the consent of the Required Lenders; provided that no such agreement shall (i) increase the Revolving Credit Commitment of any Lender without the written consent of such Lender, (ii) reduce or forgive the principal amount of any Loan or Letter of Credit Advances or reduce the rate of interest thereon, or reduce or forgive any interest or fees payable hereunder, without the written consent of each Lender directly affected thereby (provided, that any waiver of Default Rate interest shall not be considered a reduction of interest), (iii) postpone any scheduled date of payment of the principal amount of any Loan or Letter of Credit Advances, or any date for the payment of any interest, fees or other Obligations payable hereunder, or reduce the amount of, waive or excuse any such payment, or postpone the scheduled date of expiration of any Revolving Credit Commitment, without the written consent of each Lender directly affected thereby, (iv) change any provision contained in Sections 2.2(d), 2.2(e), 2.7, 2.11, 2.12, 2.13, 10.9(b) or 10.10 hereof or this Section 10.11 or Section 10.16 hereof, without the written consent of each Lender directly affected thereby, (v) increase the advance rates set forth in the definition of Borrowing Base or add new categories of eligible assets, without the written consent of each Lender, (vi) change any of the provisions of this Section or the definition of “Required Lenders” or any other provision of any Loan Document specifying the number or percentage of Lenders required to waive, amend or modify any rights thereunder or make any determination or grant any consent thereunder, without the written consent of each Lender, (vii) release the Borrower or any Guarantor from its obligation under its Guaranty (except as otherwise permitted herein or in the other Loan Documents), without the written consent of each Lender, or (viii) except as otherwise expressly provided herein, including without limitation, in Section 10.11(b) or in any Security Document, release any of the Collateral without the written consent of each Lender; provided, however, that that nothing in this Section 10.11 shall affect, limit or restrict the Agent’s right to establish, fix, reduce, increase or otherwise revise any standards of eligibility for any items included within the Borrowing Base or any Reserves, from time to time in accordance with other provisions of this Agreement and subject to the limitations set forth herein.  Anything in this Section 10.11 to the contrary, no amendment, waiver or consent shall be made with respect to Section 9 without the written consent of the Agent, and no amendment, waiver or consent shall amend, modify or otherwise affect the rights or duties of the Swingline Lender hereunder without the prior written consent of the Swingline Lender.

 

(b)           The Lenders hereby irrevocably authorize the Agent, at its option and in its sole discretion, to release any Liens granted to the Agent by the Credit Parties on any Collateral (i) upon the termination of the all Revolving Credit Commitments, payment and satisfaction in full in cash of all Obligations, (ii) constituting Property being sold or disposed of if the Credit Party disposing of such Property certifies to the Agent that the sale or disposition is made in compliance with the terms of this Agreement (and the Agent may rely conclusively on

 

101

 

any such certificate, without further inquiry), (iii) constituting Property leased to a Credit Party under a lease which has expired or been terminated in a transaction permitted under this Agreement, or (iv) as required to effect any sale or other disposition of such Collateral in connection with any exercise of remedies of the Agent and the Lenders pursuant to Article 8.  Except as provided in the preceding sentence or in Section 7.4(e)(5), the Agent will not release any Liens on Collateral without the prior written authorization of the Required Lenders; provided that, the Agent may in its discretion, release its Liens on Collateral valued in the aggregate not in excess of $1,000,000 during any calendar year without the prior written authorization of the Required Lenders.  Any such release shall not in any manner discharge, affect, or impair the Obligations or any Liens (other than those expressly being released) upon (or obligations of the Credit Parties in respect of) all interests retained by the Credit Parties, including the proceeds of any sale, all of which shall continue to constitute part of the Collateral.

 

(c)           If, in connection with any proposed amendment, waiver or consent requiring the consent of “each Lender” or “each Lender affected thereby,” the consent of the Required Lenders is obtained, but the consent of other necessary Lenders is not obtained (any such Lender whose consent is necessary but not obtained being referred to herein as a “Non-Consenting Lender”), then the Borrower may elect to replace a Non-Consenting Lender as a Lender party to this Agreement with an Eligible Assignee in compliance with all relevant provisions of Section 10.12 hereof, and contemporaneously with the replacement of such Non-Consenting Lender, the Borrower shall cause such substitute lender(s) to pay in full, as the purchase price for such assignment, the Obligations owed to such Non-Consenting Lender, including all accrued, unpaid interest thereon and any Consequential Loss owing by the Borrower to such Non-Consenting Lender as a result of such payment, without payment of any prepayment or termination fee.  In such event, such Non-Consenting Lender agrees to abide by the relevant provisions of Section 10.12 hereof in connection with the replacement of such Non-Consenting Lender by the Eligible Assignee secured by the Agent or the Borrower.  Notwithstanding the foregoing right of the Borrower to replace any such Non-Consenting Lender, neither the Agent nor any Lender shall have any obligation to the Borrower to find or locate any substitute lender or lenders to replace any such Non-Consenting Lender.

 

10.12       Successors and Assigns.

 

(a)           This Agreement shall be binding upon and inure to the benefit of the Borrower, the other Credit Parties, the Agent and the Lenders and their respective successors and permitted assigns, provided that the undertaking of the Lenders hereunder to make Loans to the Borrower and to issue Letters of Credit for the account of the Borrower shall not inure to the benefit of any successor of the Borrower.  Neither the Borrower nor any Credit Party may assign or transfer any of its rights or obligations hereunder without the prior written consent of all of the Lenders (and any attempted assignment or transfer by any Credit Party without such consent shall be null and void), and no Lender may assign or otherwise transfer its rights or obligations hereunder except in accordance with this Section 10.12.  Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than (i) the parties hereto, their respective successors and assigns permitted hereby, (ii) any participant of a Lender (to the extent provided in subparagraph (b) below), and (iii) to the extent expressly set forth herein, the Affiliates of the Agent and each of the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.

 

102

 

(b)           Each Lender may sell participations to any Person in all or part of any Loan, or all or part of its Notes, the Letter of Credit Exposure Amount, the Swingline Exposure or the Revolving Credit Commitments, to another bank or other entity, in which event, without limiting the foregoing, the provisions of Sections 10.10 and 10.16 shall inure to the benefit of each purchaser of a participation and the pro-rata treatment of payments, as described in Section 2.12, shall be determined as if such Lender had not sold such participation.  In the event any Lender shall sell any participation, (i) the Borrower, the Agent and the other Lenders shall continue to deal solely and directly with such selling Lender in connection with such selling Lender’s rights and obligations under the Loan Documents (including the Note(s) held by such selling Lender), (ii) such Lender shall retain the sole right and responsibility to enforce the obligations of the Borrower and the other Credit Parties relating to the Loans, Letter of Credit Exposure Amount and Swingline Exposure, including the right to approve any amendment, modification or waiver of any provision of this Agreement other than (and then only if expressly permitted by the applicable participation agreement) amendments, modifications or waivers with respect to (A) any reduction of fees payable hereunder to the Lender, (B) any reduction of the amount of principal or the rate of interest payable on, or the dates fixed for the scheduled repayment of principal of, the Loans and other sums to be paid to the Lenders hereunder, and (C) any postponement of any date for the payment of any amount payable in respect of the Loans of such Lender, (iii) the Credit Parties each agree, to the fullest extent it may effectively do so under applicable law, that any participant of a Lender may exercise all rights of set-off, bankers’ lien, counterclaim or similar rights with respect to such participation as fully as if such participant were a direct holder of Loans if such Lender has previously given notice of such participation to the Borrower.

 

(c)           Each Lender may assign to one or more Lenders or Eligible Assignees all or a portion of its interests, rights and obligations under this Agreement (including all or a portion of its Revolving Credit Commitment and the same portion of the related Loans at the time owing to it, the related Note or Notes held by it and its Letter of Credit Exposure Amount) (a “Ratable Assignment”); provided, however, that, (i) the Agent and the Borrower must give their respective prior written consent, which consent will not be unreasonably withheld, conditioned or delayed (except that (1) the Borrower in its sole discretion may withhold its consent when otherwise required hereunder to any proposed assignment to any affiliate of Cerberus Capital Management, Highland Capital Management or Patriarch Partners and (2) the Borrower’s consent to any such assignment shall not be required if (A) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund or (B) an Event of Default has occurred which has not been waived or cured to the satisfaction of the Agent and the Required Lenders), (ii) the aggregate amount of the applicable Revolving Credit Commitment, Loans, Letter of Credit Exposure Amount and Swingline Exposure (without duplication) of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Acceptance (as defined below) with respect to such assignment is delivered to the Agent) shall in no event be less than $10,000,000 (except for certain exceptions approved by the Borrower and the Agent) and shall be in an amount that is an integral multiple of $1,000,000 (unless all of the assigning Lender’s applicable Revolving Credit Commitment, Loans, Letter of Credit Exposure Amount and Swingline Exposure is being assigned); (iii) the aggregate amount of the applicable Revolving Credit Commitment and/or Loans of the assigning Lender immediately after each partial assignment must be at least $10,000,000 (except for certain exceptions approved by the Borrower and the Agent) and shall be in an amount which is an integral multiple of $1,000,000;

 

103

 

(iv) each partial assignment must be a pro rata assignment of the assigning Lender’s Revolving Credit Commitment, so that no Lender shall ever hold a disproportionate percentage of the Total Revolving Credit Commitment; and (v) the parties to each such assignment shall execute and deliver to the Agent, for its acceptance and recording in its records, and to the Borrower, for its acceptance if the Borrower’s approval of such assignment is otherwise required under the terms of this Section 10.12, an Assignment and Acceptance in a form required by the Agent (each an “Assignment and Acceptance”) with blanks appropriately completed, together with any Note or Notes subject to such assignment and a processing and recordation fee of $5,000 (for which the Borrower shall have no liability).  Upon such execution, delivery, acceptance and recording, from and after the effective date specified in each Assignment and Acceptance, which effective date shall be at least five (5) Business Days after the execution thereof, unless a shorter period of time may be agreed to by the Agent in its sole and absolute discretion, (A) the assignee thereunder shall be a party hereto and, to the extent provided in such Assignment and Acceptance, have the rights and obligations of a Lender hereunder and (B) the Lender thereunder shall, to the extent provided in such assignment, be released from its obligations under this Agreement (and, in the case of an Assignment and Acceptance covering all or the remaining portion of an assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto).

 

(d)           By executing and delivering an Assignment and Acceptance, the Lender assignor thereunder and the assignee thereunder confirm to and agree with each other and the other parties hereto as follows:  (i) other than the representation and warranty that it is the legal and beneficial owner of the interest being assigned thereby free and clear of any adverse claim, such Lender assignor makes no representation or warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with any Loan Document or the execution, legality, validity, enforceability, genuineness, sufficiency or value of any Loan Document or any other instrument or document furnished pursuant thereto; (ii) such assignor Lender makes no representation or warranty and assumes no responsibility with respect to the financial condition of any Credit Party or any of its Subsidiaries or the performance or observance by the Borrower or any other Credit Party of any of its obligations hereunder; (iii) such assignee confirms that it has received a copy of this Agreement and the other Loan Documents, together with copies of the financial statements of the Borrower previously delivered in accordance herewith and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into such Assignment and Acceptance; (iv) such assignee confirms that it will keep confidential all information with respect to any Credit Party furnished to it by the Borrower or such Credit Party, such assignor Lender or the Agent (other than information generally available to the public or otherwise available to the Agent on a non-confidential basis or otherwise permitted pursuant to the terms of this Agreement); (v) such assignee will, independently and without reliance upon the Agent, such assignor Lender or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents; (vi) such assignee appoints and authorizes the Agent to take such action as agent on its behalf and to exercise such powers under the Loan Documents as are delegated to the Agent by the terms hereof, together with such powers as are reasonably incidental thereto; and (vii) such assignee agrees that it will perform in accordance with their terms all obligations that by the terms of the Loan Documents are required to be performed by it as a Lender.

 

104

 

(e)           The Agent shall maintain at its office a copy of each Assignment and Acceptance delivered to it and a record of the names and addresses of the Lenders and the Revolving Credit Commitments of, and principal amount of the Loans, accrued and unpaid interest and other fees due thereunder owing to, and the Letter of Credit Exposure Amount and Swingline Exposure of, each Lender from time to time.  The entries in the register shall be conclusive, in the absence of manifest error, and the Borrower, the Agent and the Lenders may treat each person the name of which is recorded therein as a Lender hereunder for all purposes of the Loan Documents.  Such records shall be available for inspection by the Borrower or any Lender at any reasonable time and from time to time upon reasonable prior notice.

 

(f)            Upon its receipt of an Assignment and Acceptance executed by an assigning Lender and the assignee thereunder together with the Note(s) subject to such assignment, the written consent to such assignment and the fee payable in respect thereto, the Agent shall, if such Assignment and Acceptance has been completed with blanks appropriately filled, (i) accept such Assignment and Acceptance, (ii) record the information contained therein in the Register and (iii) give prompt notice thereof to the Borrower and the Lenders.  Contemporaneously with the receipt by the Borrower of such Assignment and Acceptance and the surrender Note(s), the Borrower, at its own expense, shall execute and deliver to the Agent in exchange for the surrendered Note(s), a new Note or Notes payable to the order of such assignee in an amount equal to the applicable Revolving Credit Commitment, Loans, Letter of Credit Exposure Amount and Swingline Exposure (without duplication) assumed by it pursuant to such Assignment and Acceptance and, if the assigning Lender has retained a Revolving Credit Commitment, Loans, Letter of Credit Exposure Amount and/or Swingline Exposure hereunder, a new Note or Notes to the order of the assigning Lender in an amount equal to the applicable Revolving Credit Commitment, Loans, Letter of Credit Exposure Amount and/or Swingline Exposure retained by it hereunder.  Such new Notes shall be in an aggregate principal amount equal to the aggregate principal amount of such surrendered Note(s), shall be dated the effective date of such Assignment and Acceptance and shall otherwise be in substantially the form of the surrendered Note(s).  Such surrendered Note shall be marked canceled and returned to the Borrower.

 

(g)           Any Lender may, in connection with any assignment or participation or proposed assignment or participation pursuant to this Section 10.12, disclose to the assignee or participant or proposed assignee or participant, any information relating to any Credit Party and/or any of its Subsidiaries furnished to such Lender by or on behalf of such Credit Party or such applicable Subsidiary.

 

(h)           Notwithstanding anything herein to the contrary, any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including without limitation, any pledge or assignment to secure obligations to a Federal Reserve Bank, and this Section shall not apply to any such pledge or assignment of a security interest; provided that no such pledge or assignment of a security interest shall release a Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.

 

10.13       Entire Agreement.  This Agreement and the other Loan Documents embody the entire agreement and understanding among the Credit Parties, the Agent and the Lenders relating

 

105

 

to the subject matter hereof and supersedes all prior proposals, agreements and understandings relating to the subject matter hereof.  Any conflict between the provisions of this Agreement and the provisions of any other Loan Documents shall be governed by the provisions of this Agreement.  The Credit Parties certify that they are relying on no representation, warranty, covenant or agreement except for those set forth in this Agreement and the other Loan Documents of even date herewith.

 

10.14       Severability.  If any provision of any Loan Documents shall be invalid, illegal or unenforceable in any respect under any applicable law, the validity, legality and enforceability of the remaining provisions shall not be affected or impaired thereby.

 

10.15       Disclosures.  Every reference in the Loan Documents to disclosures of the Borrower or any other Credit Party to the Agent and the Lenders in writing, to the extent that such references refer to disclosures at or prior to the execution of this Agreement, shall be deemed strictly to refer only to written disclosures delivered to the Agent and the Lenders in an orderly manner prior to or concurrently with the execution hereof.

 

10.16       Capital Adequacy.

 

(a)           If after the date of this Agreement, any Lender shall have determined that the adoption or effectiveness (regardless of whether previously announced) of any applicable Legal Requirement or treaty regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority or comparable agency charged with the interpretation or administration thereof, or compliance by any Lender with any request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, has or would have the effect of increasing the cost of, or reducing the rate of return on the capital of such Lender (or any holding company of which such Lender is a part) as a consequence of its obligations hereunder or under any Letter of Credit or its Note to a level below that which such Lender or holding company could have achieved but for such adoption, change or compliance by an amount deemed by such Lender to be material, then from time to time, upon demand by such Lender (with a copy to the Agent) in the form of a certificate stating the cause of such demand and reasonably detailed calculations therefor, the Borrower (subject to Section 10.6 hereof) agrees to pay to such Lender such additional amount or amounts as will compensate such Lender or holding company for such reduction.

 

(b)           The certificate of any Lender setting forth such amount or amounts as shall be necessary to compensate such Lender or its holding company as specified in Subsection 10.16(a) above (and setting forth the calculation thereof in reasonable detail) shall be conclusive and binding, absent manifest error.  The Borrower shall pay such Lender the amount shown as due on any such certificate within five days after such Lender delivers such certificate.  In preparing such certificate, such Lender may employ such assumptions and allocations of costs and expenses as it shall in good faith deem reasonable and may use any reasonable averaging and attribution method.

 

(c)           If any Lender requests compensation from the Borrower under this Section 10.16 or under Sections 2.9(b) or 10.17, then at any time within 120 days after the Borrower’s receipt of the certificate from such Lender regarding the circumstances and calculation of the

 

106

 

applicable compensation so requested, the Borrower shall have the right to seek and obtain one or more substitute lenders approved by the Agent (which approval shall not be unreasonably withheld so long as each such substitute lender is an Eligible Assignee) to replace such Lender hereunder in compliance with all relevant provisions of Section 10.12 hereof.  Contemporaneously with the replacement of such Lender hereunder with one or more such substitute lenders, the Borrower shall cause such substitute lender(s) to pay in full, as the purchase price for such assignment, the Obligations owed to such replaced Lender, including all accrued, unpaid interest thereon and any Consequential Loss owing by the Borrower to such replaced Lender as a result of such payment, without payment to such replaced Lender of any prepayment fee otherwise payable to such Lender under the terms of Section 2.4(b) above.  Notwithstanding the foregoing terms and provisions of this Section 10.16, (i) the Borrower shall remain obligated to make timely payment of the additional compensation set forth in the certificate presented to the Borrower by such replaced Lender under the terms of Section 10.16(b) above for the periods prior to the applicable replacement date, and (ii) neither the Agent nor any Lender shall have any obligation to the Borrower to find or locate any substitute lender or lenders to replace any Lender requesting compensation from the Borrower under this Section 10.16.

 

10.17       Taxes.

 

(a)           As used in this Section 10.17, the following terms shall have the following meanings:

 

(i)            “Indemnifiable Tax” means any Tax, but excluding, in any case, any Tax that (a) would not be imposed in respect of a payment to a Lender or the Agent under the Notes held by such Lender or the Agent or under any of the other Loan Documents except for a present or former connection between the jurisdiction of the Governmental Authority imposing such Tax and such Lender or the Agent (or a shareholder or other Person with an interest therein), including a connection arising from such Lender’s or the Agent’s (or shareholder thereof) being or having been a citizen or resident of such jurisdiction, or being or having been organized, present or engaged in a trade or business in such jurisdiction, or having or having had a permanent establishment or fixed place of business in such jurisdiction, but excluding a connection arising solely from such Lender or the Agent having executed, delivered, performed its obligations or received a payment under, or enforced, this Agreement, the Notes held by such Lender or the Agent or any other Loan Documents, (b) is imposed under United States federal income tax law or any state income or franchise tax law or (c) is described in the final sentence of Section 17(e).

 

(ii)           “Tax” means any present or future tax, levy, impost, duty, charge, assessment or fee of any nature (including interest thereon and penalties and additions thereto) that is imposed by any Governmental Authority in respect of a payment to a Lender or the Agent under the Notes or under any of the other Loan Documents.

 

(b)           If the Borrower is required by any applicable Legal Requirement to make any deduction or withholding for or on account of any Tax from any payment to be made by it under this Agreement, under the Notes or under any other Loan Documents to a Lender or the

 

107

 

Agent, then the Borrower shall (i) promptly notify the Lender or the Agent that is entitled to such payment of such requirement to so deduct or withhold such Tax, (ii) pay to the relevant Governmental Authorities the full amount required to be so deducted or withheld, (iii) promptly forward to such Lender or the Agent an official receipt (or copies thereof), or other documentation reasonably acceptable to such Lender or the Agent, evidencing such payment to such Governmental Authorities and (iv) if such Tax is an Indemnifiable Tax, pay, to the extent permitted by law to such Lender or the Agent, in addition to whatever net amount of such payment is paid to such Lender or the Agent, such additional amount as is necessary to ensure that the total amount actually received by such Lender or the Agent (free and clear of Indemnifiable Tax) will equal the full amount of the payment such Lender or the Agent would have received had no such deduction or withholding been required.  If the Borrower pays any additional amount to a Lender or the Agent pursuant to the preceding sentence and such Lender or the Agent shall receive a refund of an Indemnifiable Tax with respect to which, in the good faith opinion of such Lender or the Agent, such payment was made, such Lender or the Agent shall pay to the Borrower the amount of such refund promptly upon receipt thereof.

 

(c)           In the event that any Governmental Authority notifies the Borrower that it has improperly failed to withhold or deduct any Tax from a payment received by any Lender or the Agent under the Notes held by such Lender or the Agent or under any other Loan Documents, the Borrower agrees to timely and fully pay such Tax to such Governmental Authority and such Lender or the Agent shall, upon receipt of written notice of such payment with respect to any Tax other than an Indemnifiable Tax, promptly pay to the Borrower, an amount necessary in order that the amount of such payment to the Borrower after payment of all Taxes with respect to such payment, shall equal the amount of any Tax other than an Indemnifiable Tax that the Borrower paid to such Governmental Authority pursuant to this clause (c).

 

(d)           Each Lender or the Agent shall, upon request by the Borrower, take requested measures to mitigate the amount of Indemnifiable Tax required to be deducted or withheld from any payment made by the Borrower under this Agreement, under the Notes or under any other Loan Documents if such measures can, in the sole and absolute opinion of such Lender or the Agent, be taken without such Lender or the Agent suffering any economic, legal, regulatory or other disadvantage (provided, however, that no such Lender or the Agent shall be required to designate a funding office that is not located in the United States of America).

 

(e)           Each Lender or the Agent that (i) is organized under the laws of a jurisdiction other than the United States of America and (ii)(A) is a party hereto on the Closing Date or (B) becomes an assignee of an interest under this Agreement under Section 10.12 after the Closing Date (unless such Lender or the Agent was already a Lender or the Agent hereunder immediately prior to such assignment) shall execute and deliver to the Borrower and the Agent one or more (as the Borrower or the Agent may reasonably request) Forms W-8ECI, W-8BEN, W-8IMY (as applicable) or other applicable form, certificate or document prescribed by the United States Internal Revenue Service certifying as to such Lender’s or the Agent’s entitlement to exemption from withholding or deduction of Taxes.  The Borrower shall not be required to pay additional amounts to any Lender or the Agent pursuant to this Section 10.17 to the extent that the obligation to pay such additional amounts would not have arisen but for the failure of such Lender or the Agent to comply with this paragraph.

 

108

 

(f)            Each Lender and the Agent agrees that if it subsequently recovers, or receives a permanent net tax benefit with respect to any amounts of Taxes (i) previously paid by it and as to which it has been indemnified by or on behalf of the Borrower or (ii) previously deducted by the Borrower (including, without limitation, any Taxes deducted from any additional sums payable under clause (b) above), the relevant Lender or the Agent, as the case may be, shall reimburse the Borrower to the extent of the amount of any such recovery or permanent net tax benefit (but only to the extent of any indemnity payments made, or additional amounts paid, by or on behalf of the Borrower under this Section 10.17 with respect to the Taxes giving rise to such recovery or tax benefit); provided, however, that the Borrower, upon the request of the Lender or the Agent, agrees to repay to such Note Lender or the Agent, the amount paid over to the Borrower, in the event such Lender or the Agent is required to repay such amount to the relevant taxing authority.

 

(g)           Notwithstanding the foregoing, in no event shall the amount payable under this Section 10.17 (to the extent, if any, constituting interest under applicable laws) together with all amounts constituting interest under applicable laws and payable in connection with this Agreement or the Notes, exceed the Highest Lawful Rate or the maximum amount of interest permitted to be charged by applicable laws.

 

10.18       Waiver of Claims.  Each Credit Party hereby waives and releases the Agent and all Lenders from any and all claims or causes of action which the Borrower may own, hold or claim in respect of any of them as of the date hereof.

 

10.19       Right of Setoff.  The Lenders each are hereby authorized at any time and from time to time, without notice to any Credit Party (any such notice being expressly waived by each Credit Party), to setoff and apply any and all deposits (general or special, time or demand, provisional or final, whether or not such setoff results in any loss of interest or other penalty, and including without limitation all certificates of deposit) at any time held, and any other funds or property at any time held, and other Indebtedness at any time owing by the Agent or such Lender to or for the credit or the account of any such Credit Party against any and all of the Obligations irrespective of whether or not any of the Obligations are then due and irrespective of whether or not Agent or such Lender shall have made any demand under this Agreement, the Notes or any other Loan Document.  Each Credit Party also hereby grants to Agent and to each of the Lenders a security interest in and hereby transfers, assigns, sets over, and conveys to the Agent and to each of the Lenders, as security for payment of all Obligations, all such deposits, funds or property of any such Credit Party or Indebtedness of the Agent or any Lender to any such Credit Party.  Should the right of the Agent or any Lender to realize funds in any manner set forth hereinabove be challenged and any application of such funds be reversed, whether by court order or otherwise, the Lenders shall make restitution or refund to such Credit Party, pro rata in accordance with their respective Commitment Percentages.  Each Lender agrees to promptly notify the Borrower and the Agent after any such setoff and application, provided that the failure to give such notice will not affect the validity of such setoff and application.  The rights of the Agent and the Lenders under this Section are in addition to other rights and remedies (including without limitation other rights of setoff) which the Agent or the Lenders may have.  This Section is subject to the terms and provisions of Section 2.12 hereof.

 

109

 

10.20       Waiver of Right to Jury Trial.  EXCEPT AS PROHIBITED BY APPLICABLE LAW, EACH PARTY HERETO HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, THE NOTES, ANY OF THE OTHER LOAN DOCUMENTS OR ANY TRANSACTIONS EVIDENCED THEREBY.

 

10.21       Additional Provisions Regarding Collection of Accounts and other Collateral.

 

(a)           Each Credit Party hereby designates and constitutes the Agent or the Agent’s designee as such Credit Party’s attorney-in-fact with power to endorse such Credit Party’s name upon any notes, acceptances, checks, drafts, money orders or other evidence of payment of any Accounts or any other Collateral that may come into its possession; to sign or endorse such Credit Party’s name on any invoice, bill of lading or other title or ownership documents relating to any Accounts or Inventory, drafts against any customers of any Credit Party, assignments and verifications of Accounts and notices to customers of any Credit Party; to send verifications of Accounts; and to notify the U.S. Postal Service authorities to change the address for delivery of mail addressed to any Credit Party to such address as the Agent may designate.  All acts of said attorney or designee are hereby ratified and approved by each Credit Party, and said attorneys or designee shall not be liable for any acts of omission or commission, for any error of judgment or for any mistake of fact or law, provided that the Agent or its designee shall not be relieved of liability to the extent it is determined by a final judicial decision that its act, error or mistake constituted gross negligence or willful misconduct or willful and knowing breach of any Loan Document.  The power of attorney granted under this subparagraph is coupled with an interest and is irrevocable until all of the Obligations are paid in full and this Agreement and the Revolving Credit Commitments are terminated.

 

(b)           The Agent, without notice to or consent of any Credit Party, at any time after the occurrence and during the continuation of an Event of Default, (i) may sue upon or otherwise collect, extend the time, of payment of, or compromise or settle for cash, credit or otherwise upon any terms, any of the Accounts or any instruments or insurance applicable thereto and/or release any account debtor thereon; (ii) is authorized and empowered to accept or direct shipments of Inventory and accept the return of the goods represented by any of the Accounts; and (iii) shall have the right to receive, endorse, assign and/or deliver in its name or the name of any Credit Party any and all checks, drafts and other instruments for the payment of money relating to the Accounts, and each Credit Party hereby waives notice of presentment, protest and non-payment of any instrument so endorsed.

 

(c)           Nothing herein contained shall be construed to constitute any Credit Party as agent of the Agent for any purpose whatsoever, and the Agent shall not be responsible or liable for any shortage, discrepancy, damage, loss or destruction of any part of the Collateral wherever the same may be located and regardless of the cause thereof (except to the extent it is determined by a final judicial decision that the Agent’s or a Lender’s act or omission constituted gross negligence of willful conduct or willful and knowing breach of any Loan Document).  The Agent and the Lenders shall not, under any circumstances or in any event whatsoever, have any liability for any error or omission or delay of any kind occurring in the settlement, collection or payment of any of the Accounts or any instrument received in payment thereof or for any

 

110

 

damage resulting therefrom (except to the extent it is determined by a final judicial decision that the Agent’s or such Lender’s error, omission or delay constituted gross negligence or willful misconduct or willful and knowing breach of any Loan Document).  The Agent and the Lenders do not, by anything herein or in any assignment or otherwise, assume any Credit Party’s obligations under any contract or agreement assigned to the Agent or the Lender, and the Agent and the Lenders shall not be responsible in any way for the performance by any Credit Party of any of the terms and conditions thereof.

 

(d)           Upon the occurrence and during the continuation of any Event of Default:  (i) if any of the Accounts includes a charge for any tax payable to any governmental tax authority, the Agent is hereby authorized (but in no event obligated) in its discretion to pay the amount thereof to the proper taxing authority for, the account of any Credit Party and to charge or any Credit Party’s account therefor; and (ii) the Borrower shall notify the Agent if any Accounts include any tax due to any such taxing authority and, in the absence of such notice, the Agent shall have the right to retain the full proceeds of such Accounts and shall not be liable for any taxes that may be due from any Credit Party by reason of the sale and delivery creating such Accounts.

 

(e)           Upon the occurrence and continuation of any Event of Default, the Agent may at any time and from time to time employ and maintain in the premises of any Credit Party a custodian selected by the Agent who shall have full authority to do all acts necessary to protect the Agent’s and Lenders’ interests and to report to the Agent thereon.  Each Credit Party hereby agrees to cooperate with any such custodian and to do so whatever the Agent may reasonably request to preserve the Collateral.  All costs and expenses incurred by the Agent by reason of the employment of the custodian shall be charged to the Borrower’s account and added to the Obligations.

 

10.22       Hedging Obligations; Cash Management Obligations.

 

(a)           The term “Obligations,” as defined and used in this Agreement, includes all Hedging Obligations and Cash Management Obligations of the Borrower or any of its Subsidiaries (collectively, “Related Obligations”) to the Agent, JPMorgan, any other Lender or any of their respective affiliates and branches (each an “Obligee” and, collectively, the “Obligees”).  Accordingly, the benefit of the Loan Documents and of the provisions of this Agreement relating to the Collateral shall extend to and be available in respect of the Related Obligations solely on the condition and understanding, as among the Agent and all Obligees, that (i) the Related Obligations shall be entitled to the benefit of the Loan Documents and the Collateral to the extent expressly set forth in this Agreement and the other Loan Documents and to such extent the Agent shall hold, and have the right and power to act with respect to, the Guaranty and the Collateral on behalf of and as agent for the Obligees, but the Agent is otherwise acting solely as agent for the Lenders and shall have no fiduciary duty, duty of loyalty, duty of care, duty of disclosure or other obligation whatsoever to any Obligee, (ii) all matters, acts and omissions relating in any manner to the Guaranty, the Collateral, or the omission, creation, perfection, priority, abandonment or release of any Lien, shall be governed solely by the provisions of this Agreement and the other Loan Documents and no separate Lien, right, power or remedy shall arise or exist in favor of any Obligee under any separate instrument or agreement or in respect of any Related Obligation, (iii) each Obligee shall be bound by all

 

111

 

actions taken or omitted, in accordance with the provisions of this Agreement and the other Loan Documents, by the Agent and the Required Lenders, each of whom shall be entitled to act at its sole discretion and exclusively in its own interest given its own Revolving Credit Commitment and its own interest in the Loans, Letter of Credit Obligations and other Obligations to it arising under this Agreement or the other Loan Documents, without any duty or liability to any other Obligee or as to any Related Obligation and without regard to whether any Related Obligation remains outstanding or is deprived of the benefit of the Collateral or becomes unsecured or is otherwise affected or put in jeopardy thereby, (d) no Obligee (except the Agents and the Lenders, to the extent set forth in this Agreement) shall have any right to be notified of, or to direct, require or be heard with respect to, any action taken or omitted in respect of the Collateral or under this Agreement or the Loan Documents and (e) no Obligee shall exercise any right of setoff, banker’s lien or similar right except to the extent such right is exercised in compliance with Section 2.13.

 

(b)           Each Credit Party hereby, jointly and severally and irrevocably and unconditionally, guarantees to each of the Obligees the full and prompt payment and performance of any and all Related Obligations to each Obligee.  Such guaranty shall be an absolute, continuing, irrevocable, and unconditional guaranty of payment and performance, and not a guaranty of collection, and the Credit Parties shall remain liable on such obligations hereunder until the payment and performance in full of the Related Obligations.  No set-off, counterclaim, recoupment, reduction, or diminution of any obligation, or any defense of any kind or nature which the Borrower or any of its Subsidiaries may have against any Obligee or any other party shall be available to, or shall be asserted by, any Credit Party against any Obligee or any subsequent holder of the Related Obligations or any part thereof or against payment of the Related Obligations or any part thereof.

 

(c)           If any Credit Party becomes liable for any obligations or indebtedness owing by any Subsidiary to any Obligee by endorsement or otherwise, other than under this Section 10.22, such liability shall not be in any manner impaired or affected hereby, and the rights of each Obligee shall be cumulative of any and all other rights that any Obligee may ever have against such Credit Party.

 

(d)           In the event of default in payment or performance of any of the Related Obligations, or any part thereof, when any part of the Related Obligations becomes due, whether by its terms, by acceleration, upon demand or otherwise, the Credit Parties shall promptly pay the amount due thereon to the applicable Obligee without notice or demand in dollars and it shall not be necessary for any Obligee, in order to enforce such payment by the Credit Parties, first to institute suit or exhaust its remedies against any Subsidiary or others liable on such Related Obligations, or to enforce any rights against any collateral which shall ever have been given to secure such Related Obligations.  Notwithstanding anything to the contrary contained in this Section 10.22, each Credit Party hereby irrevocably subordinates to the prior and defeasible payment in full of the Related Obligations, any and all rights such Credit Party may now or hereafter have under any agreement or at law or in equity (including, without limitation, any law subrogating such Credit Party to the rights of any of the Obligees) to assert any claim against or seek contribution, indemnification or any other form of reimbursement from any Subsidiary or any other party liable for payment of any or all of the Related Obligations for any payment made by any Credit Party under or in connection with this Section 10.22 or otherwise.

 

112

 

(e)           Each Credit Party hereby agrees that its obligations under this Section 10.22 shall not be released, discharged, diminished, impaired, reduced, or affected for any reason or by the occurrence of any event, including, without limitation, one or more of the following events, whether or not with notice to or the consent of any Credit Party:  (i) the taking or accepting of collateral as security for any or all of the Related Obligations or the release, surrender, exchange, or subordination of any collateral now or hereafter securing any or all of the Related Obligations; (ii) any partial release of the liability of the Borrower or any other Credit Party hereunder, or the full or partial release of any other guarantor from liability for any or all of the Related Obligations; (iii) any disability of any Credit Party or any of its Subsidiaries, or the dissolution, insolvency, or bankruptcy of any Credit Party, any of its Subsidiaries, any guarantor or any other party at any time liable for the payment of any or all of the Related Obligations; (iv) any renewal, extension, modification, waiver, amendment, or rearrangement of any or all of the Related Obligations or any instrument, document, or agreement evidencing, securing, or otherwise relating to any or all of the Related Obligations; (v) any adjustment, indulgence, forbearance, waiver, or compromise that may be granted or given by any Obligee to any Credit Party, any of its Subsidiaries, or any other party ever liable for any or all of the Related Obligations; (vi) any neglect, delay, omission, failure, or refusal of any Obligee to take or prosecute any action for the collection of any of the Related Obligations or to foreclose or take or prosecute any action in connection with any instrument, document, or agreement evidencing, securing, or otherwise relating to any or all of the Related Obligations; (vii) the unenforceability or invalidity of any or all of the Related Obligations or of any instrument, document, or agreement evidencing, securing, or otherwise relating to any or all of the Related Obligations; (viii) any payment by any Subsidiary of any Credit Party or any other party to any Obligee is held to constitute a preference under applicable bankruptcy or insolvency law or if for any other reason any Obligee is required to refund any payment or pay the amount thereof to someone else; (ix) the settlement or compromise of any of the Related Obligations; (x) the non-perfection of any security interest or lien securing any or all of the Related Obligations; (xi) any impairment of any collateral securing any or all of the Related Obligations; (xii) the failure of any Obligee to sell any collateral securing any or all of the Related Obligations in a commercially reasonable manner or as otherwise required by law; (xiii) any change in the corporate existence, structure, or ownership of the Borrower or any of its Subsidiaries; or (xiv) any other circumstance which might otherwise constitute a defense available to, or discharge of, any Credit Party or any of its Subsidiaries.

 

(f)            Each Credit Party hereby waives promptness, diligence, notice of any default under the Related Obligations, demand of payment, notice of acceptance of this guaranty, presentment, notice of protest, notice of dishonor, notice of the incurring by any Subsidiary of any Credit Party of additional obligations or indebtedness, and all other notices and demands with respect to the Related Obligations and this guaranty.

 

10.23       Construction.  Each Credit Party, the Agent and each Lender acknowledge that each of them has had the benefit of legal counsel of its own choice and has been afforded an opportunity to review this Agreement and the other Loan Documents with its legal counsel and that this Agreement and the other Loan Documents shall be construed as if jointly drafted by the parties hereto.

 

113

 

10.24       Joint and Several Obligations.  Notwithstanding anything to the contrary contained herein or in any other Loan Documents, each Credit Party acknowledges that it and the other Credit Parties are jointly and severally responsible for their respective agreements, covenants, representations, warranties and obligations contained and set forth in this Agreement or in any other Loan Document to which the applicable Credit Party is a party.

 

10.25       USA Patriot Act.  Each Lender hereby notifies the Borrower that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), it may be required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Lender to identify the Borrower in accordance with the Act.

 

10.26       Confidentiality.  Each Lender agrees to keep confidential information obtained by it pursuant hereto and the other Loan Documents confidential in accordance with such Lender’s customary practices and agrees that it will only use such information in connection with the transactions contemplated by this Agreement and not disclose any of such information in connection with the transactions contemplated by this Agreement and not disclose any of such information other than (a) to such Lender’s employees, representatives, directors, attorneys, auditors, agents, professional advisors, trustees or Affiliates who are advised of the confidential nature of such information, (b) to the extent such information presently is or hereafter becomes available to such Lender on a non-confidential basis from any source of such information that is in the public domain at the time of disclosure, (c) to the extent disclosure is required by law, regulation, subpoena or judicial order or process (provided that notice of such requirement or order shall be promptly furnished to the Borrower unless such notice is legally prohibited or such disclosure is made during an examination of a Lender’s books and records by any state or federal regulatory agency), (d) to any rating agency to the extent required in connection with any rating to be assigned to such Lender, (e) to assignees or participants or prospective assignees or participants who agree to be bound by the provisions of this Section 10.26, (f) to the extent required in connection with any litigation between any Credit Party and any Lender with respect to the Loans or this Agreement and the other Loan Documents, or (g) with the Borrower’s prior written consent

 

10.27       No Rights, Duties or Obligations of Documentation Agent.  The Credit Parties, the Agent and each Lender acknowledge and agree that except for the rights, powers, obligations and liabilities under this Agreement and the other Loan Documents as a Lender, General Electric Capital Corporation, as Documentation Agent, shall have no additional rights, powers, obligations or liabilities under this Agreement or any other Loan Documents in its capacity as Documentation Agent.

 

[Remainder of Page Left Blank Intentionally]

 

114

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth above.

 

	
 
    	
WALCO   INTERNATIONAL, INC.,
    
	
 
    	
a   Delaware corporation, as Borrower
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   William F. Lacey
    
	
 
    	
Name:   
    	
William   F. Lacey
    
	
 
    	
Title:   
    	
Senior   Vice President, CFO & Treasurer
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
   Walco International, Inc.
   7 Village Circle, Suite 200
   Westlake, Texas 76262
   Attention:  William F. Lacey
   Facsimile:  (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
   Animal Health International, Inc.
   7 Village Circle, Suite 200
   Westlake, Texas 76262
   Attention:  Legal Department
   Facsimile:  (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
   Charlesbank Capital Partners 600
   Atlantic Avenue, 26th Floor
   Boston, Massachusetts 02210-2203
   Attention:  Mark Rosen and Brandon   White
   Facsimile:  (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
   Goodwin Procter LLP
   53 State Street
   Boston, Massachusetts 02109
   Attention:  Mark D. Smith
   Facsimile:  (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
JPMORGAN   CHASE BANK, N.A.,
    
	
 
    	
a   national banking association, as a Lender, as Agent and as Swingline Lender
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Kevin D. Padgett
    
	
 
    	
Name:   
    	
Kevin   D. Padgett
    
	
 
    	
Title:   
    	
Vice   President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
   2200 Ross Avenue, Sixth Floor
   Dallas, Texas 75201
   Attention:  Kevin Padgett
    
	
 
    	
 
    
	
 
    	
Domestic   Lending Office:
   2200 Ross Avenue, Sixth Floor
   Dallas, Texas 75201
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
SUNTRUST   BANK,
    
	
 
    	
a   Georgia banking corporation, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Patrick Wiggins
    
	
 
    	
Name:   
    	
Patrick   Wiggins
    
	
 
    	
Title:   
    	
Vice   President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
303   Peachtree Street, 2nd Floor
    
	
 
    	
Atlanta,   Georgia 30308
    
	
 
    	
Attention:   Mark Pickering
    
	
 
    	
Facsimile:   (404) 588-7061
    
	
 
    	
 
    
	
 
    	
Domestic   Lending Office:
    
	
 
    	
303   Peachtree Street, 2nd Floor
    
	
 
    	
Atlanta,   Georgia 30308
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
GENERAL   ELECTRIC CAPITAL CORPORATION,
    
	
 
    	
a   Delaware corporation, as a Lender and as Documentation Agent
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jeffrey Skinner
    
	
 
    	
Name:
    	
Jeffrey   A. Skinner
    
	
 
    	
 
    	
Duly   Authorized Signatory
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
500   W. Monroe, 17th Floor
    
	
 
    	
Chicago, Illinois   60661
    
	
 
    	
Attention:   Walco Account Manager
    
	
 
    	
Facsimile:   (312) 441-7026
    
	
 
    	
 
    
	
 
    	
Domestic   Lending Office:
    
	
 
    	
500   W. Monroe, 17th Floor
    
	
 
    	
Chicago, Illinois   60661
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
THE   CIT GROUP/BUSINESS CREDIT, INC.,
    
	
 
    	
a   New York corporation, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   CIT Business Credit
    
	
 
    	
5420   LBJ Freeway, Suite 200
    
	
 
    	
Dallas,   Texas 75240
    
	
 
    	
Attention:   Mark Porter
    
	
 
    	
Facsimile:   (972) 455-1690
    
	
 
    	
 
    
	
 
    	
Domestic   Lending Office:
    
	
 
    	
1211   Avenue of the Americas
    
	
 
    	
New   York, New York 10036
    

 

 

	
 
    	
GENERAL   ELECTRIC CAPITAL CORPORATION,
    
	
 
    	
a   Delaware corporation, as a Lender and as Documentation Agent
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
Duly   Authorized Signatory
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
500   W. Monroe, 17th Floor
    
	
 
    	
Chicago, Illinois   60661
    
	
 
    	
Attention:   Walco Account Manager
    
	
 
    	
Facsimile:   (312) 441-7026
    
	
 
    	
 
    
	
 
    	
Domestic   Lending Office:
    
	
 
    	
500   W. Monroe, 17th Floor
    
	
 
    	
Chicago, Illinois   60661
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
THE   CIT GROUP/BUSINESS CREDIT, INC.,
    
	
 
    	
a   New York corporation, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Michael Song
    
	
 
    	
Name:
    	
Michael   Song
    
	
 
    	
Title:
    	
Vice   President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   CIT Business Credit
    
	
 
    	
5420   LBJ Freeway, Suite 200
    
	
 
    	
Dallas,   Texas 75240
    
	
 
    	
Attention:   Walco Account Manager
    
	
 
    	
Facsimile:   (972) 455-1690
    
	
 
    	
 
    
	
 
    	
Domestic   Lending Office:
    
	
 
    	
1211   Avenue of the Americas
    
	
 
    	
New   York, New York 10036
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

119

 

 

	
 
    	
ANIMAL   HEALTH INTERNATIONAL, INC.,
    
	
 
    	
a   Delaware corporation, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   William F. Lacey
    
	
 
    	
Name:   
    	
William   F. Lacey
    
	
 
    	
Title:   
    	
Senior   Vice President, CFO & Treasurer
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
STEER   INTERMEDIATE CORPORATION,
    
	
 
    	
a   Delaware corporation, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   William F. Lacey
    
	
 
    	
Name:   
    	
William   F. Lacey
    
	
 
    	
Title:   
    	
Senior   Vice President, CFO & Treasurer
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
WALCO   HOLDINGS, INC.,
    
	
 
    	
a   Delaware corporation, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   William F. Lacey
    
	
 
    	
Name:
    	
William   F. Lacey
    
	
 
    	
Title:
    	
Senior   Vice President, CFO & Treasurer
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
WALCO   INTERMEDIATE, INC.,
    
	
 
    	
a   Delaware corporation, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   William F. Lacey
    
	
 
    	
Name:   
    	
William   F. Lacey
    
	
 
    	
Title:   
    	
Senior   Vice President, CFO & Treasurer
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
AMERICAN   LIVESTOCK SUPPLY, INC.,
    
	
 
    	
a   Delaware corporation, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jon Kuehl
    
	
 
    	
Name:   
    	
John   Kuehl
    
	
 
    	
Title:   
    	
President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
PROVINCE   LIVESTOCK SUPPLY LTD.,
    
	
 
    	
an   Alberta corporation, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Scott Pastlewaite
    
	
 
    	
Name:
    	
Scott   Pastlewaite
    
	
 
    	
Title:   
    	
President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
WESTERN   VETERINARY SUPPLIES LTD.,
    
	
 
    	
an   Alberta corporation, as a Guarantor
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Scott Pastlewaite
    
	
 
    	
Name:   
    	
Scott   Pastlewaite
    
	
 
    	
Title:   
    	
President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
WALCO   CANADA ANIMAL HEALTH LTD.,
    
	
 
    	
an   Alberta corporation, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Scott Pastlewaite
    
	
 
    	
Name:   
    	
Scott   Pastlewaite
    
	
 
    	
Title:   
    	
President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

	
 
    	
WALCO   TEXAS ANIMAL HEALTH, LLC,
    
	
 
    	
a   Texas limited liability company, as a Guarantor
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   William F. Lacey
    
	
 
    	
 
    	
William   F. Lacey, President
    
	
 
    	
 
    
	
 
    	
Address   for Notices:
    
	
 
    	
c/o   Walco International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   William F. Lacey
    
	
 
    	
Facsimile:   (817) 601-6094
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Animal   Health International, Inc.
    
	
 
    	
7   Village Circle, Suite 200
    
	
 
    	
Westlake,   Texas 76262
    
	
 
    	
Attention:   Legal Department
    
	
 
    	
Facsimile:   (817) 859-3218
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Charlesbank   Capital Partners 600
    
	
 
    	
Atlantic   Avenue, 26th Floor
    
	
 
    	
Boston,   Massachusetts 02210-2203
    
	
 
    	
Attention:   Mark Rosen and Brandon White
    
	
 
    	
Facsimile:   (617) 619-5402
    
	
 
    	
 
    
	
 
    	
With   a copy to:
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   Massachusetts 02109
    
	
 
    	
Attention:   Mark D. Smith
    
	
 
    	
Facsimile:   (617)570-1231
    

 

[CREDIT AGREEMENT - SIGNATURE PAGE(S)]

 

 

Dallas, Texas

 

	
$
    	
, 2006
    

 

FOR VALUE RECEIVED, WALCO INTERNATIONAL, INC., a California corporation (herein called “Borrower”), promises to pay to the order of                                          (herein called “Payee”), a                                     , at the banking office of JPMORGAN CHASE BANK, N.A., a national banking association acting in its capacity as Agent under the Credit Agreement (together with its successors in such capacity being herein called “Agent”), located at 2200 Ross Avenue, Sixth Floor, Dallas, Texas 75201, Attention:  Kevin Padgett, or at such other place as Agent may hereafter designate in writing, in immediately available funds and in lawful money of the United States of America, the principal sum of                                  Dollars ($                ), (or the unpaid balance of all principal advanced against this note, if that amount is less), together with interest on the unpaid principal balance of this note from time to time outstanding until maturity at the rate or rates provided for in the Credit Agreement and interest on all past due amounts, both principal and accrued interest, at the Past Due Rate; provided, that for the full term of this note, the interest rate produced by the aggregate of all sums paid or agreed to be paid to the holder of this note for the use, forbearance or detention of the debt evidenced hereby shall not exceed the Highest Lawful Rate, if any, applicable to Payee.

 

If, for any reason whatever, the interest paid or received on this note during its full term produces a rate which exceeds the Highest Lawful Rate, if any, applicable to Payee, the holder of this note shall refund to the payor or, at the holder’s option, credit against the principal of this note such portion of said interest as shall be necessary to cause the interest paid on this note to produce a rate equal to the Highest Lawful Rate, if any, applicable to payee.  All sums paid or agreed to be paid to the holder of this note for the use, forbearance or detention of the indebtedness evidenced hereby shall, to the extent permitted by applicable law, be amortized, prorated, allocated and spread in equal parts throughout the full term of this note, so that the interest rate is uniform throughout the full term of this note.

 

This note has been issued pursuant to the terms of an Amended and Restated Credit Agreement (which, as it may have been or may be amended, restated, modified or supplemented from time to time, is herein called the “Credit Agreement”) dated September 26,2006, by and among Borrower, Agent, Payee, each of the Credit Parties which is now or hereafter a Guarantor thereunder, and certain other signatory financial institutions named therein or which may be a party thereto from time to time, to which reference is made for all purposes.  This note is a Revolving Credit Note under the terms of the Credit Agreement, and advances against this note by Payee or other holder hereof, payments and prepayments hereunder and acceleration hereof shall be governed by the Credit Agreement.  Capitalized words and phrases used herein and not defined herein and which are defined in the Credit Agreement shall have the same meanings herein as are ascribed to them in the Credit Agreement.

 

The unpaid principal balance of this note at any time shall be the total of all principal lent or advanced against this note less the sum of all principal payments and permitted prepayments made on this note by or for the account of Borrower.  All loans and advances and all payments and permitted prepayments made hereon may be endorsed by the holder of this note on the schedule which is attached hereto (and hereby made a part hereof for all purposes) or otherwise

 

EXHIBIT A

 

1

 

recorded in the holder’s records; provided, that any failure to make notation of (a) any advance shall not cancel, limit or otherwise affect Borrower’s obligations or any holder’s rights with respect to that advance, or (b) any payment or permitted prepayment of principal shall not cancel, limit or otherwise affect Borrower’s entitlement to credit for that payment as of the date received by the holder.

Borrower and any and all co-makers, endorsers, guarantors and sureties severally waive notice (including, but not limited to, notice of intent to accelerate and notice of acceleration, notice of protest and notice of dishonor), demand, presentment for payment, protest, diligence in collecting and the filing of suit for the purpose of fixing liability and consent that the time of payment hereof may be extended and re-extended from time to time without notice to any of them.  Each such person agrees that his, her or its liability on or with respect to this note shall not be affected by any release of or change in any guaranty or security at any time existing or by any failure to perfect or maintain perfection of any lien against or security interest in any such security or the partial or complete unenforceability of any guaranty or other surety obligation, in each case in whole or in part, with or without notice and before or after maturity.

 

THIS NOTE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK (OTHER THAN THE CONFLICTS OF LAWS PRINCIPLES THEREOF) AND THE UNITED STATES OF AMERICA FROM TIME TO TIME IN EFFECT.

 

	
 
    	
WALCO   INTERNATIONAL, INC.,
    
	
 
    	
a   California corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

2

 

Dallas, Texas

 

	
$15,000,000.00
    	
, 2006
    

 

FOR VALUE RECEIVED, WALCO INTERNATIONAL, INC., a California corporation (herein called “Borrower”), promises to pay to the order of JPMORGAN CHASE BANK, N.A. (herein called “Payee”), a national banking association, at the banking office of JPMORGAN CHASE BANK, N.A. a national banking association acting in its capacity as Agent under the Credit Agreement (together with its successors in such capacity being herein called “Agent”), located at 2200 Ross Avenue, Sixth Floor, Dallas, Texas 75201, Attention:  Kevin Padgett, or at such other place as Agent may hereafter designate in writing, in immediately available funds and in lawful money of the United States of America, the principal sum of Fifteen Million Dollars ($ 15,000,000.00), (or the unpaid balance of all principal advanced against this note, if that amount is less), together with interest on the unpaid principal balance of this note from time to time outstanding until maturity at the rate or rates provided for in the Credit Agreement and interest on all past due amounts, both principal and accrued interest, at the Past Due Rate; provided, that for the full term of this note, the interest rate produced by the aggregate of all sums paid or agreed to be paid to the holder of this note for the use, forbearance or detention of the debt evidenced hereby shall not exceed the Highest Lawful Rate, if any, applicable to Payee.

 

If, for any reason whatever, the interest paid or received on this note during its full term produces a rate which exceeds the Highest Lawful Rate, if any, applicable to Payee, the holder of this note shall refund to the payor or, at the holder’s option, credit against the principal of this note such portion of said interest as shall be necessary to cause the interest paid on this note to produce a rate equal to the Highest Lawful Rate, if any, applicable to payee.  All sums paid or agreed to be paid to the holder of this note for the use, forbearance or detention of the indebtedness evidenced hereby shall, to the extent permitted by applicable law, be amortized, prorated, allocated and spread in equal parts throughout the full term of this note, so that the interest rate is uniform throughout the full term of this note.

 

This note has been issued pursuant to the terms of an Amended and Restated Credit Agreement (which, as it may have been or may be amended, restated, modified or supplemented from time to time, is herein called the “Credit Agreement”) dated September 26,2006, by and among Borrower, Agent, Payee, each of the Credit Parties which is now or hereafter a Guarantor thereunder, and certain other signatory financial institutions named therein or which may be a party thereto from time to time, to which reference is made for all purposes.  This note is the Swingline Note under the terms of the Credit Agreement, and advances against this note by Payee or other holder hereof, payments and prepayments hereunder and acceleration hereof shall be governed by the Credit Agreement.  Capitalized words and phrases used herein and not denned herein and which are defined in the Credit Agreement shall have the same meanings herein as are ascribed to them in the Credit Agreement.

 

The unpaid principal balance of this note at any time shall be the total of all principal lent or advanced against this note less the sum of all principal payments and permitted prepayments made on this note by or for the account of Borrower.  All loans and advances and all payments and permitted prepayments made hereon may be endorsed by the holder of this note on the schedule which is attached hereto (and hereby made a part hereof for all purposes) or otherwise

 

EXHIBIT B

 

1

 

recorded in the holder’s records; provided, that any failure to make notation of (a) any advance shall not cancel, limit or otherwise affect Borrower’s obligations or any holder’s rights with respect to that advance, or (b) any payment or permitted prepayment of principal shall not cancel, limit or otherwise affect Borrower’s entitlement to credit for that payment as of the date received by the holder.

 

Borrower and any and all co-makers, endorsers, guarantors and sureties severally waive notice (including, but not limited to, notice of intent to accelerate and notice of acceleration, notice of protest and notice of dishonor), demand, presentment for payment, protest, diligence in collecting and the filing of suit for the purpose of fixing liability and consent that the time of payment hereof may be extended and re-extended from time to time without notice to any of them.  Each such person agrees that his, her or its liability on or with respect to this note shall not be affected by any release of or change in any guaranty or security at any time existing or by any failure to perfect or maintain perfection of any lien against or security interest in any such security or the partial or complete unenforceability of any guaranty or other surety obligation, in each case in whole or in part, with or without notice and before or after maturity.

 

THIS NOTE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK (OTHER THAN THE CONFLICTS OF LAWS PRINCIPLES THEREOF) AND THE UNITED STATES OF AMERICA FROM TIME TO TIME IN EFFECT.

 

	
 
    	
WALCO   INTERNATIONAL, INC.,
    
	
 
    	
a   California corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

2

 

OFFICER’S CERTIFICATE

 

Date:

 

[Name and address of Lender

or Agent, as the case may be]

 

Attention:

 

Re:          Financial Statements Required under Amended and Restated Credit Agreement (as the same may have been amended, modified and restated from time to time, the “Credit Agreement”) dated as of                         , 2006, by and among Walco International, Inc., the financial institutions or party thereto from time to time, each of the Credit Parties which is now or hereafter a Guarantor thereunder, and JPMorgan Chase Bank, N.A., as Agent

 

Gentlemen:

 

Capitalized words and phrases used herein and not defined herein and defined in the Credit Agreement are used herein with the same meanings as are assigned to them in the Credit Agreement.

 

The undersigned hereby certifies, warrants and represents to the addressee named above that to the best knowledge of the undersigned:

 

(1)           He or she is the duly appointed and acting [Insert title of executing Responsible Officer] of Borrower;

 

(2)           The attached financial statements dated as of                                were prepared in conformity with GAAP consistently applied, subject only to normal and customary adjustments, and present fairly the financial position of Parent and its Subsidiaries, on a Consolidated and, if applicable, a consolidating basis, as of the date thereof and the results of its operations for the period covered thereby.

 

(3)           The following constitute true, correct and complete financial calculations, in accordance with the applicable provisions of the Credit Agreement (it being understood and agreed that some of such applicable provisions of the Credit Agreement may cause such financial calculations to not be in accordance with GAAP), for the Parent and its Subsidiaries, on a Consolidated basis, as of the end of the period covered by the attached financial statements:

 

	
(a)
    	
FIXED   CHARGE COVERAGE RATIO:
    
	
 
    	
 
    	
 
    
	
 
    	
(i)
    	
EBITDA   (see calculation below):
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(ii)
    	
Unfinanced   Capital Expenditures:
    	
 
    	
$
    

 

EXHIBIT C

 

1

 

	
 
    	
(iii)
    	
cash   payments of federal, state, and local income or franchise taxes:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(iv)
    	
[Line   (i) less Line (ii) less Line (iii)]:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(v)
    	
Debt   Service Expense:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(vi)
    	
cash   Interest Expense:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(vii)
    	
Unfinanced   Cash Dividends
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(viii)
    	
[Line   (v) plus Line (vi) and Line (vii)]:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(ix)
    	
Actual   Fixed Charge Coverage Ratio [ratio of Line (iv) to Line (viii)]:
    	
 
    	
 
    	
         to   1.00
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(x)
    	
Required   Fixed Charge Coverage Ratio:
    	
 
    	
 
    	
 1.10   to 1.00
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(b)
    	
CAPITAL   EXPENDITURES:
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(i)
    	
Actual   Capital Expenditures for current fiscal year:
    	
 
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(ii)
    	
Maximum   Allowed Capital Expenditures each fiscal year:
    	
 
    	
 
    	
 $5,000,000
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(c)
    	
EBITDA:
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(i)
    	
Net   Income:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(ii)
    	
Interest   Expense:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(iii)
    	
Federal,   state and local income and franchise taxes:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(iv)
    	
depreciation   and amortization expense:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(v)
    	
any   extraordinary charges:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(vi)
    	
Permitted   Management Fees:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(vii)
    	
customary   and reasonable director’s fees and board expenses for board of directors of   the Credit
    	
 
    	
$
    

 

2

 

	
 
    	
 
    	
Parties:
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(viii)
    	
amounts   used to repurchase from Charlesbank and/or any of its Affiliates the equity   securities of the Parent to the extent included within Permitted Affiliate   Transactions:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(ix)
    	
any   other non-cash charges (including without limitation, (A) the issuance   of restricted stock or stock options, (B) equity losses of Affiliates   that are not a Subsidiary of any Credit Party, and (C) all charges   attributable to the use of the purchase accounting method), but excluding any   non-cash charge in respect of an item that was included in Net Income in a   prior period and any non-cash charge that relates to the write-down or   write-off of Inventory:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(x)
    	
[Sum   of Lines (i) through (ix)]:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(xi)
    	
cash   payments made during such period in respect of non-cash charges described in   clause (ix) above taken in a prior period:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(xii)
    	
any   extraordinary gains and any non-cash items of income:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(xiii)
    	
[Line   (xi) plus Line (xii)]:
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(xiv)
    	
Actual   EBITDA [Line (x) minus Line (xiii)]
    	
 
    	
 
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(4)
    	
The   undersigned hereby certifies to his or her best knowledge as follows:
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
(a)
    	
each   representation or warranty of the Credit Parties set forth in the Credit   Agreement or any other Loan Document is true and correct in all material   respects on and as of the date hereof with the same effect as though such   representations and warranties had been made on and of this date, except for   (i) those representations and warranties which relate only to the   Closing Date or (ii) such changes in the representations and warranties   otherwise permitted
    

 

3

 

	
 
    	
 
    	
by   the terms of the Credit Agreement; and
    
	
 
    	
 
    	
 
    
	
 
    	
(b)
    	
no   Event of Default or Default under the Credit Agreement has occurred and is   still continuing.
    

 

 

	
 
    	
 
    
	
 
    	
Name:
    	
 
    

 

4

 

[Borrower’s Letterhead]

 

REQUEST FOR EXTENSION OF CREDIT

 

Date:

 

JPMorgan Chase Bank, N.A., Agent

2200 Ross Avenue, Sixth Floor

Dallas, Texas 75201

Attention:  Kevin Padgett

 

Re:          Loan under Amended and Restated Credit Agreement dated as of                                     , 2006, by and among Walco International, Inc., the financial institutions or party thereto from time to time, each of the Credit Parties which is now or hereafter a Guarantor thereunder, and JPMorgan Chase Bank, N.A., as Agent (as the same may have been amended, modified and/or restated from time to time, the “Credit Agreement”)

 

Gentlemen:

 

Capitalized words and phrases used herein, but not defined herein, shall have the same meanings as are ascribed to them in the Credit Agreement.

 

Borrower requests that a Revolving Loan be made under the Credit Agreement in the amount of $                 and that such Revolving Loan be made on                       , 20    , which is a Business Day (unless this request for a Revolving Loan is received by Agent after 1:00 p.m., Chicago, Illinois time, in which case, then on the next to occur Business Day hereafter).

 

The Revolving Loan is to be an (check one) o Alternate Base Rate Borrowing o LIBOR Borrowing.  If the Revolving Loan is to be a LIBOR Borrowing, the Interest Period is to be (check one) o one o two o three o six months.

 

[Borrower further requests that simultaneously with the making of the Revolving Loan described above, the current [Alternate Base Rate Borrowing] [LIBOR Borrowing] which matures on the same day that said Revolving Loan is to be made (i) be converted to a LIBOR Borrowing with the same Interest Period selected for such Revolving Loan and (ii) have its unpaid principal balance be combined with the new Revolving Loan so that the aggregate thereof is treated as a single LIBOR Borrowing for the Interest Period designated for the new Revolving Loan above and for all other purposes in the Credit Agreement.]

 

Borrower hereby represents and warrants as follows:

 

(i)            each representation or warranty of the Credit Parties contained in the Credit Agreement is true in all material respects on and as of the date hereof with the same effect as though such representations and warranties had been made on and 

 

EXHIBIT D

 

1

 

of this date, except for (1) those representations and warranties which relate only to the Closing Date or (2) such changes in the representations and warranties otherwise permitted by the terms of the Credit Agreement;

 

(ii)           no Event of Default or Default under the Credit Agreement has occurred and is still continuing;

 

(iii)          so far as is known to or is ascertainable by the officers of Borrower, the business and operations of Borrower and all of its Subsidiaries, as conducted at all times relevant to the transactions contemplated by the Credit Agreement to and including the close of business on the date hereof, have been and are in compliance with all applicable Legal Requirements materially affecting the business and operations of Borrower or any of its Subsidiaries.

 

The undersigned Responsible Officer executing this Request for Extension of Credit on behalf of Borrower is the duly elected, qualified and acting                                 .

 

	
 
    	
WALCO   INTERNATIONAL, INC.,
    
	
 
    	
a   California corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

2

 

RATE SELECTION NOTICE

 

Walco International, Inc., the financial institutions or party thereto from time to time (collectively, the “Lenders”), each of the Credit Parties which is now or hereafter a Guarantor thereunder, and JPMorgan Chase Bank, N.A., as Agent for and on behalf of Lenders, executed and delivered that certain Amended and Restated Credit Agreement (as amended, supplemented and restated, the “Credit Agreement”) dated as of               , 2006.  Any term used herein and not otherwise defined herein shall have the meaning herein ascribed to it in the Credit Agreement.

 

In accordance with the Credit Agreement, Borrower hereby notifies Agent of the exercise of an Interest Option.

 

	
D.
    	
Current   borrowing(s)
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
1.
    	
 
    	
Interest   Option now in effect:
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
2.
    	
 
    	
Amount:
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
3.
    	
 
    	
Expiration   of current Interest Period, if applicable:
    	
             ,20
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
E.
    	
Proposed   borrowing
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
1.
    	
 
    	
Amount:
    	
$
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
2.
    	
 
    	
Date   Interest Option is to be effective:
    	
             ,20
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
3.
    	
 
    	
Interest   Option to be applicable (check one):
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
o  
    	
Alternate   Base Rate
    	
 
    
	
 
    	
 
    	
 
    	
o
    	
LIBOR   Rate
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
4.
    	
 
    	
Interest   Period (check one if applicable):
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
o
    	
1   month 
    	
o
    	
3   months 
    	
 
    
	
 
    	
 
    	
 
    	
o
    	
2   months
    	
o
    	
6   months
    	
 
    

 

Borrower represents and warrants that the Interest Option and the Interest Period (if applicable) selected above comply with all provisions of the Credit Agreement and that there exists no Event of Default or Default under the Credit Agreement.

 

	
 
    	
WALCO   INTERNATIONAL, INC.,
    
	
 
    	
a   California corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

EXHIBIT E

 

1

 

BORROWING BASE CERTIFICATE

 

(See Attached)

 

EXHIBIT F

 

1

 

WALCO INTERNATIONAL, INC.
 Borrowing Base Calculation
 31-Aug-06

 

	
CORE BORROWING BASE
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(A)  Total Trade Accounts   Receivable excluding Intercompany Accounts
    	
 
    	
$
    	
 
    	
 
    	
67,418,745
    	
 
    
	
Ineligible Accounts Receivable
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Over 60 days past due date
    	
 
    	
 
    	
 
    	
453,598
    	
 
    
	
Credits Greater than 60 Days Past Due
    	
 
    	
 
    	
 
    	
890,080
    	
 
    
	
50 % Cross Aged
    	
 
    	
 
    	
 
    	
78,363
    	
 
    
	
Employee or other Affiliate Sales
    	
 
    	
 
    	
 
    	
38,717
    	
 
    
	
Finance Charges
    	
 
    	
 
    	
 
    	
128,979
    	
 
    
	
Reserve for Eligible Extended Term A/R in excess   of 10% of total Eligible A/R
    	
 
    	
 
    	
 
    	
4,195,534
    	
 
    
	
Extended Term Receivables 180 days from invoice   date
    	
 
    	
 
    	
 
    	
521,978
    	
 
    
	
Cash Sales/COD’s
    	
 
    	
 
    	
 
    	
37,006
    	
 
    
	
Non U.S. or Canadian Receivable
    	
 
    	
 
    	
 
    	
18,051
    	
 
    
	
Contra Accounts
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
Notes Receivable from Customers
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
Government A/R
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
Other Ineligible Categories
    	
 
    	
 
    	
 
    	
688,940
    	
 
    
	
(B)                   Total Ineligible A/R
    	
 
    	
$
    	
 
    	
 
    	
7,051,247
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Eligible   A/R (line A less line B)
    	
 
    	
$
    	
 
    	
 
    	
60,367,498
    	
 
    
	
Available   at 85% Advance Rate
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(C)                   A/R Availability
    	
 
    	
$
    	
 
    	
 
    	
51,312,374
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(D)  Total Inventory before   Ineligibles
    	
 
    	
 
    	
 
    	
83,371,994
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Ineligible   Inventory
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Intercompany Profit
    	
 
    	
$
    	
 
    	
 
    	
790,561
    	
 
    
	
Slow Moving and Obsolete including Damaged/Expired
    	
 
    	
 
    	
 
    	
983,627
    	
 
    
	
Consigned In/Out
    	
 
    	
 
    	
 
    	
1,176,542
    	
 
    
	
Freight In
    	
 
    	
 
    	
 
    	
411,417
    	
 
    
	
Raw Material
    	
 
    	
 
    	
 
    	
44,023
    	
 
    
	
Shipping materials, maintenance parts, supplies
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
Non U.S. or Canadian inventory
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
Offsite Storage
    	
 
    	
 
    	
 
    	
508,613
    	
 
    
	
Other Ineligible Categories
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
(E)                   Total Ineligible Inventory
    	
 
    	
$
    	
 
    	
 
    	
3,914,783
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Eligible   Inventory (line D less line E)
    	
 
    	
$
    	
 
    	
 
    	
79,457,211
    	
 
    
	
Available   at lower of 65% Advance Rate or 85% Net Recovery Rate
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(F)                   Inventory Availability
    	
 
    	
$
    	
 
    	
 
    	
50,216,958
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(G)   Eligible Equipment Per   Appraisals
    	
 
    	
$
    	
 
    	
 
    	
2,085,351
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(H)  Eligible Real Estate Per   Appraisals
    	
 
    	
$
    	
 
    	
 
    	
7,978,500
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Eligible Real Estate & Equipment (line G   plus line H)
    	
 
    	
$
    	
 
    	
 
    	
10,063,851
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(I)                    Real   Estate & Equipment Availability at 75% Advance Rate
    	
 
    	
$
    	
 
    	
 
    	
7,547,889
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A/R Availability
    	
 
    	
$
    	
51,312,374
    	
 
    	
 
    	
 
    
	
Inventory Availability
    	
 
    	
50,216,958
    	
 
    	
 
    	
 
    
	
RE&E Availability
    	
 
    	
7,547,889
    	
 
    	
 
    	
 
    
	
Borrowing Base (line C plus line F plus line I)
    	
 
    	
 
    	
 
    	
109,077,220
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
(J)                    Maximum   Revolver Availability
    	
 
    	
 
    	
 
    	
109,077,220
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Aggregate Outstanding Revolving Credit and   Swingline Loans
    	
 
    	
67,246,769
    	
 
    	
 
    	
 
    
	
Aggregate Letter of Credit Obligations
    	
 
    	
432,677
    	
 
    	
 
    	
 
    
	
Sales Tax Payable
    	
 
    	
72,502
    	
 
    	
 
    	
 
    
	
Landlord/Rent Reserves-estimated
    	
 
    	
256,770
    	
 
    	
 
    	
 
    
	
Environmental Reserves-estimated
    	
 
    	
445,000
    	
 
    	
 
    	
 
    
	
(K)                  Total Non-SOFA Credit   Obligations
    	
 
    	
 
    	
 
    	
68,453,718
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Core Collateral Availability (line J less line K)
    	
 
    	
$
    	
 
    	
 
    	
40,623,501
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Total Availability
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Core   Collateral
    	
 
    	
40,623,501
    	
 
    
	
 
    	
 
    	
Cash   on hand
    	
 
    	
3,372,052
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
43,995,553
    	
 
    

 

 

FORM OF INVENTORY DESIGNATION REPORT

 

(See Attached)

 

EXHIBIT G

 

1

 

Exhibit G to Walco International, Inc. Credit Agreement
 Inventory Designation Report

 

	
Subject: Walco   International, Inc., Inc
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Only insert numbers in shaded   Cells
    	
 
    	
 
    	
 
    
	
We hereby certify the following   information:
    	
 
    	
 
    	
 
    
	
Date 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
I.      Gross Inventory per General   Leger
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Core finished Goods Inventory
    	
 
    	
 
    	
 
    
	
Slow Moving/Obsolete/Damaged Finished Goods   Inventory
    	
 
    	
 
    	
 
    
	
Cosigned Inventory
    	
 
    	
 
    	
 
    
	
Intercompany Profit
    	
 
    	
 
    	
 
    
	
Other (including offsite)
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Total Gross Inventory Per General Leger
    	
 
    	
$
    	
0
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
II.    Ending Core Finished Goods   Inventory per Last Inventory Report
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
plus: Inventory Manufactured/Purchased
    	
 
    	
 
    	
 
    
	
plus: Other
    	
 
    	
 
    	
 
    
	
less: Core Finished Good Product Sales
    	
 
    	
 
    	
 
    
	
less: Transfers to Slow Moving/Obsolete/Damaged   Goods Inventory
    	
 
    	
 
    	
 
    
	
less: Shrinkage
    	
 
    	
 
    	
 
    
	
less: Other (including offsite)
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Ending Core Finished Goods Inventory as of                           ,   200      
    	
 
    	
$
    	
0
    	
 
    

 

 

DISCLOSURE SCHEDULE

 

TO

 

CREDIT AGREEMENT

 

This Disclosure Schedule has been prepared in connection with the Amended and Restated Credit Agreement (the “Agreement”), dated as of September     , 2006, by and among Walco International, Inc. (“Borrower”), a Delaware corporation, each of the Credit Parties which is now or hereafter a Guarantor thereunder, each of the financial institutions which is a signatory thereto or which may from time to time become a party thereto (individually, a “Lender” and collectively, the “Lenders”), and JPMorgan Chase Bank, N.A. (“JPMorgan”), a national banking association, as agent for the Lenders (in such capacity, together with its successors in such capacity, the “Agent”).  Unless otherwise defined in these Schedules, all capitalized terms used herein have the meanings ascribed to them in the Agreement.

 

These Disclosure Schedules are qualified in their entirety by reference to specific provisions of the Agreement.  The inclusion of any information in these Disclosure Schedules will not be deemed an admission or acknowledgement that such information is required to be listed in the Disclosure Schedules or that such items are material to the Borrower.

 

The headings, if any, of the individual sections of each of the Disclosure Schedules are inserted for convenience only and will not be deemed to constitute a part thereof or a part of the Agreement.

 

The annexes or exhibits to any Schedule form an integral part of such Schedule and are incorporated therein by reference as if set forth fully therein.

 

The information contained herein is subject to any confidentiality agreements there may be between the parties.

 

1

 

Schedule 1.1(a)

Real Estate

 

	
1.
    	
550   East Frye Road, Suite I
    
	
 
    	
Chandler,   Arizona 85225
    
	
 
    	
(Maricopa   County)
    
	
 
    	
 
    
	
2.
    	
431   W. Amador Street
    
	
 
    	
Fresno,   California 93778
    
	
 
    	
(Fresno   County)
    
	
 
    	
 
    
	
3.
    	
303   8th Avenue
    
	
 
    	
Greeley,   Colorado 80631
    
	
 
    	
(Weld   County)
    
	
 
    	
 
    
	
4.
    	
10418   Main Street
    
	
 
    	
Thonotosassa,   Florida 33592
    
	
 
    	
(Hillsborough   County)
    
	
 
    	
 
    
	
5.
    	
203   4th Avenue West
    
	
 
    	
P.O. Box   1275
    
	
 
    	
Twin   Falls, Idaho 83301
    
	
 
    	
(Twin   Falls County)
    
	
 
    	
 
    
	
6.
    	
3390   Jones Avenue
    
	
 
    	
P.O. Box   475
    
	
 
    	
Garden   City, Kansas 67846
    
	
 
    	
(Finney   County)
    
	
 
    	
 
    
	
7.
    	
3490   Jones Avenue
    
	
 
    	
Garden   City, Kansas 67846
    
	
 
    	
(Finney   County)
    
	
 
    	
 
    
	
8.
    	
901   W. Brady Avenue
    
	
 
    	
P.O. Box   459
    
	
 
    	
Clovis,   New Mexico 88101
    
	
 
    	
(Curry   County)
    
	
 
    	
 
    
	
9.
    	
1517   Highway 54 N.E.
    
	
 
    	
P.O. Box   827
    
	
 
    	
Guymon,   Oklahoma 73942
    
	
 
    	
(Texas   County)
    

 

2

 

SCHEDULE 1.1(b)

 

LENDER COMMITMENTS

 

REVOLVING CREDIT COMMITMENTS

 

	
JPMorgan Chase Bank, N.A
    	
 
    	
$
    	
35,357,142.86
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
General Electric Capital Corporation
    	
 
    	
$
    	
27,500,000.00
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
The CIT Group/Business Credit, Inc.
    	
 
    	
$
    	
23,571,428.57
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
SunTrust Bank
    	
 
    	
$
    	
23,571,428.57
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
TOTAL
    	
 
    	
$
    	
110,000,000.00
    	
 
    

 

 

	
10.
    	
7100   West Reno Avenue
    
	
 
    	
Oklahoma   City, Oklahoma 73127
    
	
 
    	
(Oklahoma   County)
    
	
 
    	
 
    
	
11.
    	
1601   East Rice Street
    
	
 
    	
Sioux   Falls, South Dakota 57103
    
	
 
    	
(Minnehaha   County)
    
	
 
    	
 
    
	
12.
    	
2840   Vanocker Road
    
	
 
    	
P.O. Box   849
    
	
 
    	
Sturgis,   South Dakota 57785
    
	
 
    	
(Meade   County)
    
	
 
    	
 
    
	
13.
    	
9602   South Washington Street
    
	
 
    	
Amarillo,   Texas 79118
    
	
 
    	
(Randall   County)
    
	
 
    	
 
    
	
14.
    	
25   Dupree Drive
    
	
 
    	
P.O. Box   1440
    
	
 
    	
Buda,   Texas 78610
    
	
 
    	
(Hays   County)
    
	
 
    	
 
    
	
15.
    	
806   West 7th Street
    
	
 
    	
P.O. Box   245
    
	
 
    	
Dalhart,   Texas 79022
    
	
 
    	
(Dallas   County)
    
	
 
    	
 
    
	
16.
    	
2112   Jo Drive
    
	
 
    	
DeSoto,   Texas 79022
    
	
 
    	
(Dallas   County)
    
	
 
    	
 
    
	
17.
    	
11199   Rojas Drive
    
	
 
    	
El   Paso, Texas 75115
    
	
 
    	
(El   Paso County)
    
	
 
    	
 
    
	
18.
    	
1802   Pulliam Street
    
	
 
    	
San   Angelo, Texas 76905
    
	
 
    	
(Tom   Green County)
    
	
 
    	
 
    
	
19.
    	
3054   W. Washington Street
    
	
 
    	
Highway   377 West
    
	
 
    	
P.O. Box   954
    
	
 
    	
Stephenville,   Texas 76401
    
	
 
    	
(Erath   County)
    

 

3

 

	
20.
    	
2921   Central Freeway North
    
	
 
    	
P.O. Box   3098
    
	
 
    	
Wichita   Falls, Texas 76306
    
	
 
    	
(Wichita   County)
    
	
 
    	
 
    
	
21.
    	
North   Highway 36
    
	
 
    	
P.O. Box   360
    
	
 
    	
Sealy,   Texas 77474
    
	
 
    	
(Austin   County)
    
	
 
    	
 
    
	
 
    	
310   s. Manhattan (1 acre empty lot)
    
	
 
    	
Amarillo,   Texas 79104
    
	
 
    	
(Randall   County)
    

 

Excluded Real Estate

 

Main & Lafayette Streets

P.O. Box 298

Mayo, Florida 32066

(Lafayette County)

 

1210 East Trail Street

P.O. Box 1635

Fort Dodge Road

Dodge City, Kansas 67801

(Ford County)

 

1449-A West Old Highway 40

Salina, Kansas 67401

(Salina County)

 

2912 SE 3rd Avenue

P.O. Box 30428

Amarillo, Texas 79104

(Potter County)

 

802 West Oaklawn Road

P.O. Box 89

Pleasanton, Texas 78064

(Atascosa County)

 

426 N. Highway 87

P.O. Box 141

Tulia, Texas 79088

(Swisher County)

 

4

 

640 South Main Street

Spanish Fork, UT 84660

(Utah County)

 

Third Party Rights to Use or Occupy Owned Properties

 

1.                                       On July 27, 2004, Borrower entered into an Agreement with Newport Laboratories, Inc. (“Newport”) whereby Borrower agreed to allow Newport to use specified assets (specifically CAVL’s customer list, a portion of the Amarillo facility, specified equipment, and the “CAVL” name except in establishing any vendor accounts) in return for a royalty on all vaccine sales by Newport to CAVL customers existing on March 1, 2004.  In conjunction with the lease described above, Newport has the right to use a portion of the property located at 9602 South Washington Street, Amarillo, TX.

 

5

 

Schedule 5.4

Other Debt

 

None.

 

6

 

Schedule 5.5

Litigation

 

Micro Beef Technologies, Inc. v. Lextron, Inc., et al., Civil Action No. 2:  00CV100 (N.D. Tex.).  Plaintiff, Micro Beef Technologies, Inc. (“MBT”) alleges that Walco infringed several of MBT’s patents concerning animal health technologies.  Walco answered, denying infringement, and counterclaimed, seeking a declaration that certain MBT patents were invalid.  In late 2005, in response to the on-going settlement discussions, and as a sign of good faith, Walco redesigned its health management software at issue.  Walco believes all of MBT’s feed additive patents expired in February 2006, however there is one feed additive patent which MBT asserts is still active.  However, even if the last feed additive patent did not expire as MBT asserts, Walco believes it to be invalid for obvious-type double patenting in view of the expired patents.  On August 2, 2006, Walco advised Micro Beef of its views on these issues.

 

Multimin USA, Inc., et al. v. Walco International, Inc., et al., Civil Action No. 4:  06-CV-260A (N.D. Tex.).  Plaintiffs Multimin USA, Inc. and Warburton Technology, Ltd (collectively “Multimin”) allege trademark infringement, violation of Lanham Act Section 43a, trademark dilution, trade secret misappropriation, breach of contract, breach of fiduciary duty, and conspiracy.  Plaintiff is seeking damages in excess of $1,000,000 for each claim, an injunction enjoining Walco from using the marks Multimin, Mineral Max and Mineral Max II, and an injunction enjoining Walco from selling Multimin, MineralMax, and MineralMax II products.  Walco answered, denying the allegations and asserting a counterclaim for attorney’s fees under Lanham Act Section 1117.  This case is currently entering the discovery phase.

 

Ricky Rushing v. Walco International Inc.; Cause Number 05-C-0750-202; State of Texas; District Court, Bowie County.  Plaintiff, a former employee of Walco, seeks a declaratory judgment with regard to certain non-solicitation covenants he agreed to as part of employment with Walco.  Walco filed a cross-complaint seeking enforcement of the non-competition covenants, and further alleging misappropriation of trade secrets and breach of fiduciary duty.  This case is currently in the discovery phase.

 

Walco International v. Chad Spitzer; Cause Number 342-210794-05, State of Texas, District Court of Tarrant County.  Plaintiff, Walco, alleges breach of contract and is seeking damages in an unspecified amount and specific performance with regard to certain non-solicitation covenants Defendant agreed to as part of employment with Walco.  This case is currently in the discovery phase.

 

In the Matter of Sales of Unregistered Pesticide Products vs. Walco International, Inc., etc.; Case #E2006/07-l, State of California, Director of the Department of Pesticide Registration.  The State of California alleges that Defendant, Walco sold unlicensed pesticides within the state of California.  The parties are pursuing settlement possibilities.

 

Other Matters:

 

In August 2006, Hays County Texas filed suit against Walco for delinquent personal property taxes.  Walco is currently investigating the matter.

 

7

 

USPTO Trademark Registration Opposition.  Cargill filed and used a “[ ] Max” mark for computer software used for livestock feed management in 2000.  In 2003, Walco filed for trademark protection for the mark “Mineral Max”.  Cargill later filed the “Golden Max” mark for nutritional supplements.  Cargill opposed Walco’s registration of the “Mineral Max” mark.  The parties have reached an agreement in principal to settle this matter.

 

USPTO Trademark Registration Opposition.  Pfizer filed and used a “LS 50” mark in connection with one of their products.  Pfizer recently opposed Walco’s registration of the “Linco S 50” mark.  Linco is descriptive of the active ingredient of Lincomicin.  S is the first initial of the second ingredient of Spectamicin, and 50, which is the amount of active ingredients (50 mg).

 

This Schedule does not include open insurance claims or products liability litigation covered by insurance.

 

8

 

Schedule 5.6

Taxes

 

Sales Tax

 

1.                                       The state of Texas is currently conducting an audit of Borrower’s payment of sales taxes.  Borrower estimates that its liability is less than $100,000.

 

2.                                       The state of California is currently conducting an audit of Borrower’s payment of sales taxes.  Borrower estimates that its liability is less than $100,000.

 

Personal Property Taxes

 

In August 2006, Hays County Texas filed suit against Walco for delinquent personal property taxes.  Walco is currently investigating the matter.

 

Canada

 

The Canada Customs and Revenue Agency sent notice in August 2005 that they would conduct an audit beginning in October of 2005 of the corporate tax returns for RX Veterinary Supplies and Services Ltd for the fiscal years ending 2002 and 2003.  No auditors ever arrived to conduct the audit.  In January 2006, these operations were sold and ceased to operate.

 

9

 

Schedule 5.8
  Subsidiaries

 

	
Credit Party
    	
 
    	
Subsidiary and Jurisdiction
   of Incorporation or
   Organization
    	
 
    	
Percentage of the Credit
   Party’s Ownership of the
   Equity Interests of the
   Subsidiary
    
	
Walco International, Inc. (Borrower), a   California corporation
    	
 
    	
Walco do Brasil Produtos Veterinarios Ltda., a Brazilian   corporation*
    	
 
    	
Credit Party owns 999 quotas; Luis Eduardo Schoueri owns 1 quota
    
	
 
    	
 
    	
Walco Mexico, S.A. De C.V., a Mexican corporation*
    	
 
    	
Credit Party owns 9,999 shares; Jose Francisco Hinojosa Cuellar owns   1 share
    
	
 
    	
 
    	
Province Livestock Supply, Ltd., a Canadian   corporation
    	
 
    	
100%
    
	
 
    	
 
    	
Western Veterinary Supplies Ltd., a Canadian   corporation
    	
 
    	
100%
    
	
 
    	
 
    	
American Livestock Supply, Inc., a Delaware   corporation
    	
 
    	
100%
    
	
 
    	
 
    	
Walco Texas Animal Health, LLC, a Texas   limited liability company
    	
 
    	
100%
    
	
 
    	
 
    	
Walco Animal Health, Ltd., a U.K.   company
    	
 
    	
100%
    
	
Walco Holdings, Inc., a Delaware   corporation
    	
 
    	
Walco Intermediate, Inc., a Delaware   corporation
    	
 
    	
100%
    
	
Walco Intermediate, Inc., a Delaware   corporation
    	
 
    	
Walco International, Inc., a Delaware   corporation
    	
 
    	
100%
    
	
Animal Health International, Inc., a Delaware   corporation
    	
 
    	
Steer Intermediate Corporation, a Delaware   corporation
    	
 
    	
100%
    
	
Steer Intermediate Corporation, a Delaware corporation
    	
 
    	
Walco Holdings, Inc., a Delaware   corporation
    	
 
    	
100%
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
American Livestock Supply, Inc., a Delaware   corporation
    	
 
    	
None.
    	
 
    	
Not applicable.
    
	
Western Veterinary Supplies Ltd., a Canadian   corporation
    	
 
    	
None.
    	
 
    	
Not applicable.
    
	
Province Livestock Supply, Ltd., a Canadian   corporation
    	
 
    	
RX Veterinary Supplies and Services Ltd., a Canadian   corporation*
    	
 
    	
100%
    
	
 
    	
 
    	
Walco Canada Animal Health Ltd., a Canadian   corporation
    	
 
    	
100%
    
	
Walco Canada Animal
    	
 
    	
None.
    	
 
    	
Not applicable.
    

 

10

 

	
Health Ltd., a Canadian corporation
    	
 
    	
 
    	
 
    	
 
    
	
Walco Texas Animal Health, LLC, a Texas limited   liability company
    	
 
    	
None.
    	
 
    	
Not applicable.
    

 

* Inactive.  Information provided is based on records available to the Borrower that may be incomplete and/or outdated.

 

Inactive Subsidiaries

 

1.         Walco do Brasil Productos Veterinarios Ltda., a Brazilian corporation

2.         Walco Mexico, S.A. De C.V., a Mexican corporation

 

11

 

Schedule 5.12

Title to Properties; Possession Under Leases

 

Leases

 

1.                           Lease between Abilene Auction, Inc. (Landlord) and Borrower (Tenant), dated as of September 1, 2005, for the property located at 3265 Judge Ely Blvd., Abilene, Texas 79601.

 

2.                           Lease between Dairy Farmers of America, Inc. (Landlord) and Borrower (Tenant), dated as of January 2, 2002, for the property located at 6350 North 2150 West, Almaga, Utah 84335.

 

3.                           Lease between Angelo L. Mazzei and Mary E. Mazzei (Landlord) and Borrower (Tenant), dated as of August 1, 2004, for the property located at 4840 East Brundage Lane, Bakersfield, California 93307.

 

4.                           Lease between Roger Dunn (Landlord) and Borrower (Tenant), dated as of May 1, 2000, for the property located at 990 River Oaks Road, Boaz, Alabama 35950.

 

5.                           Lease between Muenster Livestock Auction Commission, Inc. (Landlord) and HiPro (Tenant), dated as of February 1, 2003, for the property located at Business Highway 287 North, Bowie, Texas 76230.

 

6.                           Lease between William Nels Smith (Landlord) and Borrower (Tenant), dated as of November 30, 1987, for the property located at 15760 S.E. 130th Street, Clackamus, Oregon 97015.

 

7.                           Lease between Arrow-Stevens Realty LLC (Landlord) and Borrower (Tenant), dated as of September 1, 2002, for the property located at 315 Industrial Drive, Clinton, North Carolina 28328.

 

8.                           Lease between Daniel C. Porter (Landlord) and Borrower (Tenant), dated as of June 1, 1997, for the property located at 2540 4th Street East, Dickinson, North Dakota 58601.

 

9.                           Lease between Steven D. Smith and Jody L. Smith (Landlord) and Borrower (Tenant), dated as of January 1, 2001, for the property located at 2091 Last Chance Road, Elko, Nevada 89801.

 

10.                     Lease between 9960 McCombs L.P. (Landlord) and Borrower (Tenant), dated as of September 1, 2005, for the property located at 11220 Rojas Drive, El Paso, Texas 79935.

 

11.                     Lease between Dan Urquart (Landlord) and Borrower (Tenant), dated as of November 1, 1991, for the property located at 150 Industrial Way, Fallon, Nevada 89406.

 

12.                     Lease between R. F. Wartig (Landlord) and Borrower (Tenant), dated as of July 1, 2001, for the property located at 4221 North Broad Street, Fremont, Nebraska 68025.

 

12

 

13.                     Lease between Panhandle Green Inc. (Landlord) and Borrower (Tenant), dated as of April 1, 1993, for the property located at 2840 N. 10th Street, Gering, Nebraska 69341 (Mailing address:  2838 N. 10th Street, Gering, Nebraska 69341).

 

14.                     Lease between McGuire Partners - Solana Limited Partnership (Landlord) and Borrower (Tenant), dated as of March 18, 2005, for the property located at 7 Village Circle Westlake, Texas 76262.

 

15.                     Lease between Tarrant County Ltd. Partnership (Landlord) and Borrower (Tenant), dated as of June 5, 2002, for the property located at 1240 E. Northwest Highway, Grapevine, Texas 76051.

 

16.                     Lease between John D. Buchanan (Landlord) and Borrower (Tenant), dated as of July 1, 1991, for the property located at 4700 10th Avenue South, Great Falls, Montana 59405.

 

17.                     Lease between Nebraska Trust Company, Trustee of the Robert J. McBride Trust (Landlord) and Borrower (Tenant), dated as of January 1, 2004, for the property located at 120 S. Lincoln, Hastings, Nebraska 68901.

 

18.                     Lease between Ralph Rollin Olson and Mabel M. Olson (Landlord) and Borrower (Tenant), dated as of May 1, 1993, for the property located at Puukapu, Waimea South Kohala, HI 96743 (Mailing Address:  1 Kauka Lane, Kamuela, Hawaii 96743).

 

19.                     Lease between Maurice N. Waters (Landlord) and Borrower (Tenant), dated as of July 1, 1994, for the property located at 200 West First Street, Hereford, Texas 79045.

 

20.                     Lease between Triple R Associates LLP (Landlord) and Borrower (Tenant), dated as of December 15, 1997, for the property located at 613 Atlas Avenue, Madison, Wisconsin 53708.

 

21.                     Lease between Shelby Distribution Park, LLC (Landlord) and Borrower (Tenant), dated as of February 1, 2004, for the property located at 4605 Hickory Hill Road, Memphis, Tennessee 38141.

 

22.                     Lease between Christopher R. Folk (Landlord) and Borrower (Tenant), dated as of June 28, 1999, for the property located at 4869 E. Raines Road, Memphis, Tennessee 38175.

 

23.                     Lease between 11 Street Investments, Limited Partnership (Landlord) and Borrower (Tenant), dated as of June 25, 2004, for the property located at 1908 Rockefeller Drive, Ceres, CA.

 

24.                     Lease between Workman Enterprises, Inc. (Landlord) and Borrower (Tenant), dated as of May 1, 2004, for the property located at 1409 South University Drive, Nacogdoches, Texas 75961.

 

25.                     Lease between Walker, LLC (Landlord) and Borrower (Tenant), dated as of May 1, 2003, for the property located at 2300 Northwest 9th Street, Okeechobee, Florida.

 

13

 

26.                     Lease between Carl Ross d/b/a Safari Business Center (Landlord) and Borrower (Tenant), dated as Of April 1, 2004, for the property located at 1906 E. Cedar Avenue, Ontario, California 91761.

 

27.                     Lease between Andrew F. Giambroni and Beverly Ann Giambroni, as trustees of the Giambroni Family Trust (Landlord) and Borrower (Tenant), dated as of September 1, 1998, for the property located at 115 Metzger Road, Red Bluff, California 96080.

 

28.                     Lease between Joe W. Bevers (Landlord) and Borrower (Tenant), dated as of December 1, 2001, for the property located at 1709-1713 S. E. Main Street, Roswell, New Mexico 88201.

 

29.                     Sublease between Charlie Schwab (Landlord) and Borrower (Tenant), dated as of September 1, 2005, for the property located at 1961 S. Highway 83, Scott City, Kansas 67871.

 

30.                     Lease between G F Land Partnership (Landlord) and Borrower (Tenant), dated as of August 25, 2006, for the property located at 1421 38th Avenue W., Spencer, Iowa 51301.

 

31.                     Lease between The Oscar M. Hall Revocable Trust, Oscar M. Hall and Margie L. Hall (Landlord) and Borrower (Tenant), dated as of April 1, 2000, for the property located at 1202 and 1204 ESI Drive, Springdale, Arkansas 72764.

 

32.                     Lease between CBS Real Estate Group Partnership (Landlord) and Borrower (Tenant), dated as of November 1, 2000, for the property located at 3058 W. Washington Street, Stephenville, Texas 76401.

 

33.                     Lease between John W. Eakin and Carl van der Merwe (Landlord) and Borrower (Tenant), dated as of December 1, 2004, for the property located at 120 E. South Hill Road, Sunnyside, Washington 98944.

 

34.                     Lease between Dairyman’s Cooperative Creamery Association (Landlord) and Borrower (Tenant), dated as of September 1, 1995, for the property located at 979 Bardsley, Tulare, California.

 

35.                     Lease between H & H Properties (Landlord) and Borrower (Tenant), dated as of May 1, 1994, for the property located at 408 N. Highway 87, Tulia, Texas 79088.

 

36.                     Lease between LPR Livestock Auction (Landlord) and Borrower (Tenant), dated as of May 1, 1996, for the property located at 1815 South Kings Highway, Texarkana, Texas 75501.

 

37.                     Lease between R. S. Properties of Walcott (Landlord) and Borrower (Tenant), dated as of November 1, 1994, for the property located at 126 E. Meadow Lane, Walcott, Iowa 52773.

 

14

 

38.                     Lease between Bobby and Barbara Nance (Landlord) and Borrower (Tenant), dated as of October 8, 2001, for the property located at 3031 W. Pawnee, Suite 400, Wichita, Kansas 67213.

 

39.                     Lease between Charles Rose and Ross Zimmerman (Landlord) and Borrower (Tenant), dated as of November 1, 2002, for the property located at 4320 W. Winnemucca Blvd., Winnemucca, Nevada 89445.

 

40.                     Lease between David Brown and Teresa Brown (Landlord) and Borrower (Tenant), dated as of February 20, 2003, for the property located at 1615 Avenue E, Wisner, Nebraska 68791.

 

41.                     Lease between Grafton West (Landlord) and Walco (Canada) Animal Health, Inc. (Tenant), dated as of July 1, 2005, for the property located at 9471 - 49th Street, Edmonton, Alberta T6B 2L8.

 

42.                     Lease between Crestline Builders Market (1977) Ltd. (Landlord) and Western Veterinary Supply Ltd. (Tenant), dated as of November 1, 2003, for the property located at 3026 -2nd Avenue North, Lethbridge, Alberta T1H 3C6.

 

43.                     Oral Lease between J. Mrak and R. Mrak (Landlord) and RX Veterinary Supplies and Services Ltd. for the property located at 2620 - 2nd Avenue North, Lethbridge, Alberta T1H3C4.

 

44.                     Oral Lease between Warehouse Rentals Ltd. (Landlord) and RX Veterinary Supplies and Services Ltd. for the property located at 6823 - 52nd Avenue, Red Deer, Alberta T4N 4L2.

 

45.                     Lease between Garden City Leasing Company LLC (Landlord) and Borrower (Tenant), dated as of January 10, 2005, for the property located at 3997 W. Jones Avenue, Garden City, Kansas 67846.

 

46.                     Lease between Camary Properties L.L.C. (Landlord) and Borrower (Tenant), dated March 9, 205, for the property located at 1215 E. Morris Street, Ste. Al, Hammond, Louisiana 70403.

 

47.                     Lease between Woodward Livestock Auction, Inc. (Landlord) and Borrower (Tenant), dated January 1, 2006, for the property located at 900 North Lakeview, Woodward, Oklahoma.

 

48.                     Lease between RJN Properties, Ltd. (Landlord) and Walco International, Inc. (Tenant), commencing October 2, 2002, for property located at 1412 N. Getty, Uvalde, Texas 78802.

 

49.                     Lease between S&S Dairy Supply, Inc. (Landlord) and Walco Texas Animal Health, LLC, dated September 18, 2006, for property located at 20115 Texas Highway 11 East, Winnsboro, Texas 75494.

 

15

 

Walco Holdings, Inc. is also party from time to time to leases for storage space which are not individually, or in the aggregate, material to the business of Walco Holdings, Inc..

 

16

 

Schedule 5.13
  Assumed Names

 

Sunwest Industries

DVM Resources

Walco Feed Additives

Central Arizona Veterinary Laboratories (“CAVL”)

Holt

Holt Products

InfoTech

ITA

M & M Supply Company of Florida

Paragon

R & R Olson

RXV Products

Walco Technologies

 

17

 

Schedule 5.16

Agreements

 

To the extent not paid off as of the Closing Date:

 

1.                                       The Credit Agreement, dated as of June 30, 2005, by and among Walco International, Inc. (“Borrower”) and other Guarantors named therein as guarantors, the Lenders named therein, JPMorgan Chase Bank, N.A., a national banking association, as Administrative Agent and General Electric Capital Corporation, as Documentation Agent.

 

2.                                       The secured term loan agreement, dated June 30, 2005 by and among Walco International, Inc. (“Borrower”) and Merrill Lynch PCG, Inc. (the Lender”).

 

3.                                       Standby Letter of Credit as amended issued by Borrower in favor of Employers Insurance of Wausau dated as of July 20, 2005 in the amount of $300,000.00.

 

4.                                       Standby Letter of Credit as amended issued by Borrower in favor of Aetna Life Insurance Company dated as of December 28, 2005 in the amount of $132,677.10.

 

18

 

Schedule 5.17

Environmental Matters

 

None.

 

19

 

Schedule 5.22

Transactions with Related Parties

 

This Schedule does not include agreements that are expected to terminate as of the Closing Date, promissory notes that are expected to be paid in full as of the Closing Date, or agreements with parties that are expected to no longer be an officer, director, shareholder or Affiliate of any of the Credit Parties as of the Closing Date.

 

1.                                       Corporate Development and Administrative Services Agreement, dated as of June 30, 2005, among Charlesbank Capital Partners, LLC, Animal Health International, Inc., f/k/a Steer Parent Corporation, and Borrower.

 

2.                                       Employment Agreement by and between Borrower and Jim Robison, dated as of May 1, 1997, as amended.

 

3.                                       Employment Agreement by and between Borrower and Greg Eveland, dated as of September 1, 1997, as amended.

 

4.                                       Employment Agreement by and between Borrower and William Lacey, dated as of August 15, 2003, as amended.

 

5.                                       Employment Agreement by and between Borrower and Mark Moon, dated as of June 3, 2002, as amended.

 

6.                                       Employment Agreement by and between Borrower and Damian Olthoff, dated as of April 1, 2006.

 

7.                                       Employment Agreement by and between Borrower and Nicholas Reid, dated as of February 1, 2006.

 

8.                                       Employment Agreement by and between Borrower and Scott Postlewaite, dated as of May 13, 2002.

 

9.                                       Stockholders Agreement, dated as of June 29, 2005, among Animal Health International, Inc., f/k/a Steer Parent Corporation and the Stockholders (as defined therein).

 

10.                                 Steer Parent Corporation 2005 Stock Option and Grant Plan and the Restricted Stock Agreements entered into pursuant thereto and any issuances of equity securities and related agreements thereunder.

 

11.                                 Director Indemnification Agreement by and between Animal Health International, Inc., f/k/a Steer Parent Corporation and James C. Robison, dated as of June 30, 2005.

 

12.                                 Director Indemnification Agreement by and between Animal Health International, Inc., f/k/a Steer Parent Corporation and Brandon White, dated as of June 30, 2005.

 

20

 

13.                                 Director Indemnification Agreement by and between Animal Health International, Inc., f/k/a Steer Parent Corporation and Michael Eisenson, dated as of June 30, 2005.

 

14.                                 Director Indemnification Agreement by and between Animal Health International, Inc., f/k/a Steer Parent Corporation and Mark Rosen, dated as of June 30, 2005.

 

15.                                 Borrower has severance agreements in place with the following additional individuals:

 

21

 

Schedule 5.23

Patents, Trademarks and Copyrights

 

United States Trademark Registrations

 

	
Trademark
    	
 
    	
Registration No.
    	
 
    	
Filing Date
    	
 
    	
Issuance Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
-50   BELOW
    	
 
    	
2,332,021
    	
 
    	
02/18/99
    	
 
    	
03/21/00
    
	
AFTER-BIRTH
    	
 
    	
2,655,779
    	
 
    	
02/28/01
    	
 
    	
12/03/02
    
	
AGRI   PHARM (words & design)
    	
 
    	
1,027,733
    	
 
    	
07/11/74
    	
 
    	
12/23/75
    
	
AGRI   BLOCK
    	
 
    	
3,106,174
    	
 
    	
12/14/04
    	
 
    	
06/20/06
    
	
AGRI   PHARM (standard character)
    	
 
    	
3,060,223
    	
 
    	
02/09/05
    	
 
    	
02/21/06
    
	
AMERICAN   LIVESTOCK SUPPLY
    	
 
    	
2,249,071
    	
 
    	
11/24/97
    	
 
    	
06/01/99
    
	
ANEM-X   (stylized)
    	
 
    	
2,448,175
    	
 
    	
10/16/98
    	
 
    	
05/01/01
    
	
COCCICOR
    	
 
    	
1,698,740
    	
 
    	
07/24/91
    	
 
    	
07/07/92
    
	
COMEBACK
    	
 
    	
2,255,087
    	
 
    	
12/08/97
    	
 
    	
06/22/99
    
	
COVERT
    	
 
    	
2,647,268
    	
 
    	
12/18/00
    	
 
    	
11/05/02
    
	
DERMALOG
    	
 
    	
2,580,432
    	
 
    	
03/16/01
    	
 
    	
06/11/02
    
	
DEXASONE
    	
 
    	
2,857,871
    	
 
    	
12/20/02
    	
 
    	
06/29/04
    
	
DUO   PEN
    	
 
    	
962,500
    	
 
    	
05/08/72
    	
 
    	
07/03/73
    
	
EQUI-DEX   CHERRY
    	
 
    	
3,033.11
    	
 
    	
05/06/04
    	
 
    	
12/20/05
    
	
EXALT
    	
 
    	
2,456,199
    	
 
    	
06/21/99
    	
 
    	
05/29/01
    
	
EXIT
    	
 
    	
2,058,430
    	
 
    	
02/12/96
    	
 
    	
04/29/97
    
	
E-Z   Tear
    	
 
    	
3140682
    	
 
    	
05/17/05
    	
 
    	
09/05/06
    
	
FIRST   COMPANION
    	
 
    	
2,392,486
    	
 
    	
10/11/96
    	
 
    	
10/10/00
    
	
GOOD   START
    	
 
    	
1,955,002
    	
 
    	
03/29/95
    	
 
    	
02/06/96
    
	
GUAGE
    	
 
    	
2,644,536
    	
 
    	
12/22/00
    	
 
    	
10/29/02
    
	
ITA   (and design)
    	
 
    	
2,521,274
    	
 
    	
06/01/00
    	
 
    	
12/18/01
    
	
IVERMAX
    	
 
    	
2,733,324
    	
 
    	
08/25/02
    	
 
    	
07/01/03
    
	
KETA-STHETIC
    	
 
    	
1,915,956
    	
 
    	
10/17/94
    	
 
    	
09/05/95
    
	
LUBISEPTOL
    	
 
    	
1,837,664
    	
 
    	
07/23/93
    	
 
    	
05/31/94
    
	
NASAL-VAX
    	
 
    	
2,701,501
    	
 
    	
12/28/01
    	
 
    	
03/25/03
    
	
NEOVET
    	
 
    	
1,063,116
    	
 
    	
08/25/76
    	
 
    	
04/12/77
    
	
Octagon   Logo
    	
 
    	
1,383,793
    	
 
    	
06/12/85
    	
 
    	
02/18/86
    
	
ORIGIN
    	
 
    	
2,453,950
    	
 
    	
06/21/99
    	
 
    	
05/22/01
    
	
OTO   SOOTHE
    	
 
    	
2,656,711
    	
 
    	
02/05/02
    	
 
    	
12/03/02
    
	
OXY-MYCIN
    	
 
    	
1,087,993
    	
 
    	
08/17/77
    	
 
    	
03/28/78
    
	
PACESETTER   (and design)
    	
 
    	
2,751,326
    	
 
    	
04/11/01
    	
 
    	
08/12/03
    
	
PARAGON
    	
 
    	
2,069,515
    	
 
    	
05/31/96
    	
 
    	
06/10/97
    
	
PERFECT   COAT
    	
 
    	
3,074,544
    	
 
    	
05/07/04
    	
 
    	
03/28/06
    
	
RE-NU
    	
 
    	
3,088,524
    	
 
    	
05/07/04
    	
 
    	
05/02/06
    
	
RESIST
    	
 
    	
2,794,958
    	
 
    	
01/30/03
    	
 
    	
12/16/03
    
	
RXV
    	
 
    	
1,408,163
    	
 
    	
06/12/85
    	
 
    	
09/09/86
    
	
RXV   PRODUCTS
    	
 
    	
1,376,847
    	
 
    	
06/12/85
    	
 
    	
01/07/86
    
	
RXV   RESCUE
    	
 
    	
2,314,616
    	
 
    	
02/18/99
    	
 
    	
02/01/00
    
	
RXV-BP-1
    	
 
    	
1,831,046
    	
 
    	
07/23/93
    	
 
    	
04/19/94
    
	
SCOURVAX
    	
 
    	
2,716,602
    	
 
    	
09/13/01
    	
 
    	
05/13/03
    
	
SUPPRESSOR
    	
 
    	
2,012,726
    	
 
    	
02/27/95
    	
 
    	
10/29/96
    
	
SUPRA-SULFA
    	
 
    	
1,064,285
    	
 
    	
11/07/75
    	
 
    	
04/26/77
    
	
TETNI-VAX
    	
 
    	
2,730,779
    	
 
    	
06/24/03
    	
 
    	
06/24/03
    

 

22

 

	
Trademark
    	
 
    	
Registration No.
    	
 
    	
Filing Date
    	
 
    	
Issuance Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
TRIPLE-HISTAMINE
    	
 
    	
2,129,878
    	
 
    	
06/10/96
    	
 
    	
01/20/98
    
	
VITA-JEC
    	
 
    	
969,052
    	
 
    	
08/02/72
    	
 
    	
09/25/73
    
	
VITA-ORAL
    	
 
    	
1,831,045
    	
 
    	
07/23/93
    	
 
    	
04/19/94
    
	
WI/WALCO   (and design)
    	
 
    	
2,193,857
    	
 
    	
11/04/97
    	
 
    	
10/06/98
    

 

United States Trademark Applications

 

	
Trademark
    	
 
    	
Serial No.
    	
 
    	
Filing Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
AGRI-BOND
    	
 
    	
78-532437
    	
 
    	
12/14/04
    
	
AMERICAN   PET SUPPLY
    	
 
    	
78/313,745
    	
 
    	
10/15/03
    
	
ANIMALHEALTHPROS
    	
 
    	
78/260,482
    	
 
    	
06/10/03
    
	
ANNEXUS
    	
 
    	
78-756274
    	
 
    	
11/17/05
    
	
BOVI   FRESH
    	
 
    	
78-554368
    	
 
    	
01/26/05
    
	
BOVI-PLAZ
    	
 
    	
78/329,287
    	
 
    	
11/18/03
    
	
BP-1
    	
 
    	
78/343,671
    	
 
    	
12/19/03
    
	
CANINE   IMUNO-VAX
    	
 
    	
78/188,989
    	
 
    	
11/26/02
    
	
CEFTI-JEC
    	
 
    	
78/808,086
    	
 
    	
02/06/06
    
	
CHORHEXIZOLE
    	
 
    	
78/766,781
    	
 
    	
12/05/05
    
	
DIA-ROBE
    	
 
    	
78-793141
    	
 
    	
01/17/06
    
	
DIGEST-RITE
    	
 
    	
78-766789
    	
 
    	
12/05/05
    
	
D/TOX/BESC
    	
 
    	
78/231,751
    	
 
    	
03/31/03
    
	
EQUI/MINTIC/SPR
    	
 
    	
78/219,137
    	
 
    	
02/26/03
    
	
EQUI-BOOST
    	
 
    	
78/211,133
    	
 
    	
02/05/03
    
	
EQUI-DEX   APPLE
    	
 
    	
78/414,155
    	
 
    	
05/06/04
    
	
EQUI-SPONGE
    	
 
    	
78/903,864
    	
 
    	
06/08/06
    
	
EQUI-THRUSH
    	
 
    	
78/250,992
    	
 
    	
05/16/03
    
	
EXCELLENCE   IN ANIMAL HEALTH
    	
 
    	
78/208,459
    	
 
    	
01/29/03
    
	
EXILE
    	
 
    	
78/907,720
    	
 
    	
06/14/06
    
	
FIRST   IMPRESSIONS
    	
 
    	
78/573,006
    	
 
    	
02/23/05
    
	
GUT   CHECK
    	
 
    	
78-766808
    	
 
    	
12/05/05
    
	
JUST   LIKE MOM
    	
 
    	
78-554372
    	
 
    	
01/26/05
    
	
LAST   FLIGHT
    	
 
    	
78/863,712
    	
 
    	
04/18/06
    
	
LINCO   S 50
    	
 
    	
78-434457
    	
 
    	
01/14/04
    
	
LINCO-JECT
    	
 
    	
78/226,420
    	
 
    	
03/17/03
    
	
MASTI-VAX
    	
 
    	
78-790013
    	
 
    	
01/12/06
    
	
MINERAL   MAX
    	
 
    	
76/489,397
    	
 
    	
02/11/03
    
	
MIRACLE   FLX PELLETS
    	
 
    	
78/414,146
    	
 
    	
05/06/04
    
	
MIRACLE   FLX SOLUTION
    	
 
    	
78/414,141
    	
 
    	
05/06/04
    
	
MIRACLE   HOOF
    	
 
    	
78/414,150
    	
 
    	
05/06/04
    
	
MIRACLE   SAND OUT
    	
 
    	
78-809119
    	
 
    	
02/07/06
    
	
MIRACLE   SHEEN
    	
 
    	
78/861,802
    	
 
    	
04/14/06
    
	
MIRACLE   WEIGHT GAIN
    	
 
    	
78-793011
    	
 
    	
01/17/06
    
	
NAX-C-FUR
    	
 
    	
78/836,278
    	
 
    	
03/14/06
    
	
NONE   (LOGO ONLY)
    	
 
    	
78-791114
    	
 
    	
01/13/06
    
	
NUTRI-SORB
    	
 
    	
78/260,476
    	
 
    	
06/10/03
    
	
OUTLAST
    	
 
    	
78-766802
    	
 
    	
12/05/05
    
	
RANCH   PACK
    	
 
    	
78-593519
    	
 
    	
03/23/05
    

 

23

 

	
RESCUE
    	
 
    	
78-590051
    	
 
    	
03/18/05
    
	
RXV
    	
 
    	
78-780389
    	
 
    	
12/23/05
    
	
SHU   FLY
    	
 
    	
78-766793
    	
 
    	
12/05/05
    
	
VETQUI   CELL
    	
 
    	
78-903,908
    	
 
    	
06/08/06
    
	
WI   WALCO TECHNOLOGIES EXCELLENCE IN ANIMAL MANAGEMENT
    	
 
    	
78-836276
    	
 
    	
03/14/05
    

 

United States Patents (owned)

 

	
Patent
    	
 
    	
Patent Number
    	
 
    	
Filing Date
    	
 
    	
Issuance
   Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
“Accurate Metering Control Systems and Method for   Livestock Feeding Operation.”
    	
 
    	
5,424,957
    	
 
    	
10/07/93
    	
 
    	
06/13/95
    

 

State Trademark Registrations

 

	
Trademark
    	
 
    	
Registration
    No.
    	
 
    	
Issue Date
    	
 
    	
State
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
HOLT PRODUCTS COMPANY
    	
 
    	
061,016
    	
 
    	
12/17/97
    	
 
    	
Wisconsin
    	
 
    
	
HOLT PRODUCTS
    	
 
    	
061,017
    	
 
    	
12/17/97
    	
 
    	
Wisconsin
    	
 
    
	
HOLT
    	
 
    	
061,018
    	
 
    	
12/17/97
    	
 
    	
Wisconsin
    	
 
    

 

Canadian Trademark Registrations

 

	
Trademark
    	
 
    	
Registration No.
    	
 
    	
Issue Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SUPPRESSOR
    	
 
    	
CA1249362
    	
 
    	
3/3/05
    
	
NOROMYCIN
    	
 
    	
CA1249363
    	
 
    	
3/3/05
    
	
NOROVET
    	
 
    	
CA1249364
    	
 
    	
3/3/05
    

 

Patent Applications

 

	
Patent Title
    	
 
    	
Application
   No.
    	
 
    	
Filing Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Calf   Bottle
    	
 
    	
10/995,452
    	
 
    	
11/23/04
    

 

24

 

Patents

 

	
Patent
    	
 
    	
Patent No.
    	
 
    	
Filing Date
    	
 
    	
Issue Date
    
	
Accurate Metering and Control System and Method   for Livestock Feeding Operation (1)
    	
 
    	
5,424,957
    	
 
    	
10/7/1993
    	
 
    	
6/13/1995
    

 

(1) This patent will be assigned from Info Tech to Borrower.

 

USPTO Trademark Registration Opposition. Cargill filed and used a “[ ] Max” mark for computer software used for livestock feed management in 2000. In 2003, Walco International filed for trademark protection for the mark “Mineral Max”.  Cargill later filed the “Golden Max” mark for nutritional supplements.  Cargill opposed Walco International’s registration of the “Mineral Max” mark.  The matter is currently pending before the U.S. Trademark and Trial Appeal Board.

 

USPTO Trademark Registration Opposition. Pfizer filed and used a “LS 50” mark in connection with one of their products.  Pfizer recently opposed Walco International’s registration of the “Linco S 50” mark.  Linco is descriptive of the active ingredient of Lincomicin. S is the first initial of the second ingredient of Spectamicin, and 50, which is the amount of active ingredients (50 mg).

 

25

 

Schedule 6.15
  Financial Institutions and Accounts

 

	
Division
   Name
    	
 
    	
Bank
   Name
    	
 
    	
Bank
   Location
    
	
Guymon,   OK
    	
 
    	
The   City National Bank & Trust
    	
 
    	
Guymon,   OK
    
	
Hereford,   TX
    	
 
    	
First   National Bank
    	
 
    	
Hereford,   TX
    
	
Pleasanton,   TX
    	
 
    	
Texas   Champion Bank
    	
 
    	
Charlotte,   TX
    
	
Greeley,   CO
    	
 
    	
Bank   of Colorado
    	
 
    	
Sterling,   CO
    
	
Gering,   NE
    	
 
    	
US   Bank
    	
 
    	
St.   Paul, MN
    
	
Fremont,   NE
    	
 
    	
US   Bank
    	
 
    	
St.   Paul, MN
    
	
Tulia,   TX
    	
 
    	
Wells   Fargo Bank
    	
 
    	
Tulia,   TX
    
	
Wichita   Falls, TX
    	
 
    	
State   National Bank
    	
 
    	
Iowa   Park, TX
    
	
Sioux   Falls, SD
    	
 
    	
Wells   Fargo South Dakota, N.A.
    	
 
    	
Sioux   Falls, SD
    
	
Hastings,   NE
    	
 
    	
Heritage   Bank
    	
 
    	
Hastings,   NE
    
	
Mayo,   FL
    	
 
    	
Lafayette   County State Bank
    	
 
    	
Mayo,   FL
    
	
Dunn,   NC
    	
 
    	
Centura
    	
 
    	
Dunn,   NC
    
	
Sturgis,   SD
    	
 
    	
First   Western Bank
    	
 
    	
Sturgis,   SD
    
	
Nacogdoches,   TX
    	
 
    	
Bancorp   South
    	
 
    	
Nacogdoches,   TX
    
	
Sealy,   TX
    	
 
    	
Citizens   State Bank
    	
 
    	
Sealy,   TX
    
	
Texarkana,   TX
    	
 
    	
Capital   One Bank
    	
 
    	
Texarkana,   TX
    
	
Bowie,   TX
    	
 
    	
Jackboro   Nat’l Bank/The Bowie Bank
    	
 
    	
Bowie,   TX
    
	
Wisner,   NE
    	
 
    	
The   Citizens Natl Bank of Wisner
    	
 
    	
Wisner,   NE
    
	
Dickinson,   ND
    	
 
    	
Bank   of the West
    	
 
    	
Dickinson,   ND
    
	
Spanish   Fork, UT
    	
 
    	
Zions   First National Bank
    	
 
    	
Spanish   Fork, UT
    
	
Billings/Great   Fall, MT
    	
 
    	
First   Interstate Bank
    	
 
    	
Great   Falls, MT
    
	
Cache   Valley
    	
 
    	
Zions   First National Bank
    	
 
    	
Spanish   Fork, UT
    
	
Kamuela,   HI
    	
 
    	
First   Hawaiian Bank
    	
 
    	
Kamuela,   HI
    
	
Holt-Deposits
    	
 
    	
M&l   Marshall & llsley Bank #50720
    	
 
    	
Madison,   Wl
    
	
Canada-Walco
    	
 
    	
Royal   Bank of Canada
    	
 
    	
Lethbridge   AB
    
	
Canada-RX   Vet Supplies
    	
 
    	
Royal   Bank of Canada
    	
 
    	
Lethbridge   AB
    
	
Canada-Western   Vet
    	
 
    	
Royal   Bank of Canada
    	
 
    	
Lethbridge   AB
    
	
Divisional   Depository (Multiple Divisions)
    	
 
    	
Bank   of America
    	
 
    	
Fresno,   CA
    
	
Credit   Card Depository
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Credit   Card Depository-Holt
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
COD   Secure Depository
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Lock   Box Account
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Corporate   Miscellaneous Deposit
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Corporate   Petty Cash Account
    	
 
    	
Bank   of America
    	
 
    	
Grapevine,   TX
    
	
Main   Concentration Account
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Health   Plan Disbursements
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Payroll   Disbursements
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
FEDI   Account
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
AP   Main Disbursements Pos Pay
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
FSA   Funding Account
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
CAPS   Funding Account
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Walco   International Holdings Inc.
    	
 
    	
Chase   Bank
    	
 
    	
Dallas,   TX
    
	
Woodward,   OK
    	
 
    	
MidFirst   Bank
    	
 
    	
Woodward,   OK
    

 

26

 

With the following exceptions, signatories on all above accounts are William F. Lacey, Henry Moomaw III, and Barry Fischer:

 

1.                                       Signatories on the accounts with Royal Bank of Canada are Scott Postlewaite, Allen Carmichael.

 

27

 

Schedule 7.2

Liens

 

This Schedule does not include liens of Fleet National Bank, individually and as administrative agent or collateral agent, with respect to assets of various entities, because release and termination of such liens are expected to be filed on the Closing Date.

 

Alberta Registries (Canada)

 

Province Livestock Supply Ltd.

 

1.                                       GMAC LeaseCo Corporation holds a security interest in several GMC vehicles.  The registration numbers are 04110511997, 04110512060, 04110512607, and 04111513661.

2.                                      Chrysler Financial Canada and DaimlerChrysler Services Canada Inc. hold a security interest in a 2003 Jeep Liberty.  The registration number is 03012001263.

3.                                       Ford Credit Canada Leasing Company holds a security interest in a 2004 Ford F350.  The registration number is 04060112242.

4.                                       Citicorp Vendor Finance, Ltd. holds a security interest in equipment.  The registration number is 03110619602.

 

Walco International, Inc.

 

1.                                       Citicorp Vendor Finance, Ltd. holds a security interest in equipment.  The registration number is 03110619602.

 

UCC (United States)

 

Walco International, Inc.

 

1.                                       Bayer Corporation and Bayer Healthcare LLC hold a security interest in all Baytril 100 Injectible Solution, now owned or hereafter acquired, and the proceeds and Accounts Receivable arising from the sale thereof.  The financing statements were filed in California, and the file numbers are 9829360201, 00076C0196, 0315560782, 04-1006521019, and 0418161115.

2.                                       Crown Credit Company holds a security interest in specific equipment.  The financing statements were filed in California, and the file numbers are 0205360593, 0233160846, 04-1003386126, 05-7022314024, and 0205360600.

3.                                       Minolta Business Solutions, Inc. (fka Minolta Business Systems, Inc.) holds a security interest in specific leased equipment and specific equipment.  The financing statements were filed in California, and the file numbers are 0229160559 and 0310060586.

4.                                       IBM Credit Corporation and IBM Credit LLC hold a security interest in specific leased equipment.  The financing statements were filed in California, and the file numbers are 0300860032, 0300960480, and 0302760566.

5.                                       Inter-Tel Leasing Inc. holds a security interest in Axxess Telephone System.  The financing statement was filed in California, and the file number is 0406160615.

 

28

 

6.                                       Citicorp Del Lease, Inc., DBA Citicorp Dealer Finance, holds a security interest in specific equipment.  The financing statement was filed in California, and the file number is 0218160669.

 

29

 

Schedule 7.6
  Permitted Affiliate Transactions

 

SEE SCHEDULE 5.22

 

30

 

Schedule 7.18
  Restrictive Agreements

 

None.

 

31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]